D000001 Calcimycin 1974 11 19 2003 07 30 1984 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was A 23187 1975-90 (see under ANTIBIOTICS 1975-83) use CALCIMYCIN to search A 23187 1975-90 91; was A 23187 1975-90 (see under ANTIBIOTICS 1975-83) Antibiotics (1973-1974) Carboxylic Acids (1973-1974) D03.438.221.173 NLM SYSTEM NLM M0000001 Calcimycin C0000699 4-Benzoxazolecarboxylic acid, 5-(methylamino)-2-((3,9,11-trimethyl-8-(1-methyl-2-oxo-2-(1H-pyrrol-2-yl)ethyl)-1,7-dioxaspiro(5.5)undec-2-yl)methyl)-, (6S-(6alpha(2S*,3S*),8beta(R*),9beta,11alpha))- 52665-69-7 An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems. T109 Organic Chemical T195 Antibiotic D000900 Anti-Bacterial Agents D007476 Ionophores M0000001 M0353609 T000002 Calcimycin 1999 01 01 NLM (1975) M0353609 A-23187 C0878412 0 T109 Organic Chemical T195 Antibiotic M0000001 M0353609 T000001 A-23187 1990 03 08 A A 23187 NLM (1991) T000001 A 23187 T000003 Antibiotic A23187 1990 03 08 NLM (1991) T000003 A23187, Antibiotic T000004 A23187 1974 11 11 UNK (19XX) D000002 Temefos 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG TN 111 for eff on insects 96; was ABATE 1972-95 (see under INSECTICIDES, ORGANOTHIOPHOSPHATE 1972-90) 96; was ABATE 1972-95 (see under INSECTICIDES, ORGANOTHIOPHOSPHATE 1972-90) Insecticides (1966-1971) D02.719.900 NLM CCR sjn M0000002 Temefos C0000714 Phosphorothioic acid, O,O'-(thiodi-4,1-phenylene) O,O,O',O'-tetramethyl ester 3383-96-8 An organothiophosphate insecticide. T115 Organophosphorus Compound T131 Hazardous or Poisonous Substance D007311 Insecticides, Organothiophosphate M0000002 M0352201 M0000002 M0352200 M0000002 M0352199 T000008 Temefos 1999 01 01 INN (19XX) USAN (1974) M0352201 Abate C0878195 0 T115 Organophosphorus Compound T131 Hazardous or Poisonous Substance M0000002 M0352201 T000005 Abate 1994 11 14 NLM (1996) M0352200 Difos C0878196 0 T115 Organophosphorus Compound T131 Hazardous or Poisonous Substance M0000002 M0352200 T000006 Difos 1986 10 07 UNK (19XX) M0352199 Temephos C0917846 0 T115 Organophosphorus Compound T131 Hazardous or Poisonous Substance M0000002 M0352199 T000007 Temephos 1994 12 01 NLM (1996) D000003 Abattoirs 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000592 standards ST Q000706 statistics & numerical data SN Q000941 ethics ES J01.576.423.200.700.100 NLM JLS SJN M0000003 Abattoirs C0000715 Places where animals are slaughtered and dressed for market. T073 Manufactured Object T000009 Abattoirs 1999 01 01 NLM (1966) T000009 Abattoir T000010 Slaughterhouses 1974 03 29 UNK (19XX) T000010 Slaughterhouse D000004 Abbreviations 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 includes acronyms; IM; no qualif L01.143.506.598.400.556.131 NLM kle sjn M0000004 Abbreviations C0000723 Shortened forms of written words or phrases used for brevity. T170 Intellectual Product T000011 Abbreviations 1999 01 01 NLM (1966) T000011 Abbreviation D000005 Abdomen 1999 01 01 2002 07 02 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000196 embryology EM Q000254 growth & development GD Q000294 innervation IR Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000531 radionuclide imaging RI Q000601 surgery SU Q000736 ultrasonography US Q000821 virology VI GEN: prefer specifics; abdom muscles = ABDOMINAL MUSCLES but RECTUS ABDOMINIS is available; abdominal pain = ABDOMINAL PAIN; abrupt dis requiring emerg surg = ABDOMEN, ACUTE D000005 Abdomen Q000293 injuries D000007 Abdominal Injuries D000005 Abdomen Q000530 radiography D011860 Radiography, Abdominal A01.047 NLM ags sjn M0000005 Abdomen C0000726 That portion of the body that lies between the THORAX and the PELVIS. T029 Body Location or Region T000012 Abdomen 1999 01 01 NLM (1966) T000012 Abdomens D000006 Abdomen, Acute 1999 01 01 2003 07 09 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C23.888.646.100.200 C23.888.821.030.249 NLM lkt sjn M0000006 Abdomen, Acute C0000727 A clinical syndrome with acute abdominal pain that is severe, localized, and rapid onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases. T184 Sign or Symptom T000013 Abdomen, Acute 1999 01 01 NLM (1966) T000013 Abdomens, Acute T000013 Acute Abdomen T000013 Acute Abdomens D000007 Abdominal Injuries 1999 01 01 1991 06 21 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI general term for inj of organs in the abdom cavity; prefer specific organs /inj C21.866.017 NLM PXP PLS M0000007 Abdominal Injuries C0000733 General or unspecified injuries involving organs in the abdominal cavity. T037 Injury or Poisoning T000015 Abdominal Injuries 1999 01 01 ABDOMINAL INJ NLM (1966) T000014 Injuries, Abdominal 1986 01 01 INJ ABDOMINAL UNK (19XX) T000014 Abdominal Injury T000014 Injury, Abdominal D000008 Abdominal Neoplasms 1999 01 01 1995 06 08 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI general term for neopl of organs in the abdom cavity; prefer specific organ/neopl terms; /blood supply /chem /second /secret /ultrastruct permitted; coord IM with histol type of neopl if given (IM) C04.588.033 NLM KEV PLS M0000008 Abdominal Neoplasms C0000735 T191 Neoplastic Process T000016 Abdominal Neoplasms 1999 01 01 ABDOMINAL NEOPL NLM (1966) T000016 Abdominal Neoplasm T000016 Neoplasm, Abdominal T000016 Neoplasms, Abdominal D000009 Abdominal Muscles 1999 01 01 2002 07 02 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI RECTUS ABDOMINIS is available; hernia = HERNIA, VENTRAL; /growth: coord with MUSCLE DEVELOPMENT; /embryol: coord with MUSCLE DEVELOPMENT if pertinent 93; was ABDOMINAL WALL 1966-92 use ABDOMINAL MUSCLES to search ABDOMINAL WALL 1966-92 93; was ABDOMINAL WALL 1963-92 D034861 Abdominal Wall A02.633.567.050 NLM ags sjn M0000009 Abdominal Muscles C0000739 Muscles forming the ABDOMINAL WALL including RECTUS ABDOMINIS, external and internal oblique muscles, transversus abdominis, and quadratus abdominis. (from Stedman, 25th ed) T024 Tissue T000018 Abdominal Muscles 1999 01 01 NLM (1966) T000018 Abdominal Muscle T000018 Muscle, Abdominal T000018 Muscles, Abdominal D000010 Abducens Nerve 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI neopl = ABDUCENS NERVE DISEASES (IM) + CRANIAL NERVE NEOPLASMS (IM) + histol type of neopl (IM) 77; was ABDUCENT NERVE 1963-76 use ABDUCENS NERVE to search ABDUCENT NERVE 1966-76 77; was ABDUCENT NERVE 1963-76 D000010 Abducens Nerve Q000293 injuries D020222 Abducens Nerve Injury A08.800.800.120.030 NLM KEV sjn M0000010 Abducens Nerve C0000741 The 6th cranial nerve. The abducens nerve originates in the abducens nucleus of the pons and sends motor fibers to the lateral rectus muscles of the eye. Damage to the nerve or its nucleus disrupts horizontal eye movement control. T023 Body Part, Organ, or Organ Component T000019 Abducens Nerve 1999 01 01 NLM (1966) T000019 Abducens Nerves T000019 Nerve, Abducens T000019 Nerves, Abducens T000021 Abducent Nerve 1976 05 26 UNK (19XX) T000021 Abducent Nerves T000021 Nerve, Abducent T000021 Nerves, Abducent T000022 Cranial Nerve VI 1996 07 31 NLM (1998) T000022 Cranial Nerve VIs T000022 Nerve VI, Cranial T000022 Nerve VIs, Cranial T000022 VI, Cranial Nerve T000022 VIs, Cranial Nerve T000020 Sixth Cranial Nerve 1996 07 31 NLM (1998) T000020 Cranial Nerve, Sixth T000020 Cranial Nerves, Sixth T000020 Nerve, Sixth Cranial T000020 Nerves, Sixth Cranial T000020 Sixth Cranial Nerves D000011 Abelson murine leukemia virus 1979 04 16 2002 07 02 1991 01 01 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection: coord IM with RETROVIRIDAE INFECTIONS (IM) + TUMOR VIRUS INFECTIONS (IM) + LEUKEMIA, EXPERIMENTAL (IM) 2002 (1980) 2002; see ABELSON LEUKEMIA VIRUS 1991-2001, see MOUSE LEUKEMIA VIRUSES 1980-1990 Mouse Leukemia Viruses (1966-1979) B04.820.650.375.525.020 B04.909.574.807.375.525.020 B04.909.777.731.375.525.020 AEP ags sjn M0000011 Abelson murine leukemia virus C0000742 A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND, MALONEY, or RAUSCHER MURINE LEUKEMIA VIRUS. T005 Virus T445670 Abelson murine leukemia virus 2001 05 04 NLM (2002) T000023 Abelson Leukemia Virus 1999 01 01 NLM (1980) T000023 Leukemia Virus, Abelson T000023 Virus, Abelson Leukemia D000012 Abetalipoproteinemia 1999 01 01 2001 07 25 1966 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with HYPOBETALIPOPROTEINEMIA 1966(1964) 1966 D001055 Apolipoproteins B C10.228.140.163.100.050 C15.378.147.068 C16.320.565.150.050 C16.320.565.556.500.220 C18.452.100.100.050 C18.452.648.151.050 C18.452.648.556.500.220 NLM nns sjn M0000012 Abetalipoproteinemia C0000744 A disorder of lipid metabolism inherited as an autosomal recessive trait characterized by the near absence of APOLIPOPROTEINS B and apoB-containing lipoproteins in plasma. Microsomal triglyceride transfer protein is deficient or absent in enterocytes. Clinical and laboratory findings include acanthocytosis, hypocholesterolemia, peripheral neuropathy, posterior column degeneration, ataxia, and steatorrhea. Intellectual abilities may also be impaired. (Menkes, Textbook of Child Neurology, 5th ed, p118; Curr Opin Lipidol 1994 Apr;5(2):81-6) T047 Disease or Syndrome T000024 Abetalipoproteinemia 1999 01 01 NLM (1964) T000024 Abetalipoproteinemias T000025 Bassen-Kornzweig Syndrome 1974 03 29 UNK (19XX) T000025 Bassen Kornzweig Syndrome T365901 Apolipoprotein B Deficiency Disease 1999 11 04 APOLIPOPROTEIN B DEFIC DIS NLM (2000) T365902 Betalipoprotein Deficiency Disease 1999 11 04 BETALIPOPROTEIN DEFIC DIS NLM (2000) T365902 Betalipoprotein Deficiency Diseases T365902 Deficiency Diseases, Betalipoprotein T365902 Disease, Betalipoprotein Deficiency T365902 Diseases, Betalipoprotein Deficiency T365903 Microsomal Triglyceride Transfer Protein Deficiency Disease 1999 11 04 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFIC DIS NLM (2000) T365904 Bassen-Kornzweig Disease 1999 11 04 BASSEN KORNZWEIG DIS NLM (2000) T365904 Bassen Kornzweig Disease T365904 Bassen-Kornzweig Diseases T365904 Diseases, Bassen-Kornzweig T365905 Deficiency Disease, Apolipoprotein B 1999 11 04 DEFIC DIS APOLIPOPROTEIN B NLM (2000) T365906 Deficiency Disease, Betalipoprotein 1999 11 04 DEFIC DIS BETALIPOPROTEIN NLM (2000) T365907 Deficiency Disease, Microsomal Triglyceride Transfer Protein 1999 11 04 DEFIC DIS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN NLM (2000) D000013 Abnormalities 1999 01 01 2000 06 22 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI GEN only: prefer /abnorm: Manual 19.7+, 19.8.1; do not use /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; policy: Manual 23.20+; TN 109: relation to /congen & INFANT, NEWBORN, DISEASES pre-explosion = ABNORMALITIES (PX) D000013 Abnormalities Q000139 chemically induced D000014 Abnormalities, Drug-Induced C16.131 NLM jls sjn M0000013 Abnormalities C0000768 Congenital malformations of organs or parts. T019 Congenital Abnormality T000026 Abnormalities 1999 01 01 ABNORM NLM (1966) T000026 Abnormality T000028 Abnormalities, Congenital 1978 12 18 ABNORM CONGEN UNK (19XX) T000028 Abnormality, Congenital T000028 Congenital Abnormality T000027 Birth Defects 1976 05 08 UNK (19XX) T000027 Birth Defect T000027 Defect, Birth T000027 Defects, Birth T000029 Congenital Abnormalities 1978 12 18 CONGEN ABNORM POPLINE (1978) T000031 Congenital Defects 1977 03 22 CONGEN DEFECTS UNK (19XX) T000030 Defects, Congenital 1977 03 22 DEFECTS CONGEN UNK (19XX) T000030 Congenital Defect T000030 Defect, Congenital T000032 Deformities 1974 03 29 UNK (19XX) T000032 Deformity D000014 Abnormalities, Drug-Induced 1999 01 01 1999 11 03 1964 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI IM; do not use /chem ind /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific chem /adv eff-pois-tox (IM) + specific organ /abnorm or specific abnorm /chem ind (IM); Manual 23.20.3 64 64 D013723 Teratogens C16.131.042 NLM kle sjn M0000014 Abnormalities, Drug-Induced C0000771 Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. T019 Congenital Abnormality T000034 Abnormalities, Drug-Induced 1999 01 01 ABNORM DRUG IND NLM (1964) T000034 Abnormalities, Drug Induced T000033 Drug-Induced Abnormalities 1977 12 07 DRUG IND ABNORM UNK (19XX) T000033 Abnormality, Drug-Induced T000033 Drug Induced Abnormalities T000033 Drug-Induced Abnormality D000015 Abnormalities, Multiple 1999 01 01 1999 11 08 1968 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI IM; do not use /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific abnorm (IM); Manual 23.20.2 68 68 Abnormalities (1966-1967) D008607 Mental Retardation C16.131.077 NLM KEV sjn M0000015 Abnormalities, Multiple C0000772 T019 Congenital Abnormality T000036 Abnormalities, Multiple 1999 01 01 ABNORM MULTIPLE NLM (1968) T000035 Multiple Abnormalities 1986 01 01 MULTIPLE ABNORM UNK (19XX) D000016 Abnormalities, Radiation-Induced 1978 03 20 1999 11 03 1979 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI IM; do not use /compl /congen & do not coord with INFANT, NEWBORN, DISEASES; coord IM with specific abnorm (IM) 79 79 Abnormalities (1966-1978) Radiation Injuries (1966-1978) C16.131.080 C21.866.733.031 G03.850.810.300.360.031 AEP kle sjn M0000016 Abnormalities, Radiation-Induced C0000773 Congenital changes in the morphology of organs produced by exposure to ionizing or non-ionizing radiation. T019 Congenital Abnormality T000038 Abnormalities, Radiation-Induced 1999 01 01 ABNORM RAD IND NLM (1979) T000038 Abnormalities, Radiation Induced T000037 Radiation-Induced Abnormalities 1978 03 20 RAD IND ABNORM UNK (19XX) T000037 Abnormality, Radiation-Induced T000037 Radiation Induced Abnormalities T000037 Radiation-Induced Abnormality D000017 ABO Blood-Group System 1975 07 25 2003 07 09 1976 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT IM; coord with disease /blood (IM), not /immunol nor /genet; TN 230 76; was ABO FACTORS 1963-75 use ABO BLOOD-GROUP SYSTEM to search ABO FACTORS 1966-75 76; was ABO FACTORS 1963-75 D24.611.216.301.290.031 D24.611.216.705.230.031 SH nns sjn M0000017 ABO Blood-Group System C0000778 0 The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. T022 Body System M0000017 M0000018 M0000017 M0000019 T000040 ABO Blood-Group System 1999 01 01 NLM (1976) T000040 ABO Blood Group System T000040 ABO Blood-Group Systems T000040 Blood-Group System, ABO T000040 Blood-Group Systems, ABO T000040 System, ABO Blood-Group T000040 Systems, ABO Blood-Group T000039 ABH Blood Group 1988 06 07 UNK (19XX) T000039 ABH Blood Groups T000039 Blood Group, ABH T000039 Blood Groups, ABH T000041 H Blood Group 1980 08 04 UNK (19XX) T000041 Blood Group, H T000041 Blood Groups, H T000041 H Blood Groups T000042 H Blood Group System 1984 09 20 UNK (19XX) M0000018 ABO Factors C0000779 0 T129 Immunologic Factor M0000017 M0000018 T000043 ABO Factors 1975 07 22 UNK (19XX) T000043 ABO Factor T000043 Factor, ABO T000043 Factors, ABO M0000019 Blood Group H Type 1 Antigen C0005805 0 T129 Immunologic Factor M0000017 M0000019 T000044 Blood Group H Type 1 Antigen 1984 03 05 UNK (19XX) D000018 Abomasum 1999 01 01 1995 05 18 1968 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI a ruminant's 4th stomach; dis: coord IM with STOMACH DISEASES /vet (IM); neopl: coord IM with STOMACH NEOPLASMS /vet (IM) + histol type /vet (IM); ulcer: coord IM with STOMACH ULCER /vet (IM) 68 68 Stomach (1966-1967) A13.869.106 NLM TGC PLS M0000020 Abomasum C0000780 The fourth stomach of ruminating animals. It is also called the "true" stomach. It is an elongated pear-shaped sac lying on the floor of the abdomen, on the right-hand side, and roughly between the seventh and twelfth ribs. It leads to the beginning of the small intestine. (From Black's Veterinary Dictionary, 17th ed) T023 Body Part, Organ, or Organ Component T000045 Abomasum 1999 01 01 NLM (1968) T000045 Abomasums D000019 Abortifacient Agents 1999 01 01 2003 07 09 1975 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not use /ther use for use of abortifacients as abortifacients 75 75 Abortion, Induced (1970-1974) D010120 Oxytocics D07.131 D27.505.696.875.131 D27.505.954.705.131 NLM ssb sjn M0000021 Abortifacient Agents C0000782 0 Chemical substances that interrupt pregnancy after implantation. T121 Pharmacologic Substance T000046 Abortifacient Agents 1999 01 01 POPLINE (1978) T000046 Agents, Abortifacient T000047 Contraceptive Agents, Postconception 1978 12 18 POPLINE (1978) T000047 Agents, Postconception Contraceptive T000047 Postconception Contraceptive Agents T000048 Abortifacients 1991 10 09 NLM (1993) D000020 Abortifacient Agents, Nonsteroidal 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not use /ther use for use of the abortifacients as abortifacients 91(75); was see under ABORTIFACIENT AGENTS 1975-90 91; was see under ABORTIFACIENT AGENTS 1975-90 Abortion, Induced (1970-1974) specific chemical (1971-1974) D07.131.100 D27.505.696.875.131.100 D27.505.954.705.131.100 NLM ssb sjn M0000022 Abortifacient Agents, Nonsteroidal C0000783 0 Non-steroidal chemical compounds with abortifacient activity. T121 Pharmacologic Substance T000050 Abortifacient Agents, Nonsteroidal 1999 01 01 NLM (1975) T000050 Agents, Nonsteroidal Abortifacient T000050 Nonsteroidal Abortifacient Agents T000049 Abortifacient Agents, Non-Steroidal 1977 12 07 UNK (19XX) T000049 Abortifacient Agents, Non Steroidal T000049 Agents, Non-Steroidal Abortifacient T000049 Non-Steroidal Abortifacient Agents D000021 Abortifacient Agents, Steroidal 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not use /ther use for use of the abortifacients as abortifacients 91(75); was see under ABORTIFACIENT AGENTS 1975-90 91; was see under ABORTIFACIENT AGENTS 1975-90 Abortion, Induced (1970-1974) specific chemical (1970-1974) D07.131.200 D27.505.696.875.131.200 D27.505.954.705.131.200 NLM ssb sjn M0000023 Abortifacient Agents, Steroidal C0000784 0 Steroidal compounds with abortifacient activity. T110 Steroid T121 Pharmacologic Substance T000051 Abortifacient Agents, Steroidal 1999 01 01 NLM (1975) T000051 Agents, Steroidal Abortifacient T000051 Steroidal Abortifacient Agents T000052 Steroid Abortifacients 1978 12 18 POPLINE (1978) T000052 Abortifacients, Steroid D000022 Abortion, Spontaneous 1999 01 01 2002 07 02 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI /chem ind permitted but do not confuse with ABORTION, INDUCED (E4); /chem ind: consider also ABORTIFACIENT AGENTS; don't forget also check tags HUMAN & FEMALE & PREGNANCY 99(63) 99; see ABORTION 1966-98; for ABORTION, SPONTANEOUS see ABORTION 1992-98 D000022 Abortion, Spontaneous Q000662 veterinary D000034 Abortion, Veterinary D000019 Abortifacient Agents D037881 Aborted Fetus C13.703.039 NLM hjn sjn M0000024 Abortion, Spontaneous C0000786 Expulsion of the products of conception before the completion of gestation without deliberate interference. T047 Disease or Syndrome M0000024 M0000025 T000053 Abortion, Spontaneous 1999 01 01 POPLINE (1978) T000053 Abortions, Spontaneous T000053 Spontaneous Abortions T000054 Miscarriage 1974 03 29 UNK (19XX) T000054 Miscarriages T484312 Spontaneous Abortion 2002 03 04 NLM (2003) M0000025 Abortion, Tubal C0000822 T047 Disease or Syndrome M0000024 M0000025 T000055 Abortion, Tubal 1978 12 18 POPLINE (1978) T000055 Abortions, Tubal T000055 Tubal Abortion T000055 Tubal Abortions D000023 Abortion Applicants 1974 11 19 1992 03 25 1976 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000193 education ED Q000266 history HI Q000331 legislation & jurisprudence LJ Q000523 psychology PX Q000706 statistics & numerical data SN don't forget also check tags HUMAN & FEMALE & PREGNANCY 76(75); was see under ABORTION 1975 76; was see under ABORTION 1975 Abortion, Induced (1970-1974) Abortion, Therapeutic (1966-1974) M01.050 NLM PLS PLS M0000026 Abortion Applicants C0000788 Individuals requesting induced abortions. T101 Patient or Disabled Group M0000026 M0000027 M0000026 M0000028 T000056 Abortion Applicants 1999 01 01 NLM (1975) T000056 Abortion Applicant T000056 Applicant, Abortion T000056 Applicants, Abortion T000057 Abortion Seekers 1974 11 11 POPLINE (1978) T000057 Abortion Seeker T000057 Seeker, Abortion T000057 Seekers, Abortion M0000027 Abortion Seekers, Refused C0000796 T101 Patient or Disabled Group M0000026 M0000027 T000058 Abortion Seekers, Refused 1978 12 18 POPLINE (1978) T000058 Abortion Seeker, Refused T000058 Refused Abortion Seeker T000058 Refused Abortion Seekers T000058 Seeker, Refused Abortion T000058 Seekers, Refused Abortion M0000028 Abortion Seekers, Repeated C0000797 T101 Patient or Disabled Group M0000026 M0000028 T000059 Abortion Seekers, Repeated 1978 12 18 POPLINE (1978) T000059 Abortion Seeker, Repeated T000059 Repeated Abortion Seeker T000059 Repeated Abortion Seekers T000059 Seeker, Repeated Abortion T000059 Seekers, Repeated Abortion D000024 Abortion, Criminal 1999 01 01 2002 07 02 2003 2004 Q000145 classification CL Q000191 economics EC Q000208 ethnology EH Q000266 history HI Q000331 legislation & jurisprudence LJ Q000517 prevention & control PC Q000523 psychology PX Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES Q000009 adverse effects AE Q000401 mortality MO don't forget also check tags HUMAN & FEMALE & PREGNANCY; for abortifacients in crim abort see note on ABORTION, INDUCED I01.198.240.089 NLM lkt sjn M0000029 Abortion, Criminal C0000804 Illegal termination of pregnancy. T033 Finding T000060 Abortion, Criminal 1999 01 01 NLM (1966) T000060 Abortions, Criminal T000060 Criminal Abortion T000060 Criminal Abortions T000062 Abortion, Illegal 1977 03 17 POPLINE (1978) T000061 Illegal Abortion 1977 03 17 BIOETHICS (1989) T000061 Abortions, Illegal T000061 Illegal Abortions D000025 Abortion, Eugenic 1974 11 19 2003 07 30 1991 01 01 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES do not use /util except by MeSH definition; don't forget also check tags HUMAN or ANIMALS & FEMALE & PREGNANCY 91(75); was see under ABORTION, INDUCED 1975-90 91; was see under ABORTION, INDUCED 1975-90 E04.520.050.050 NLM ags sjn M0000030 Abortion, Eugenic C0000806 Abortion performed because of possible fetal defects. T061 Therapeutic or Preventive Procedure M0000030 M0000031 T000064 Abortion, Eugenic 1999 01 01 NLM (1975) T000063 Eugenic Abortion 1974 11 11 UNK (19XX) T000063 Abortions, Eugenic T000063 Eugenic Abortions M0000031 Abortion, Selective C0086966 T061 Therapeutic or Preventive Procedure M0000030 M0000031 T000065 Abortion, Selective 1995 03 22 POPLINE (1994) T000065 Abortions, Selective T000065 Selective Abortions T000066 Selective Abortion 1977 03 17 BIOETHICS (1974) D000026 Abortion, Habitual 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C13.703.039.089 NLM lkt sjn M0000032 Abortion, Habitual C0000809 Three or more consecutive spontaneous abortions. T047 Disease or Syndrome T000067 Abortion, Habitual 1999 01 01 POPLINE (1978) T000067 Abortions, Habitual T000067 Habitual Abortion T000067 Habitual Abortions T000068 Abortion, Recurrent 1996 07 25 NLM (1998) T000068 Abortions, Recurrent T000068 Recurrent Abortion T000068 Recurrent Abortions T000069 Miscarriage, Recurrent 1997 10 08 NLM (1999) T000069 Miscarriages, Recurrent T000069 Recurrent Miscarriage T000069 Recurrent Miscarriages D000027 Abortion, Incomplete 1974 11 11 1999 11 03 1975 09 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI not all conception products are expelled; restrict to spontaneous, not induced abortions; don't forget also check tags FEMALE & PREGNANCY 75 75 Abortion, Spontaneous (1966-1974) C13.703.039.093 NLM ndw sjn M0000033 Abortion, Incomplete C0000810 Abortion in which not all the products of conception have been expelled. T047 Disease or Syndrome T000070 Abortion, Incomplete 1999 01 01 NLM (1975) T000070 Abortions, Incomplete T000070 Incomplete Abortion T000070 Incomplete Abortions D000028 Abortion, Induced 1999 01 01 2002 07 02 1971 01 01 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES do not use /util except by MeSH definition; for use of an abortifacient here or in ABORTION, CRIMINAL, coord IM with abortifacient agent (IM with no qualif, not /adv eff unless text specifically discusses adverse eff); don't forget also check tags FEMALE & PREGNANCY 71; was see under ABORTION, CRIMINAL & ABORTION, THERAPEUTIC 1963-70, was see under ABORTION, LEGAL 1964-70; EMBRYOTOMY was heading 1963-85 use ABORTION, INDUCED to search EMBRYOTOMY 1966-85; search ABORTION, CRIMINAL & ABORTION, LEGAL & ABORTION, THERAPEUTIC 1966-70 71; was see under ABORTION, CRIMINAL & ABORTION, THERAPEUTIC 1963-70, was see under ABORTION, LEGAL 1964-70; EMBRYOTOMY was heading 1963-85 Abortion, Criminal (1966-1970) Abortion, Legal (1966-1970) Abortion, Therapeutic (1966-1970) D037881 Aborted Fetus E04.520.050 NLM hjn sjn M0000037 Abortion, Induced C0392535 Intentional removal of a fetus from the uterus by any of a number of techniques. (POPLINE, 1978) T061 Therapeutic or Preventive Procedure M0000037 M0000045 M0000037 M0000035 M0000037 M0000043 M0000037 M0000036 M0000037 M0000038 M0000037 M0000039 M0000037 M0000044 M0000037 M0000040 M0000037 M0000041 M0000037 M0000042 M0000037 M0000034 T000076 Abortion, Induced 1999 01 01 ABORTION IND BIOETHICS (1999) POPLINE (1978) T373837 Abortion (Induced) 1999 11 09 NLM (2000) T373837 Abortions (Induced) T000075 Induced Abortion 1981 08 26 IND ABORTION UNK (19XX) T000075 Abortions, Induced T000075 Induced Abortions M0000045 Abortion Failure C0282034 T046 Pathologic Function T068 Human-caused Phenomenon or Process M0000037 M0000045 T000085 Abortion Failure 1995 03 22 POPLINE (1994) T000085 Abortion Failures T000085 Failure, Abortion T000085 Failures, Abortion M0000035 Abortion Rate C0000794 T081 Quantitative Concept M0000037 M0000035 T000073 Abortion Rate 1978 12 18 POPLINE (1978) T000073 Abortion Rates T000073 Rate, Abortion T000073 Rates, Abortion M0000043 Abortion Techniques C0078884 T061 Therapeutic or Preventive Procedure M0000037 M0000043 T000083 Abortion Techniques 1990 01 10 NLM (1991) T000083 Abortion Technique T000083 Technique, Abortion T000083 Techniques, Abortion T000082 Abortion Technics 1978 12 18 NLM (1979) T000082 Abortion Technic T000082 Technic, Abortion T000082 Technics, Abortion M0000036 Abortion, Drug-Induced C0000805 T061 Therapeutic or Preventive Procedure M0000037 M0000036 T000074 Abortion, Drug-Induced 1978 12 18 ABORTION DRUG IND POPLINE (1978) T000074 Abortion, Drug Induced T000074 Abortions, Drug-Induced T000074 Drug-Induced Abortion T000074 Drug-Induced Abortions M0000038 Abortion, Rivanol C0000815 T061 Therapeutic or Preventive Procedure M0000037 M0000038 T000077 Abortion, Rivanol 1979 09 27 POPLINE (1978) T000077 Abortions, Rivanol T000077 Rivanol Abortion T000077 Rivanol Abortions M0000039 Abortion, Saline-Solution C0000816 T061 Therapeutic or Preventive Procedure M0000037 M0000039 T000078 Abortion, Saline-Solution 1978 12 18 ABORTION SALINE SOL POPLINE (1978) T000078 Abortion, Saline Solution T000078 Abortions, Saline-Solution T000078 Saline-Solution Abortion T000078 Saline-Solution Abortions M0000044 Abortion, Soap-Solution C0162303 T061 Therapeutic or Preventive Procedure M0000037 M0000044 T000084 Abortion, Soap-Solution 1978 12 18 ABORTION SOAP SOL POPLINE (1978) T000084 Abortion, Soap Solution T000084 Abortions, Soap-Solution T000084 Soap-Solution Abortion T000084 Soap-Solution Abortions M0000040 Anti-Abortion Groups C0003193 T093 Health Care Related Organization M0000037 M0000040 T000079 Anti-Abortion Groups 1985 08 08 POPLINE (1986) T000079 Anti Abortion Groups T000079 Anti-Abortion Group T000079 Group, Anti-Abortion T000079 Groups, Anti-Abortion M0000041 Embryotomy C0013951 T061 Therapeutic or Preventive Procedure M0000037 M0000041 T000080 Embryotomy 1985 06 06 UNK (19XX) T000080 Embryotomies M0000042 Fertility Control, Postconception C0032748 T061 Therapeutic or Preventive Procedure M0000037 M0000042 T000081 Fertility Control, Postconception 1978 12 18 POPLINE (1978) T000081 Postconception Fertility Control M0000034 Previous Abortion C0000790 T184 Sign or Symptom M0000037 M0000034 T000072 Previous Abortion 1978 12 18 POPLINE (1978) T000072 Abortion, Previous T000072 Abortions, Previous T000072 Previous Abortions T000071 Abortion History 1978 12 18 ABORTION HIST POPLINE (1978) T000071 Abortion Histories T000071 Histories, Abortion T000071 History, Abortion D000029 Abortion, Legal 1999 01 01 1999 11 03 1964 01 01 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES /adv eff permitted; do not use /util (except by MeSH definition) /vet; don't forget also HUMAN & FEMALE & PREGNANCY 64 64 E04.520.050.055 NLM kle sjn M0000047 Abortion, Legal C0000812 Termination of pregnancy under conditions allowed under local laws. (POPLINE Thesaurus, 1991) T061 Therapeutic or Preventive Procedure M0000047 M0000046 T000087 Abortion, Legal 1999 01 01 POPLINE (1978) T000087 Abortions, Legal T000087 Legal Abortion T000087 Legal Abortions M0000046 Abortion on Demand C0000793 T061 Therapeutic or Preventive Procedure M0000047 M0000046 T000086 Abortion on Demand 1977 03 17 BIOETHICS (1989) D000030 Abortion, Missed 1999 01 01 1993 08 10 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI dead fetus retained 2 or more months; /prev /ther /vet permitted; don't forget also check tags FEMALE & PREGNANCY C13.703.039.173 NLM RAZ PLS M0000048 Abortion, Missed C0000814 The retention in the uterus of a dead fetus two months or more after its death. T047 Disease or Syndrome M0000048 M0000049 T000088 Abortion, Missed 1999 01 01 NLM (1966) T000088 Abortions, Missed T000088 Missed Abortion T000088 Missed Abortions M0000049 Products of Conception, Retention C0033270 T047 Disease or Syndrome M0000048 M0000049 T000089 Products of Conception, Retention 1978 12 27 POPLINE (1978) D000031 Abortion, Septic 1999 01 01 1993 06 02 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI infected abortion; /prev /ther permitted; /vet permitted only if discussed as "septic" abortion: do not use automatically for animal abortion in brucellosis, vibriosis, trichomoniasis, etc. in animals; don't forget also check tags FEMALE & PREGNANCY C01.539.674.173 C13.703.039.256 C13.703.700.173 NLM TAP PLS M0000050 Abortion, Septic C0000817 Infected abortion in which there is dissemination of microorganisms and their products into the maternal systemic circulation. T047 Disease or Syndrome T000090 Abortion, Septic 1999 01 01 POPLINE (1978) T000090 Abortions, Septic T000090 Septic Abortion T000090 Septic Abortions D000032 Abortion, Therapeutic 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES do not use /util except by MeSH definition; don't forget also check tags FEMALE & PREGNANCY E04.520.050.060 NLM PXP SJN M0000051 Abortion, Therapeutic C0000820 Abortion induced to save the life or health of a pregnant woman. (From Dorland, 28th ed) T061 Therapeutic or Preventive Procedure T000092 Abortion, Therapeutic 1999 01 01 ABORTION THER POPLINE (1978) T000091 Therapeutic Abortion 1977 03 17 THER ABORTION BIOETHICS (1974) T000091 Abortions, Therapeutic T000091 Therapeutic Abortions D000033 Abortion, Threatened 1999 01 01 1993 06 02 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI pain & bleeding in early pregn heralding abortion; /prev /ther /vet permitted; don't forget check tags FEMALE & PREGNANCY C13.703.039.339 NLM TAP PLS M0000052 Abortion, Threatened C0000821 Condition of vaginal bleeding with or without pain in early pregnancy which may presage an abortion. T047 Disease or Syndrome T000093 Abortion, Threatened 1999 01 01 NLM (1966) T000093 Abortions, Threatened T000093 Threatened Abortion T000093 Threatened Abortions D000034 Abortion, Veterinary 1999 01 01 2003 07 30 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI IM + specific type of abortion with /vet (NIM); don't forget also check tags ANIMALS & FEMALE & PREGNANCY C13.703.039.422 C22.021 NLM ags sjn M0000053 Abortion, Veterinary C0000823 Premature expulsion of the fetus in animals. T047 Disease or Syndrome T000095 Abortion, Veterinary 1999 01 01 ABORTION VET NLM (1966) T000094 Veterinary Abortion 1986 01 01 VET ABORTION UNK (19XX) T000094 Abortions, Veterinary T000094 Veterinary Abortions D000035 Abreaction 1999 01 01 1997 06 20 1968 01 01 1998 1999 2000 2001 2002 2003 2004 no qualif 68 68 F04.754.720.107 NLM PXP SJN M0000054 Abreaction C0000828 A process in psychotherapy in which the patient is "desensitized" to emotionally painful, often forgotten (repressed) memories by recalling and reacting to them in the "safety" of the treatment setting. T041 Mental Process T000096 Abreaction 1999 01 01 NLM (1968) T000096 Abreactions D000036 Abrin 1974 11 19 2002 07 02 1991 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under PLANT PROTEINS 1975-90 91; was see under PLANT PROTEINS 1975-90 Disulfides (1973-1974) Plant Proteins (1971-1975) D12.776.503.499.249 D12.776.765.678.249 D24.611.093.377.207 NLM KEV sjn M0000055 Abrin C0000829 Abrins 1393-62-0 A toxic lectin from the seeds of jequirity, Abrus precatorius L. Very active poison. Five different proteins have so far been isolated: Abrus agglutinin, the component responsible for hemagglutininating activity, & abrins a-d, the toxic principles each consisting of two peptide chains are held together by disulfide bonds. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000055 M0000056 M0000055 M0000057 T000097 Abrin 1999 01 01 NLM (1975) M0000056 Abrin A C0000830 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000055 M0000056 T000098 Abrin A 1981 06 08 UNK (19XX) M0000057 Abrin C C0000831 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000055 M0000057 T000099 Abrin C 1981 06 08 UNK (19XX) D000037 Abruptio Placentae 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI premature separation of placenta; do not use /congen & do not coord with INFANT, NEWBORN, DISEASES C13.703.420.078 C13.703.590.132 NLM kle sjn M0000058 Abruptio Placentae C0000832 Premature separation of the normally implanted placenta. T047 Disease or Syndrome T000100 Abruptio Placentae 1999 01 01 NLM (1966) D000038 Abscess 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI IM; coord IM with site (organ/dis term) (IM) + precoord organism/infect term (IM); if unspecified bacterial abscess do not coord with BACTERIAL INFECTIONS (since most abscesses are bact) but coord with specific bact infect term if given (as ABSCESS + STAPH INFECTIONS) D004653 Empyema C01.539.830.025 C23.550.470.756.100 NLM KEV sjn M0000059 Abscess C0000833 Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. T046 Pathologic Function T000101 Abscess 1999 01 01 NLM (1966) T000101 Abscesses D000039 Peritonsillar Abscess 1999 01 01 1994 05 27 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI for coord read note on ABSCESS 89; was ABSCESS, PERITONSILLAR 1963-88 use PERITONSILLAR ABSCESS to search ABSCESS, PERITONSILLAR 1966-88 89; was ABSCESS, PERITONSILLAR 1963-88 C01.539.830.025.675 C07.550.700 C08.730.817.700 C09.775.500 NLM PLS PLS M0000060 Peritonsillar Abscess C0031157 An abscess in the peritonsillar tissue extending into the tonsil capsule, resulting from suppuration of the tonsil. (Dorland, 27th ed) T047 Disease or Syndrome T000103 Peritonsillar Abscess 1999 01 01 NLM (1966) T000102 Abscess, Peritonsillar 1988 05 23 UNK (19XX) T000102 Abscesses, Peritonsillar T000102 Peritonsillar Abscesses D000040 Abscisic Acid 1974 11 19 2002 07 02 1991 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 93(75) 93; see ABSCISSINS 1991-92, see CYCLOHEXANECARBOXYLIC ACID 1975-90 Cyclohexanecarboxylic Acids (1974) D02.241.223.268.034 D02.455.849.765.033 D11.303.760.030 NLM CCR sjn M0000061 Abscisic Acid C0000843 2,4-Pentadienoic acid, 5-(1-hydroxy-2,6,6-trimethyl-4-oxo-2-cyclohexen-1-yl)-3-methyl-, (S-(Z,E))- 21293-29-8 Abscission-accelerating plant growth substance isolated from young cotton fruit, leaves of sycamore, birch, and other plants, and from potatoes, lemons, avocados, and other fruits. T109 Organic Chemical T123 Biologically Active Substance D010937 Plant Growth Regulators 113349-29-4 ((Z,E)-isomer) 14375-45-2 ((+-)-isomer) 14398-53-9 ((R)-isomer) 14674-85-2 ((E,Z)-(+-)-isomer) 2228-72-0 ((E,E)-(+-)-isomer) 41621-76-5 ((R)-isomer, monoammonium salt) 52392-36-6 ((E,E)-isomer) 6755-41-5 ((E,E)-isomer) 7773-56-0 (cpd w/o isomeric designation) M0000061 M0330680 M0000061 M0330738 M0000061 M0330679 M0000061 M0330678 M0000061 M0330677 M0000061 M0330737 T000104 Abscisic Acid 1999 01 01 NLM (1975) T000106 Abscissic Acid 1992 03 25 NLM (1993) T000105 Abscissins 1992 04 15 NLM (1993) M0330680 Abscisic Acid Monoammonium Salt, (R)-Isomer C0887514 41621-76-5 T109 Organic Chemical T121 Pharmacologic Substance M0000061 M0330680 T360874 Abscisic Acid Monoammonium Salt, (R)-Isomer 1999 09 13 NLM (1999) M0330738 Abscisic Acid, (+,-)-Isomer C0887539 14375-45-2 T109 Organic Chemical T123 Biologically Active Substance M0000061 M0330738 T360932 Abscisic Acid, (+,-)-Isomer 1999 09 13 NLM (1999) M0330679 Abscisic Acid, (E,E)-(+-)-Isomer C0887513 2228-72-0 T109 Organic Chemical T123 Biologically Active Substance M0000061 M0330679 T360873 Abscisic Acid, (E,E)-(+-)-Isomer 1999 09 13 NLM (1999) M0330678 Abscisic Acid, (E,Z)-(+,-)-Isomer C0887512 14674-85-2 T109 Organic Chemical T121 Pharmacologic Substance M0000061 M0330678 T360872 Abscisic Acid, (E,Z)-(+,-)-Isomer 1999 09 13 NLM (1999) M0330677 Abscisic Acid, (R)-Isomer C0887511 14398-53-9 T109 Organic Chemical T121 Pharmacologic Substance M0000061 M0330677 T360871 Abscisic Acid, (R)-Isomer 1999 09 13 NLM (1999) M0330737 Abscisic Acid, (Z,E)-Isomer C0917770 113349-29-4 T109 Organic Chemical T121 Pharmacologic Substance M0000061 M0330737 T360931 Abscisic Acid, (Z,E)-Isomer 1999 09 13 NLM (1999) D000041 Absenteeism 1999 01 01 1994 05 27 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 IM; no qualif was in Cat F & J 1967-82, was in Cat F & I 1963-66 F02.784.692.107 NLM JLS PLS M0000062 Absenteeism C0000849 Chronic absence from work or other duty. T055 Individual Behavior T000107 Absenteeism 1999 01 01 NLM (1966) D000042 Absorption 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES almost never IM; coord NIM with substance /pharmacokin (IM) or organ /metab (IM) when absorptive process, degree or rate in article; TN 1: relation to metab & importance in pharmacol G06.535.023 H01.181.529.023 NLM PXP SJN M0000063 Absorption C0000854 The taking in or incorporation of gaseous or liquid substances, light, or heat. It includes the metabolic absorption of exogenous nutrients, chemicals, and drugs into microorganisms, tissues, and organs. T070 Natural Phenomenon or Process T000108 Absorption 1999 01 01 NLM (1966) T000108 Absorptions D000043 Abstracting and Indexing 1999 01 01 2002 07 02 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000379 methods MT IM; med abstracting & indexing: do not coord with MEDICINE; do not confuse with Publication Type ABSTRACTS OR MEETING ABSTRACTS 66; INDEXES see REFERENCE BOOKS 1996-98; INDEX see REFERENCE BOOKS 1984-98 66; INDEXES see REFERENCE BOOKS 1996-98 L01.453.245.100 NLM nns sjn M0000065 Abstracting and Indexing C0000858 Shortening or summarizing of documents; assigning of descriptors for referencing documents. T057 Occupational Activity M0000065 M0000066 M0000065 M0000064 M0000065 M0372380 T000111 Abstracting and Indexing 1999 01 01 ABSTRACTING INDEXING NLM (1966) T000110 Indexing and Abstracting 1979 03 29 INDEXING ABSTRACTING UNK (19XX) M0000066 Index C0918012 T170 Intellectual Product M0000065 M0000066 T000113 Index 1998 05 27 NLM (1999) POPLINE (1984) T000113 Indices T000112 Indexes 1998 05 27 NLM (1999) M0000064 Abstracting C0000857 T057 Occupational Activity M0000065 M0000064 T000109 Abstracting 1979 03 29 UNK (19XX) M0372380 Indexing C0021200 T057 Occupational Activity M0000065 M0372380 T000114 Indexing 1974 03 29 UNK (19XX) D000044 Dental Abutments 1999 01 01 1997 06 20 1970 01 01 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000382 microbiology MI Q000469 parasitology PS Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000821 virology VI Q000941 ethics ES Q000523 psychology PX tooth or root used as anchor for denture or implant, etc.; DF: DENT ABUTMENTS 91; was ABUTMENTS, DENTAL 1970-90 use DENTAL ABUTMENTS to search ABUTMENTS, DENTAL 1970-90 91; was ABUTMENTS, DENTAL 1970-90 Dental Cavity Preparation (1966-1969) Denture, Partial (1966-1969) E06.780.345.500 E07.695.190.175 NLM PXP SJN M0000067 Dental Abutments C0000866 Natural teeth or teeth roots used as anchorage for a fixed or removable denture or other prosthesis (such as an implant) serving the same purpose. T023 Body Part, Organ, or Organ Component T074 Medical Device T000118 Dental Abutments 1999 01 01 DENT ABUTMENTS NLM (1970) T000115 Abutment, Dental 1990 01 25 ABUTMENT DENT NLM (1991) T000116 Dental Abutment 1990 04 09 DENT ABUTMENT NLM (1991) T000117 Abutments, Dental 1990 04 09 ABUTMENTS DENT NLM (1991) D000045 Acacia 1999 01 01 2002 07 02 1991 01 01 2003 2004 Q000009 adverse effects AE Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000633 toxicity TO Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI acacia pharmaceut agents are probably GUM ARABIC; coord with specific PLANT COMPONENTS term if pertinent; for use in therapy coord IM with PHYTOTHERAPY (IM) + disease/drug ther (IM) + PLANT PREPARATIONS or its indentations/ther use (IM or NIM) + specific plant chemical /ther use (IM) if pertinent; Manual 26.29 91(86)63; was see under TREES 1986-90; was heading 1963-85 91,63-85; was see under TREES 1986-90; was heading 1963-85 B06.388.100.401.025 NLM ssb sjn M0000068 Acacia C0000869 A plant genus of the family FABACEAE. The gums and tanning agents obtained from Acacia are called GUM ARABIC. The common name of catechu is more often used for Areca catechu (ARECA). T002 Plant M0000068 M0397059 T000119 Acacia 1999 01 01 NLM (1986) T000120 Locust Tree 1985 05 14 UNK (19XX) T000121 Wattle Tree 1985 05 14 UNK (19XX) M0397059 Acacia catechu T002 Plant M0000068 M0397059 T459714 Acacia catechu 2001 08 30 NLM (2003) D000046 Academic Medical Centers 1979 06 01 1999 11 03 1980 01 01 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES specify geog; DF: ACAD MED CENTERS 80; was see HOSPITALS, UNIVERSITY 1979 search HOSPITALS, UNIVERSITY 1979 80; was see HOSPITALS, UNIVERSITY 1979 Hospitals, Teaching (1968-1974) Hospitals, University (1975-1979) N02.278.020 EC kle sjn M0000069 Academic Medical Centers C0000872 Medical complexes consisting of medical school, hospitals, clinics, libraries, administrative facilities, etc. T073 Manufactured Object T093 Health Care Related Organization T000127 Academic Medical Centers 1999 01 01 ACAD MED CENTERS NLM (1980) T000128 Center, University Medical 1989 11 29 CENTER UNIV MED NLM (1991) T000124 Centers, Academic Medical 1989 11 29 CENTERS ACAD MED NLM (1991) T000129 Centers, University Medical 1989 11 29 CENTERS UNIV MED NLM (1991) T000125 Medical Center, Academic 1989 11 29 MED CENTER ACAD NLM (1991) T000130 Medical Center, University 1989 11 29 MED CENTER UNIV NLM (1991) T000123 Center, Academic Medical 1989 11 29 CENTER ACAD MED NLM (1991) T000122 Academic Medical Center 1989 11 29 ACAD MED CENTER NLM (1991) T000126 Medical Centers, Academic 1979 06 15 MED CENTERS ACAD UNK (19XX) T000132 Medical Centers, University 1979 06 15 MED CENTERS UNIV UNK (19XX) T000131 University Medical Center 1989 11 29 UNIV MED CENTER NLM (1991) T000133 University Medical Centers 1979 06 01 UNIV MED CENTERS UNK (19XX) D000047 Academies and Institutes 1999 01 01 1999 11 03 1970 01 01 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES not for educ acad & institutes ( = SCHOOLS or its indentions); Acad of Med: do not index also under MEDICINE; NY Acad of Med: when geog coord needed use NEW YORK CITY; DF: ACADEMIES 70(65) 70 N03.540.052 NLM kle sjn M0000071 Academies and Institutes C0000877 Organizations representing specialized fields which are accepted as authoritative; may be non-governmental, university or an independent research organization, e.g., National Academy of Sciences, Brookings Institution, etc. T092 Organization M0000071 M0000070 M0000071 M0000072 M0000071 M0000073 T000137 Academies and Institutes 1999 01 01 ACADEMIES INSTITUTES NLM (1965) T000135 Academy and Institute 1989 11 30 ACAD INSTITUTE NLM (1991) T000135 Institute and Academy T000136 Institutes and Academies 1979 03 29 INSTITUTES ACAD UNK (19XX) M0000070 Academies C0000876 T092 Organization M0000071 M0000070 T000134 Academies 1979 03 29 ACAD UNK (19XX) T000134 Academy M0000072 Institutes C0021622 T092 Organization M0000071 M0000072 T000138 Institutes 1974 03 29 UNK (19XX) M0000073 Research Institutes C0035172 T092 Organization M0000071 M0000073 T000139 Research Institutes 1977 03 17 BIOETHICS (1974) T000139 Institute, Research T000139 Institutes, Research T000139 Research Institute D000048 Acanthamoeba 1987 04 30 2003 07 09 1988 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI infection: coord IM with AMEBIASIS (IM); for antigens, coord with ANTIGENS, PROTOZOAN, for antibodies, coord with ANTIBODIES, PROTOZOAN 88 88 Amoeba (1966-1987) B01.500.841.750.656.475.100.075.080 EC ags sjn M0000074 Acanthamoeba C0000879 A genus of free-living soil amoebae that produces no flagellate stage. Its organisms are pathogens for several infections in humans and have been found in the eye, bone, brain, and respiratory tract. T009 Invertebrate T000140 Acanthamoeba 1999 01 01 NLM (1988) D000049 Acanthocephala 1999 01 01 2003 07 09 1974 01 01 2004 Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI infection: coord IM with HELMINTHIASIS (IM); for antigens, coord with ANTIGENS, HELMINTH, for antibodies, coord with ANTIBODIES, HELMINTH 74; was see under HELMINTHS 1963-73 search HELMINTHS 1966-73 74; was see under HELMINTHS 1963-73 B01.500.500.132 NLM ags sjn M0000075 Acanthocephala C0000881 A phylum of parasitic worms, closely related to tapeworms and containing two genera: Moniliformis, which sometimes infects man, and Macracanthorhynchus, which infects swine. T009 Invertebrate T000141 Acanthocephala 1999 01 01 NLM (1974) T000142 Thorny-Headed Worms 1975 01 01 UNK (19XX) D000050 Acanthocytes 1974 11 11 2003 07 09 1991 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI A 11 qualif 91(75); was see under ERYTHROCYTES, ABNORMAL 1975-90 91; was see under ERYTHROCYTES, ABNORMAL 1975-90 A11.118.290.330.100 A11.443.240.330.100 A15.145.229.334.330.100 NLM nns sjn M0000076 Acanthocytes C0000886 Erythrocytes with protoplasmic projections giving the cell a thorny appearance. T025 Cell T000143 Acanthocytes 1999 01 01 NLM (1975) T000143 Acanthocyte D000051 Acantholysis 1999 01 01 1999 11 03 1991 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI ACANTHOLYSIS BULLOSA see EPIDERMOLYSIS BULLOSA is also available 91(69); was see under SKIN DISEASES 1969-90 91; was see under SKIN DISEASES 1969-90 Skin/pathology (1966-1968) specific skin disease/pathology (1966-1968) C17.800.865.070 C23.550.035 NLM KEV sjn M0000077 Acantholysis C0000887 Separation of the prickle cells of the stratum spinosum of the epidermis, resulting in atrophy of the prickle cell layer. It is seen in diseases such as pemphigus vulgaris (see PEMPHIGUS) and KERATOSIS FOLLICULARIS. T046 Pathologic Function T000144 Acantholysis 1999 01 01 NLM (1969) T000144 Acantholyses D000052 Acanthosis Nigricans 1999 01 01 1993 06 02 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI a type of melanosis C17.800.621.430.530.100 NLM TAP PLS M0000078 Acanthosis Nigricans C0000889 A circumscribed melanosis consisting of a brown-pigmented, velvety verrucosity or fine papillomatosis appearing in the axillae and other body folds. It occurs in association with endocrine disorders, underlying malignancy, administration of certain drugs, or as in inherited disorder. T047 Disease or Syndrome T000145 Acanthosis Nigricans 1999 01 01 NLM (1966) D000053 Acari 1999 01 01 2003 07 09 1975 01 01 2004 Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI acaricides: index under INSECTICIDES even though Acari are not insects 75 75 Arachnida (1966-1974) B01.500.131.166.132 NLM ags sjn M0000079 Acari C0000890 A large, subclass of arachnids comprising the MITES and TICKS, including parasites of plants, animals, and humans, as well as several important disease vectors. T009 Invertebrate T000146 Acari 1999 01 01 NLM (1975) D000054 Acceleration 1999 01 01 1992 03 25 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE IM H01.671.538.107 NLM TAP PLS M0000080 Acceleration C0000894 T067 Phenomenon or Process T000147 Acceleration 1999 01 01 NLM (1966) T000147 Accelerations D000055 Accessory Nerve 1999 01 01 2001 07 25 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI neopl = ACCESSORY NERVE DISEASES (IM) + CRANIAL NERVE NEOPLASMS (IM) + histol type of neopl (IM) A08.800.800.120.060 NLM ags sjn M0000081 Accessory Nerve C0000905 The 11th cranial nerve. The accessory nerve originates from neurons in the medulla and in the cervical spinal cord. It has a cranial root, which joins the vagus (10th cranial) nerve and sends motor fibers to the muscles of the larynx, and a spinal root, which sends motor fibers to the trapezius and the sternocleidomastoid muscles. Damage to the nerve produces weakness in head rotation and shoulder elevation. T023 Body Part, Organ, or Organ Component T000148 Accessory Nerve 1999 01 01 NLM (1966) T000148 Accessory Nerves T000148 Nerve, Accessory T000148 Nerves, Accessory T000150 Cranial Nerve XI 1996 07 31 NLM (1998) T000149 Eleventh Cranial Nerve 1996 07 31 NLM (1998) T000149 Cranial Nerve, Eleventh T000149 Cranial Nerves, Eleventh T000149 Eleventh Cranial Nerves T000149 Nerve, Eleventh Cranial T000149 Nerves, Eleventh Cranial T000151 Spinal Accessory Nerve 1974 03 29 UNK (19XX) T000151 Accessory Nerve, Spinal T000151 Accessory Nerves, Spinal T000151 Nerve, Spinal Accessory T000151 Nerves, Spinal Accessory T000151 Spinal Accessory Nerves D000056 Accident Prevention 1999 01 01 1991 05 22 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif D011482 Protective Devices G03.850.110.060 NLM TGC PLS M0000083 Accident Prevention C0000918 T061 Therapeutic or Preventive Procedure T078 Idea or Concept T000153 Accident Prevention 1999 01 01 ACCIDENT PREV NLM (1966) T000152 Prevention, Accident 1986 01 01 PREV ACCIDENT UNK (19XX) T000152 Accident Preventions T000152 Preventions, Accident D000057 Accident Proneness 1974 11 11 2002 07 02 1975 09 01 2003 2004 no qualif 75 75 Accidents (1966-1974) F01.145.015 NLM TGC sjn M0000084 Accident Proneness C0000919 Tendency toward involvement in accidents. Implies certain personality characteristics which predispose to accidents. T055 Individual Behavior T000154 Accident Proneness 1999 01 01 NLM (1975) T000154 Accident Pronenesses T000154 Proneness, Accident T000154 Pronenesses, Accident D000058 Accidental Falls 1986 06 24 2003 07 09 1991 01 01 2004 Q000191 economics EC Q000401 mortality MO Q000517 prevention & control PC Q000706 statistics & numerical data SN coord IM with specific inj (IM) if pertinent 91(87); was see under ACCIDENTS 1987-90 91; was see under ACCIDENTS 1987-90 Accidents (1966-1986) G03.850.110.085 SH lkt sjn M0000085 Accidental Falls C0000921 Falls due to slipping or tripping which result in injury. T037 Injury or Poisoning T000156 Accidental Falls 1999 01 01 NLM (1987) T000155 Falls, Accidental 1986 06 24 UNK (19XX) T000155 Accidental Fall T000155 Fall, Accidental D000059 Accidents 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD GEN or unspecified; prefer specifics D000059 Accidents Q000517 prevention & control D000056 Accident Prevention G03.850.110 NLM kle sjn M0000086 Accidents C0000924 T037 Injury or Poisoning T000157 Accidents 1999 01 01 POPLINE (1986) T000157 Accident D000060 Accidents, Aviation 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD IM; coord with specific inj (IM) G03.850.110.185 NLM kle sjn M0000087 Accidents, Aviation C0000928 T037 Injury or Poisoning T068 Human-caused Phenomenon or Process T000158 Accidents, Aviation 1999 01 01 NLM (1966) T000158 Accident, Aviation T000158 Aviation Accident T000158 Aviation Accidents D000061 Accidents, Home 1999 01 01 1999 11 03 1970 01 01 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD IM; coord with specific inj (IM) 70(69) 70 Accidents (1966-1968) G03.850.110.205 NLM kle sjn M0000088 Accidents, Home C0000929 T067 Phenomenon or Process T000160 Accidents, Home 1999 01 01 NLM (1969) T000159 Home Accidents 1974 03 29 UNK (19XX) T000159 Accident, Home T000159 Home Accident D000062 Accidents, Occupational 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD IM; coord with specific occupation (IM); DF: ACCIDENTS OCCUP 79; was in Cat G & J 1979-82, was ACCIDENTS, INDUSTRIAL in Cat G & J 1967-78 & Cat G & I 1963-66 use ACCIDENTS, OCCUPATIONAL to search ACCIDENTS, INDUSTRIAL 1966-78 79; was ACCIDENTS, INDUSTRIAL 1963-78 G03.850.110.250 NLM kle sjn M0000090 Accidents, Occupational C0000931 Unforeseen occurrences, especially of an injurious character due to factors involving one's employment. (From Dorland, 28th ed, p10) T067 Phenomenon or Process M0000090 M0000089 T000164 Accidents, Occupational 1999 01 01 ACCIDENTS OCCUP NLM (1966) T000163 Occupational Accidents 1995 03 08 OCCUP ACCIDENTS NLM (1996) T000163 Accident, Occupational T000163 Occupational Accident M0000089 Accidents, Industrial C0000930 T067 Phenomenon or Process M0000090 M0000089 T000162 Accidents, Industrial 1978 05 08 ACCIDENTS INDUST UNK (19XX) T000161 Industrial Accidents 1995 03 15 INDUST ACCIDENTS NLM (1996) T000161 Accident, Industrial T000161 Industrial Accident D000063 Accidents, Traffic 1999 01 01 2001 07 25 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000331 legislation & jurisprudence LJ Q000401 mortality MO Q000517 prevention & control PC Q000523 psychology PX Q000706 statistics & numerical data SN Q000639 trends TD implies automobile accid so do not coord with AUTOMOBILES unless the auto is especially discussed; coord IM with BICYCLING (IM) or MOTORCYCLES (IM) if pertinent; not for railroad accidents ( = RAILROADS + ACCIDENTS) or all-terrain vehicles, motorbikes or snowmobiles ( = OFF-ROAD MOTOR VEHICLES + ACCIDENTS) D012622 Seat Belts D017278 Air Bags G03.850.110.320 NLM mdb sjn M0000091 Accidents, Traffic C0000932 Accidents on streets, roads, and highways involving drivers, passengers, pedestrians, or vehicles. Traffic accidents refer to AUTOMOBILES (passenger cars, buses, and trucks), BICYCLING, and MOTORCYCLES but not OFF-ROAD MOTOR VEHICLES; RAILROADS nor snowmobiles. T067 Phenomenon or Process T000166 Accidents, Traffic 1999 01 01 NLM (1966) T000165 Traffic Accidents 1993 05 24 BIOETHICS (1982) T000165 Accident, Traffic T000165 Traffic Accident D000064 Acclimatization 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES includes to climate, altitude, weather but not to gravity ( = ADAPTATION, PHYSIOLOGICAL) G04.185.057.500.133 G07.062.133 NLM lkt sjn M0000092 Acclimatization C0000934 Adaptation to a new environment or to a change in the old. T040 Organism Function T000168 Acclimatization 1999 01 01 NLM (1966) T000167 Acclimation 1994 10 31 NLM (1996) D000065 Accommodation, Ocular 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES adjustment of lens to distance; do not confuse with ADAPTATION, OCULAR, adjustment of eye to light G11.697.716.079 NLM nns sjn M0000093 Accommodation, Ocular C0000936 The dioptric adjustment of the eye (to attain maximal sharpness of retinal imagery for an object of regard) referring to the ability, to the mechanism, or to the process. It is the effecting of refractive changes by changes in the shape of the crystalline lens. Loosely, it refers to ocular adjustments for vision at various distances. (Cline et al., Dictionary of Visual Science, 4th ed) T042 Organ or Tissue Function T000169 Accommodation, Ocular 1999 01 01 NLM (1966) T000169 Accommodations, Ocular T000169 Ocular Accommodation T000169 Ocular Accommodations D000066 Accounting 1999 01 01 1996 06 10 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000379 methods MT IM; coord with SPEC (IM) or specific financial endeavor (IM) N03.219.463.030 NLM TGC PLS M0000094 Accounting C0000938 System of recording financial transactions. T057 Occupational Activity T090 Occupation or Discipline T000170 Accounting 1999 01 01 NLM (1966) T000170 Accountings D000067 Accounts Payable and Receivable 1977 05 05 1990 05 30 1991 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif; DF: ACCOUNTS PAYABLE 91(78); was see under ACCOUNTING 1978-90 91; was see under ACCOUNTING 1978-90 Accounting (1966-1977) N03.219.463.030.080 EC PLS PLS M0000096 Accounts Payable and Receivable C0000940 Short-term debt obligations and assets occurring in the regular course of operational transactions. T081 Quantitative Concept M0000096 M0000095 T000172 Accounts Payable and Receivable 1999 01 01 ACCOUNTS PAYABLE RECEIVABLE NLM (1978) M0000095 Accounts Payable C0000939 T081 Quantitative Concept M0000096 M0000095 T000171 Accounts Payable 1990 03 08 NLM (1991) D000068 Accreditation 1999 01 01 1994 06 03 1966 01 01 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000379 methods MT by the profession; do not confuse with LICENSURE (by the state) 66(64) 66 D002568 Certification D008004 Licensure N03.706.110.070 N05.700.200.100 NLM NLM PLS M0000097 Accreditation C0000941 Certification as complying with a standard set by non-governmental organizations, applied for by institutions, programs, and facilities on a voluntary basis. T064 Governmental or Regulatory Activity T000173 Accreditation 1999 01 01 NLM (1964) T000173 Accreditations D000069 Acculturation 1999 01 01 1991 11 02 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif ASSIMILATION was see under ACCULTURATION 1968-82 use ACCULTURATION to search ASSIMILATION 1968-82 I01.076.201.450.050 I01.880.143.079 NLM PLS PLS M0000098 Acculturation C0000943 Process of cultural change in which one group or members of a group assimilates various cultural patterns from another. T054 Social Behavior M0000098 M0000099 T000174 Acculturation 1999 01 01 POPLINE (1986) T000174 Acculturations M0000099 Assimilation C0085849 T054 Social Behavior M0000098 M0000099 T000175 Assimilation 1982 04 29 UNK (19XX) T000175 Assimilations D000070 Acebutolol 1974 11 19 2000 06 21 1975 09 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 75 75 Anilides (1974) Ethanolamines (1974) Phenyl Ethers (1974) Propylamines (1974) D02.033.100.624.025 D02.033.755.624.025 D02.092.063.624.025 NLM CCR sjn M0000100 Acebutolol C0000946 Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)- 37517-30-9 A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. T109 Organic Chemical T121 Pharmacologic Substance D000319 Adrenergic beta-Antagonists D000889 Anti-Arrhythmia Agents D000959 Antihypertensive Agents 34381-68-5 (HCl) M0000100 M0331293 M0000100 M0000102 M0000100 M0000101 T000176 Acebutolol 1999 01 01 BAN (19XX) INN (19XX) USAN (1973) T000177 Acetobutolol 1983 06 29 UNK (19XX) M0331293 Acebutolol Hydrochloride C0543447 34381-68-5 M0000100 M0331293 T361487 Acebutolol Hydrochloride 1999 09 13 NLM (1999) T361487 Hydrochloride, Acebutolol M0000102 M&B-17803 A C0699750 0 T109 Organic Chemical T121 Pharmacologic Substance M0000100 M0000102 T000179 M&B-17803 A 1980 07 30 UNK (19XX) T000179 M&B 17803 A T000179 M&B17803 A T000180 M & B 17803A 1990 03 08 NLM (1991) M0000101 Sectral C0036543 0 T109 Organic Chemical T121 Pharmacologic Substance M0000100 M0000101 T000178 Sectral 1980 07 30 UNK (19XX) D000072 Acedapsone 1975 07 25 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(76); was see under DAPSONE 1976-90 91; was see under DAPSONE 1976-90 Acetamides (1975) Acetanilides (1972-1974) Dapsone/analogs & derivatives (1975) Sulfones (1972-1974) D02.886.590.263.050 SH CCR sjn M0000103 Acedapsone C0000949 Acetamide, N,N'-(sulfonyldi-4,1-phenylene)bis- 77-46-3 Acetylated sulfone that is slowly metabolized to give long-term, low blood levels of DAPSONE. It has antimicrobial and antimalarial action, but is mainly used as a depot leprostatic agent. T109 Organic Chemical T121 Pharmacologic Substance D000890 Anti-Infective Agents D000962 Antimalarials D007917 Leprostatic Agents M0000103 M0352360 M0000103 M0352359 T000183 Acedapsone 1999 01 01 BAN (19XX) INN (19XX) USAN (1970) T000181 4',4'''-Sulfonylbis(acetanilide) 1980 08 13 UNK (19XX) T000182 4,4'-Diacetyldiaminodiphenylsulfone 1980 08 13 UNK (19XX) T000182 4,4' Diacetyldiaminodiphenylsulfone T000184 Acetyldiphenazonum 1975 07 25 UNK (19XX) T000185 DADDS 1975 07 25 UNK (19XX) T000186 Diacetyldapsone 1975 07 25 UNK (19XX) T000189 Sulfadiamine 1990 01 24 NLM (1991) M0352360 Hansolar C0878207 0 T109 Organic Chemical T121 Pharmacologic Substance M0000103 M0352360 T000187 Hansolar 1990 01 24 NLM (1991) M0352359 Rodilone C0878206 0 T109 Organic Chemical T121 Pharmacologic Substance M0000103 M0352359 T000188 Rodilone 1990 01 24 NLM (1991) D000073 Acenaphthenes 1999 01 01 1993 06 03 1973 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG aromatic hydrocarbons 73(72) 73 Naphthalenes (1966-1971) D04.615.050 NLM PLS PLS M0000104 Acenaphthenes C0000954 0 Tricyclic ethylene-bridged naphthalene derivatives. They are found in petroleum residues and coal tar and used as dye intermediates, in the manufacture of plastics, and in insecticides and fungicides. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid T000190 Acenaphthenes 1999 01 01 NLM (1972) D000074 Acenocoumarol 1999 01 01 2001 07 25 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D03.438.150.446.520.079 NLM ssb sjn M0000105 Acenocoumarol C0000956 2H-1-Benzopyran-2-one, 4-hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)- 152-72-7 A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233) T109 Organic Chemical T121 Pharmacologic Substance D000925 Anticoagulants M0000105 M0372274 M0000105 M0000106 M0000105 M0372275 M0000105 M0372276 M0000105 M0372277 M0000105 M0372278 T000192 Acenocoumarol 1999 01 01 INN (19XX) T000191 Acenocoumarin 1976 12 30 UNK (19XX) T000193 Nicoumalone 1976 12 30 BAN (19XX) M0372274 Sinkumar 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0372274 T000194 Sinkumar 1980 07 31 UNK (19XX) M0000106 Sinthrome C0699933 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0000106 T000199 Sinthrome 1980 08 04 UNK (19XX) M0372275 Sintrom 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0372275 T000195 Sintrom 1983 09 16 UNK (19XX) M0372276 Syncoumar 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0372276 T000196 Syncoumar 1981 10 23 UNK (19XX) M0372277 Syncumar 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0372277 T000197 Syncumar 1981 09 17 UNK (19XX) M0372278 Synthrom 0 T109 Organic Chemical T121 Pharmacologic Substance M0000105 M0372278 T000198 Synthrom 1980 08 04 UNK (19XX) D000075 Acepromazine 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D03.494.741.029 NLM ssb sjn M0000107 Acepromazine C0000959 Ethanone, 1-(10-(3-(dimethylamino)propyl)-10H-phenothiazin-2-yl)- 61-00-7 A phenothiazine that is used in the treatment of PSYCHOSES. T109 Organic Chemical T121 Pharmacologic Substance D014150 Antipsychotic Agents D018492 Dopamine Antagonists 3598-37-6 (maleate) M0000107 M0330684 M0000107 M0431450 M0000107 M0431451 M0000107 M0431452 T000200 Acepromazine 1999 01 01 BAN (19XX) INN (19XX) T000201 Acetazine 1976 12 30 UNK (19XX) T000202 Acetopromazine 1976 12 30 UNK (19XX) T000203 Acetylpromazine 1976 12 30 UNK (19XX) M0330684 Acepromazine Maleate C0000960 3598-37-6 T109 Organic Chemical T121 Pharmacologic Substance M0000107 M0330684 T000204 Acepromazine Maleate 1983 09 09 USAN (1973) T000204 Maleate, Acepromazine M0431450 Calmivet 0 T109 Organic Chemical T121 Pharmacologic Substance M0000107 M0431450 T504829 Calmivet 2002 07 18 FR T504830 Vétoquinol Brand of Acepromazine Maleate 2002 07 18 NLM (2003) M0431451 Plegicil 0 T109 Organic Chemical T121 Pharmacologic Substance M0000107 M0431451 T504831 Plegicil 2002 07 18 ES T504832 Seid Brand of Acepromazine Maleate 2002 07 18 NLM (2003) M0431452 Vetranquil 0 T109 Organic Chemical T121 Pharmacologic Substance M0000107 M0431452 T504833 Vetranquil 2002 07 18 FR T504834 Sanofi Brand of Acepromazine Maleate 2002 07 18 NLM (2003) D000076 Acetabularia 1999 01 01 2003 07 09 1991 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000382 microbiology MI Q000469 parasitology PS a green alga 91(72); was see under ALGAE, GREEN 1972-90 91; was see under ALGAE, GREEN 1972-90 Algae, Green (1970-1971) B02.080.133 NLM ags sjn M0000109 Acetabularia C0000961 A genus of green algae found in the Mediterranean and other warm seas. T003 Alga T000205 Acetabularia 1999 01 01 NLM (1972) T000205 Acetabularias D000077 Acetabulum 1999 01 01 1978 04 20 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI point of union of the 3 pelvic bones; do not confuse with HIP or HIP JOINT or PELVIC BONES; fract = ACETABULUM /inj (IM) + FRACTURES (IM) A02.835.232.611.108 NLM SMH MED M0000110 Acetabulum C0000962 T023 Body Part, Organ, or Organ Component T000206 Acetabulum 1999 01 01 NLM (1966) T000206 Acetabulums D000079 Acetaldehyde 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D02.047.064 NLM TAP PLS M0000111 Acetaldehyde C0000966 Acetaldehyde 75-07-0 A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis. T109 Organic Chemical T000207 Acetaldehyde 1999 01 01 NLM (1966) T000208 Ethanal 1991 02 22 NLM (1992) D000080 Acetals 1999 01 01 1992 05 07 1974 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 74(72) 74 Ethers (1966-1971) D02.355.071 NLM TAP PLS M0000112 Acetals C0000967 0 T109 Organic Chemical T000209 Acetals 1999 01 01 NLM (1972) D000081 Acetamides 1999 01 01 1998 06 10 1973 01 01 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 73(71) 73 Acetic Acids (1966-1970) Amides (1966-1970) D02.065.064 D02.241.081.038.108 NLM ADP SJN M0000113 Acetamides C0000968 0 Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis. T109 Organic Chemical T000210 Acetamides 1999 01 01 NLM (1971) D000082 Acetaminophen 1999 01 01 2002 07 02 1965 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 1965; for ACEPHEN use MECLOFENOXATE 1990-2002 1965; for ACEPHEN see MECLOFENOXATE 1990-2002 D02.065.199.092.040 NLM ssb sjn M0000115 Acetaminophen C0000970 Acetamide, N-(4-hydroxyphenyl)- 103-90-2 Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. T109 Organic Chemical T121 Pharmacologic Substance D018712 Analgesics, Non-Narcotic M0000115 M0000120 M0000115 M0000117 M0000115 M0000114 M0000115 M0000118 M0000115 M0000119 M0000115 M0000116 M0000115 M0418290 M0000115 M0000121 T000213 Acetaminophen 1999 01 01 USP (19XX) T000212 Acetamidophenol 1977 11 18 UNK (19XX) T000214 Acetominophen 1981 06 25 UNK (19XX) T000215 Hydroxyacetanilide 1974 03 29 UNK (19XX) T000220 N-(4-Hydroxyphenyl)acetanilide 1995 03 30 NLM (1996) T000216 N-Acetyl-p-aminophenol 1980 08 13 UNK (19XX) T000217 p-Acetamidophenol 1980 08 13 UNK (19XX) T000218 p-Hydroxyacetanilide 1980 08 01 UNK (19XX) T000219 Paracetamol 1974 03 29 BAN (19XX) INN (19XX) T494124 APAP 2002 05 15 BAN (19XX) M0000120 Panadol C0699141 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000120 T000225 Panadol 1983 09 15 UNK (19XX) M0000117 Acamol C0699138 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000117 T000222 Acamol 1993 09 02 NLM (1995) M0000114 Acetaco C0000964 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000114 T000211 Acetaco 1986 10 22 UNK (19XX) M0000118 Anacin-3 C0699139 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000118 T000223 Anacin-3 1986 11 19 UNK (19XX) T000223 Anacin 3 T000223 Anacin3 M0000119 Datril C0699140 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000119 T000224 Datril 1986 11 19 UNK (19XX) M0000116 Algotropyl C0002046 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000116 T000221 Algotropyl 1980 08 25 UNK (19XX) M0418290 Acephen 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0418290 T007288 Acephen 1990 05 09 NLM (1991) M0000121 Tylenol C0699142 0 T109 Organic Chemical T121 Pharmacologic Substance M0000115 M0000121 T000226 Tylenol 1983 02 23 UNK (19XX) D000083 Acetanilides 1999 01 01 1995 05 18 1968 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 79; was ACETANILIDE 1968-78, was ACETANILID 1963-67 use ACETANILIDES to search ACETANILIDE 1968-78 & ACETANILID 1966-67 79; was ACETANILIDE 1968-78, was ACETANILID 1963-67 D02.065.199.092 NLM TAP PLS M0000123 Acetanilides C0000974 0 N-Phenylacetamide. Precursor of many drugs, dyes and other compounds in chemical synthesis; formerly used as analgesic and antipyretic, but often causes lethal methemoglobinemia. Synonyms: acetylaniline; acetylaminobenzene; antifebrin. T109 Organic Chemical T121 Pharmacologic Substance M0000123 M0000122 T000229 Acetanilides 1999 01 01 NLM (1968) M0000122 Acetanilide C0000973 0 T109 Organic Chemical T121 Pharmacologic Substance M0000123 M0000122 T000227 Acetanilide 1978 05 16 UNK (19XX) T000228 Acetanilid 1977 11 18 UNK (19XX) D000084 Acetate Kinase 1977 12 08 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(79); was see under PHOSPHOTRANSFERASES, ATP 1979-90 91; was see under PHOSPHOTRANSFERASES, ATP 1979-90 Acetates (1966-1978) Acetic Acids (1968-1978) Phosphotransferases (1966-1973) Phosphotransferases, ATP (1974-1978) D08.811.913.696.630.025 RLS ssb sjn M0000124 Acetate Kinase C0000977 ATP:acetate phosphotransferase EC 2.7.2.1 An enzyme that catalyzes reversibly the phosphorylation of acetate in the presence of a divalent cation and ATP with the formation of acetylphosphate and ADP. It is important in the glycolysis process. EC 2.7.2.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-42-3 (CAS RN) T000230 Acetate Kinase 1999 01 01 NLM (1979) T000230 Kinase, Acetate T000231 Acetokinase 1992 10 14 NLM (1994) D000085 Acetates 1999 01 01 1998 06 10 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN or unspecified; prefer specifics ACETIC ACID ESTERS was heading 1975-96 (see under ACETIC ACIDS 1975-90) ACETIC ACID ESTERS was heading 1975-96 (see under ACETIC ACIDS 1975-90) D02.241.081.038.208.025 NLM ADP SJN M0000125 Acetates C0000979 0 Salts or esters of acetic acid in which the terminal hydrogen atom is replaced by a metal, for instance copper acetate Cu(CH3COO)2, or where substitution is by a radical, for instance ethyl acetate CH3COOC2H5. (From Hawley's Condensed Chemical Dictionary, 12th ed) T109 Organic Chemical M0000125 M0000126 T000232 Acetates 1999 01 01 NLM (1966) M0000126 Acetic Acid Esters C0677649 0 T109 Organic Chemical M0000125 M0000126 T000233 Acetic Acid Esters 1996 01 30 NLM (1997) T000233 Acid Esters, Acetic T000233 Esters, Acetic Acid D000086 Acetazolamide 1999 01 01 2001 07 25 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D03.383.871.867.060 NLM ssb sjn M0000127 Acetazolamide C0000981 Acetamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)- 59-66-5 One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) T109 Organic Chemical T121 Pharmacologic Substance D000927 Anticonvulsants D002257 Carbonic Anhydrase Inhibitors D004232 Diuretics 1424-27-7 (mono-Na salt) M0000127 M0000128 M0000127 M0330686 M0000127 M0000130 M0000127 M0000129 M0000127 M0000131 T000234 Acetazolamide 1999 01 01 BAN (19XX) INN (19XX) USP (19XX) M0000128 Acetazolamide Sodium, (Sterile) C0282036 0 T109 Organic Chemical T121 Pharmacologic Substance M0000127 M0000128 T000235 Acetazolamide Sodium, (Sterile) 1994 08 19 USP (19XX) M0330686 Acetazolamide, Monosodium Salt C0949206 1424-27-7 T109 Organic Chemical T121 Pharmacologic Substance M0000127 M0330686 T360880 Acetazolamide, Monosodium Salt 1999 09 13 NLM (1999) T360880 Monosodium Salt Acetazolamide M0000130 Diacarb C0699248 0 T109 Organic Chemical T121 Pharmacologic Substance M0000127 M0000130 T000237 Diacarb 1980 08 01 UNK (19XX) M0000129 Diamox C0591362 0 T109 Organic Chemical T121 Pharmacologic Substance M0000127 M0000129 T000236 Diamox 1980 07 31 UNK (19XX) M0000131 Diuramide C0699249 0 T109 Organic Chemical T121 Pharmacologic Substance M0000127 M0000131 T000238 Diuramide 1981 01 30 UNK (19XX) D000088 Acetic Acids 1999 01 01 2003 07 09 1968 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not confuse with ACETIC ACID; note X ref ACETIC ACID ESTERS see ACETATES; acetic acid salts = ACETATES 68 68 Acetates (1966-1967) D02.241.081.038 D10.251.400.092 NLM ssb sjn M0000132 Acetic Acids C0000985 0 Acetic acid and its derivatives which may be formed by substitution reactions. Mono- and di-substituted, as well as halogenated compounds have been synthesized. T109 Organic Chemical T000239 Acetic Acids 1999 01 01 NLM (1968) T000239 Acids, Acetic D000089 Acetic Anhydrides 1977 12 08 1998 06 10 1991 01 01 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(79); was see under ACETIC ACIDS 1979-90 91; was see under ACETIC ACIDS 1979-90 Acetates (1966-1967) Acetic Acids (1968-1978) Anhydrides (1966-1978) D02.113.075 D02.241.081.038.270 RLS ADP SJN M0000133 Acetic Anhydrides C0000987 0 Compounds used extensively as acetylation, oxidation and dehydrating agents and in the modification of proteins and enzymes. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid T000240 Acetic Anhydrides 1999 01 01 NLM (1979) T000240 Anhydrides, Acetic D000090 Acetoacetates 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D02.241.607.080 D02.522.585.175 NLM jmp sjn M0000134 Acetoacetates C0000988 0 Salts and derivatives of acetoacetic acid. T109 Organic Chemical T000241 Acetoacetates 1999 01 01 NLM (1966) D000091 Acetobacter 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI do not confuse with ACETOBACTERIUM 1966 1966 B03.440.400.425.100.100 B03.660.050.010.010 NLM ags sjn M0000135 Acetobacter C0000990 A species of gram-negative bacteria of the family ACETOBACTERACEAE found in FLOWERS and FRUIT. Cells are ellipsoidal to rod-shaped and straight or slightly curved. T007 Bacterium T000242 Acetobacter 1999 01 01 NLM (1966) D000092 Acetohexamide 1999 01 01 2000 06 21 1966 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66(64) 66 D02.886.590.795.071 D02.948.828.071 NLM CCR sjn M0000136 Acetohexamide C0000992 Benzenesulfonamide, 4-acetyl-N-((cyclohexylamino)carbonyl)- 968-81-0 A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. T109 Organic Chemical T121 Pharmacologic Substance D007004 Hypoglycemic Agents M0000136 M0352361 T000243 Acetohexamide 1999 01 01 BAN (19XX) INN (19XX) USP (19XX) M0352361 Dymelor C0733364 0 T109 Organic Chemical T121 Pharmacologic Substance M0000136 M0352361 T000244 Dymelor 1986 11 19 UNK (19XX) D000093 Acetoin 1974 11 19 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under BUTANONES 1975-90 91; was see under BUTANONES 1975-90 Alcohols, Butyl (1972-1974) Butanones (1970-1974) D02.522.296.100 NLM CCR sjn M0000137 Acetoin C0000996 2-Butanone, 3-hydroxy- 513-86-0 A product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide. T119 Lipid T123 Biologically Active Substance T000245 Acetoin 1999 01 01 NLM (1975) T000246 Acetylmethylcarbinol 1974 11 11 UNK (19XX) D000094 Acetoin Dehydrogenase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under ALCOHOL OXIDOREDUCTASES 1975-90 91; was see under ALCOHOL OXIDOREDUCTASES 1975-90 Alcohol Oxidoreductases (1972-1974) Butanones (1972-1974) D08.811.682.047.050 NLM ssb sjn M0000138 Acetoin Dehydrogenase C0000997 Acetoin:NAD+ oxidoreductase EC 1.1.1.5 An enzyme that catalyzes the conversion of acetoin to diacetyl in the presence of NAD. EC 1.1.1.5. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000247 Acetoin Dehydrogenase 1999 01 01 NLM (1975) T000247 Dehydrogenase, Acetoin T000248 Diacetyl Reductase 1974 11 11 UNK (19XX) T000248 Reductase, Diacetyl D000095 Acetolactate Synthase 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under KETOACID-LYASES 1975-90 91; was see under KETOACID-LYASES 1975-90 Ketoacid-Lyases (1972-1974) Pyruvates (1972-1974) D08.811.520.224.600.100 NLM ssb sjn M0000140 Acetolactate Synthase C0000999 Acetolactate pyruvate-lyase (carboxylating) EC 4.1.3.18 A flavoprotein that catalyzes the formation of acetolactate from 2 moles of pyruvate in the biosynthesis of valine and the formation of acetohydroxybutyrate from pyruvate and alpha-ketobutyrate in the biosynthesis of isoleucine. EC 4.1.3.18. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-45-6 (CAS RN) M0000140 M0000139 M0000140 M0000141 T000251 Acetolactate Synthase 1999 01 01 NLM (1975) T000251 Synthase, Acetolactate T000250 Acetohydroxy Acid Synthetase 1974 11 11 UNK (19XX) T000250 Acid Synthetase, Acetohydroxy T000250 Synthetase, Acetohydroxy Acid T000252 Acetohydroxy Acid Synthase 1974 11 11 UNK (19XX) T000252 Acid Synthase, Acetohydroxy T000252 Synthase, Acetohydroxy Acid T000253 Acetolactate Synthetase 1974 11 11 UNK (19XX) T000253 Synthetase, Acetolactate M0000139 Acetohydroxyacid Synthetase I C0000995 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000140 M0000139 T000249 Acetohydroxyacid Synthetase I 1987 08 10 UNK (19XX) T000249 I, Acetohydroxyacid Synthetase T000249 Synthetase I, Acetohydroxyacid M0000141 Acetoxyhydroxyacid Synthase III C0001013 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000140 M0000141 T000254 Acetoxyhydroxyacid Synthase III 1983 10 14 UNK (19XX) T000254 III, Acetoxyhydroxyacid Synthase T000254 Synthase III, Acetoxyhydroxyacid D000096 Acetone 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG acetonemia & acetonuria go under KETONE BODIES D02.522.064 D02.522.585.342 NLM CCR sjn M0000142 Acetone C0001002 2-Propanone 67-64-1 A colorless liquid used as a solvent and an antiseptic. It is one of the ketone bodies produced during ketoacidosis. T109 Organic Chemical D012997 Solvents T000255 Acetone 1999 01 01 NLM (1966) D000097 Acetonitriles 1974 11 11 1992 05 07 1975 09 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 75 75 Nitriles (1969-1974) D02.626.080 NLM TAP PLS M0000143 Acetonitriles C0001004 0 Compounds in which a methyl group is attached to the cyano moiety. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid T000256 Acetonitriles 1999 01 01 NLM (1975) T000257 Cyanomethanes 1974 11 11 UNK (19XX) T000258 Ethane Nitriles 1974 11 11 UNK (19XX) T000258 Nitriles, Ethane T000259 Methyl Cyanides 1974 11 11 UNK (19XX) T000259 Cyanides, Methyl D000098 Acetophenones 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D02.522.120 NLM TAP PLS M0000144 Acetophenones C0001006 0 T109 Organic Chemical T000260 Acetophenones 1999 01 01 NLM (1966) D000099 Acetoxyacetylaminofluorene 1974 11 11 1999 11 03 1991 01 01 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under 2-ACETYLAMINOFLUORENE/analogs & derivatives 1980-90; was see under FLUORENES 1975-79 91; was see under 2-ACETYLAMINOFLUORENE/analogs & derivatives 1980-90; was see under FLUORENES 1975-79 Acetamides (1973-1974) Acetates (1966-1967) Acetic Acids (1968-1972) Amides (1966-1972) Fluorenes (1966-1974) D02.065.064.150.100 D02.241.081.038.108.080.070 D04.615.389.050.060 NLM adp sjn M0000145 Acetoxyacetylaminofluorene C0001011 Acetamide, N-(acetyloxy)-N-9H-fluoren-2-yl- 6098-44-8 An alkylating agent that forms DNA ADDUCTS at the C-8 position in GUANINE, resulting in single strand breaks. It has demonstrated carcinogenic action. T109 Organic Chemical T131 Hazardous or Poisonous Substance D000477 Alkylating Agents T000262 Acetoxyacetylaminofluorene 1999 01 01 NLM (1975) T000261 Acetoxyacetamidofluorene 1979 05 22 UNK (19XX) T000263 Acetoxyfluorenylacetamide 1974 11 11 UNK (19XX) T000264 N-Acetoxy-2-acetylaminofluorene 1987 08 10 UNK (19XX) T000264 N Acetoxy 2 acetylaminofluorene T000265 N-Acetoxy-N-acetyl-2-aminofluorene 1980 08 25 UNK (19XX) T000265 N Acetoxy N acetyl 2 aminofluorene D000100 Acetrizoic Acid 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D02.241.223.100.140.100.375.880.020 NLM adp sjn M0000146 Acetrizoic Acid C0001017 Benzoic acid, 3-(acetylamino)-2,4,6-triiodo- 85-36-9 An iodinated radiographic contrast medium used as acetrizoate sodium in HYSTEROSALPINGOGRAPHY. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid D003287 Contrast Media M0000146 M0000152 M0000146 M0000147 M0000146 M0000148 M0000146 M0000149 M0000146 M0000150 M0000146 M0000151 T000266 Acetrizoic Acid 1999 01 01 NLM (1966) T000266 Acid, Acetrizoic M0000152 Acetrizoate Sodium C0546847 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000152 T000272 Acetrizoate Sodium 1981 01 30 UNK (19XX) T000272 Sodium, Acetrizoate M0000147 Jodopax C0022399 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000147 T000267 Jodopax 1983 10 14 UNK (19XX) M0000148 Salpix C0036137 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000148 T000268 Salpix 1983 03 30 UNK (19XX) M0000149 Triiotrast C0041018 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000149 T000269 Triiotrast 1981 10 23 UNK (19XX) M0000150 Visotrast 300 C0042808 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000150 T000270 Visotrast 300 1981 01 30 UNK (19XX) T000270 300, Visotrast M0000151 Visotrast 400 C0042809 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000146 M0000151 T000271 Visotrast 400 1981 01 30 UNK (19XX) T000271 400, Visotrast D000101 Acetyl-CoA C-Acetyltransferase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT do not confuse with ACETYL-COA C-ACYLTRANSFERASE 98(75) 98(75); see ACETYL-COA ACETYLTRANSFERASE 1991-97; see ACETYLTRANSFERASES 1975-90 Acetoacetates (1974) Acetyl Coenzyme A (1973-1974) Acetyltransferases (1973-1974) D08.811.913.050.134.060 NLM ssb sjn M0000153 Acetyl-CoA C-Acetyltransferase C0001019 Acetyl-CoA:acetyl-CoA C-acetyltransferase EC 2.3.1.9 An enzyme that catalyzes the reversible formation of acetoacetyl-CoA from two molecules of acetyl-CoA. EC 2.3.1.9. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-46-7 (CAS RN) M0000153 M0000154 T000277 Acetyl-CoA C-Acetyltransferase 1999 01 01 ACETYL COA ACETYLTRANSFERASE C NLM (1975) T000277 Acetyl CoA C Acetyltransferase T000277 C-Acetyltransferase, Acetyl-CoA T000273 Acetoacetyl CoA Thiolase 1975 02 06 UNK (19XX) T000273 CoA Thiolase, Acetoacetyl T000273 Thiolase, Acetoacetyl CoA T000274 Acetyl-CoA Acetyltransferase 1996 12 03 NLM (1998) T000274 Acetyl CoA Acetyltransferase T000274 Acetyltransferase, Acetyl-CoA T000275 Acetyl Coenzyme A Acetyltransferase 1976 03 17 UNK (19XX) T000276 Thiolase 1983 03 30 UNK (19XX) M0000154 Thiolase I C0039911 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000153 M0000154 T000278 Thiolase I 1981 09 18 UNK (19XX) D000102 Acetyl-CoA C-Acyltransferase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT do not confuse with ACETYL-COA C-ACETYLTRANSFERASE 98(75) 98; use ACETYL COA ACYLTRANSFERASE 1991-97, ACYLTRANSFERASES 1975-90 Acetyl Coenzyme A (1973-1974) Acyltransferases (1973-1974) D08.811.913.050.080 NLM ssb sjn M0000155 Acetyl-CoA C-Acyltransferase C0001021 Acyl-CoA:acetyl-CoA C-acyltransferase EC 2.3.1.16 Enzyme that catalyzes the final step of fatty acid oxidation in which acetyl-CoA is released and the CoA ester of a fatty acid two carbons shorter is formed. EC 2.3.1.16. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9029-97-4 (CAS RN) T000288 Acetyl-CoA C-Acyltransferase 1999 01 01 ACETYL COA ACYLTRANSFERASE C NLM (1975) T000288 Acetyl CoA C Acyltransferase T000288 C-Acyltransferase, Acetyl-CoA T000279 2-Methylacetoacetyl CoA Thiolase 1987 08 10 UNK (19XX) T000279 CoA Thiolase, 2-Methylacetoacetyl T000279 Thiolase, 2-Methylacetoacetyl CoA T000280 3-Ketoacyl CoA Thiolase 1975 02 06 KETOACYL COA THIOLASE 03 UNK (19XX) T000280 CoA Thiolase, 3-Ketoacyl T000280 Thiolase, 3-Ketoacyl CoA T000281 3-Ketothiolase 1974 11 11 KETOTHIOLASE 3 UNK (19XX) T000282 3-Oxoacyl-Coenzyme A Thiolase 1987 08 12 UNK (19XX) T000282 Thiolase, 3-Oxoacyl-Coenzyme A T000283 Acetyl CoA Acyltransferase 1996 12 03 NLM (1998) T000283 Acyltransferase, Acetyl CoA T000283 CoA Acyltransferase, Acetyl T000284 beta-Ketothiolase 1976 05 17 UNK (19XX) T000284 beta Ketothiolase T000285 Acetyl Coenzyme A Acyltransferase 1976 03 17 UNK (19XX) T000286 beta-Ketoacyl Thiolase 1991 02 25 NLM (1992) T000286 Thiolase, beta-Ketoacyl T000286 beta Ketoacyl Thiolase T000287 3-Oxoacyl CoA Thiolase 1980 11 20 UNK (19XX) T000287 CoA Thiolase, 3-Oxoacyl T000287 Thiolase, 3-Oxoacyl CoA D000103 Acetyl-CoA Carboxylase 1999 01 01 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(73); was see under LIGASES 1973-90 91; was see under LIGASES 1973-90 D08.811.464.257.050 NLM ssb sjn M0000156 Acetyl-CoA Carboxylase C0001022 Acetyl-CoA:carbon-dioxide ligase (ADP-forming) EC 6.4.1.2 A carboxylating enzyme that catalyzes the conversion of ATP, acetyl-CoA, and HCO3- to ADP, orthophosphate, and malonyl-CoA. It is a biotinyl-protein that also catalyzes transcarboxylation. The plant enzyme also carboxylates propanoyl-CoA and butanoyl-CoA (From Enzyme Nomenclature, 1992) EC 6.4.1.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9023-93-2 (CAS RN) T000289 Acetyl-CoA Carboxylase 1999 01 01 NLM (1973) T000289 Acetyl CoA Carboxylase T000289 Carboxylase, Acetyl-CoA T000290 Acetyl Coenzyme A Carboxylase 1976 03 17 UNK (19XX) D000104 Acetyl-CoA Hydrolase 1977 05 17 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(78); was see under THIOLESTER HYDROLASES 1978-90 91; was see under THIOLESTER HYDROLASES 1978-90 Thiolester Hydrolases (1973-1977) D08.811.277.352.897.075 RLS ssb sjn M0000157 Acetyl-CoA Hydrolase C0001024 Acetyl-CoA hydrolase EC 3.1.2.1 An enzyme that catalyzes reversibly the hydrolysis of acetyl-CoA to yield CoA and acetate. The enzyme is involved in the oxidation of fatty acids. EC 3.1.2.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000293 Acetyl-CoA Hydrolase 1999 01 01 NLM (1978) T000293 Acetyl CoA Hydrolase T000293 Hydrolase, Acetyl-CoA T000291 Acetyl-CoA Acylase 1977 05 17 UNK (19XX) T000291 Acetyl CoA Acylase T000291 Acylase, Acetyl-CoA T000294 Acetyl Coenzyme A Hydrolase 1977 05 17 UNK (19XX) T000292 Acetyl-CoA Deacylase 1977 05 17 UNK (19XX) T000292 Acetyl CoA Deacylase T000292 Deacylase, Acetyl-CoA D000105 Acetyl Coenzyme A 1999 01 01 2003 07 09 1978 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000031 analogs & derivatives AA do not confuse with ACYL COENZYME A 78(73); was see under COENZYME A 1975-77 78; was see under COENZYME A 1975-77 Coenzyme A (1966-1972) D08.211.211.300.075 D13.695.667.138.382.300.020 D13.695.827.068.382.300.020 NLM ssb sjn M0000158 Acetyl Coenzyme A C0001026 Coenzyme A, S-acetate 72-89-9 Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent. T114 Nucleic Acid, Nucleoside, or Nucleotide T119 Lipid T123 Biologically Active Substance T000295 Acetyl Coenzyme A 1999 01 01 NLM (1973) T000295 A, Acetyl Coenzyme T000295 Coenzyme A, Acetyl T000296 Acetyl CoA 1976 03 17 UNK (19XX) T000296 CoA, Acetyl D000106 Acetate-CoA Ligase 1975 07 18 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 95; was ACETYL COENZYME A SYNTHETASE 1991-94; was see under COENZYME A SYNTHETASES 1976-90 use ACETATE-COA LIGASE to search ACETYL COENZYME A SYNTHETASE 1991-94 95; was ACETYL COENZYME A SYNTHETASE 1991-94; was see under COENZYME A SYNTHETASES 1976-90 Acetyl Coenzyme A (1974-1975) Coenzyme A Synthetases (1974-1975) D08.811.464.267.500.200 RLS ssb sjn M0000159 Acetate-CoA Ligase C0001028 Acetate:CoA ligase (AMP-forming) EC 6.2.1.1 An enzyme that catalyzes the formation of CoA derivatives from ATP, acetate, and CoA to form AMP, pyrophosphate, and acetyl CoA. It acts also on propionates and acrylates. EC 6.2.1.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9012-31-1 (CAS RN) T000301 Acetate-CoA Ligase 1999 01 01 NLM (1976) T000301 Acetate CoA Ligase T000301 Ligase, Acetate-CoA T000297 Acetate Thiokinase 1975 06 30 UNK (19XX) T000297 Thiokinase, Acetate T000298 Acetothiokinase 1982 09 03 UNK (19XX) T000302 Acetyl CoA Synthetase 1976 05 17 UNK (19XX) T000302 CoA Synthetase, Acetyl T000302 Synthetase, Acetyl CoA T000299 Acetyl Activating Enzyme 1975 06 30 UNK (19XX) T000299 Activating Enzyme, Acetyl T000299 Enzyme, Acetyl Activating T000300 Acetyl Coenzyme A Synthetase 1994 03 05 NLM (1995) D000107 Acetylation 1999 01 01 1999 11 03 1991 01 01 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE almost never IM; enzymatic acetylation: coord NIM with ACETYLTRANSFERASES (IM) + substrate (NIM) or specific acetyltransferase (IM) 91(73); was see under CHEMISTRY, ORGANIC 1973-90 91; was see under CHEMISTRY, ORGANIC 1973-90 Chemistry, Organic (1966-1972) G06.535.095.052 H01.181.404.095.052 NLM ags sjn M0000160 Acetylation C0001038 Formation of an acetyl derivative. (Stedman, 25th ed) T070 Natural Phenomenon or Process T000303 Acetylation 1999 01 01 NLM (1973) T000303 Acetylations D000108 Acetylcarnitine 1977 05 17 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 1991(1978); use CARNITINE 1978-1990; for MEDOSAN use ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL (NM) 1988-2003 1991; see CARNITINE 1978-1990; MEDOSAN was indexed under ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL 1988-2003 Carnitine (1966-1977) D11.786.708.168.090 RLS ssb sjn M0000161 Acetylcarnitine C0001040 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt 14992-62-2 An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS. T109 Organic Chemical T121 Pharmacologic Substance T127 Vitamin D018697 Nootropic Agents 104220-24-8 3040-38-8 ((R)-isomer) M0000161 M0000163 M0000161 M0330692 M0000161 M0000164 M0000161 M0444058 M0000161 M0156842 T000304 Acetylcarnitine 1999 01 01 NLM (1978) T000305 Acetyl Carnitine 1977 05 17 UNK (19XX) T000305 Carnitine, Acetyl M0000163 Acetyl-L-Carnitine C0524474 0 T109 Organic Chemical T121 Pharmacologic Substance M0000161 M0000163 T000307 Acetyl-L-Carnitine 1997 09 03 NLM (1999) T000307 Acetyl L Carnitine T000306 Levocarnitine Acetyl 1996 11 20 NLM (1998) M0330692 Acetylcarnitine, (R)-Isomer C0887516 3040-38-8 T109 Organic Chemical T121 Pharmacologic Substance M0000161 M0330692 T360886 Acetylcarnitine, (R)-Isomer 1999 09 13 NLM (1999) M0000164 Alcar C0600146 0 T109 Organic Chemical T121 Pharmacologic Substance M0000161 M0000164 T000308 Alcar 1997 09 03 NLM (1999) M0444058 Branigen 0 T109 Organic Chemical T121 Pharmacologic Substance M0000161 M0444058 T529165 Branigen 2002 12 26 NLM (2004) T533714 Glaxo Brand of Acetyl L-Carnitine 2003 02 26 NLM (2004) T533714 Glaxo Brand of Acetyl L Carnitine M0156842 Medosan C0633601 104220-24-8 T109 Organic Chemical T121 Pharmacologic Substance M0000161 M0156842 T186847 Medosan NLM (2004) T533715 Sigma-Tau brand of Acetyl L-Carnitine 2003 02 26 NLM (2004) T533715 Sigma Tau brand of Acetyl L Carnitine D000109 Acetylcholine 1999 01 01 2000 06 28 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 1998; for MIOCHOL use ACETYLCHOLINE (NM) 1981-1997; for CHLOROACETYLCHOLINE use ACETYLCHOLINE (NM) 1969-2000; for BROMOACETYLCHOLINE use ACETYLCHOLINE (NM) 1969-2000 1998; MIOCHOL (now ACETYLCHOLINE) was indexed under ACETYLCHOLINE & MANNITOL 1981-97; CHLOROACETYLCHOLINE was indexed under ACETYLCHOLINE 1975-2000 & under CHLORINE 1974-1975; BROMOACETYLCHOLINE was indexed under ACETYLCHOLINE/analogs & derivatives 1974-2000 & ACETYLCHOLINE 1969-1974 D011950 Receptors, Cholinergic D018678 Cholinergic Agents D02.092.211.111 D14.600.020 NLM jmp sjn M0000165 Acetylcholine C0001041 Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl- 51-84-3 A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine D014665 Vasodilator Agents 2260-50-6 (iodide) 52978-03-7 (sulfate (1:1)) 56-13-3 (hydroxide) 60-31-1 66-23-9 7632-27-1 (fluoride) 77822-10-7 (picrate (1:1)) 78213-25-9 (L-tartrate) 927-86-6 (perchlorate) M0000165 M0330693 M0000165 M0330700 M0000165 M0330701 M0000165 M0049582 M0000165 M0330698 M0000165 M0330695 M0000165 M0049840 M0000165 M0330699 M0000165 M0330694 M0000165 M0000167 T000309 Acetylcholine 1999 01 01 NLM (1966) T000310 2-(Acetyloxy)-N,N,N-trimethylethanaminium 1993 11 23 NLM (1995) M0330693 Acetylcholine Iodide C0887517 2260-50-6 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330693 T360887 Acetylcholine Iodide 1999 09 13 NLM (1999) T360887 Iodide, Acetylcholine M0330700 Acetylcholine L-Tartrate C0887521 78213-25-9 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330700 T360894 Acetylcholine L-Tartrate 1999 09 13 NLM (1999) T360894 Acetylcholine L Tartrate T360894 L-Tartrate, Acetylcholine M0330701 Acetylcholine Perchlorate C0887522 927-86-6 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330701 T360895 Acetylcholine Perchlorate 1999 09 13 NLM (1999) T360895 Perchlorate, Acetylcholine M0049582 Acetylcholine Bromide C0054106 66-23-9 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0049582 T360891 Acetylcholine Bromide 1999 09 13 NLM (1999) T360891 Bromide, Acetylcholine T079585 Bromoacetylcholine NLM (2001) M0330698 Acetylcholine Fluoride C0887520 7632-27-1 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330698 T360892 Acetylcholine Fluoride 1999 09 13 NLM (1999) T360892 Fluoride, Acetylcholine M0330695 Acetylcholine Hydroxide C0887519 56-13-3 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330695 T360889 Acetylcholine Hydroxide 1999 09 13 NLM (1999) T360889 Hydroxide, Acetylcholine M0049840 Acetylcholine Chloride C0055389 60-31-1 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0049840 T000313 Acetylcholine Chloride 1994 08 08 BAN (19XX) INN (1996) USP (1996) T079843 Chloroacetylcholine NLM (2001) M0330699 Acetylcholine Picrate (1:1) C0085739 77822-10-7 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330699 T360893 Acetylcholine Picrate (1:1) 1999 09 13 NLM (1999) T000311 Acetylcholine Picrate 1991 03 08 NLM (1992) M0330694 Acetylcholine Sulfate (1:1) C0887518 52978-03-7 T109 Organic Chemical T121 Pharmacologic Substance T124 Neuroreactive Substance or Biogenic Amine M0000165 M0330694 T360888 Acetylcholine Sulfate (1:1) 1999 09 13 NLM (1999) M0000167 Miochol C0282037 0 T109 Organic Chemical T121 Pharmacologic Substance M0000165 M0000167 T000312 Miochol 1996 12 06 NLM (1998) D000110 Acetylcholinesterase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT reactivation or reactivators: coord NIM (with no qualif) with CHOLINESTERASE REACTIVATORS (IM) D000110 Acetylcholinesterase Q000037 antagonists & inhibitors D002800 Cholinesterase Inhibitors D08.811.277.352.100.170.176 NLM ssb sjn M0000169 Acetylcholinesterase C0001044 Acetylcholine acetylhydrolase EC 3.1.1.7 An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and ACETATE. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000169 M0000170 T000315 Acetylcholinesterase 1999 01 01 NLM (1966) T000314 Acetylcholine Hydrolase 1981 07 28 UNK (19XX) T000314 Hydrolase, Acetylcholine M0000170 Acetylthiocholinesterase C0001067 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000169 M0000170 T000316 Acetylthiocholinesterase 1981 04 27 UNK (19XX) D000111 Acetylcysteine 1999 01 01 2001 07 25 1966 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66(64) 66 D12.125.166.230.259 NLM CCR sjn M0000171 Acetylcysteine C0001047 L-Cysteine, N-acetyl- 616-91-1 The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance D000998 Antiviral Agents D005100 Expectorants D016166 Free Radical Scavengers 128645-11-4 (Zn salt) 18829-79-3 (HCl) 19542-74-6 (mono-Na salt) 26117-28-2 ((D)-isomer) 50807-78-8 (mono-NH3 salt) 63664-54-0 (Na salt) 7218-04-4 ((DL)-isomer) M0000171 M0331339 M0000171 M0331342 M0000171 M0331337 M0000171 M0331341 M0000171 M0331336 M0000171 M0000172 M0000171 M0000173 M0000171 M0331340 M0000171 M0331338 M0000171 M0000174 M0000171 M0000175 T000317 Acetylcysteine 1999 01 01 USAN (1963) T000318 Mercapturic Acid 1974 03 29 UNK (19XX) T000318 Acid, Mercapturic T000319 N-Acetyl-L-cysteine 1981 12 18 UNK (19XX) T000319 N Acetyl L cysteine T000320 N-Acetylcysteine 1980 07 30 UNK (19XX) T000320 N Acetylcysteine M0331339 Acetylcysteine, (D)-Isomer C0887744 26117-28-2 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331339 T361533 Acetylcysteine, (D)-Isomer 1999 09 13 NLM (1999) M0331342 Acetylcysteine, (DL)-Isomer C0887746 7218-04-4 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331342 T361536 Acetylcysteine, (DL)-Isomer 1999 09 13 NLM (1999) M0331337 Acetylcysteine Hydrochloride C0887742 18829-79-3 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331337 T361531 Acetylcysteine Hydrochloride 1999 09 13 NLM (1999) T361531 Hydrochloride, Acetylcysteine M0331341 Acetylcysteine Sodium C0772506 63664-54-0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331341 T361535 Acetylcysteine Sodium 1999 09 13 NLM (1999) T361535 Sodium, Acetylcysteine M0331336 Acetylcysteine Zinc C0887741 128645-11-4 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331336 T361530 Acetylcysteine Zinc 1999 09 13 NLM (1999) T361530 Zinc, Acetylcysteine M0000172 Broncholysin C0699250 0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0000172 T000321 Broncholysin 1987 10 21 UNK (19XX) M0000173 Fluimucil C0699251 0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0000173 T000322 Fluimucil 1987 10 21 UNK (19XX) M0331340 Acetylcysteine, Monoammonium Salt C0949207 50807-78-8 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331340 T361534 Acetylcysteine, Monoammonium Salt 1999 09 13 NLM (1999) T361534 Monoammonium Salt Acetylcysteine M0331338 Acetylcysteine, Monosodium Salt C0949208 19542-74-6 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0331338 T361532 Acetylcysteine, Monosodium Salt 1999 09 13 NLM (1999) T361532 Monosodium Salt Acetylcysteine M0000174 Mucomyst C0699252 0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0000174 T000323 Mucomyst 1986 11 19 UNK (19XX) M0000175 Mucosolvin C0699253 0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance M0000171 M0000175 T000324 Mucosolvin 1983 09 14 UNK (19XX) D000112 Acetyldigitoxins 1999 01 01 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG Q000096 biosynthesis BI do not confuse with ACETYLDIGOXINS 91(80); was see under DIGITOXIN 1980-90; was ACETYLDIGITOXIN see under DIGITOXIN 1966-79 use ACETYLDIGITOXINS to search ACETYLDIGITOXIN 1975-79 & DIGITOXIN 1966-74 91; was see under DIGITOXIN 1980-90; was ACETYLDIGITOXIN see under DIGITOXIN 1966-79 D04.808.155.160.278.259 D04.808.155.580.261.336.259 D09.203.408.180.261.336.259 NLM ssb sjn M0000177 Acetyldigitoxins C0001049 0 Cardioactive derivatives of lanatoside A or of DIGITOXIN. They are used for fast digitalization in congestive heart failure. T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance D000889 Anti-Arrhythmia Agents D002316 Cardiotonic Agents D004791 Enzyme Inhibitors M0000177 M0000178 M0000177 M0000179 M0000177 M0000181 M0000177 M0000176 M0000177 M0000180 T000326 Acetyldigitoxins 1999 01 01 NLM (1975) T000327 Desglucolanatosides A 1979 02 23 UNK (19XX) M0000178 Adicin C0001517 0 T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance M0000177 M0000178 T000328 Adicin 1981 01 30 UNK (19XX) M0000179 alpha-Acetyldigitoxin C0002238 0 T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance M0000177 M0000179 T000329 alpha-Acetyldigitoxin 1981 01 30 UNK (19XX) T000329 alpha Acetyldigitoxin M0000181 Acetyldigitoxin C0520442 0 T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance M0000177 M0000181 T000331 Acetyldigitoxin 1979 02 23 UNK (19XX) M0000176 Acedoxin C0000951 0 T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance M0000177 M0000176 T000325 Acedoxin 1980 08 13 UNK (19XX) M0000180 Digitoxin Monoacetate C0012259 0 T110 Steroid T118 Carbohydrate T121 Pharmacologic Substance M0000177 M0000180 T000330 Digitoxin Monoacetate 1980 08 13 UNK (19XX) T000330 Monoacetate, Digitoxin D000113 Acetyldigoxins 1978 03 16 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG Digitalis glycosides; do not confuse with ACETYLDIGITOXINS; alpha isomer & beta isomer go here 91(79); was see under DIGOXIN 1979-90 91; was see under DIGOXIN 1979-90 Digoxin (1966-1978) D04.808.155.160.349.050 D04.808.155.580.261.436.050 D09.203.408.180.261.436.050 SH ssb sjn M0000182 Acetyldigoxins C0001050 0 Alpha- or beta-acetyl derivatives of DIGOXIN or lanatoside C from Digitalis lanata. They are better absorbed and longer acting than digoxin and are used in congestive heart failure. T110 Steroid T121 Pharmacologic Substance D000889 Anti-Arrhythmia Agents D002316 Cardiotonic Agents D004791 Enzyme Inhibitors M0000182 M0000185 M0000182 M0431720 M0000182 M0000184 M0000182 M0431713 M0000182 M0431715 M0000182 M0431717 M0000182 M0431719 M0000182 M0431718 M0000182 M0431716 M0000182 M0431714 M0000182 M0431712 M0000182 M0000183 M0000182 M0431729 T000332 Acetyldigoxins 1999 01 01 NLM (1979) T000333 Desglucolanatosides C 1978 03 16 UNK (19XX) M0000185 Novodigal C0028462 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0000185 T000336 Novodigal 1980 08 13 DE T505235 Lilly Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505235 Acetyldigoxin Lilly Brand M0431720 Stillacor 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431720 T505252 Stillacor 2002 07 19 DE T505253 Wolff Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505253 Acetyldigoxin Wolff Brand M0000184 beta-Acetyldigoxin C0005185 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0000184 T000335 beta-Acetyldigoxin 1980 08 13 UNK (19XX) T000335 beta Acetyldigoxin M0431713 Digotab 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431713 T505238 Digotab 2002 07 19 DE T505239 ASTA Medica Brand of Acetyldigoxin 2002 07 19 NLM (2003) M0431715 Digoxin Didier 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431715 T505242 Digoxin Didier 2002 07 19 DE T505242 Didier, Digoxin T505243 Hormosan Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505243 Acetyldigoxin Hormosan Brand M0431717 glycotop 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431717 T505246 glycotop 2002 07 19 DE T505247 R.A.N. Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505247 Acetyldigoxin R.A.N. Brand M0431719 Longdigox 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431719 T505250 Longdigox 2002 07 19 DE T505251 Gepepharn Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505251 Acetyldigoxin Gepepharn Brand M0431718 Kardiamed 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431718 T505248 Kardiamed 2002 07 19 DE T505249 Medice Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505249 Acetyldigoxin Medice Brand M0431716 Gladixol N 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431716 T505244 Gladixol N 2002 07 19 DE T505244 N, Gladixol T505245 Corax Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505245 Acetyldigoxin Corax Brand M0431714 digox von ct 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431714 T505240 digox von ct 2002 07 19 DE T505240 ct, digox von T505240 von ct, digox T505241 ct-Arzneimittel Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505241 Acetyldigoxin ct-Arzneimittel Brand T505241 ct Arzneimittel Brand of Acetyldigoxin M0431712 Digostada 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431712 T505236 Digostada 2002 07 19 DE T505237 Stada Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505237 Acetyldigoxin Stada Brand M0000183 alpha-Acetyldigoxin C0002239 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0000183 T000334 alpha-Acetyldigoxin 1980 08 13 UNK (19XX) T000334 alpha Acetyldigoxin M0431729 beta-Acetyldigoxin-ratiopharm 0 T110 Steroid T121 Pharmacologic Substance M0000182 M0431729 T505261 beta-Acetyldigoxin-ratiopharm 2002 07 19 DE T505261 beta Acetyldigoxin ratiopharm T505261 betaAcetyldigoxinratiopharm T505262 ratiopharm Brand of Acetyldigoxin 2002 07 19 NLM (2003) T505262 Acetyldigoxin ratiopharm Brand D000114 Acetylene 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D02.455.326.397.259 NLM TAP PLS M0000186 Acetylene C0001052 Ethyne 74-86-2 T109 Organic Chemical T000337 Acetylene 1999 01 01 NLM (1966) D000115 Acetylesterase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT D08.811.277.352.100.050 NLM ssb sjn M0000187 Acetylesterase C0001053 Acetic-ester acetylhydrolase EC 3.1.1.6 An enzyme that catalyzes the conversion of acetate esters and water to alcohols and acetate. EC 3.1.1.6. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000340 Acetylesterase 1999 01 01 NLM (1966) T000338 Acetate Esterase 1984 09 18 UNK (19XX) T000338 Esterase, Acetate T000341 Acid Esterase 1983 03 30 UNK (19XX) T000341 Esterase, Acid T000342 Esterase-17 1983 09 16 UNK (19XX) T000342 Esterase 17 T000339 Acetylase 1974 03 29 UNK (19XX) D000116 Acetylgalactosamine 1974 11 19 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under GALACTOSAMINE 1975-90 91; was see under GALACTOSAMINE 1975-90 Galactosamine (1973-1974) D09.203.067.342.356.050 NLM CCR sjn M0000188 Acetylgalactosamine C0001055 Galactose, 2-(acetylamino)-2-deoxy- 31022-50-1 The N-acetyl derivative of galactosamine. T118 Carbohydrate T123 Biologically Active Substance T000346 Acetylgalactosamine 1999 01 01 NLM (1975) T000343 2-Acetamido-2-D-galactopyranose 1981 11 13 UNK (19XX) T000343 2 Acetamido 2 D galactopyranose T000344 2-Acetamido-2-Deoxy-D-Galactose 1980 08 13 UNK (19XX) T000344 2 Acetamido 2 Deoxy D Galactose T000347 N-Acetyl-D-Galactosamine 1989 02 08 NLM (1989) T000347 N Acetyl D Galactosamine T000345 2-Acetamido-2-Deoxygalactose 1981 11 13 UNK (19XX) T000345 2 Acetamido 2 Deoxygalactose D000117 Acetylglucosamine 1974 11 11 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under GLUCOSAMINE 1975-90 91; was see under GLUCOSAMINE 1975-90 Glucosamine (1973-1974) D09.203.067.342.531.050 NLM CCR sjn M0000189 Acetylglucosamine C0001056 D-Glucose, 2-(acetylamino)-2-deoxy- 7512-17-6 The N-acetyl derivative of glucosamine. T118 Carbohydrate T123 Biologically Active Substance T000350 Acetylglucosamine 1999 01 01 NLM (1975) T000348 2-Acetamido-2-Deoxy-D-Glucose 1985 01 03 UNK (19XX) T000348 2 Acetamido 2 Deoxy D Glucose T000351 N-Acetyl-D-Glucosamine 1980 08 13 UNK (19XX) T000351 N Acetyl D Glucosamine T000349 2-Acetamido-2-Deoxyglucose 1982 11 23 UNK (19XX) T000349 2 Acetamido 2 Deoxyglucose D000118 Acetylglucosaminidase 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under GLUCOSAMINIDASE 1975-90 91; was see under GLUCOSAMINIDASE 1975-90 Acetamides (1973-1974) Glucosaminidase (1972-1974) D08.811.277.450.483.531.080 NLM ssb sjn M0000190 Acetylglucosaminidase C0001057 EC 3.2.1.30 2-Acetamido-2-deoxy-beta-D-glucoside acetamidodeoxygluco-hydrolase. Catalyzes the hydrolysis of terminal, non-reducing 2-acetamido-2-deoxy-beta-glucose residues in chitobiose and higher analogs as well as in glycoproteins. Has been used widely in structural studies on bacterial cell walls and in the study of diseases such as mucolipidosis and various inflammatory disorders of muscle and connective tissue. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000352 Acetylglucosaminidase 1999 01 01 NLM (1975) T000353 Beta-D-Acetamido-2-Deoxyglucosidase 1986 10 07 UNK (19XX) T000353 Beta D Acetamido 2 Deoxyglucosidase T000354 beta-D-N-acetylglucosaminidase 1981 11 13 UNK (19XX) T000354 beta D N acetylglucosaminidase T000355 Beta-N-Acetylglucosaminidase 1981 01 08 UNK (19XX) T000355 Beta N Acetylglucosaminidase T000356 Chitobiase 1980 07 31 UNK (19XX) T000357 N,N-Diacetylchitobiase 1987 12 08 UNK (19XX) T000357 N,N Diacetylchitobiase T000358 N-Ac-beta-Glucosaminidase 1981 11 02 UNK (19XX) T000358 N Ac beta Glucosaminidase T000359 N-Acetyl-beta-D-glucosaminidase 1984 04 11 ACETYL BETA GLUCOSAMINIDASE UNK (19XX) T000359 N Acetyl beta D glucosaminidase T000360 NAGase 1988 09 12 UNK (19XX) D000119 Acetylmuramyl-Alanyl-Isoglutamine 1978 02 01 2000 06 21 1983 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn permitted; DF: AMAIG 83(79); was see under GLYCOPEPTIDES 1979-82 83; was see under GLYCOPEPTIDES 1979-82 Glycopeptides (1971-1978) Peptides (1966-1970) Polysaccharides (1966-1970) D09.203.067.550.050 D09.203.811.522.050 D12.644.233.050 SH CCR sjn M0000191 Acetylmuramyl-Alanyl-Isoglutamine C0001060 D-alpha-Glutamine, N2-(N-(N-acetylmuramoyl)-L-alanyl)- 53678-77-6 Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance T129 Immunologic Factor D000276 Adjuvants, Immunologic M0000191 M0000192 T000362 Acetylmuramyl-Alanyl-Isoglutamine 1999 01 01 AMAIG NLM (1979) T000361 Acetylmuramyl Alanyl Isoglutamine 1978 02 01 UNK (19XX) T000361 Alanyl Isoglutamine, Acetylmuramyl T000361 Isoglutamine, Acetylmuramyl Alanyl T000363 Muramyl Dipeptide 1980 05 14 UNK (19XX) T000363 Dipeptide, Muramyl M0000192 Mur-NAc-L-Ala-D-isoGln C0086659 0 T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance T129 Immunologic Factor M0000191 M0000192 T000364 Mur-NAc-L-Ala-D-isoGln 1978 02 01 UNK (19XX) T000364 Mur NAc L Ala D isoGln T000365 N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide 1982 02 04 UNK (19XX) T000365 N Acetyl Muramyl L Alanyl D Glutamic alpha Amide T000366 N-Acetylmuramyl-L-Alanyl-D-Isoglutamine 1980 08 13 UNK (19XX) T000366 N Acetylmuramyl L Alanyl D Isoglutamine D000120 Acecainide 1979 02 27 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 96; was ACETYLPROCAINAMIDE 1980-95 (see under PROCAINAMIDE 1980-90) 96; was ACETYLPROCAINAMIDE 1980-95 (see under PROCAINAMIDE 1980-90) Procainamide (1966-1974) /analogs & derivatives (1975-1979) D02.241.223.100.054.055.015 SH CCR sjn M0000193 Acecainide C0001061 Benzamide, 4-(acetylamino)-N-(2-(diethylamino)ethyl)- 32795-44-1 A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure. T109 Organic Chemical T121 Pharmacologic Substance D000889 Anti-Arrhythmia Agents 34118-92-8 (mono-HCl) M0000193 M0000194 T000367 Acecainide 1999 01 01 INN (19XX) T000368 Acetylprocainamide 1994 08 19 NLM (1996) T000369 N-Acetylprocainamide 1980 08 13 UNK (19XX) T000369 N Acetylprocainamide M0000194 Acecainide Hydrochloride C0282038 34118-92-8 T109 Organic Chemical T121 Pharmacologic Substance M0000193 M0000194 T000370 Acecainide Hydrochloride 1994 08 12 USAN (1977) T000370 Hydrochloride, Acecainide T360896 Acecainide Monohydrochloride 1999 09 13 NLM (1999) T360896 Monohydrochloride, Acecainide D000121 Acetylserotonin N-Methyltransferase 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT DF: HIOMT 98(75) 98; see ACETYLSEROTONIN METHYLTRANSFERASE 1991-97; see METHYLTRANSFERASES 1975-90 Methyltransferases (1974) Serotonin (1974) D08.811.913.555.500.100 NLM ssb sjn M0000195 Acetylserotonin N-Methyltransferase C0001064 S-Adenosyl-L-methionine:N-acetylserotonin O-methyltransferase EC 2.1.1.4 An enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine to N-acetylserotonin to form N-acetyl-5-methoxytryptamine (MELATONIN). EC 2.1.1.4. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9029-77-0 (CAS RN) T000374 Acetylserotonin N-Methyltransferase 1999 01 01 ACETYLSEROTONIN METHYLTRANSFERASE N HIOMT NLM (1975) T000374 Acetylserotonin N Methyltransferase T000374 N-Methyltransferase, Acetylserotonin T000371 Acetylserotonin Methyltransferase 1997 04 25 NLM (1998) T000371 Methyltransferase, Acetylserotonin T000372 Hydroxyindole O-Methyltransferase 1974 11 11 HYDROXYINDOLE METHYLTRANSFERASE O UNK (19XX) T000372 Hydroxyindole O Methyltransferase T000372 O-Methyltransferase, Hydroxyindole T000373 Oxyindol-O-Methyltransferase 1982 01 20 UNK (19XX) T000373 Oxyindol O Methyltransferase D000122 Acetylthiocholine 1974 11 19 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under CHOLINE 1975-90 91; was see under CHOLINE 1975-90 Acetylcholine (1972-1974) Sulfhydryl Compounds (1973-1974) D02.092.102.232.800.030 D02.675.276.232.800.030 NLM CCR sjn M0000196 Acetylthiocholine C0001066 Ethanaminium, 2-(acetylthio)-N,N,N-trimethyl- 4468-05-7 An agent used as a substrate in assays for cholinesterases, especially to discriminate among enzyme types. T109 Organic Chemical T121 Pharmacologic Substance T000376 Acetylthiocholine 1999 01 01 NLM (1975) T000375 (2-Mercaptoethyl)trimethylammonium Acetate 1980 08 13 UNK (19XX) D000123 Acetyltransferases 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 73 73 Acyltransferases (1966-1972) D08.811.913.050.134 NLM ssb sjn M0000197 Acetyltransferases C0001068 EC 2.3.1. Enzymes catalyzing the transfer of an acetyl group, usually from acetyl coenzyme A, to another compound. EC 2.3.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9012-30-0 (CAS RN) T000377 Acetyltransferases 1999 01 01 NLM (1973) D000124 Achievement 1999 01 01 1991 11 02 1965 01 01 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif 65(64) 65 F01.658.059 F02.784.629.054 NLM PLS PLS M0000198 Achievement C0001072 Success in bringing an effort to the desired end; the degree or level of success attained in some specified area (esp. scholastic) or in general. T055 Individual Behavior T000378 Achievement 1999 01 01 POPLINE (1978) T000378 Achievements D000125 Achilles Tendon 1999 01 01 2001 07 25 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI rupture = ACHILLES TENDON /inj (IM) + RUPTURE (NIM) A02.880.176 NLM nns sjn M0000199 Achilles Tendon C0001074 T023 Body Part, Organ, or Organ Component T000379 Achilles Tendon 1999 01 01 NLM (1966) T000379 Achilles Tendons T000379 Tendon, Achilles T000379 Tendons, Achilles D000126 Achlorhydria 1999 01 01 2003 07 09 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI ACHYLIA GASTRICA was see under ACHLORHYDRIA 1963-78 use ACHLORHYDRIA to search ACHYLIA GASTRICA 1966-78 ACHYLIA GASTRICA was see under ACHLORHYDRIA 1963-78 D005750 Gastric Juice C06.405.748.045 C18.452.076.087 NLM lkt sjn M0000200 Achlorhydria C0001075 A lack of HYDROCHLORIC ACID in GASTRIC JUICE despite stimulation of gastric secretion. T046 Pathologic Function M0000200 M0000201 T000380 Achlorhydria 1999 01 01 NLM (1966) T000381 Achylia Gastrica 1978 02 27 UNK (19XX) M0000201 Hypochlorhydria C0079581 T046 Pathologic Function M0000200 M0000201 T000382 Hypochlorhydria 1990 02 13 NLM (1991) D000127 Acholeplasma 1975 07 25 2003 07 09 1976 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI 76 76 Mycoplasma (1966-1975) B03.440.560.074.150 JW ags sjn M0000202 Acholeplasma C0001076 A genus of gram-negative organisms including saprophytic and parasitic or pathogenic species. T007 Bacterium T000383 Acholeplasma 1999 01 01 NLM (1976) D000128 Acholeplasma laidlawii 1975 07 25 2003 07 09 1976 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI in sewage, dung, soil & animals 76; was MYCOPLASMA LAIDLAWII 1972-75 use ACHOLEPLASMA LAIDLAWII to search MYCOPLASMA LAIDLAWII 1972-75 76; was MYCOPLASMA LAIDLAWII 1972-75 Mycoplasma (1966-1971) B03.440.560.074.150.500 JW ags sjn M0000203 Acholeplasma laidlawii C0001077 An organism originally isolated from sewage, manure, humus, and soil, but recently found as a parasite in mammals and birds. T007 Bacterium T000384 Acholeplasma laidlawii 1999 01 01 NLM (1976) T000385 Mycoplasma laidlawii 1975 07 11 UNK (19XX) D000129 Acholeplasmataceae 1975 07 25 2003 07 09 1976 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI free-living saphrophytes & mammalian & avian parasites 76 76 Bacteria (1966-1974) Mycoplasmataceae (1975) B03.440.560.074 JW ags sjn M0000204 Acholeplasmataceae C0001078 Gram-negative organisms including apparently free-living saprophytes as well as mammalian and avian parasites, and possibly pathogens. T007 Bacterium T000386 Acholeplasmataceae 1999 01 01 NLM (1976) D000130 Achondroplasia 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C05.116.099.343.110 C05.116.099.708.017 C16.320.029 NLM nns sjn M0000205 Achondroplasia C0001080 An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, genu varum, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001) T019 Congenital Abnormality T000387 Achondroplasia 1999 01 01 NLM (1966) T000387 Achondroplasias D000134 Acid Etching, Dental 1976 04 13 2003 07 09 1991 01 01 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES etching of tooth surface to increase adhesion of resins; do not use for etching of metal appliances for better adhesion ( = specific appliance (IM) + METALLURGY (NIM) ); do not use for etching of veneers or resins ( = specific dent restoration); DF: ACID ETCHING DENT 91(77); was see under BONDING, DENTAL 1977-90 91; was see under BONDING, DENTAL 1977-90 Bonding, Dental (1971-1976) Dental Enamel (1966-1976) Phosphoric Acids (1968-1976) E06.095.585.111 SMH ssb sjn M0000206 Acid Etching, Dental C0001100 Preparation of TOOTH surfaces and DENTAL MATERIALS with etching agents, usually phosphoric acid, to roughen the surface to increase adhesion or osteointegration. T061 Therapeutic or Preventive Procedure T000390 Acid Etching, Dental 1999 01 01 ACID ETCHING DENT NLM (1977) T000389 Dental Acid Etching 1990 04 09 DENT ACID ETCHING NLM (1991) T000388 Etching, Dental Acid 1990 02 09 ETCHING DENT ACID NLM (1991) D000135 Acid Phosphatase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT /defic permitted: TN 222; prostate-specific acid phosphatase (PROSTATE + ACID PHOSPHATASE): do not confuse with PROSTATE-SPECIFIC ANTIGEN, a serine proteinase /blood was BLOOD ACID PHOSPHATASE 1963-67 use ACID PHOSPHATASE to search BLOOD ACID PHOSPHATASE 1966-67 /blood was BLOOD ACID PHOSPHATASE 1963-67 D08.811.277.352.650.025 NLM ssb sjn M0000208 Acid Phosphatase C0001109 Orthophosphoric-monoester phosphohydrolase (acid optimum) EC 3.1.3.2 An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9001-77-8 (CAS RN) M0000208 M0000209 T000393 Acid Phosphatase 1999 01 01 NLM (1966) M0000209 Acid beta-Glycerophosphatase C0205638 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000208 M0000209 T000394 Acid beta-Glycerophosphatase 1981 04 27 UNK (19XX) T000394 Acid beta Glycerophosphatase D000136 Acid-Base Equilibrium 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES consider also ACID-BASE IMBALANCE D000138 Acidosis D000471 Alkalosis D002021 Buffers D006863 Hydrogen-Ion Concentration G06.184.029 G07.621.110 G09.188.250.051 H01.181.529.428.176 NLM nns sjn M0000210 Acid-Base Equilibrium C0001117 The balance between acids and bases in the BODY FLUIDS. The pH (HYDROGEN-ION CONCENTRATION) of the arterial BLOOD provides an index for the total body acid-base balance. T042 Organ or Tissue Function M0000210 M0000211 T000395 Acid-Base Equilibrium 1999 01 01 NLM (1966) T000395 Acid Base Equilibrium T000395 Equilibrium, Acid-Base T000396 Acid-Base Balance 1994 10 31 NLM (1996) T000396 Acid Base Balance T000396 Balance, Acid-Base M0000211 Anion Gap C0003074 T034 Laboratory or Test Result T070 Natural Phenomenon or Process M0000210 M0000211 T000397 Anion Gap 1980 05 09 UNK (19XX) T000397 Anion Gaps T000397 Gap, Anion T000397 Gaps, Anion D000137 Acid-Base Imbalance 1975 07 25 1991 06 17 1976 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 76; was NON MESH before 1976 76 Acid-Base Equilibrium (1966-1975) C18.452.076 SMH PLS PLS M0000212 Acid-Base Imbalance C0001118 Disturbances in the ACID-BASE EQUILIBRIUM of the body. T046 Pathologic Function T000398 Acid-Base Imbalance 1999 01 01 NLM (1976) T000398 Acid Base Imbalance T000398 Acid-Base Imbalances T000398 Imbalance, Acid-Base T000398 Imbalances, Acid-Base D000138 Acidosis 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI an acid-base imbalance; GEN & unspecified; prefer specifics C18.452.076.176 NLM TGC SJN M0000213 Acidosis C0001122 A pathologic condition resulting from accumulation of acid or depletion of the alkaline reserve (bicarbonate) content of the blood and body tissues, and characterized by an increase in hydrogen ion concentration (decrease in pH). (Dorland, 27th ed) T046 Pathologic Function T000399 Acidosis 1999 01 01 NLM (1966) T000399 Acidoses D000140 Acidosis, Lactic 1986 04 18 1993 05 24 1987 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI accumulation of lactic acid 87 87 Acidosis (1966-1986) Lactates (1966-1986) C18.452.076.176.180 VDK TGC PLS M0000214 Acidosis, Lactic C0001125 Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as diabetes mellitus, leukemia, or liver failure. T047 Disease or Syndrome T000401 Acidosis, Lactic 1999 01 01 NLM (1987) T000400 Lactic Acidosis 1986 04 18 UNK (19XX) D000141 Acidosis, Renal Tubular 1999 01 01 2001 07 25 1965 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI does not include TYPE IV RENAL TUBULAR ACIDOSIS 65 65 C12.777.419.815.093 C16.320.565.851.093 C18.452.076.176.210 C18.452.648.851.093 NLM nns sjn M0000215 Acidosis, Renal Tubular C0001126 A rare sometimes familial disorder of the renal tubule characterized by the inability to excrete urine of normal acidity. This leads to a hyperchloremic acidosis which is often associated with one or more secondary complications such as hypercalcinuria with nephrolithiasis and nephrocalcinosis, rickets, or osteomalacia and severe potassium depletion. T047 Disease or Syndrome M0000215 M0000216 M0000215 M0000217 T000402 Acidosis, Renal Tubular 1999 01 01 NLM (1965) T000402 Acidoses, Renal Tubular T000402 Renal Tubular Acidoses T000402 Renal Tubular Acidosis T000402 Tubular Acidoses, Renal T000402 Tubular Acidosis, Renal M0000216 Type I Renal Tubular Acidosis C0259810 T047 Disease or Syndrome M0000215 M0000216 T000405 Type I Renal Tubular Acidosis 1997 05 19 NLM (1998) T000404 Acidosis, Renal Tubular, Type I 1997 05 19 NLM (1998) T000409 Classic Distal Renal Tubular Acidosis 1997 05 19 NLM (1998) T000403 Distal Renal Tubular Acidosis 1997 05 19 NLM (1998) M0000217 Type II Renal Tubular Acidosis C0268435 T047 Disease or Syndrome M0000215 M0000217 T000408 Type II Renal Tubular Acidosis 1997 05 19 NLM (1998) T000407 Acidosis, Renal Tubular, Type II 1997 05 19 NLM (1998) T000406 Proximal Renal Tubular Acidosis 1997 05 19 NLM (1998) D000142 Acidosis, Respiratory 1999 01 01 1999 11 08 1967 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 67 67 Acidosis (1966) C08.618.846.093 C18.452.076.176.310 NLM adp sjn M0000219 Acidosis, Respiratory C0001127 Respiratory retention of carbon dioxide. It may be chronic or acute. T047 Disease or Syndrome T000411 Acidosis, Respiratory 1999 01 01 NLM (1967) T000410 Respiratory Acidosis 1974 03 29 UNK (19XX) T000410 Acidoses, Respiratory T000410 Respiratory Acidoses D000143 Acids 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; avoid; do not use for specific acids, acid-fast bacteria, acid reactions, etc. D01.029 NLM TPW SJN M0000220 Acids C0001128 0 Chemical compounds which yield hydrogen ions or protons when dissolved in water, whose hydrogen can be replaced by metals or basic radicals, or which react with bases to form salts and water (neutralization). An extension of the term includes substances dissolved in media other than water. (Grant & Hackh's Chemical Dictionary, 5th ed) T103 Chemical T000412 Acids 1999 01 01 NLM (1966) D000144 Acids, Acyclic 1999 01 01 1997 06 20 1998 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; prefer specifics; used for mapping supplementary chemicals 98; use explode 1967-97 98 D02.241.081 NLM ADP SJN M0000221 Acids, Acyclic C0001129 0 Carboxylic acids that have open-chain molecular structures as opposed to ring-shaped structures. T109 Organic Chemical T000414 Acids, Acyclic 1999 01 01 NLM (1966) T000413 Acyclic Acids 1996 12 16 NLM (1998) D000145 Acids, Aldehydic 1999 01 01 1997 06 20 1998 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; prefer specifics; used for mapping supplementary chemicals 98; use explode 1967-97 98 D02.241.152 NLM ADP SJN M0000222 Acids, Aldehydic C0001130 0 Dicarboxylic acids in which one of the carboxyl groups (-COOH) has been replaced by an aldehyde group (-CHO). T109 Organic Chemical T000416 Acids, Aldehydic 1999 01 01 NLM (1966) T000415 Aldehydic Acids 1996 12 16 NLM (1998) D000146 Acids, Carbocyclic 1999 01 01 1998 09 09 1998 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; prefer specifics; used for mapping supplementary chemicals; do not confuse with CARBOXYLIC ACIDS 98; use explode 1967-97 98 D02.241.223 NLM SJN PLS M0000223 Acids, Carbocyclic C0001131 0 Carboxylic acids that have a homocyclic ring structure in which all the ring atoms are carbon. T109 Organic Chemical T000418 Acids, Carbocyclic 1999 01 01 NLM (1966) T000417 Carbocyclic Acids 1996 12 16 NLM (1998) D000147 Acids, Heterocyclic 1999 01 01 1997 06 20 1998 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; prefer specifics; used for mapping supplementary chemicals 98; use explode 1967-97 98 D03.066 NLM ADP SJN M0000224 Acids, Heterocyclic C0001132 0 A class of acids containing a ring structure in which atleast one atom other than CARBON is incorporated. T109 Organic Chemical T000420 Acids, Heterocyclic 1999 01 01 NLM (1966) T000419 Heterocyclic Acids 1996 12 16 NLM (1998) D000148 Acids, Noncarboxylic 1999 01 01 1997 06 20 1998 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN; prefer specifics; used for mapping supplementary chemicals 98; use explode 1968-97 98 D01.029.260 NLM ADP SJN M0000225 Acids, Noncarboxylic C0001133 0 Inorganic acids with a non metal, other than carbon, attached to hydrogen, or an acid radical containing no carbon. T197 Inorganic Chemical T000422 Acids, Noncarboxylic 1999 01 01 NLM (1966) T000421 Noncarboxylic Acids 1996 12 16 NLM (1998) D000149 Acidulated Phosphate Fluoride 1976 04 16 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT 91(77); was see under SODIUM FLUORIDE 1984-90; was see under FLUORIDES 1977-83 91; was see under SODIUM FLUORIDE 1984-90; was see under FLUORIDES 1977-83 Fluorides (1966-1976) Fluorides, Topical (1966-1976) Phosphates (1966-1976) D01.303.350.300.875.050 D01.695.625.675.650.025 D01.857.725.050 D25.223.015 RLS adp sjn M0000226 Acidulated Phosphate Fluoride C0001134 Phosphoric acid, mixt. with sodium fluoride (NaF) 39456-59-2 A sodium fluoride solution, paste or powder, which has been acidulated to pH 3 to 4 and buffered with a phosphate. It is used in the prevention of dental caries. T122 Biomedical or Dental Material T197 Inorganic Chemical T000425 Acidulated Phosphate Fluoride 1999 01 01 NLM (1977) T000423 Acid Phosphate Fluoride 1980 08 13 UNK (19XX) T000423 Fluoride, Acid Phosphate T000424 Phosphate Fluoride, Acidulated 1976 04 14 UNK (19XX) T000424 Fluoride, Acidulated Phosphate D000150 Acinetobacter 1999 01 01 2003 07 09 1976 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI infection = ACINETOBACTER INFECTIONS 76(75); was see under ACHROMOBACTER 1974-75; HERELLEA was HERELLA see ACINETOBACTER 1976-91; MIMA was MIMAE see ACINETOBACTER 1976-91; MIMAE was heading 1963-75; COLLOIDES was see ACINETOBACTER 1976-91 search ALCALIGENES 1974; use ACINETOBACTER to search MIMAE 1966-91, HERELLA 1976-91, & COLLOIDES 1976-91 76; was see under ACHROMOBACTER 1974-75; HERELLEA was HERELLA see ACINETOBACTER 1976-91; MIMA was MIMAE see ACINETOBACTER 1976-91; MIMAE was heading 1963-75; COLLOIDES was see ACINETOBACTER 1976-91 Alcaligenes (1974) B03.440.400.425.537.050 B03.660.250.530.050 NLM ags sjn M0000227 Acinetobacter C0001138 A genus of gram-negative bacteria of the family MORAXELLACEAE, found in soil and water and of uncertain pathogenicity. T007 Bacterium M0000227 M0000228 M0000227 M0000229 T000426 Acinetobacter 1999 01 01 NLM (1975) M0000228 Herellea C0019268 T007 Bacterium M0000227 M0000228 T000427 Herellea 1991 04 02 NLM (1992) M0000229 Mima C0026150 T007 Bacterium M0000227 M0000229 T000428 Mima 1991 04 02 NLM (1992) D000151 Acinetobacter Infections 1976 04 16 2003 07 09 1977 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI gram-neg bact infect 77; was MIMAE INFECTIONS 1968-76 use ACINETOBACTER INFECTIONS to search MIMAE INFECTIONS 1968-76 77; was MIMAE INFECTIONS 1968-76 Acinetobacter (1966-1967) C01.252.400.560.022 FPG ags sjn M0000230 Acinetobacter Infections C0001139 Infections with bacteria of the genus ACINETOBACTER. T047 Disease or Syndrome T000430 Acinetobacter Infections 1999 01 01 ACINETOBACTER INFECT NLM (1977) T000429 Infections, Acinetobacter 1991 02 28 INFECT ACINETOBACTER NLM (1992) T000429 Acinetobacter Infection T000429 Infection, Acinetobacter T000431 Infections, Mimae 1991 02 28 INFECT MIMAE NLM (1992) T000431 Infection, Mimae T000431 Mimae Infection T000432 Mimae Infections 1976 04 14 MIMAE INFECT UNK (19XX) D000152 Acne Vulgaris 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI an acneiform eruption 93; was ACNE 1963-92 use ACNE VULGARIS to search ACNE 1966-92 93; was ACNE 1963-92 C17.800.030.150 C17.800.271.125.200 C17.800.794.111 NLM lkt sjn M0000231 Acne Vulgaris C0001144 A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors. T047 Disease or Syndrome T000434 Acne Vulgaris 1999 01 01 POPLINE (1978) T000433 Acne 1992 04 02 NLM (1993) D000153 Acne Keloid 1999 01 01 2001 07 25 1991 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI acneiform eruption with keloid scarring 91(75); was see under FOLLICULITIS 1975-90 search FOLLICULITIS 1966-74 91; was see under FOLLICULITIS 1975-90 C17.300.200.425.125 C17.800.030.030 C17.800.120.425.125 C17.800.271.125.125 C17.800.329.500.261 NLM lkt sjn M0000232 Acne Keloid C0001145 A type of acneiform disorder in which secondary pyogenic infection in and around pilosebaceous structures ends in keloidal scarring. It manifests as persistent folliculitis of the back of the neck associated with occlusion of the follicular orifices. It is most often encountered in black or Asian men. T047 Disease or Syndrome T000435 Acne Keloid 1999 01 01 NLM (1975) T000435 Acne Keloids T000435 Keloid, Acne T000435 Keloids, Acne T000436 Folliculitis Keloidalis 1992 04 06 NLM (1993) T000437 Keloidal Acne 1992 04 06 NLM (1993) T000437 Acne, Keloidal T000437 Keloidal Acnes T000438 Acne Keloidalis 1992 04 06 NLM (1993) D000154 Aconitate Hydratase 1999 01 01 2003 07 09 1978 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 78(73); was see under HYDRO-LYASES 1975-77 78; was see under HYDRO-LYASES 1975-77 Hydro-Lyases (1966-1972) D08.811.520.241.300.050 NLM ssb sjn M0000233 Aconitate Hydratase C0001156 Citrate(isocitrate) hydro-lyase EC 4.2.1.3 An enzyme that catalyzes the reversible hydration of cis-aconitate to yield citrate or isocitrate. It is one of the citric acid cycle enzymes. EC 4.2.1.3. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9024-25-3 (CAS RN) T000440 Aconitate Hydratase 1999 01 01 NLM (1973) T000440 Hydratase, Aconitate T000439 Aconitase 1977 04 01 UNK (19XX) T000441 Citrate Hydro-Lyase 1977 05 17 UNK (19XX) T000441 Citrate Hydro Lyase T000441 Hydro-Lyase, Citrate T000442 Isocitrate Hydro-Lyase 1977 05 17 UNK (19XX) T000442 Hydro-Lyase, Isocitrate T000442 Isocitrate Hydro Lyase T000443 Citrate Hydrolyase 1980 08 13 UNK (19XX) T000443 Hydrolyase, Citrate D000155 Aconite 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG an alkaloid; do not confuse with ACONITINE D03.132.026 NLM TAP PLS M0000234 Aconite C0001157 Aconite 8063-12-5 T109 Organic Chemical T121 Pharmacologic Substance T123 Biologically Active Substance T131 Hazardous or Poisonous Substance T000444 Aconite 1999 01 01 NLM (1966) D000156 Aconitic Acid 1999 01 01 1992 05 07 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(73); was see under TRICARBOXYLIC ACIDS 1973-90 91; was see under TRICARBOXYLIC ACIDS 1973-90 D02.241.081.901.177 NLM TAP PLS M0000235 Aconitic Acid C0001158 1-Propene-1,2,3-tricarboxylic acid 499-12-7 T109 Organic Chemical T123 Biologically Active Substance T000447 Aconitic Acid 1999 01 01 NLM (1975) T000447 Acid, Aconitic T000445 Achilleic Acid 1980 08 13 UNK (19XX) T000445 Acid, Achilleic T000448 Acontic Acid 1980 08 13 UNK (19XX) T000448 Acid, Acontic T000450 Carboxyglutaconic Acid 1980 08 13 UNK (19XX) T000450 Acid, Carboxyglutaconic T000452 Citridinic Acid 1980 08 13 UNK (19XX) T000452 Acid, Citridinic T000454 Pyrocitric Acid 1980 08 13 UNK (19XX) T000454 Acid, Pyrocitric T000453 Equisetic Acid 1980 08 13 UNK (19XX) T000453 Acid, Equisetic T000451 Citridic Acid 1980 08 13 UNK (19XX) T000451 Acid, Citridic T000449 Adonic Acid 1980 08 13 UNK (19XX) T000449 Acid, Adonic T000446 Aconitate 1980 08 13 UNK (19XX) D000157 Aconitine 1974 11 19 2002 07 02 1991 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not confuse with ACONITE 91(75); was see under ACONITE 1975-90 91; was see under ACONITE 1975-90 Aconite (1972-1974) D03.132.030 NLM TWD sjn M0000236 Aconitine C0001159 Aconitane-3,8,13,14,15-pentol, 20-ethyl-1,6,16-trimethoxy-4-(methoxymethyl)-, 8-acetate 14-benzoate, (1alpha,3alpha,6alpha,14alpha,15alpha,16beta)- 302-27-2 A alkaloid from the root of Aconitum napellus L. and other aconites. Activates voltage-gated Na+ channels. Has been used to induce arrhythmia in experimental animals. Shows antiinflammatory and antineuralgic properties. T109 Organic Chemical T121 Pharmacologic Substance D000276 Adjuvants, Immunologic T000456 Aconitine 1999 01 01 NLM (1975) T000455 Acetylbenzoylaconine 1974 11 11 UNK (19XX) D000158 Acoustic Impedance Tests 1977 04 22 1997 06 20 1978 01 01 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES do not use /util except by MeSH definition 78 78 Audiometry (1966-1977) Ear, Middle (1966-1977) Tympanic Membrane (1966-1977) E01.370.382.375.050 SMH PXP SJN M0000237 Acoustic Impedance Tests C0001161 Objective tests of middle ear function based on the difficulty (impedance) or ease (admittance) of sound flow through the middle ear. These include static impedance and dynamic impedance (i.e., tympanometry and impedance tests in conjunction with intra-aural muscle reflex elicitation). This term is used also for various components of impedance and admittance (e.g., compliance, conductance, reactance, resistance, susceptance). T060 Diagnostic Procedure M0000237 M0000238 M0000237 M0000239 M0000237 M0000240 T000458 Acoustic Impedance Tests 1999 01 01 NLM (1978) T000457 Impedance Tests, Acoustic 1977 04 20 UNK (19XX) T000457 Acoustic Impedance Test T000457 Impedance Test, Acoustic T000457 Test, Acoustic Impedance T000457 Tests, Acoustic Impedance M0000238 Tympanometry C0085853 T060 Diagnostic Procedure M0000237 M0000238 T000459 Tympanometry 1977 04 20 UNK (19XX) M0000239 Electroacoustic Impedance Tests C0086204 T060 Diagnostic Procedure M0000237 M0000239 T000460 Electroacoustic Impedance Tests 1977 04 20 UNK (19XX) T000460 Electroacoustic Impedance Test T000460 Impedance Test, Electroacoustic T000460 Impedance Tests, Electroacoustic T000460 Test, Electroacoustic Impedance T000460 Tests, Electroacoustic Impedance M0000240 Audiometry, Impedance C0205639 T060 Diagnostic Procedure M0000237 M0000240 T000461 Audiometry, Impedance 1977 04 20 UNK (19XX) T000461 Impedance Audiometry D000159 Vestibulocochlear Nerve 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI neopl: coord VESTIBULOCOCHLEAR NERVE DISEASES (IM) with CRANIAL NERVE NEOPLASMS (IM) + histol type of neopl (IM) but note that NEUROMA, ACOUSTIC is also available 2000(1963) 2000; see ACOUSTIC NERVE 1963-1999; for VESTIBULOCOCHLEAR NERVE see ACOUSTIC NERVE 1963-1999 A08.800.800.120.910 NLM ags sjn M0000241 Vestibulocochlear Nerve C0001162 The 8th cranial nerve. The vestibulocochlear nerve has a cochlear part (COCHLEAR NERVE) which is concerned with hearing and a vestibular part (VESTIBULAR NERVE) which mediates the sense of balance and head position. The fibers of the cochlear nerve originate from neurons of the SPIRAL GANGLION and project to the cochlear nuclei (COCHLEAR NUCLEUS). The fibers of the vestibular nerve arise from neurons of Scarpa's ganglion and project to the VESTIBULAR NUCLEI. T023 Body Part, Organ, or Organ Component T000465 Vestibulocochlear Nerve 1992 11 16 NLM (1994) T000465 Nerve, Vestibulocochlear T000465 Nerves, Vestibulocochlear T000465 Vestibulocochlear Nerves T000466 Cranial Nerve VIII 1996 07 31 NLM (1998) T000466 Cranial Nerve VIIIs T000466 Nerve VIIIs, Cranial T000466 VIIIs, Cranial Nerve T000464 Eighth Cranial Nerve 1996 07 31 NLM (1998) T000464 Cranial Nerve, Eighth T000464 Cranial Nerves, Eighth T000464 Eighth Cranial Nerves T000464 Nerve, Eighth Cranial T000464 Nerves, Eighth Cranial D000160 Vestibulocochlear Nerve Diseases 1978 05 22 2001 07 25 1980 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI coord IM with COCHLEAR NERVE (IM) for cochlear nerve dis or with VESTIBULAR NERVE (IM) for vestibular nerve dis: neopl: coord IM with CRANIAL NERVE NEOPLASMS (IM) + histol type of neopl (IM); DF: ACOUSTIC NERVE DIS 2000(1979) 2000; see ACOUSTIC NERVE DISEASES 1980-1999, use PERIPHERAL NERVE DISEASES 1979 Acoustic Nerve (1966-1978) Cochlear Nerve (1966-1978) Peripheral Nerve Diseases (1966-1978) Vestibular Nerve (1966-1978) D006313 Hearing Loss, Central D020209 Cranial Nerve Injuries C09.218.807.800 C10.292.910 RC nns sjn M0000242 Vestibulocochlear Nerve Diseases C0001163 Diseases of the vestibular and/or cochlear (acoustic) nerves, which join to form the vestibulocochlear nerve. VESTIBULAR NEURITIS, cochlear neuritis, and acoustic neuromas (NEUROMA, ACOUSTIC) are relatively common conditions that affect these nerves. Clinical manifestations vary with which nerve is primarily affected, and include hearing loss, vertigo, and tinnitus. T047 Disease or Syndrome M0000242 M0333671 M0000242 M0333672 M0000242 M0333670 T365622 Vestibulocochlear Nerve Diseases 1999 11 03 VESTIBULOCOCHLEAR NERVE DIS NLM (2000) T365622 Vestibulocochlear Nerve Disease T365623 Cranial Nerve VIII Diseases 1999 11 03 CRANIAL NERVE VIII DIS NLM (2000) T365626 Cranial Nerve VIII Disorders 1999 11 03 NLM (2000) T365627 Eighth Cranial Nerve Diseases 1999 11 03 EIGHTH CRANIAL NERVE DIS NLM (2000) M0333671 Acoustic Nerve Diseases C0750885 T047 Disease or Syndrome M0000242 M0333671 T000467 Acoustic Nerve Diseases 1999 01 01 ACOUSTIC NERVE DIS NLM (1979) T000467 Acoustic Nerve Disease T365628 Acoustic Nerve Disorders 1999 11 03 NLM (2000) T365628 Acoustic Nerve Disorder T365624 Cochlear Nerve Diseases 1999 11 03 COCHLEAR NERVE DIS NLM (2000) T365624 Cochlear Nerve Disease T365629 Cochlear Nerve Disorders 1999 11 03 NLM (2000) T365629 Cochlear Nerve Disorder M0333672 Cochlear Neuritis C0750884 T047 Disease or Syndrome M0000242 M0333672 T365631 Cochlear Neuritis 1999 11 03 NLM (2000) T365631 Cochlear Neuritides T365631 Neuritides, Cochlear T365631 Neuritis, Cochlear M0333670 Vestibular Nerve Diseases C0750886 T047 Disease or Syndrome M0000242 M0333670 T365625 Vestibular Nerve Diseases 1999 11 03 VESTIBULAR NERVE DIS NLM (2000) T365625 Vestibular Nerve Disease T365630 Vestibular Nerve Disorders 1999 11 03 NLM (2000) T365630 Vestibular Nerve Disorder D000161 Acoustic Stimulation 1999 01 01 2001 07 25 1973 01 01 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES Q000193 education ED Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000458 organization & administration OG 73(72) 73 Sound (1966-1971) D005072 Evoked Potentials, Auditory D009147 Music Therapy E02.190.888.030 E02.779.124 E05.723.136 NLM ssb sjn M0000243 Acoustic Stimulation C0001164 Use of sound to elicit a response in the nervous system. T060 Diagnostic Procedure T061 Therapeutic or Preventive Procedure T000469 Acoustic Stimulation 1999 01 01 NLM (1973) T000468 Stimulation, Acoustic 1976 04 22 UNK (19XX) T000470 Auditory Stimulation 1990 10 02 NLM (1992) T000471 Stimulation, Auditory 1990 10 02 NLM (1992) D000162 Acoustics 1999 01 01 1995 03 13 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000295 instrumentation IS in speech & hearing research & for the environment (home, hospital, facilities, theater, etc.) D011571 Psychoacoustics D013061 Speech Acoustics H01.671.031 NLM TGC PLS M0000244 Acoustics C0001166 The branch of physics that deals with sound and sound waves. In medicine it is often applied in procedures in speech and hearing studies. With regard to the environment, it refers to the characteristics of a room, auditorium, theatre, building, etc. that determines the audibility or fidelity of sounds in it. (From Random House Unabridged Dictionary, 2d ed) T070 Natural Phenomenon or Process T000472 Acoustics 1999 01 01 NLM (1966) T000472 Acoustic D000163 Acquired Immunodeficiency Syndrome 1983 03 18 1999 11 08 1983 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI caused by HIV; coord IM with HIV-1 or HIV-2 (IM) if pertinent; /epidemiol: consider also HIV SEROPREVALENCE; AIDS-RELATED OPPORTUNISTIC INFECTIONS is available if particularly discussed: see note there; for lymphoma with AIDS, use LYMPHOMA, AIDS-RELATED 83 83 Immunologic Deficiency Syndromes (1979-1982) D006679 HIV Seropositivity D015492 AIDS Serodiagnosis D015526 AIDS Dementia Complex D015528 HIV Seroprevalence D016483 Lymphoma, AIDS-Related D020943 AIDS Arteritis, Central Nervous System C02.782.815.616.400.040 C02.800.801.400.040 C02.839.040 C20.673.480.040 AEP KEV sjn M0000245 Acquired Immunodeficiency Syndrome C0001175 An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. T047 Disease or Syndrome T000474 Acquired Immunodeficiency Syndrome 1999 01 01 ACQUIRED IMMUNODEFIC SYNDROME POPLINE (1986) T000476 Acquired Immune Deficiency Syndrome 1985 10 24 ACQUIRED IMMUNE DEFIC SYNDROME NLM (1986) T000477 Acquired Immuno-Deficiency Syndrome 1983 03 18 ACQUIRED IMMUNO DEFIC SYNDROME UNK (19XX) T000477 Acquired Immuno Deficiency Syndrome T000477 Acquired Immuno-Deficiency Syndromes T000477 Immuno-Deficiency Syndrome, Acquired T000477 Immuno-Deficiency Syndromes, Acquired T000477 Syndrome, Acquired Immuno-Deficiency T000477 Syndromes, Acquired Immuno-Deficiency T000475 AIDS 1983 03 18 BIOETHICS (1983) T000473 Immunodeficiency Syndrome, Acquired 1983 03 18 IMMUNODEFIC SYNDROME ACQUIRED UNK (19XX) T000473 Acquired Immunodeficiency Syndromes T000473 Immunodeficiency Syndromes, Acquired T000473 Syndrome, Acquired Immunodeficiency T000473 Syndromes, Acquired Immunodeficiency T000478 Immunologic Deficiency Syndrome, Acquired 1983 03 18 IMMUNOL DEFIC SYNDROME ACQUIRED UNK (19XX) D000164 Acremonium 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI 86(63) 86; see CEPHALOSPORIUM 1963-85 B05.381.025 NLM ags sjn M0000246 Acremonium C0001180 A mitosporic fungal genus with many reported ascomycetous teleomorphs. Cephalosporin antibiotics are derived from this genus. T004 Fungus T000479 Acremonium 1999 01 01 NLM (1966) T000480 Cephalosporium 1985 02 11 UNK (19XX) D000165 Acridine Orange 1978 02 01 2001 07 25 1979 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000031 analogs & derivatives AA D25-26 qualif 79 79 Acridines (1966-1978) Dimethylamines (1974) D03.494.046.250.150 SH jmp sjn M0000247 Acridine Orange C0001185 3,6-Acridinediamine, N,N,N',N'-tetramethyl-, monohydrochloride 65-61-2 A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid D005456 Fluorescent Dyes D009153 Mutagens 494-38-2 (parent cpd) M0000247 M0373511 M0000247 M0373513 M0000247 M0373512 M0000247 M0330707 T000482 Acridine Orange 1999 01 01 NLM (1979) T000482 Orange, Acridine M0373511 Basic Orange 3RN C0919265 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000247 M0373511 T000483 Basic Orange 3RN 1991 02 20 NLM (1992) T000483 Orange 3RN, Basic M0373513 C.I. 46005 C0919264 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000247 M0373513 T000484 C.I. 46005 1991 02 20 NLM (1992) M0373512 C.I. Basic Orange 14 C0919263 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000247 M0373512 T000485 C.I. Basic Orange 14 1991 02 20 NLM (1992) M0330707 Tetramethyl Acridine Diamine C0087077 494-38-2 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000247 M0330707 T000487 Tetramethyl Acridine Diamine 1978 02 01 UNK (19XX) T000487 Acridine Diamine, Tetramethyl T000487 Diamine, Tetramethyl Acridine T000481 3,6-Bis(dimethylamino)acridine 1980 08 13 UNK (19XX) T360901 Acridine Orange Base 1999 09 13 NLM (1999) T360901 Base, Acridine Orange T360901 Orange Base, Acridine T000486 Rhoduline Orange 1991 02 20 NLM (1992) T000486 Orange, Rhoduline D000166 Acridines 1999 01 01 1991 11 02 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif; acridinamines & acridinylamines = AMINOACRIDINES D03.494.046 NLM PLS PLS M0000249 Acridines C0001186 0 T109 Organic Chemical T000488 Acridines 1999 01 01 POPLINE (1984) D000167 Acriflavine 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000031 analogs & derivatives AA D25-26 qualif 91(75); was see under AMINOACRIDINES 1982-90; was see under ACRIDINES 1963-81 search ACRIDINES 1966-74 91; was see under AMINOACRIDINES 1982-90; was see under ACRIDINES 1963-81 D03.494.046.250.177 NLM jmp sjn M0000250 Acriflavine C0001187 Acridinium, 3,6-diamino-10-methyl-, chloride, mixt. with 3,6-acridinediamine 8048-52-0 3,6-Diamino-10-methylacridinium chloride mixt. with 3,6-acridinediamine. Fluorescent dye used as a local antiseptic and also as a biological stain. It intercalates into nucleic acids thereby inhibiting bacterial and viral replication. T109 Organic Chemical T121 Pharmacologic Substance T130 Indicator, Reagent, or Diagnostic Aid D000891 Anti-Infective Agents, Local D005456 Fluorescent Dyes 65589-70-0 (cpd with unknown MF) 8018-07-3 (di-HCl) 8063-24-9 (tri-HCl) M0000250 M0330709 M0000250 M0330710 T000489 Acriflavine 1999 01 01 NLM (1975) T000492 Euflavin 1978 12 18 UNK (19XX) T000490 Euflavine 1976 12 23 UNK (19XX) T000491 Xanthacridinum 1976 12 23 UNK (19XX) M0330709 Acriflavine Dihydrochloride C0282039 8018-07-3 T109 Organic Chemical T121 Pharmacologic Substance T130 Indicator, Reagent, or Diagnostic Aid M0000250 M0330709 T360903 Acriflavine Dihydrochloride 1999 09 13 NLM (1999) T360903 Dihydrochloride, Acriflavine T000494 Acriflavine Chloride 1994 10 20 INN (19XX) NLM (1996) T000494 Chloride, Acriflavine M0330710 Acriflavine Trichydrochloride C0887523 8063-24-9 T109 Organic Chemical T121 Pharmacologic Substance T130 Indicator, Reagent, or Diagnostic Aid M0000250 M0330710 T360904 Acriflavine Trichydrochloride 1999 09 13 NLM (1999) T360904 Trichydrochloride, Acriflavine D000168 Acrocephalosyndactylia 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI congen deform of skull, fingers & toes; do not use /congen & do not coord with INFANT, NEWBORN, DISEASES C05.116.099.370.894.232.015 C05.116.099.370.894.819.100 C05.660.207.240.100 C05.660.585.800.100 C05.660.906.364.100 C05.660.906.819.100 C16.131.621.207.240.100 C16.131.621.585.800.100 C16.131.621.906.364.100 C16.131.621.906.819.100 NLM kle sjn M0000253 Acrocephalosyndactylia C0001193 Craniostenosis characterized by acrocephaly and syndactyly, probably occurring as an autosomal dominant trait and usually as a new mutation. (Dorland, 27th ed) T019 Congenital Abnormality M0000253 M0000256 M0000253 M0000255 M0000253 M0000254 T000495 Acrocephalosyndactylia 1999 01 01 NLM (1966) T000495 Acrocephalosyndactylias M0000256 Apert Syndrome C0685204 T019 Congenital Abnormality M0000253 M0000256 T000498 Apert Syndrome 1984 04 06 UNK (19XX) T000498 Syndrome, Apert M0000255 Pfeiffer Syndrome C0265303 T019 Congenital Abnormality M0000253 M0000255 T000497 Pfeiffer Syndrome 1995 09 26 NLM (1997) T000497 Syndrome, Pfeiffer M0000254 Saethre-Chotzen Syndrome C0175699 T019 Congenital Abnormality T047 Disease or Syndrome M0000253 M0000254 T000496 Saethre-Chotzen Syndrome 1996 06 20 NLM (1997) T000496 Saethre Chotzen Syndrome T000496 Syndrome, Saethre-Chotzen D000169 Acrodermatitis 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI dermatitis of hands or feet so do not bother to coord with HAND DERMATOSES or FOOT DERMATOSES unless particularly discussed C16.131.831.066 C17.800.174.100 C17.800.804.066 NLM nns sjn M0000257 Acrodermatitis C0001197 Inflammation involving the skin of the extremities, especially the hands and feet. Several forms are known, some idiopathic and some hereditary. The infantile form is called Gianotti-Crosti syndrome. T047 Disease or Syndrome M0000257 M0000258 T000499 Acrodermatitis 1999 01 01 NLM (1966) T000499 Acrodermatitides M0000258 Gianotti-Crosti Syndrome C0263372 T047 Disease or Syndrome M0000257 M0000258 T000500 Gianotti-Crosti Syndrome 1998 02 23 NLM (1999) T000500 Gianotti Crosti Syndrome T000500 Syndrome, Gianotti-Crosti T000501 Infantile Papular Acrodermatitis 1998 02 23 NLM (1999) T000501 Acrodermatitides, Infantile Papular T000501 Acrodermatitis, Infantile Papular T000501 Infantile Papular Acrodermatitides T000501 Papular Acrodermatitides, Infantile T000501 Papular Acrodermatitis, Infantile D000170 Acrodynia 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C10.668.829.025 C10.720.475.600.150 C21.613.647.500.100 NLM KEV sjn M0000259 Acrodynia C0001198 A condition seen primarily in childhood, most often resulting from chronic exposure to MERCURY COMPOUNDS which may result in ENCEPHALOPATHY and POLYNEUROPATHY. Clinical features include pain, swelling and pinkish discoloration of the fingers and toes, weakness in the extremities, extreme irritability, HYPERESTHESIA, and alterations in level of consciousness. (From Menkes, Textbook of Child Neurology, 5th ed, p603) T037 Injury or Poisoning T000502 Acrodynia 1999 01 01 NLM (1966) T000504 Feer Disease 1984 06 15 FEER DIS UNK (19XX) T000505 Feer's Disease 1974 03 29 FEERS DIS UNK (19XX) T000505 Feers Disease T000506 Pink Disease 1974 03 29 PINK DIS UNK (19XX) T000507 Swift Disease 1984 06 15 SWIFT DIS UNK (19XX) T000508 Swift's Disease 1974 03 29 SWIFTS DIS UNK (19XX) T000508 Swifts Disease T369773 Acrodynic Erythema 1999 11 03 NLM (2000) T369773 Erythema, Acrodynic T369774 Chronic Childhood Mercurialism 1999 11 03 NLM (2000) T369774 Childhood Mercurialism, Chronic T369774 Childhood Mercurialisms, Chronic T369774 Chronic Childhood Mercurialisms T369774 Mercurialism, Chronic Childhood D000171 Acrolein 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(73); was see under ALDEHYDES 1973-90 search ALDEHYDES 1966-72 91; was see under ALDEHYDES 1973-90 D02.047.122 NLM CCR sjn M0000260 Acrolein C0001204 2-Propenal 107-02-8 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000260 M0350817 T000511 Acrolein 1999 01 01 NLM (1973) T000509 2-Propenal 1980 08 13 UNK (19XX) T000509 2 Propenal T000510 Acraldehyde 1980 08 13 UNK (19XX) T000512 Acrylaldehyde 1980 08 13 UNK (19XX) T000513 Acrylic Aldehyde 1980 08 13 UNK (19XX) T000513 Aldehyde, Acrylic T000514 Allyl Aldehyde 1980 08 13 UNK (19XX) T000514 Aldehyde, Allyl T000516 Ethylene Aldehyde 1980 08 13 UNK (19XX) T000516 Aldehyde, Ethylene M0350817 Aqualin C0878175 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000260 M0350817 T000515 Aqualin 1980 08 13 UNK (19XX) D000172 Acromegaly 1999 01 01 2002 07 03 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI coord with GROWTH HORMONE /secret (in animals) or SOMATROPIN /secret (in humans) if pertinent C05.116.132.082 C10.228.140.617.738.250.100 C19.700.355.179 NLM sjn sjn M0000261 Acromegaly C0001206 A disorder caused by excessive secretion of GROWTH HORMONE, characterized by bony enlargement of the face (especially prognathism), hands, feet, head, and thorax. Impaired glucose tolerance; HYPERTENSION; ARTHRITIS; diffuse hyperplasia of soft tissues; CARPAL TUNNEL SYNDROME; visceromegaly; and MUSCULAR WEAKNESS are frequently associated with this condition. The most common etiology is a GROWTH HORMONE secreting pituitary ADENOMA (see also PITUITARY NEOPLASMS). (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) T047 Disease or Syndrome T000517 Acromegaly 1999 01 01 NLM (1966) T365908 Inappropriate Growth Hormone Secretion Syndrome (Acromegaly) 1999 11 04 INAPPROPRIATE GROWTH HORMONE SECRET SYNDROME ACROMEGALY NLM (2000) T365909 Somatotropin Hypersecretion Syndrome (Acromegaly) 1999 11 04 SOMATOTROPIN HYPERSECRET SYNDROME ACROMEGALY NLM (2000) T365909 Hypersecretion Syndrome, Somatotropin (Acromegaly) T365909 Hypersecretion Syndromes, Somatotropin (Acromegaly) T365909 Somatotropin Hypersecretion Syndromes (Acromegaly) T365909 Syndrome, Somatotropin Hypersecretion (Acromegaly) T365909 Syndromes, Somatotropin Hypersecretion (Acromegaly) T365910 Inappropriate GH Secretion Syndrome (Acromegaly) 1999 11 04 INAPPROPRIATE GH SECRET SYNDROME ACROMEGALY NLM (2000) D000173 Acromioclavicular Joint 1999 01 01 1999 11 08 1979 01 01 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI dislocation: coord (IM) with DISLOCATIONS (IM) 79(75); was see under SHOULDER JOINT 1965-78, was see under SHOULDER 1963-64 search SHOULDER JOINT 1966-74 79; was see under SHOULDER JOINT 1965-78, was see under SHOULDER 1963-64 Shoulder Joint (1966-1974) A02.835.583.032 NLM jls sjn M0000262 Acromioclavicular Joint C0001208 The gliding joint formed by the outer extremity of the CLAVICLE and the inner margin of the acromion process of the SCAPULA. T030 Body Space or Junction T000518 Acromioclavicular Joint 1999 01 01 NLM (1975) T000518 Acromioclavicular Joints T000518 Joint, Acromioclavicular T000518 Joints, Acromioclavicular D000174 Acromion 1999 01 01 1999 11 03 1991 01 01 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI part of the scapula; fracture = ACROMION /inj (IM) + FRACTURES (IM), not SHOULDER FRACTURES 91(75); was see under SCAPULA 1975-90 search SCAPULA 1966-74 91; was see under SCAPULA 1975-90 A02.835.232.087.783.261 NLM jls sjn M0000263 Acromion C0001209 The lateral extension of the spine of the SCAPULA and the highest point of the SHOULDER. T023 Body Part, Organ, or Organ Component T000519 Acromion 1999 01 01 NLM (1975) T000519 Acromions D000175 Acronine 1974 11 19 2002 07 02 1991 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn permitted if by plant 91(75); was see under ALKALOIDS 1975-90 91; was see under ALKALOIDS 1975-90 Acridines (1971-1974) Alkaloids (1971-1974) D03.132.035 D03.494.046.220 NLM ssb sjn M0000264 Acronine C0001210 7H-Pyrano(2,3-c)acridin-7-one, 3,12-dihydro-6-methoxy-3,3,12-trimethyl- 7008-42-6 A pyrano-acridone alkaloid found in RUTACEAE plants. T109 Organic Chemical T121 Pharmacologic Substance D000972 Antineoplastic Agents, Phytogenic T000520 Acronine 1999 01 01 INN (19XX) USAN (1969) T000522 Acronycin 1974 11 11 UNK (19XX) T000521 Acronycine 1974 11 11 UNK (19XX) D000176 Acrosin 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under SERINE ENDOPEPTIDASES 1975-90 91; was see under SERINE PROTEINASES 1975-90 Peptide Peptidohydrolases (1973-1974) D08.811.277.656.300.760.030 NLM ssb sjn M0000265 Acrosin C0001214 EC 3.4.21.10 A trypsin-like enzyme of spermatozoa which is not inhibited by alpha 1 antitrypsin. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000265 M0000266 T000523 Acrosin 1999 01 01 NLM (1975) T000524 Acrosomal proteinase 1974 11 11 UNK (19XX) T000524 proteinase, Acrosomal T000525 Akrosin 1974 11 11 UNK (19XX) M0000266 M beta-Acrosin C0024388 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000265 M0000266 T000526 M beta-Acrosin 1984 09 18 UNK (19XX) T000526 M beta Acrosin T000526 beta-Acrosin, M D000177 Acrosome 1974 11 11 2003 07 09 1991 01 01 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI 91(75); was see under SPERMATOZOA 1975-90 91; was see under SPERMATOZOA 1975-90 D020101 Acrosome Reaction A05.360.490.890.820.100 A11.284.430.214.190.875.190.550.040 A11.497.760.400.100 NLM nns sjn M0000267 Acrosome C0001216 The cap-like structure covering the anterior portion of SPERM HEAD. Acrosome, derived from LYSOSOMES, is a membrane-bound organelle that contains the required hydrolytic and proteolytic enzymes necessary for sperm penetration of the egg in FERTILIZATION. T026 Cell Component T000527 Acrosome 1999 01 01 NLM (1975) T000527 Acrosomes D000178 Acrylamides 1999 01 01 1998 06 10 1973 01 01 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG ACRYLAMIDE is also available 73(71) 73 Acrylates (1966-1970) D02.065.122 D02.241.081.069.094 NLM ADP SJN M0000268 Acrylamides C0001218 0 Colorless, odorless crystals that are used extensively in research laboratories for the preparation of polyacrylamide gels for electrophoresis and in organic synthesis, and polymerization. Some of its polymers are used in sewage and wastewater treatment, permanent press fabrics, and as soil conditioning agents. T109 Organic Chemical T000528 Acrylamides 1999 01 01 NLM (1971) D000179 Acrylates 1999 01 01 1992 05 07 1966 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66 66 D02.241.081.069 NLM TAP PLS M0000269 Acrylates C0001219 0 T109 Organic Chemical T000529 Acrylates 1999 01 01 NLM (1966) D000180 Acrylic Resins 1999 01 01 1991 06 24 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif D003764 Dental Materials D25.720.716.822.111 NLM TAP PLS M0000270 Acrylic Resins C0001222 0 T122 Biomedical or Dental Material T000530 Acrylic Resins 1999 01 01 NLM (1966) T000530 Resins, Acrylic D000181 Acrylonitrile 1976 04 13 1998 06 10 1991 01 01 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(77) 91; see NITRILES 1977-90 Acrylates (1968-1976) Nitriles (1968-1976) Vinyl Compounds (1973-1976) D02.626.095 RLS KEV SJN M0000271 Acrylonitrile C0001223 2-Propenenitrile 107-13-1 A highly poisonous compound used widely in the manufacture of plastics, adhesives and synthetic rubber. T109 Organic Chemical T131 Hazardous or Poisonous Substance D002273 Carcinogens T000531 Acrylonitrile 1999 01 01 NLM (1977) T000532 Vinyl Cyanide 1976 04 13 UNK (19XX) T000532 Cyanide, Vinyl D000182 ACTH Syndrome, Ectopic 1979 05 29 1996 06 10 1991 01 01 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI caused by "ACTH production by non-pituitary neoplasms"; do not use /blood supply /chem /second /secret /ultrastruct; coord IM with precoord organ/neopl term with /secret (IM) + histol type of neopl /secret (IM) 91(80); was see under NEOPLASTIC ENDOCRINE-LIKE SYNDROMES 1980-90 91; was see under NEOPLASTIC ENDOCRINE-LIKE SYNDROMES 1980-90 Adrenocorticotropic Hormone (1966-1979) C04.588.322.443.317 C04.730.713.317 C19.344.443.317 C19.576.317 VDK TPW PLS M0000272 ACTH Syndrome, Ectopic C0001231 Symptom complex due to ACTH production by non-pituitary neoplasms. T047 Disease or Syndrome T000534 ACTH Syndrome, Ectopic 1999 01 01 NLM (1980) T000533 Ectopic ACTH Syndrome 1979 05 29 UNK (19XX) T000533 ACTH Syndromes, Ectopic T000533 Ectopic ACTH Syndromes T000533 Syndrome, Ectopic ACTH T000533 Syndromes, Ectopic ACTH D000183 Actihaemyl 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under TISSUE EXTRACTS 1975-90 91; was see under TISSUE EXTRACTS 1975-90 Blood (1973-1974) Tissue Extracts (1973-1974) D20.777.050 D24.185.893.050 NLM ssb sjn M0000273 Actihaemyl C0001237 Actihaemyl 37239-28-4 An extract from calf blood containing inorganic salts, amino acids, polypeptides and purines, but no proteins nor antigenic substances or blood group characteristics. Its exact composition is unknown. It has been proposed as a radiation-protective agent. T109 Organic Chemical T121 Pharmacologic Substance T123 Biologically Active Substance M0000273 M0373514 T000535 Actihaemyl 1999 01 01 NLM (1975) T000537 Solcoseryl 1974 11 11 UNK (19XX) M0373514 S 1021 C0949209 0 T109 Organic Chemical T121 Pharmacologic Substance T123 Biologically Active Substance M0000273 M0373514 T000536 S 1021 1980 07 31 UNK (19XX) T000536 1021, S D000184 Acting Out 1999 01 01 1997 06 20 1968 01 01 1998 1999 2000 2001 2002 2003 2004 no qualif 68 68 Psychoanalytic Therapy (1966-1967) F01.393.047 NLM PXP SJN M0000274 Acting Out C0001241 Expressing unconscious emotional conflicts or feelings, often of hostility or love, through overt behavior. T055 Individual Behavior T000538 Acting Out 1999 01 01 NLM (1968) D000185 Actinin 1975 07 23 1995 06 08 1985 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG a muscle & microfilament protein; /biosyn /physiol permitted 85(76); was see under MUSCLE PROTEINS 1976-84 85; was see under MUSCLE PROTEINS 1976-84 Muscle Proteins (1970-1975) D12.776.210.500.095 D12.776.220.525.065 RLS AGS PLS M0000275 Actinin C0001245 Actinins, alpha- 11003-00-2 A protein factor that regulates the length of R-actin. It is chemically similar, but immunochemically distinguishable from actin. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000275 M0000276 M0000275 M0000277 M0000275 M0000278 T000539 Actinin 1999 01 01 NLM (1976) M0000276 beta-Actinin C0005187 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000275 M0000276 T000540 beta-Actinin 1983 03 30 UNK (19XX) T000540 beta Actinin M0000277 Eu-Actinin C0015145 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000275 M0000277 T000541 Eu-Actinin 1981 06 04 UNK (19XX) T000541 Eu Actinin M0000278 alpha-Actinin C0600147 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000275 M0000278 T000542 alpha-Actinin 1984 04 16 UNK (19XX) T000542 alpha Actinin D000186 Actinium 1999 01 01 2001 07 25 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG naturally radioactive; IM D01.268.033.033 D01.268.271.545.033 D01.268.556.025 D01.552.517.042 D01.552.544.025 NLM jmp sjn M0000279 Actinium C0001246 Actinium 7440-34-8 Actinium. A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, atomic number 89, and atomic weight 227.0278. Its principal isotope is 227 and decays primarily by beta-emission. T196 Element, Ion, or Isotope T000543 Actinium 1999 01 01 NLM (1966) D000187 Actinobacillosis 1999 01 01 2003 07 30 1968 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI a vet dis entity caused by Actinobacillus lignieresii: do not confuse with ACTINOBACILLUS INFECTIONS; check tag ANIMALS 68 68 Cattle Diseases (1966-1967) C01.252.400.700.030.178 C22.039 NLM ags sjn M0000280 Actinobacillosis C0001247 A disease characterized by suppurative and granulomatous lesions in the respiratory tract, upper alimentary tract, skin, kidneys, joints, and other tissues. Actinobacillus lignieresii infects cattle and sheep while A. equuli infects horses and pigs. T047 Disease or Syndrome T000544 Actinobacillosis 1999 01 01 NLM (1968) T000544 Actinobacilloses D000188 Actinobacillus 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI infection = ACTINOBACILLUS INFECTIONS or ACTINOBACILLOSIS: see notes there B03.440.450.009 B03.660.250.550.050 NLM ags sjn M0000281 Actinobacillus C0001248 A genus of PASTEURELLACEAE described as gram-negative, nonsporeforming, nonmotile, facultative anaerobes. Most members are found both as pathogens and commensal organisms in the respiratory, alimentary, and genital tracts of animals. T007 Bacterium T000545 Actinobacillus 1999 01 01 NLM (1966) D000189 Actinobacillus Infections 1999 01 01 1991 06 17 1972 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with ACTINOBACILLOSIS, a specific vet dis entity caused by A. lignieresii 72 72 Actinobacillosis (1968-1971) Actinobacillus (1966-1971) C01.252.400.700.030 NLM PXP PLS M0000282 Actinobacillus Infections C0001249 Infections with bacteria of the genus ACTINOBACILLUS. T047 Disease or Syndrome T000547 Actinobacillus Infections 1999 01 01 ACTINOBACILLUS INFECT NLM (1972) T000546 Infections, Actinobacillus 1991 02 28 INFECT ACTINOBACILLUS NLM (1992) T000546 Actinobacillus Infection T000546 Infection, Actinobacillus D000190 Actinomyces 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI a genus of the family ACTINOMYCETACEAE of the order ACTINOMYCETALES; infection = ACTINOMYCOSIS B03.510.024.049.050.050 B03.510.460.400.400.049.049.178 NLM SYSTEM sjn M0000283 Actinomyces C0001250 A genus of gram-positive, rod-shaped bacteria whose organisms are nonmotile. Filaments that may be present in certain species are either straight or wavy and may have swollen or clubbed heads. T007 Bacterium T000548 Actinomyces 1999 01 01 NLM (1966) D000191 Actinomycetaceae 1999 01 01 2003 07 09 1975 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI a family of the order ACTINOMYCETALES 75 75 Actinomycetales (1966-1974) B03.510.024.049.050 B03.510.460.400.400.049.049 NLM SYSTEM sjn M0000284 Actinomycetaceae C0001253 A family of bacteria including numerous parasitic and pathogenic forms. T007 Bacterium T000549 Actinomycetaceae 1999 01 01 NLM (1975) D000192 Actinomycetales 1999 01 01 2003 07 09 1967 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI infection = ACTINOMYCETALES INFECTIONS 67; was ACTINOMYCETES 1963-66; CORYNEBACTERIACEAE was heading 1975-91 (see under CORYNEFORM GROUP 1976-90); CORYNEFORM GROUP was heading 1976-91 use ACTINOMYCETALES to search ACTINOMYCETES 1966; CORYNEBACTERIACEAE 1975-91; CORYNEFORM GROUP 1976-91 67; was ACTINOMYCETES 1963-66; CORYNEBACTERIACEAE was heading 1975-91 (see under CORYNEFORM GROUP 1976-90); CORYNEFORM GROUP was heading 1976-91 B03.510.024.049 NLM SYSTEM sjn M0000285 Actinomycetales C0001254 An order of gram-positive, primarily aerobic BACTERIA that tend to form branching filaments. T007 Bacterium M0000285 M0000286 M0000285 M0000287 T000550 Actinomycetales 1999 01 01 NLM (1967) M0000286 Corynebacteriaceae C0010147 T007 Bacterium M0000285 M0000286 T000551 Corynebacteriaceae 1991 04 15 UNK (1992) M0000287 Coryneform Group C0010158 T007 Bacterium M0000285 M0000287 T000552 Coryneform Group 1991 04 15 UNK (1992) D000193 Actinomycetales Infections 1999 01 01 1993 06 02 1972 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI gram-pos bact infect by organism of the order ACTINOMYCETALES; do not confuse with ACTINOMYCOSIS, infection by genus ACTINOMYCES 77; was ACTINOMYCETE INFECTIONS 1972-76 use ACTINOMYCETALES INFECTIONS to search ACTINOMYCETE INFECTIONS 1972-76 77; was ACTINOMYCETE INFECTIONS 1972-76 Actinomyces (1966-1971) Actinomycetales (1966-1971) C01.252.410.040 NLM PLS PLS M0000289 Actinomycetales Infections C0001255 Infections with bacteria of the order ACTINOMYCETALES. T047 Disease or Syndrome T000555 Actinomycetales Infections 1999 01 01 ACTINOMYCETALES INFECT NLM (1972) T000554 Infections, Actinomycetales 1991 03 21 INFECT ACTINOMYCETALES NLM (1992) T000554 Actinomycetales Infection T000554 Infection, Actinomycetales T000556 Infections, Actinomycete 1991 03 21 INFECT ACTINOMYCETE NLM (1992) T000556 Actinomycete Infection T000556 Infection, Actinomycete T000557 Actinomycete Infections 1978 03 22 ACTINOMYCETE INFECT UNK (19XX) D000196 Actinomycosis 1999 01 01 1993 06 02 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI bact infect, not fungal despite "-mycosis": = infection by genus ACTINOMYCES; do not confuse with ACTINOMYCETALES INFECTIONS, infection by order ACTINOMYCETALES; pulm actinomycosis = ACTINOMYCOSIS (IM) + LUNG DISEASES (IM), not LUNG DISEASES, FUNGAL C01.252.410.040.137 NLM PLS PLS M0000290 Actinomycosis C0001261 Infections with bacteria of the genus ACTINOMYCES. T047 Disease or Syndrome T000560 Actinomycosis 1999 01 01 NLM (1966) T000560 Actinomycoses T000558 Infections, Actinomyces 1991 04 12 INFECT ACTINOMYCES NLM (1992) T000558 Actinomyces Infection T000558 Infection, Actinomyces T000559 Actinomyces Infections 1991 04 12 ACTINOMYCES INFECT NLM (1992) D000197 Actinomycosis, Cervicofacial 1999 01 01 1994 02 08 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI bact infect, not fungal despite "-mycosis": = infect by genus ACTINOMYCES C01.252.410.040.137.262 C01.252.825.110 C01.539.800.720.110 C17.800.838.765.110 NLM PXP PLS M0000291 Actinomycosis, Cervicofacial C0001264 A form of ACTINOMYCOSIS characterized by slow-growing inflammatory lesions of the lymph nodes that drain the mouth (lumpy jaw), reddening of the overlying skin, and intraperitoneal abscesses. T047 Disease or Syndrome T000561 Actinomycosis, Cervicofacial 1999 01 01 NLM (1966) T000561 Actinomycoses, Cervicofacial T000561 Cervicofacial Actinomycoses T000561 Cervicofacial Actinomycosis D000198 Spectinomycin 1999 01 01 2003 07 30 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 93; was ACTINOSPECTACIN 1973-92; SPECTINOMYCIN was see ACTINOSPECTACIN 1978-92 use SPECTINOMYCIN to search ACTINOSPECTACIN 1966-92 (as Prov 1966-72) 93; was ACTINOSPECTACIN 1965-92 (Prov 1965-72); SPECTINOMYCIN was see ACTINOSPECTACIN 1978-92 D03.494.835 NLM SYSTEM NLM M0000292 Spectinomycin C0001268 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9alpha,9aalpha,10abeta))- 1695-77-8 An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea. T109 Organic Chemical T195 Antibiotic D000900 Anti-Bacterial Agents 21736-83-4 (di-HCl, anhydrous) 22189-32-8 (di-HCl, pentahydrate) M0000292 M0000293 M0000292 M0330711 M0000292 M0330712 M0000292 M0000294 T000563 Spectinomycin 1999 01 01 BAN (19XX) INN (19XX) T000562 Actinospectacin 1992 03 12 NLM (1993) M0000293 Spectam C0037796 0 T109 Organic Chemical T195 Antibiotic M0000292 M0000293 T000564 Spectam 1981 06 08 UNK (19XX) M0330711 Spectinomycin Dihydrochloride, Anhydrous C0887524 21736-83-4 T109 Organic Chemical T195 Antibiotic M0000292 M0330711 T360905 Spectinomycin Dihydrochloride, Anhydrous 1999 09 13 NLM (1999) T360905 Anhydrous Spectinomycin Dihydrochloride M0330712 Spectinomycin Hydrochloride C0887525 22189-32-8 T109 Organic Chemical T195 Antibiotic M0000292 M0330712 T000566 Spectinomycin Hydrochloride 1992 03 12 NLM (1993) USAN (1962) USP (19XX) T360906 Spectinomycin Dihydrochloride, Pentahydrate 1999 09 13 NLM (1999) M0000294 Trobicin C0041157 0 T109 Organic Chemical T195 Antibiotic M0000292 M0000294 T000565 Trobicin 1986 11 17 UNK (19XX) D000199 Actins 1999 01 01 2001 08 03 1973 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG muscle & microfilament proteins; /biosyn /drug eff /physiol /ultrastruct permitted; alpha-actin, beta-actin, gamma-actin, etc. go here 82; was ACTIN 1971-81 (Prov 1971-72) use ACTINS to search ACTIN 1971-81 (as Prov 1971-72) 82; was ACTIN 1973-81 Muscle Proteins (1966-1970) D12.776.210.500.100 D12.776.220.525.075 NLM sjn sjn M0000296 Actins C0001271 0 Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000297 M0000296 M0000298 M0000296 M0000299 M0000296 M0000300 M0000296 M0000301 M0000296 M0000302 T000568 Actins 1999 01 01 NLM (1971) T000567 Actin 1981 05 12 NLM (1982) M0000297 alpha-Actin C0002240 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000297 T000569 alpha-Actin 1980 07 30 UNK (19XX) T000569 alpha Actin M0000298 alpha-Isoactin C0002278 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000298 T000570 alpha-Isoactin 1984 09 19 UNK (19XX) T000570 alpha Isoactin M0000299 beta-Actin C0005186 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000299 T000571 beta-Actin 1980 07 30 UNK (19XX) T000571 beta Actin M0000300 G-Actin C0016890 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000300 T000573 G-Actin 1985 06 05 UNK (19XX) T000573 G Actin T000572 F-Actin 1985 06 05 UNK (19XX) T000572 F Actin T000574 N-Actin 1991 01 14 NLM (1992) T000574 N Actin M0000301 gamma-Actin C0017019 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000301 T000575 gamma-Actin 1980 07 30 UNK (19XX) T000575 gamma Actin M0000302 Isoactin C0022142 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000296 M0000302 T000576 Isoactin 1983 10 14 UNK (19XX) D000200 Action Potentials 1999 01 01 1998 06 10 1968 01 01 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES do not confuse with SYNAPTIC POTENTIALS see SYNAPTIC TRANSMISSION 68(67) 68 Electrophysiology (1966) G07.453.697.100 G11.561.450.100 NLM PXP SJN M0000303 Action Potentials C0001272 The electric response of a nerve or muscle to its stimulation. T043 Cell Function M0000303 M0000304 T000577 Action Potentials 1999 01 01 NLM (1967) T000577 Action Potential T000577 Potential, Action T000577 Potentials, Action M0000304 Spike Potentials C0524475 T043 Cell Function M0000303 M0000304 T000578 Spike Potentials 1996 10 10 NLM (1998) T000578 Potential, Spike T000578 Potentials, Spike T000578 Spike Potential D000201 Activation Analysis 1999 01 01 2002 07 02 1967 01 01 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000941 ethics ES an anal chem technique; NIM; DF: ACTIVATION ANAL 67(63) 67 E05.196.039 NLM lkt sjn M0000305 Activation Analysis C0001282 A method of chemical analysis based on the detection of characteristic radionuclides following a nuclear bombardment. It is also known as radioactivity analysis. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) T059 Laboratory Procedure T000580 Activation Analysis 1999 01 01 ACTIVATION ANAL NLM (1963) T000579 Analysis, Activation 1986 01 01 ANAL ACTIVATION UNK (19XX) T000579 Activation Analyses T000579 Analyses, Activation D000202 Activator Appliances 1974 12 12 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000382 microbiology MI Q000469 parasitology PS Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000821 virology VI Q000941 ethics ES 91(75); was see under ORTHODONTIC APPLIANCES, REMOVABLE 1975-90 91; was see under ORTHODONTIC APPLIANCES, REMOVABLE 1975-90 E06.658.453.560.100 E06.658.453.578.100 NLM nns sjn M0000306 Activator Appliances C0001283 Loose-fitting removable orthodontic appliances which redirect the pressures of the facial and masticatory muscles onto the teeth and their supporting structures to produce improvements in tooth arrangements and occlusal relations. T074 Medical Device M0000306 M0000307 M0000306 M0000308 M0000306 M0000311 M0000306 M0000312 T000581 Activator Appliances 1999 01 01 NLM (1975) T000581 Activator Appliance T000581 Appliance, Activator T000581 Appliances, Activator T000583 Function Activator 1992 01 27 NLM (1993) T000583 Activator, Function T000583 Activators, Function T000583 Function Activators T000582 Orthodontic Appliances, Activator 1974 12 05 UNK (19XX) T000582 Activator Orthodontic Appliance T000582 Activator Orthodontic Appliances T000582 Appliance, Activator Orthodontic T000582 Appliances, Activator Orthodontic T000582 Orthodontic Appliance, Activator M0000307 Andresen Appliance C0002839 T074 Medical Device M0000306 M0000307 T000584 Andresen Appliance 1974 12 05 UNK (19XX) T000584 Appliance, Andresen M0000308 Bionator C0005548 T074 Medical Device M0000306 M0000308 T000585 Bionator 1974 12 05 UNK (19XX) T000585 Bionators M0000311 Harvold Activator C0162307 T074 Medical Device M0000306 M0000311 T000588 Harvold Activator 1992 01 27 NLM (1993) T000588 Activator, Harvold M0000312 Jasper Jumper C0162308 T074 Medical Device M0000306 M0000312 T000589 Jasper Jumper 1992 01 27 NLM (1993) T000589 Jumper, Jasper D000203 Activities of Daily Living 1999 01 01 1997 06 20 1968 01 01 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000523 psychology PX IM; DF: note short X ref 68; SELF CARE (REHABILITATION) was SELF CARE see ACTIVITIES OF DAILY LIVING 1979-80 use ACTIVITIES OF DAILY LIVING to search SELF CARE 1979-80 68; SELF CARE (REHABILITATION) was SELF CARE see ACTIVITIES OF DAILY LIVING 1979-80 Rehabilitation (1966-1967) D017567 Karnofsky Performance Status D018434 Sickness Impact Profile E02.831.067 I03.050 N02.421.784.110 NLM PXP SJN M0000313 Activities of Daily Living C0001288 The performance of the basic activities of self care, such as dressing, ambulation, eating, etc., in rehabilitation. T056 Daily or Recreational Activity T061 Therapeutic or Preventive Procedure M0000313 M0000314 M0000313 M0000315 M0000313 M0000316 T000591 Activities of Daily Living 1999 01 01 NLM (1968) T000590 Activities, Daily Living 1989 07 10 NLM (1990) T000590 Activity, Daily Living T000590 Daily Living Activities T000590 Daily Living Activity T000590 Living Activities, Daily T000590 Living Activity, Daily T000592 ADL 1974 03 29 UNK (19XX) M0000314 Limitation of Activity, Chronic C0008693 T080 Qualitative Concept M0000313 M0000314 T000594 Limitation of Activity, Chronic 1978 01 12 UNK (19XX) T000593 Chronic Limitation of Activity 1978 01 12 UNK (19XX) M0000315 Independent Living C0021189 T056 Daily or Recreational Activity M0000313 M0000315 T000595 Independent Living 1983 06 10 UNK (19XX) T000595 Living, Independent M0000316 Self Care (Rehabilitation) C0086967 T056 Daily or Recreational Activity M0000313 M0000316 T000596 Self Care (Rehabilitation) 1980 05 19 SELF CARE REHABIL UNK (19XX) T000596 Care, Self (Rehabilitation) T000596 Cares, Self (Rehabilitation) T000596 Self Cares (Rehabilitation) D000204 Activity Cycles 1999 01 01 1992 05 18 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES less than 24 hours 91(75); was see under CIRCADIAN RHYTHM 1975-90 search CIRCADIAN RHYTHM 1968-74 91; was see under CIRCADIAN RHYTHM 1975-90 G07.450.730.190.025 NLM TAP PLS M0000317 Activity Cycles C0001289 Bouts of physical irritability or movement alternating with periods of quiescence. It includes biochemical activity and hormonal activity which may be cellular. These cycles are shorter than 24 hours and include sleep-wakefulness cycles and the periodic activation of the digestive system. T079 Temporal Concept M0000317 M0000318 T000597 Activity Cycles 1999 01 01 NLM (1975) T000597 Activity Cycle T000597 Cycle, Activity T000597 Cycles, Activity M0000318 Ultradian Cycles C0087128 T079 Temporal Concept M0000317 M0000318 T000598 Ultradian Cycles 1985 06 18 UNK (19XX) T000598 Cycle, Ultradian T000598 Cycles, Ultradian T000598 Ultradian Cycle D000205 Actomyosin 1999 01 01 2001 08 03 1973 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG a muscle protein; /biosyn /physiol permitted 73(71); was see under MUSCLE PROTEINS 1963-72 search MUSCLE PROTEINS 1966-70 73; was see under MUSCLE PROTEINS 1963-72 Muscle Proteins (1966-1970) D12.776.210.500.154 NLM sjn sjn M0000319 Actomyosin C0001291 Actomyosins 9013-26-7 A protein complex of actin and MYOSINS occurring in muscle. It is the essential contractile substance of muscle. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance T000599 Actomyosin 1999 01 01 NLM (1971) D000206 Actuarial Analysis 1978 05 08 1992 05 13 1979 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES IM; few qualif apply 79 79 E05.318.740.100 G03.850.520.830.100 H01.548.832.067 N05.715.360.750.100 EC PLS PLS M0000320 Actuarial Analysis C0001296 The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs. T057 Occupational Activity T000601 Actuarial Analysis 1999 01 01 ACTUARIAL ANAL NLM (1979) T000600 Analysis, Actuarial 1978 05 08 ANAL ACTUARIAL UNK (19XX) T000600 Actuarial Analyses T000600 Analyses, Actuarial D000208 Acute Disease 1999 01 01 1999 11 08 1968 01 01 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000453 epidemiology EP Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000628 therapy TH IM GEN only; usually NIM with specific dis IM; no qualif when NIM; Manual 23.16+ 68 68 C23.550.291.125 NLM KEV sjn M0000322 Acute Disease C0001314 Disease having a short and relatively severe course. T047 Disease or Syndrome T000603 Acute Disease 1999 01 01 ACUTE DIS NLM (1968) T000603 Acute Diseases T000603 Disease, Acute T000603 Diseases, Acute D000209 Acute-Phase Proteins 1986 04 14 1995 06 02 1987 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG blood proteins; /biosyn /drug eff /physiol permitted 87 87 Blood Proteins (1966-1986) C-Reactive Protein (1966-1986) Glycoproteins (1966-1986) D12.776.124.050 RLS JRT PLS M0000324 Acute-Phase Proteins C0001347 0 Proteins that are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. These proteins can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumor markers. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000324 M0000323 T000607 Acute-Phase Proteins 1999 01 01 NLM (1987) T000607 Acute Phase Proteins T000605 Acute-Phase Protein 1989 10 12 NLM (1989) T000605 Acute Phase Protein T000605 Protein, Acute-Phase T000608 Acute-Phase Reactants 1986 04 14 UNK (19XX) T000608 Acute Phase Reactants T000609 Reactants, Acute-Phase 1986 04 14 UNK (19XX) T000609 Reactants, Acute Phase T000606 Proteins, Acute-Phase 1986 04 14 UNK (19XX) T000606 Proteins, Acute Phase M0000323 Acute-Phase Glycoproteins C0001346 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000324 M0000323 T000604 Acute-Phase Glycoproteins 1986 04 14 UNK (19XX) T000604 Acute Phase Glycoproteins T000604 Glycoproteins, Acute-Phase D000210 Acute-Phase Reaction 1986 03 25 1999 11 03 1991 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI note category: in presence of a dis, use /etiol, not /compl 92; was ACUTE PHASE REACTION 1987-91 (see under INFLAMMATION 1987-90) use ACUTE-PHASE REACTION to search ACUTE PHASE REACTION 1987-91 92; was ACUTE PHASE REACTION 1987-91 (see under INFLAMMATION 1987-90) Acute Disease (1968-1986) Inflammation (1966-1986) C23.550.470.099 SH KEV sjn M0000325 Acute-Phase Reaction C0001349 An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma. T033 Finding T046 Pathologic Function T000611 Acute-Phase Reaction 1999 01 01 NLM (1987) T000611 Acute Phase Reaction T000612 Acute-Phase State 1986 03 25 UNK (19XX) T000612 Acute Phase State T000612 State, Acute-Phase T000610 Reaction, Acute-Phase 1986 03 25 UNK (19XX) T000610 Reaction, Acute Phase T000613 Response, Acute-Phase 1986 03 25 UNK (19XX) T000613 Acute-Phase Response T000613 Response, Acute Phase D000212 Acyclovir 1982 05 05 2002 07 02 1983 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 83 83 Guanine (1966-1982) D03.438.759.758.399.454.250 SH ags sjn M0000326 Acyclovir C0001367 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- 59277-89-3 A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance D000998 Antiviral Agents 69657-51-8 M0000326 M0000327 M0000326 M0421529 M0000326 M0000329 M0000326 M0353794 M0000326 M0000328 T000615 Acyclovir 1999 01 01 BAN (19XX) USAN (1979) USP (19XX) T000614 Acycloguanosine 1982 05 05 UNK (19XX) T000617 Aciclovir 1982 05 05 UNK (19XX) T000618 9-((2-Hydroxyethoxy)methyl)guanine 1996 11 22 NLM (1998) M0000327 Acyclovir Sodium C0282040 69657-51-8 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000326 M0000327 T000619 Acyclovir Sodium 1994 08 05 USAN (1984) T000619 Sodium, Acyclovir M0421529 Genvir 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000326 M0421529 T490920 Genvir 2002 04 25 NLM (2003) M0000329 Virolex C0699254 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000326 M0000329 T000621 Virolex 1996 11 22 NLM (1998) M0353794 Wellcome-248U C0700911 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000326 M0353794 T000616 Wellcome-248U 1982 05 05 UNK (19XX) T000616 Wellcome 248U T000616 Wellcome248U M0000328 Zovirax C0592290 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000326 M0000328 T000620 Zovirax 1982 05 05 UNK (19XX) D000213 Acyl Carrier Protein 1977 05 20 1992 05 22 1978 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 78 78 Carrier Proteins (1971-1977) D12.776.157.050 RLS TAP PLS M0000330 Acyl Carrier Protein C0001369 0 Consists of a polypeptide chain and 4'-phosphopantetheine linked to a serine residue by a phosphodiester bond. Acyl groups are bound as thiol esters to the pantothenyl group. Acyl carrier protein is involved in every step of fatty acid synthesis by the cytoplasmic system. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000330 M0000331 T000622 Acyl Carrier Protein 1999 01 01 NLM (1978) T000622 Carrier Protein, Acyl T000622 Protein, Acyl Carrier M0000331 Myristoyl-ACP C0027140 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000330 M0000331 T000623 Myristoyl-ACP 1984 10 02 UNK (19XX) T000623 Myristoyl ACP D000214 Acyl Coenzyme A 1977 05 20 2003 07 09 1978 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT do not confuse with ACETYL COENZYME A 78 78 Coenzyme A (1966-1977) D08.211.211.300 D13.695.667.138.382.300 D13.695.827.068.382.300 RLS ssb sjn M0000332 Acyl Coenzyme A C0001374 0 S-Acyl coenzyme A. Fatty acid coenzyme A derivatives that are involved in the biosynthesis and oxidation of fatty acids as well as in ceramide formation. T114 Nucleic Acid, Nucleoside, or Nucleotide T119 Lipid T000624 Acyl Coenzyme A 1999 01 01 NLM (1978) T000624 Coenzyme A, Acyl T000625 Fatty Acyl CoA 1977 05 20 UNK (19XX) T000625 Acyl CoA, Fatty T000625 CoA, Fatty Acyl T000626 Long-Chain Acyl CoA 1977 05 20 UNK (19XX) T000626 Acyl CoA, Long-Chain T000626 CoA, Long-Chain Acyl T000626 Long Chain Acyl CoA T000627 Acyl CoA 1977 05 20 UNK (19XX) T000627 CoA, Acyl D000215 Acylation 1999 01 01 2000 06 21 1974 01 01 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE almost never IM; enzymatic acylation: coord NIM with ACYLTRANSFERASES (IM) + substrate (NIM) or specific acyltransferase (IM); ACETYLATION & ACETYLTRANSFERASES are also available 74(71) 74 Chemistry, Organic (1966-1970) G06.535.095 H01.181.404.095 NLM adp sjn M0000333 Acylation C0001383 The addition of an organic acid radical into a molecule. T070 Natural Phenomenon or Process T000628 Acylation 1999 01 01 NLM (1971) D000216 N-Acylneuraminate Cytidylyltransferase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 98(75); see NUCLEOTIDYLTRANSFERASES 1975-90 98; see ACYLNEURAMINATE CYTIDYLYLTRANSFERASE 1991-97; see NUCLEOTIDYLTRANSFERASES 1975-90 Cytosine Nucleotides (1973-1974) Neuraminic Acids (1973-1974) Nucleotidyltransferases (1973-1974) D08.811.913.696.445.035 NLM ssb sjn M0000334 N-Acylneuraminate Cytidylyltransferase C0001388 CTP:N-acylneuraminate cytidylyltransferase EC 2.7.7.43 An enzyme that forms CMP-acylneuraminic acids, which donate the N-acylneuraminic acid residues to the terminal sugar residue of a ganglioside or glycoprotein. EC 2.7.7.43. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9067-82-7 (CAS RN) T000636 N-Acylneuraminate Cytidylyltransferase 1999 01 01 ACYLNEURAMINATE Z NLM (1975) T000636 Cytidylyltransferase, N-Acylneuraminate T000636 N Acylneuraminate Cytidylyltransferase T000629 Acylneuraminate Cytidylyltransferase 1996 12 04 NLM (1998) T000629 Cytidylyltransferase, Acylneuraminate T000630 CMP Sialate Pyrophosphorylase 1975 02 06 UNK (19XX) T000630 Pyrophosphorylase, CMP Sialate T000630 Sialate Pyrophosphorylase, CMP T000631 CMP Sialate Synthase 1975 02 06 UNK (19XX) T000631 Sialate Synthase, CMP T000631 Synthase, CMP Sialate T000632 CMP-N-Acetylneuraminic Acid Synthetase 1974 11 11 CMP ACETYLNEURAMINIC ACID SYNTHETASE N UNK (19XX) T000632 CMP N Acetylneuraminic Acid Synthetase T000632 Synthetase, CMP-N-Acetylneuraminic Acid T000633 Cytidine 5'-Monophosphosialic Acid Synthetase 1981 04 27 UNK (19XX) T000633 Cytidine 5' Monophosphosialic Acid Synthetase T000634 Cytidine 5-Monophosphosialate Synthase 1988 08 08 UNK (19XX) T000634 Cytidine 5 Monophosphosialate Synthase T000634 Synthase, Cytidine 5-Monophosphosialate T000635 CMP-Sialic Acid Synthetase 1991 01 14 NLM (1992) T000635 CMP Sialic Acid Synthetase T000635 Synthetase, CMP-Sialic Acid D000217 Acyltransferases 1999 01 01 2003 07 09 1964 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 64 64 D08.811.913.050 NLM ssb sjn M0000335 Acyltransferases C0001390 EC 2.3. Enzymes from the transferase class that catalyze the transfer of acyl groups from donor to acceptor, forming either esters or amides. (From Enzyme Nomenclature 1992) EC 2.3. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000637 Acyltransferases 1999 01 01 NLM (1964) D000218 Adamantane 1974 11 19 1997 06 20 1980 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG a cycloparaffin 80(75); was see under BRIDGED COMPOUNDS 1975-79; DIAMANTANE was see ADAMANTANE 1975-95 use ADAMANTANE to search DIAMANTANE 1975-95 80; was see under BRIDGED COMPOUNDS 1975-79; DIAMANTANE was see ADAMANTANE 1975-95 Bridged Compounds (1966-1974) Cycloparaffins (1966-1974) D02.455.426.100.050 D02.455.426.392.368.075 NLM TPW SJN M0000336 Adamantane C0001392 Tricyclo(3.3.1.1(3,7))decane 281-23-2 A tricyclo bridged hydrocarbon. T109 Organic Chemical T000638 Adamantane 1999 01 01 NLM (1975) T000639 Diamantane 1994 09 06 NLM (1996) D000219 Adams-Stokes Syndrome 1999 01 01 1999 11 03 1965 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI transient asystole or ventric fibrill in AV block 65(63); was see under HEART BLOCK 1963-64 65; was see under HEART BLOCK 1963-64 C14.280.067.558.137 C23.550.073.425.025 NLM TAP sjn M0000337 Adams-Stokes Syndrome C0001396 Transient asystole or ventricular fibrillation in the presence of atrioventricular block. T047 Disease or Syndrome T000641 Adams-Stokes Syndrome 1999 01 01 NLM (1963) T000641 Adams Stokes Syndrome T000641 Syndrome, Adams-Stokes T000640 Stokes-Adams Syndrome 1986 04 18 UNK (19XX) T000640 Stokes Adams Syndrome T000640 Syndrome, Stokes-Adams T000642 Adam-Stokes Attacks 1990 09 05 NLM (1992) T000642 Adam Stokes Attacks T000642 Attacks, Adam-Stokes T000643 Stokes-Adams Attacks 1986 04 18 UNK (19XX) T000643 Attacks, Stokes-Adams T000643 Stokes Adams Attacks D000220 Adaptation, Biological 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES much of biol adapt will be ADAPTATION, PHYSIOLOGICAL as more specific; mimicry except for MOLECULAR MIMICRY goes here; DF: ADAPTATION BIOL D000222 Adaptation, Physiological G04.185.057 NLM lkt sjn M0000338 Adaptation, Biological C0001398 Changes in biological features that help an organism cope with its ENVIRONMENT. These changes include physiological (ADAPTATION, PHYSIOLOGICAL), phenotypic and genetic changes. T070 Natural Phenomenon or Process T000645 Adaptation, Biological 1999 01 01 ADAPTATION BIOL NLM (1966) T000646 Adaptation, Biologic 1978 06 26 UNK (19XX) T000646 Biologic Adaptation T000644 Biological Adaptation 1989 08 31 BIOL ADAPTATION NLM (1990) D000221 Adaptation, Ocular 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES adjustment of eye to variations in intensity of light; do not confuse with ACCOMMODATION, OCULAR, adjustment of lens to distance G11.697.716.154 NLM nns sjn M0000339 Adaptation, Ocular C0001399 The adjustment of the eye to variations in the intensity of light. Light adaptation is the adjustment of the eye when the light threshold is increased; DARK ADAPTATION when the light is greatly reduced. (From Cline et al., Dictionary of Visual Science, 4th ed) T042 Organ or Tissue Function M0000339 M0000340 T000647 Adaptation, Ocular 1999 01 01 NLM (1966) T000647 Adaptations, Ocular T000647 Ocular Adaptation T000647 Ocular Adaptations M0000340 Light Adaptation C0237452 T042 Organ or Tissue Function M0000339 M0000340 T000648 Light Adaptation 1995 02 16 NLM (1996) T000648 Adaptation, Light T000648 Adaptations, Light T000648 Light Adaptations D000222 Adaptation, Physiological 1999 01 01 2003 07 09 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES DF: ADAPTATION PHYSIOL G04.185.057.500 G07.062 NLM lkt sjn M0000341 Adaptation, Physiological C0001400 T040 Organism Function T000651 Adaptation, Physiological 1999 01 01 ADAPTATION PHYSIOL NLM (1966) T000649 Adaptations, Physiological 1993 01 29 ADAPTATIONS PHYSIOL NLM (1994) T000649 Physiological Adaptations T000652 Adaptation, Physiologic 1978 06 26 UNK (19XX) T000652 Physiologic Adaptation T000652 Physiologic Adaptations T000653 Adaptations, Physiologic 1993 01 29 NLM (1994) T000650 Physiological Adaptation 1978 06 26 PHYSIOL ADAPTATION UNK (19XX) D000223 Adaptation, Psychological 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES human & animal; DF: ADAPTATION PSYCHOL D012917 Social Adjustment F01.058 NLM KEV sjn M0000342 Adaptation, Psychological C0683269 A state of harmony between internal needs and external demands and the processes used in achieving this condition. (From APA Thesaurus of Psychological Index Terms, 8th ed) T055 Individual Behavior M0000342 M0000344 M0000342 M0000343 M0000342 M0000345 T000655 Adaptation, Psychological 1999 01 01 ADAPTATION PSYCHOL NLM (1966) T000656 Adaptation, Psychologic 1978 06 26 UNK (19XX) T000656 Psychologic Adaptation T363879 Adjustment, Psychological 1999 11 08 ADJUSTMENT PSYCHOL NLM (2000) T363879 Adjustments, Psychological T000654 Psychological Adaptation 1978 06 26 PSYCHOL ADAPTATION UNK (19XX) T363880 Psychological Adjustment 1999 11 08 PSYCHOL ADJUSTMENT NLM (2000) M0000344 Behavior, Adaptive C0085880 T055 Individual Behavior M0000342 M0000344 T000658 Behavior, Adaptive 1991 04 29 NLM (1992) T000658 Adaptive Behavior T000658 Adaptive Behaviors T000658 Behaviors, Adaptive M0000343 Coping Behavior C0009967 T055 Individual Behavior M0000342 M0000343 T000657 Coping Behavior 1983 06 06 UNK (19XX) T000657 Behavior, Coping T000657 Behaviors, Coping T000657 Coping Behaviors M0000345 Coping Skills C0086059 T055 Individual Behavior M0000342 M0000345 T000659 Coping Skills 1991 04 29 NLM (1992) T000659 Coping Skill T000659 Skill, Coping T000659 Skills, Coping D000224 Addison's Disease 1999 01 01 1994 06 28 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI an autoimmune dis with adrenal hypofunction C19.053.264.263 C20.111.163 NLM PLS PLS M0000346 Addison's Disease C0001403 A disease characterized by hypotension, weight loss, anorexia, weakness, and sometimes a bronze-like melanotic hyperpigmentation of the skin. It is due to tuberculosis- or autoimmune-induced disease (hypofunction) of the adrenal glands that results in deficiency of aldosterone and cortisol. In the absence of replacement therapy, it is usually fatal. T047 Disease or Syndrome T000661 Addison's Disease 1999 01 01 ADDISONS DIS NLM (1966) T000661 Addisons Disease T000661 Disease, Addison's T000660 Addison Disease 1981 03 16 ADDISON DIS UNK (19XX) T000660 Disease, Addison D000225 Adenine 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG Q000096 biosynthesis BI Q000502 physiology PH /biosyn/physiol permitted D03.438.759.138 NLM jmp sjn M0000347 Adenine C0001407 1H-Purin-6-amine 73-24-5 A purine base and a fundamental unit of ADENINE NUCLEOTIDES. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance T000662 Adenine 1999 01 01 JAN (19XX) NLM (1966) USP (19XX) T000663 Vitamin B4 1997 03 11 VITAMIN B A 04 NLM (1998) T000663 B4, Vitamin D000226 Mitochondrial ADP, ATP Translocases 1975 07 18 2002 07 02 1991 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 2003(1976) 2003; see ADENINE NUCLEOTIDE TRANSLOCASE 1991-2002 & NUCLEOTIDYLTRANSFERASES 1976-1990 Adenine Nucleotides (1972-1975) Nucleotidyltransferases (1972-1975) D12.776.157.530.625.875.500 D12.776.543.585.450.162.235 D12.776.543.585.625.875.500 D12.776.575.750.500 RLS jmp sjn M0000348 Mitochondrial ADP, ATP Translocases C0001412 9068-80-8 A class of nucleotide translocases found abundantly in mitochondria that function as integral components of the inner mitochondrial membrane. They facilitate the exchange of ADP and ATP between the cytosol and the mitochondria, thereby linking the subcellular compartments of ATP production to those of ATP utilization. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000348 M0408259 T469223 Mitochondrial ADP, ATP Translocases 2001 11 08 NLM (2003) T000672 Adenine Nucleotide Carrier (Mitochondrial) 1980 08 25 UNK (19XX) T469224 Mitochondrial ADP-ATP Carriers 2001 11 08 NLM (2003) T469224 ADP-ATP Carriers, Mitochondrial T469224 Mitochondrial ADP ATP Carriers M0408259 Adenine Nucleotide Translocase 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000348 M0408259 T000664 Adenine Nucleotide Translocase 1999 01 01 NLM (1976) T000665 ADP Translocase 1982 11 23 UNK (19XX) T000667 ADP,ATP Carrier 1983 06 17 UNK (19XX) T000668 ADP,ATP Translocator Protein 1983 06 17 UNK (19XX) T000669 ATP Translocase 1982 11 23 UNK (19XX) T000666 ATP,ADP-Carrier 1983 06 17 UNK (19XX) T000670 ATP-ADP Translocase 1981 04 27 UNK (19XX) D000227 Adenine Nucleotides 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted D13.695.667.138 D13.695.827.068 NLM TGC PLS M0000352 Adenine Nucleotides C0001413 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T000676 Adenine Nucleotides 1999 01 01 NLM (1966) T000676 Nucleotides, Adenine T000677 Adenosine Phosphates 1977 04 01 UNK (19XX) T000677 Phosphates, Adenosine D000228 Adenine Phosphoribosyltransferase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT DF: APRT 91(75); was see under PENTOSYLTRANSFERASES 1975-90 91; was see under PENTOSYLTRANSFERASES 1975-90 Adenine (1972-1974) Pentosephosphates (1972-1974) Pentosyltransferases (1972-1974) Pyrophosphoric Acids (1972-1974) D08.811.913.400.725.100 NLM ssb sjn M0000353 Adenine Phosphoribosyltransferase C0001414 AMP:pyrophosphate phospho-D-ribosyltransferase EC 2.4.2.7 An enzyme catalyzing the formation of AMP from adenine and phosphoribosylpyrophosphate. It can act as a salvage enzyme for recycling of adenine into nucleic acids. EC 2.4.2.7. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-80-9 (CAS RN) T000678 Adenine Phosphoribosyltransferase 1999 01 01 APRT NLM (1975) T000678 Phosphoribosyltransferase, Adenine T000679 AMP Pyrophosphorylase 1974 11 11 UNK (19XX) T000679 Pyrophosphorylase, AMP T000680 APRTase 1988 11 02 UNK (19XX) T000681 Transphosphoribosidase 1975 08 22 UNK (19XX) D000229 Dependovirus 1977 12 05 2001 07 25 1979 01 01 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection: coord IM with PARVOVIRIDAE INFECTIONS (IM) 94; was ADENO-ASSOCIATED VIRUSES 1979-93; was ADENO-ASSOCIATED VIRUSES see SATELLITE VIRUSES 1975-78; DEPENDOVIRUS was see PARVOVIRIDAE 1992-93 use DEPENDOVIRUS to search ADENO-ASSOCIATED VIRUSES 1979-93; use SATELLITE VIRUSES 1975-78; use PARVOVIRIDAE to search DEPENDOVIRUS 1992-93 94; was ADENO-ASSOCIATED VIRUSES 1979-93; was ADENO-ASSOCIATED VIRUSES see SATELLITE VIRUSES 1975-78; DEPENDOVIRUS was see PARVOVIRIDAE 1992-93 Adenoviridae (1966) Satellite Viruses (1967-1978) Viruses (1966) B04.280.580.650.170 B04.909.204.671.650.170 AEP ags sjn M0000354 Dependovirus C0001417 A genus of the family PARVOVIRIDAE, subfamily PARVOVIRINAE, which are dependent on a coinfection with helper adenoviruses or herpesviruses for their efficient replication. The type species is Adeno-associated virus 2. T005 Virus T000686 Dependovirus 1999 01 01 NLM (1979) T000686 Dependoviruses T000683 Virus, Adeno-Associated 1993 11 30 VIRUS ADENO ASSOC NLM (1995) T000682 Adeno-Associated Virus 1993 11 30 ADENO ASSOC VIRUS NLM (1995) T000682 Adeno Associated Virus T000685 Adeno-Associated Viruses 1992 12 10 ADENO ASSOC VIRUSES NLM (1994) T000685 Adeno Associated Viruses T000684 Viruses, Adeno-Associated 1993 11 30 VIRUSES ADENO ASSOC NLM (1995) D000230 Adenocarcinoma 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI coord IM with precoord organ/neopl term (IM) C04.557.470.200.025 NLM jls sjn M0000355 Adenocarcinoma C0001418 A malignant epithelial tumor with a glandular organization. T191 Neoplastic Process M0000355 M0000356 M0000355 M0000357 M0000355 M0000360 M0000355 M0000358 M0000355 M0000359 T000687 Adenocarcinoma 1999 01 01 NLM (1966) T000687 Adenocarcinomas T000688 Adenoma, Malignant 1996 12 16 NLM (1998) T000688 Adenomas, Malignant T000688 Malignant Adenoma T000688 Malignant Adenomas M0000356 Adenocarcinoma, Basal Cell C0205641 T191 Neoplastic Process M0000355 M0000356 T000689 Adenocarcinoma, Basal Cell 1993 03 26 NLM (1994) T000689 Adenocarcinomas, Basal Cell T000689 Basal Cell Adenocarcinoma T000689 Basal Cell Adenocarcinomas M0000357 Adenocarcinoma, Oxyphilic C0205642 T191 Neoplastic Process M0000355 M0000357 T000690 Adenocarcinoma, Oxyphilic 1993 03 26 NLM (1994) T000690 Adenocarcinomas, Oxyphilic T000690 Oxyphilic Adenocarcinoma T000690 Oxyphilic Adenocarcinomas M0000360 Adenocarcinoma, Tubular C0205645 T191 Neoplastic Process M0000355 M0000360 T000694 Adenocarcinoma, Tubular 1993 03 26 NLM (1994) T000694 Adenocarcinomas, Tubular T000694 Tubular Adenocarcinoma T000694 Tubular Adenocarcinomas T000695 Carcinoma, Tubular 1993 03 26 NLM (1994) T000695 Carcinomas, Tubular T000695 Tubular Carcinoma T000695 Tubular Carcinomas M0000358 Carcinoma, Cribriform C0205643 T191 Neoplastic Process M0000355 M0000358 T000691 Carcinoma, Cribriform 1993 03 26 NLM (1994) T000691 Carcinomas, Cribriform T000691 Cribriform Carcinoma T000691 Cribriform Carcinomas M0000359 Carcinoma, Granular Cell C0205644 T191 Neoplastic Process M0000355 M0000359 T000693 Carcinoma, Granular Cell 1993 03 26 NLM (1994) T000693 Carcinomas, Granular Cell T000693 Granular Cell Carcinoma T000693 Granular Cell Carcinomas T000692 Adenocarcinoma, Granular Cell 1993 03 26 NLM (1994) T000692 Adenocarcinomas, Granular Cell T000692 Granular Cell Adenocarcinoma T000692 Granular Cell Adenocarcinomas D000231 Adenocarcinoma, Papillary 1999 01 01 1995 06 08 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /blood supply /chem /second /secret /ultrastruct permitted; coord IM with precoord organ/neopl term (IM) C04.557.470.200.025.085 NLM KEV PLS M0000361 Adenocarcinoma, Papillary C0001420 An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed) T191 Neoplastic Process T000696 Adenocarcinoma, Papillary 1999 01 01 NLM (1966) T000696 Adenocarcinomas, Papillary T000696 Papillary Adenocarcinoma T000696 Papillary Adenocarcinomas D000232 Adenofibroma 1999 01 01 1995 06 08 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI do not confuse with FIBROADENOMA; /blood supply /chem /secret /ultrastruct permitted; coord IM with precoord organ/neopl term (IM) C04.557.450.565.590.595.050 C04.557.470.625.050 NLM KEV PLS M0000362 Adenofibroma C0001422 A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed) T191 Neoplastic Process M0000362 M0000363 T000697 Adenofibroma 1999 01 01 NLM (1966) T000697 Adenofibromas M0000363 Fibroadenosis C0016024 T191 Neoplastic Process M0000362 M0000363 T000698 Fibroadenosis 1978 12 18 POPLINE (1978) D000233 Adenoidectomy 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES do not use /util except by MeSH definition E04.580.068 NLM PXP SJN M0000364 Adenoidectomy C0001425 Excision of the adenoids. (Dorland, 28th ed) T061 Therapeutic or Preventive Procedure T000699 Adenoidectomy 1999 01 01 NLM (1966) T000699 Adenoidectomies D000234 Adenoids 1999 01 01 2003 07 09 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI surg: probably ADENOIDECTOMY D000233 Adenoidectomy A10.549.100 A15.382.520.604.100 NLM jmp sjn M0000365 Adenoids C0001428 T023 Body Part, Organ, or Organ Component T000700 Adenoids 1999 01 01 NLM (1966) T000700 Adenoid T000701 Pharyngeal Tonsil 1996 07 11 NLM (1998) T000701 Pharyngeal Tonsils T000701 Tonsils, Pharyngeal T000702 Tonsil, Pharyngeal 1996 07 11 NLM (1998) D000235 Adenolymphoma 1999 01 01 1995 06 08 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /blood supply /chem /secret /ultrastruct permitted; coord IM with precoord organ/neopl term (IM) C04.557.435.075 NLM KEV PLS M0000366 Adenolymphoma C0001429 A benign tumor characterized histologically by tall columnar epithelium within a lymphoid tissue stroma. It is usually found in the salivary glands, especially the parotid. T191 Neoplastic Process T000703 Adenolymphoma 1999 01 01 NLM (1966) T000703 Adenolymphomas T000704 Cystadenoma Lymphomatosum, Papillary 1980 05 09 UNK (19XX) T000704 Papillary Cystadenoma Lymphomatosum T000705 Warthin Tumor 1980 05 09 UNK (19XX) T000705 Tumor, Warthin D000236 Adenoma 1999 01 01 1999 11 09 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI GEN or unspecified; prefer specifics; coord IM with precoord organ/neopl term (IM) C04.557.470.035 NLM jls sjn M0000367 Adenoma C0001430 A benign epithelial tumor with a glandular organization. T191 Neoplastic Process M0000367 M0000368 M0000367 M0000369 M0000367 M0000370 M0000367 M0000371 M0000367 M0000372 M0000367 M0000373 T000706 Adenoma 1999 01 01 NLM (1966) T000706 Adenomas M0000368 Adenoma, Basal Cell C0205646 T191 Neoplastic Process M0000367 M0000368 T000707 Adenoma, Basal Cell 1993 03 26 NLM (1994) T000707 Adenomas, Basal Cell T000707 Basal Cell Adenoma T000707 Basal Cell Adenomas M0000369 Adenoma, Follicular C0205647 T191 Neoplastic Process M0000367 M0000369 T000708 Adenoma, Follicular 1993 03 26 NLM (1994) T000708 Adenomas, Follicular T000708 Follicular Adenoma T000708 Follicular Adenomas M0000370 Adenoma, Microcystic C0205648 T191 Neoplastic Process M0000367 M0000370 T000709 Adenoma, Microcystic 1993 03 26 NLM (1994) T000709 Adenomas, Microcystic T000709 Microcystic Adenoma T000709 Microcystic Adenomas M0000371 Adenoma, Monomorphic C0205649 T191 Neoplastic Process M0000367 M0000371 T000710 Adenoma, Monomorphic 1993 03 26 NLM (1994) T000710 Adenomas, Monomorphic T000710 Monomorphic Adenoma T000710 Monomorphic Adenomas M0000372 Adenoma, Papillary C0205650 T191 Neoplastic Process M0000367 M0000372 T000711 Adenoma, Papillary 1993 03 26 NLM (1994) T000711 Adenomas, Papillary T000711 Papillary Adenoma T000711 Papillary Adenomas M0000373 Adenoma, Trabecular C0205651 T191 Neoplastic Process M0000367 M0000373 T000712 Adenoma, Trabecular 1993 03 26 NLM (1994) T000712 Adenomas, Trabecular T000712 Trabecular Adenoma T000712 Trabecular Adenomas D000237 Adenoma, Basophil 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /blood supply /chem /secret /ultrastruct permitted; coord IM with PITUITARY NEOPLASMS (IM) 94; was ADENOMA, BASOPHILIC 1963-93 use ADENOMA, BASOPHIL to search ADENOMA, BASOPHILIC 1966-93 94; was ADENOMA, BASOPHILIC 1963-93 D003480 Cushing Syndrome D010911 Pituitary Neoplasms C04.557.465.625.650.075 C04.557.470.035.075 C04.557.580.625.650.075 NLM KEV sjn M0000374 Adenoma, Basophil C0001431 A small tumor of the anterior lobe of the pituitary gland whose cells stain with basic dyes. It may give rise to excessive secretion of ACTH, resulting in CUSHING SYNDROME. (Dorland, 27th ed) T191 Neoplastic Process T000713 Adenoma, Basophil 1999 01 01 NLM (1966) T000713 Adenomas, Basophil T000713 Basophil Adenoma T000713 Basophil Adenomas T000714 Adenoma, Basophilic 1993 05 13 NLM (1994) T000714 Adenomas, Basophilic T000714 Basophilic Adenoma T000714 Basophilic Adenomas D000238 Adenoma, Chromophobe 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI coord IM with PITUITARY NEOPLASMS (IM) D010911 Pituitary Neoplasms C04.557.465.625.650.095 C04.557.470.035.095 C04.557.580.625.650.095 NLM jls sjn M0000375 Adenoma, Chromophobe C0001432 A benign tumor of the anterior pituitary in which the cells do not stain with acidic or basic dyes. T191 Neoplastic Process T000715 Adenoma, Chromophobe 1999 01 01 NLM (1966) T000715 Adenomas, Chromophobe T000715 Chromophobe Adenoma T000715 Chromophobe Adenomas D000239 Adenoma, Acidophil 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /blood supply /chem /secret /ultrastruct permitted; coord IM with PITUITARY NEOPLASMS (IM) 94; was ADENOMA, EOSINOPHILIC 1963-93 use ADENOMA, ACIDOPHIL to search ADENOMA, EOSINOPHILIC 1966-93 94; was ADENOMA, EOSINOPHILIC 1963-93 D000172 Acromegaly D005877 Gigantism D010911 Pituitary Neoplasms C04.557.465.625.650.025 C04.557.470.035.025 C04.557.580.625.650.025 NLM KEV sjn M0000376 Adenoma, Acidophil C0001433 A benign tumor, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumors may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhea. (Dorland, 27th ed) T191 Neoplastic Process T000716 Adenoma, Acidophil 1999 01 01 NLM (1966) T000716 Acidophil Adenoma T000716 Acidophil Adenomas T000716 Adenomas, Acidophil T000718 Adenoma, Acidophilic 1993 03 29 NLM (1994) T000718 Acidophilic Adenoma T000718 Acidophilic Adenomas T000718 Adenomas, Acidophilic T000719 Adenoma, Eosinophil 1993 03 29 NLM (1994) T000719 Adenomas, Eosinophil T000719 Eosinophil Adenoma T000719 Eosinophil Adenomas T000717 Adenoma, Eosinophilic 1993 03 29 NLM (1994) T000717 Adenomas, Eosinophilic T000717 Eosinophilic Adenoma T000717 Eosinophilic Adenomas D000241 Adenosine 1999 01 01 2001 07 25 1972 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 72; was see under NUCLEOSIDES 1963-71 search NUCLEOSIDES 1966-71 72; was see under NUCLEOSIDES 1963-71 Nucleosides (1966-1971) D13.570.583.138 D13.570.800.096 D14.600.030 NLM ssb sjn M0000377 Adenosine C0001443 Adenosine 58-61-7 A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance D000700 Analgesics D000889 Anti-Arrhythmia Agents D014665 Vasodilator Agents M0000377 M0372279 T000720 Adenosine 1999 01 01 BAN (19XX) NLM (1972) USAN (1988) M0372279 Adenocard C0813510 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000377 M0372279 T000721 Adenocard 1996 11 21 NLM (1998) D000242 Cyclic AMP 1999 01 01 2001 07 25 1972 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted; cAMP receptor protein, cyclic AMP receptor protein: index under RECEPTORS, CYCLIC AMP; DF: CYCL AMP 94; was ADENOSINE CYCLIC MONOPHOSPHATE 1980-93, was ADENOSINE CYCLIC-3',5'-MONOPHOSPHATE 1978-79, was ADENOSINE CYCLIC 3',5' MONOPHOSPHATE 1968-77 (Prov 1968-71); CYCLIC AMP was see ADENOSINE CYCLIC MONOPHOSPHATE 1976-93; ADENOSINE CYCLIC 2',3'-MONOPHOSPHATE was see ADENOSINE CYCLIC MONOPHOSPHATE 1980-93 use CYCLIC AMP to search ADENOSINE CYCLIC MONOPHOSPHATE & ADENOSINE CYCLIC 2',3'-MONOPHOSPHATE 1980-93 & ADENOSINE CYCLIC-3',5'-MONOPHOSPHATE 1968-79 (as Prov 1968-71) 94; was ADENOSINE CYCLIC MONOPHOSPHATE 1980-93, was ADENOSINE CYCLIC-3',5'-MONOPHOSPHATE 1978-79, was ADENOSINE CYCLIC 3',5' MONOPHOSPHATE 1972-77; CYCLIC AMP was see ADENOSINE CYCLIC MONOPHOSPHATE 1976-93; ADENOSINE CYCLIC 2',3'-MONOPHOSPHATE was see ADENOSINE CYCLIC MONOPHOSPHATE 1980-93 Adenine Nucleotides (1966-1968) D011953 Receptors, Cyclic AMP D13.695.462.200 D13.695.667.138.395 D13.695.827.068.395 NLM ssb sjn M0000378 Cyclic AMP C0001455 Adenosine, cyclic 3',5'-(hydrogen phosphate) 60-92-4 An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance 33116-15-3 (Na salt) 37839-81-9 (mono-Na salt) 55576-98-2 (mono-K salt) 66067-13-8 (di-Na salt) 68407-13-6 (mono-NH4 salt) 86594-34-5 ((R)-isomer) M0000378 M0330722 M0000378 M0330720 M0000378 M0330721 M0000378 M0330719 M0000378 M0330718 M0000378 M0330717 T000726 Cyclic AMP 1999 01 01 CYCL AMP POPLINE (1984) T000726 AMP, Cyclic T000724 Adenosine Cyclic 3',5'-Monophosphate 1979 05 22 ADENOSINE CYCLIC MONOPHOSPHATE 03 05 UNK (19XX) T000724 3',5'-Monophosphate, Adenosine Cyclic T000724 Adenosine Cyclic 3',5' Monophosphate T000724 Cyclic 3',5'-Monophosphate, Adenosine T000722 Adenosine Cyclic 3,5 Monophosphate 1984 07 27 UNK (19XX) T000725 Adenosine Cyclic Monophosphate 1992 12 18 NLM (1994) T000725 Cyclic Monophosphate, Adenosine T000725 Monophosphate, Adenosine Cyclic T000723 Adenosine Cyclic-3',5'-Monophosphate 1985 06 12 UNK (19XX) T000723 Cyclic-3',5'-Monophosphate, Adenosine M0330722 Cyclic AMP, (R)-Isomer C0887531 86594-34-5 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330722 T360916 Cyclic AMP, (R)-Isomer 1999 09 13 NLM (1999) M0330720 Cyclic AMP, Disodium Salt C0949210 66067-13-8 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330720 T360914 Cyclic AMP, Disodium Salt 1999 09 13 NLM (1999) M0330721 Cyclic AMP, Monoammonium Salt C0971857 68407-13-6 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330721 T360915 Cyclic AMP, Monoammonium Salt 1999 09 13 NLM (1999) M0330719 Cyclic AMP, Monopotassium Salt C0949211 55576-98-2 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330719 T360913 Cyclic AMP, Monopotassium Salt 1999 09 13 NLM (1999) M0330718 Cyclic AMP, Monosodium Salt C0949212 37839-81-9 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330718 T360912 Cyclic AMP, Monosodium Salt 1999 09 13 NLM (1999) M0330717 Cyclic AMP, Sodium Salt C0969626 33116-15-3 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000378 M0330717 T360911 Cyclic AMP, Sodium Salt 1999 09 13 NLM (1999) D000243 Adenosine Deaminase 1974 11 27 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT /defic: consider also SEVERE COMBINED IMMUNODEFICIENCY or SCID 91(75); was see under NUCLEOSIDE DEAMINASES 1975-90 91; was see under NUCLEOSIDE DEAMINASES 1975-90 Adenosine (1972-1974) Aminohydrolases (1972-1974) D08.811.277.151.486.075 NLM ssb sjn M0000379 Adenosine Deaminase C0001457 Adenosine aminohydrolase EC 3.5.4.4 An enzyme that catalyzes the hydrolysis of adenosine to inosine with the elimination of ammonia. Since there are wide tissue and species variations in the enzyme, it has been used as a tool in the study of human and animal genetics and in medical diagnosis. EC 3.5.4.4. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000728 Adenosine Deaminase 1999 01 01 NLM (1975) T000728 Deaminase, Adenosine T000727 Adenosine Aminohydrolase 1974 11 25 UNK (19XX) T000727 Aminohydrolase, Adenosine D000244 Adenosine Diphosphate 1999 01 01 1990 06 07 1973 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 73(71) 73 Adenine Nucleotides (1966-1970) D13.695.667.138.124 D13.695.827.068.124 NLM PLS PLS M0000380 Adenosine Diphosphate C0001459 Adenosine 5'-(trihydrogen diphosphate) 58-64-0 Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000380 M0000381 T000730 Adenosine Diphosphate 1999 01 01 NLM (1971) T000730 Diphosphate, Adenosine T000729 Adenosine 5'-Pyrophosphate 1989 05 17 NLM (1990) T000729 5'-Pyrophosphate, Adenosine T000729 Adenosine 5' Pyrophosphate T000731 Adenosine Pyrophosphate 1974 03 29 UNK (19XX) T000731 Pyrophosphate, Adenosine T000732 ADP 1975 01 01 UNK (19XX) M0000381 Magnesium ADP C0024468 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000380 M0000381 T000733 Magnesium ADP 1989 05 12 NLM (1990) T000733 ADP, Magnesium T000734 MgADP 1989 05 12 NLM (1990) D000245 Adenosine Diphosphate Glucose 1974 11 19 1990 05 30 1991 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1975-90 90; was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1975-90 Adenosine (1973-1974) Glucose (1973-1974) Nucleoside Diphosphate Sugars (1973-1974) D09.203.408.620.569.070.075 D13.695.667.138.124.070.075 D13.695.827.068.124.070.075 D13.695.827.708.070.075 NLM PLS PLS M0000382 Adenosine Diphosphate Glucose C0001460 Adenosine 5'-(trihydrogen diphosphate), P'-alpha-D-glucopyranosyl ester 2140-58-1 Serves as the glycosyl donor for formation of bacterial glycogen, amylose in green algae, and amylopectin in higher plants. T114 Nucleic Acid, Nucleoside, or Nucleotide T118 Carbohydrate T123 Biologically Active Substance T000735 Adenosine Diphosphate Glucose 1999 01 01 NLM (1975) T000735 Diphosphate Glucose, Adenosine T000735 Glucose, Adenosine Diphosphate T000736 Adenosine Pyrophosphateglucose 1974 11 11 UNK (19XX) T000736 Pyrophosphateglucose, Adenosine T000737 ADP Glucose 1976 05 13 UNK (19XX) T000737 Glucose, ADP T000738 ADPG 1974 11 11 UNK (19XX) T000739 Adenosine Diphosphoglucose 1974 11 11 UNK (19XX) T000739 Diphosphoglucose, Adenosine D000246 Adenosine Diphosphate Ribose 1979 05 22 2002 07 02 1987 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 87(80); was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1980-86 87; was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1980-86 Adenine Nucleotides (1966-1970) Adenosine Diphosphate Sugars (1975-1979) Nucleoside Diphosphate Sugars (1971-1974) Ribose (1966-1974) /AA (1975-1979) D09.203.408.620.569.070.125 D13.695.667.138.124.070.125 D13.695.827.068.124.070.125 D13.695.827.708.070.125 RLS nns sjn M0000383 Adenosine Diphosphate Ribose C0001461 Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose 20762-30-5 An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins. T114 Nucleic Acid, Nucleoside, or Nucleotide T118 Carbohydrate T123 Biologically Active Substance T000741 Adenosine Diphosphate Ribose 1999 01 01 NLM (1980) T000741 Diphosphate Ribose, Adenosine T000741 Ribose, Adenosine Diphosphate T000740 Adenosine 5'-Diphosphoribose 1980 09 22 UNK (19XX) T000740 5'-Diphosphoribose, Adenosine T000740 Adenosine 5' Diphosphoribose T000742 Adenosine Diphosphoribose 1979 05 22 UNK (19XX) T000742 Diphosphoribose, Adenosine T000743 ADP Ribose 1979 05 22 UNK (19XX) T000743 Ribose, ADP T475384 ADPribose 2001 12 31 NLM (2003) T475385 ADP-Ribose 2001 12 31 NLM (2003) D000247 Adenosine Diphosphate Sugars 1974 11 19 1992 05 07 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1975-90 91; was see under NUCLEOSIDE DIPHOSPHATE SUGARS 1975-90 Adenosine (1973-1974) Nucleoside Diphosphate Sugars (1973-1974) D09.203.408.620.569.070 D13.695.667.138.124.070 D13.695.827.068.124.070 D13.695.827.708.070 NLM TGC PLS M0000384 Adenosine Diphosphate Sugars C0001462 0 Esters formed between the aldehydic carbon of sugars and the terminal phosphate of adenosine diphosphate. T114 Nucleic Acid, Nucleoside, or Nucleotide T118 Carbohydrate T000744 Adenosine Diphosphate Sugars 1999 01 01 NLM (1975) T000744 Diphosphate Sugars, Adenosine T000744 Sugars, Adenosine Diphosphate T000745 ADP Sugars 1976 05 07 UNK (19XX) T000745 Sugars, ADP D000248 Adenosine Kinase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under PHOSPHOTRANSFERASES, ATP 1975-90 91; was see under PHOSPHOTRANSFERASES, ATP 1975-90 Adenosine (1974) Phosphotransferases, ATP (1974) D08.811.913.696.620.010 NLM ssb sjn M0000385 Adenosine Kinase C0001464 ATP:adenosine 5'-phosphotransferase EC 2.7.1.20 An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-72-9 (CAS RN) T000746 Adenosine Kinase 1999 01 01 NLM (1975) T000746 Kinase, Adenosine D000249 Adenosine Monophosphate 1999 01 01 2001 07 25 1973 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 73(71); ADENYLIC ACID was ADENYLIC ACIDS see under ADENINE NUCLEOTIDES 1963-72 to search ADENYLIC ACIDS use ADENOSINE MONOPHOSPHATE 1971-73, ADENOSINE MONOPHOSPHATE & ADENINE NUCLEOTIDES 1971-72, & ADENINE NUCLEOTIDES 1966-70 73; ADENYLIC ACID was ADENYLIC ACIDS see under ADENINE NUCLEOTIDES 1963-72 Adenine Nucleotides (1966-1970) D13.695.667.138.180 D13.695.827.068.180 NLM jmp sjn M0000389 Adenosine Monophosphate C0001465 5'-Adenylic acid 61-19-8 Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000389 M0000386 M0000389 M0000387 M0000389 M0000388 M0000389 M0392623 T000751 Adenosine Monophosphate 1999 01 01 NLM (1971) T000752 Adenylic Acid 1974 03 29 UNK (19XX) T000753 AMP 1974 03 29 UNK (19XX) M0000386 Adenosine 2'-Phosphate C0001444 0 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000389 M0000386 T000747 Adenosine 2'-Phosphate 1984 09 20 UNK (19XX) T000747 Adenosine 2' Phosphate M0000387 Adenosine 3'-Phosphate C0001445 0 T114 Nucleic Acid, Nucleoside, or Nucleotide M0000389 M0000387 T000748 Adenosine 3'-Phosphate 1984 09 20 UNK (19XX) T000748 Adenosine 3' Phosphate M0000388 Phosphaden C0001448 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000389 M0000388 T000750 Phosphaden 1980 03 19 UNK (19XX) M0392623 Adenosine 5'-Phosphate C0877812 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000389 M0392623 T000749 Adenosine 5'-Phosphate 1984 09 20 UNK (19XX) D000250 Adenosine Phosphosulfate 1978 03 06 1992 05 07 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(79); was see under ADENOSINE MONOPHOSPHATE 1979-90 91; was see under ADENOSINE MONOPHOSPHATE 1979-90 Adenine Nucleotides (1966-1970) Adenosine Monophosphate (1971-1978) Sulfuric Acids (1966-1975) D13.695.667.138.180.080 D13.695.827.068.180.080 RLS TGC PLS M0000390 Adenosine Phosphosulfate C0001468 5'-Adenylic acid, monoanhydride with sulfuric acid 485-84-7 5'-Adenylic acid, monoanhydride with sulfuric acid. The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS. T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance T000755 Adenosine Phosphosulfate 1999 01 01 NLM (1979) T000755 Phosphosulfate, Adenosine T000754 Adenosine 5'-Phosphosulfate 1988 10 11 UNK (19XX) T000754 5'-Phosphosulfate, Adenosine T000754 Adenosine 5' Phosphosulfate T000756 Adenylyl Sulfate 1978 03 10 UNK (19XX) T000756 Sulfate, Adenylyl T000757 Phospho-Adenylsulfate 1980 08 25 UNK (19XX) T000757 Phospho Adenylsulfate D000251 Adenosinetriphosphatase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT DF: note short X ref 93; was ADENOSINE TRIPHOSPHATASE 1963-92 use ADENOSINETRIPHOSPHATASE to search ADENOSINE TRIPHOSPHATASE 1966-92 93; was ADENOSINE TRIPHOSPHATASE 1963-92 D08.811.277.040.025 NLM ssb sjn M0000391 Adenosinetriphosphatase C0001473 ATP phosphohydrolase EC 3.6.1.3 A group of enzymes which catalyze the hydrolysis of ATP coupled with another function such as transporting Ca(2+) across a membrane. These enzymes may be dependent on Ca(2+), Mg(2+), anions, H+, or DNA. EC 3.6.1.3. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9000-83-3 (CAS RN) M0000391 M0000392 T000758 Adenosinetriphosphatase 1999 01 01 NLM (1966) T000759 ATPase 1976 05 13 NLM (1977) T000760 Adenosine Triphosphatase 1992 04 13 NLM (1993) T000760 Triphosphatase, Adenosine M0000392 ATP-A C0004210 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000391 M0000392 T000761 ATP-A 1980 08 01 UNK (19XX) D000252 Ca(2+)-Transporting ATPase 1978 03 06 2003 07 09 1979 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT DF: CA ATPASE 93; was ADENOSINE TRIPHOSPHATASE, CALCIUM 1979-92; CALCIUM PUMP was heading 1992-93; CALCIUM PUMP PROTEIN was see ADENOSINE TRIPHOSPHATASE, CALCIUM 1992; CALCIUM ADENOSINETRIPHOSPHATASE was CALCIUM ADENOSINE TRIPHOSPHATASE see ADENOSINE TRIPHOSPHATASE, CALCIUM 1989-92 use CA(2+)-TRANSPORTING ATPASE to search ADENOSINE TRIPHOSPHATASE, CALCIUM 1979-92, CALCIUM PUMP 1992-93, CALCIUM PUMP PROTEIN 1992, & CALCIUM ADENOSINE TRIPHOSPHATASE 1989-92 93; was ADENOSINE TRIPHOSPHATASE, CALCIUM 1979-92; CALCIUM PUMP was heading 1992-93; CALCIUM PUMP PROTEIN was see ADENOSINE TRIPHOSPHATASE, CALCIUM 1992; CALCIUM ADENOSINETRIPHOSPHATASE was CALCIUM ADENOSINE TRIPHOSPHATASE see ADENOSINE TRIPHOSPHATASE, CALCIUM 1989-92 Adenosine Triphosphatase (1966-1978) Calcium (1966-1978) D017301 Ca(2+) Mg(2+)-ATPase D08.811.277.040.025.125 D12.776.157.530.450.250.500 D12.776.543.585.450.250.500 RLS ssb sjn M0000393 Ca(2+)-Transporting ATPase C0001476 ATP phosphohydrolase (Ca(2+)-transporting) EC 3.6.1.38 An enzyme found in the sarcoplasmic reticulum vesicle membrane. During the relaxation of skeletal muscles and muscle rich in mitochondria, this enzyme catalyzes the active transport of calcium into the sarcoplasmic reticulum vesicles from the sarcoplasm. It requires micromolar concentrations of Ca(2+) and utilizes MgATP as a substrate. (Prog Biophys Mol Biol 1988;52(1):1). EC 3.6.1.38. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000770 Ca(2+)-Transporting ATPase 1999 01 01 CA 02 TRANSPORTING ATPASE CA ATPASE NLM (1979) T000762 Adenosine Triphosphatase, Calcium 1992 04 10 NLM (1993) T000762 Calcium Adenosine Triphosphatase T000762 Triphosphatase, Calcium Adenosine T000763 Calcium-ATPase 1992 04 21 NLM (1993) T000764 ATPase, Calcium 1978 03 10 ATPASE CA UNK (19XX) T000765 Calcium ATPase 1978 03 10 UNK (19XX) T000766 Calcium Pump 1993 02 11 CA PUMP NLM (1994) T000767 Ca2+ ATPase 1992 04 21 NLM (1993) T000767 ATPase, Ca2+ T000768 Adenosinetriphosphatase, Calcium 1992 04 02 NLM (1993) T000769 Calcium Adenosinetriphosphatase 1988 06 03 UNK (19XX) D000254 Na(+)-K(+)-Exchanging ATPase 1978 03 06 2003 07 09 1979 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT DF: NA K ATPASE 94; was NA(+) K(+)-TRANSPORTING ATPASE 1993; was ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1979-92; SODIUM-POTASSIUM PUMP was heading 1992-93; POTASSIUM PUMP & SODIUM PUMP were see SODIUM-POTASSIUM PUMP 1992-93; SODIUM POTASSIUM PUMP PROTEIN was see ADENOSINE TRIPHOSPHATASE, SODIUM POTSSIUM 1992; SODIUM, POTASSIUM ADENOSINE TRIPHOSPHATASE was SODIUM POTASSIUM ADENOSINE TRIPHOSPHATASE see ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1989-92 use NA(+)-K(+)-EXCHANGING ATPASE to search NA(+) K(+)-TRANSPORTING ATPASE 1993, SODIUM-POTASSIUM PUMP, POTASSIUM PUMP & SODIUM PUMP 1992-93, ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1979-92, SODIUM, POTASSIUM PUMP PROTEIN 1992 & SODIUM, POTASSIUM ADENOSINE TRIPHOSPHATASE 1989-92 94; was NA(+) K(+)-TRANSPORTING ATPASE 1993; was ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1979-92; SODIUM-POTASSIUM PUMP was heading 1992-93; POTASSIUM PUMP & SODIUM PUMP were see SODIUM-POTASSIUM PUMP 1992-93; SODIUM, POTASSIUM PUMP PROTEIN was see ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1992; SODIUM, POTASSIUM ADENOSINETRIPHOSPHATASE was SODIUM, POTASSIUM ADENOSINE TRIPHOSPHATASE see ADENOSINE TRIPHOSPHATASE, SODIUM, POTASSIUM 1989-92 Adenosine Triphosphatase (1966-1978) Potassium (1966-1978) Sodium (1966-1978) D08.811.277.040.025.600 D12.776.157.530.450.250.750 D12.776.543.585.450.250.750 RLS ssb sjn M0000394 Na(+)-K(+)-Exchanging ATPase C0001479 ATP phosphohydrolase (Na(+)-K(+)-transporting) EC 3.6.1.37 An enzyme that catalyzes the active transport system of sodium and potassium ions across the cell wall. Sodium and potassium ions are closely coupled with membrane ATPase which undergoes phosphorylation and dephosphorylation, thereby providing energy for transport of these ions against concentration gradients. EC 3.6.1.37. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000780 Na(+)-K(+)-Exchanging ATPase 1999 01 01 NA K EXCHANGING ATPASE NA K ATPASE NLM (1979) T000771 Adenosinetriphosphatase, Sodium, Potassium 1992 04 02 NLM (1993) T000772 Sodium, Potassium Adenosinetriphosphatase 1988 06 03 UNK (19XX) T000772 Adenosinetriphosphatase Sodium, Potassium T000773 ATPase, Sodium, Potassium 1978 03 10 ATPASE NA K UNK (19XX) T000774 Sodium, Potassium ATPase 1978 03 10 UNK (19XX) T000774 ATPase Sodium, Potassium T000775 Potassium Pump 1993 02 11 K PUMP NLM (1994) T000775 Pump, Potassium T000782 Sodium, Potassium Adenosine Triphosphatase 1992 04 14 NLM (1993) T000781 Adenosine Triphosphatase, Sodium, Potassium 1992 04 14 NLM (1993) T000776 Sodium Pump 1993 02 11 NA PUMP NLM (1994) T000776 Pump, Sodium T000777 Sodium-Potassium Pump 1993 02 11 NA K PUMP NLM (1994) T000777 Pump, Sodium-Potassium T000777 Sodium Potassium Pump T000778 Na(+) K(+)-Transporting ATPase 1993 07 02 NLM (1994) T000779 Na(+)-K(+)-Transporting ATPase 1992 11 20 NLM (1994) D000255 Adenosine Triphosphate 1999 01 01 2001 07 25 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 1998; for CHROMIUM ADENOSINE TRIPHOSPHATE use ADENOSINE TRIPHOSPHATE (NM) 1974-1997; for MANGANESE ATP use ADENOSINE TRIPHOSPHATE (NM) 1981-2001 1998; CHROMIUM ADENOSINE TRIPHOSPHATE was indexed under ADENOSINE TRIPHSOPHATE 1974-1997 and CHROMIUM 1974-1982; MANGANESE ATP was indexed under ADENOSINE TRIPHOSPHATE 1981-2001 D13.695.667.138.236 D13.695.827.068.236 D14.600.033 NLM ssb sjn M0000395 Adenosine Triphosphate C0001480 Adenosine 5'-(tetrahydrogen triphosphate) 56-65-5 An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance T123 Biologically Active Substance 1476-84-2 56842-80-9 M0000395 M0000402 M0000395 M0000400 M0000395 M0000401 M0000395 M0000396 M0000395 M0000398 M0000395 M0167313 M0000395 M0372280 M0000395 M0372281 T000783 Adenosine Triphosphate 1999 01 01 NLM (1966) T000784 Adenylpyrophosphate 1974 03 29 UNK (19XX) T000785 ATP 1974 03 29 UNK (19XX) M0000402 Adenosine Triphosphate, Calcium Salt C0006618 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000395 M0000402 T000798 Adenosine Triphosphate, Calcium Salt 1997 02 26 NLM (1998) T000789 CaATP 1985 05 28 UNK (19XX) M0000400 Adenosine Triphosphate, Chromium Ammonium Salt C0949213 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000395 M0000400 T000793 Adenosine Triphosphate, Chromium Ammonium Salt 1997 02 26 NLM (1998) M0000401 Adenosine Triphosphate, Chromium Salt C0109657 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000395 M0000401 T000795 Adenosine Triphosphate, Chromium Salt 1997 02 26 NLM (1998) T000794 Chromium Adenosine Triphosphate 1997 02 26 NLM (1998) T000796 Cr(H2O)4 ATP 1997 02 26 NLM (1998) T000797 CrATP 1997 02 26 NLM (1998) M0000396 Adenosine Triphosphate, Magnesium Chloride C0004221 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance T123 Biologically Active Substance M0000395 M0000396 T442914 Adenosine Triphosphate, Magnesium Chloride 2001 04 13 NLM (2002) T000788 ATP-MgCl2 1989 04 24 NLM (1990) T000788 ATP MgCl2 M0000398 Adenosine Triphosphate, Magnesium Salt C0024471 1476-84-2 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000395 M0000398 T000790 Adenosine Triphosphate, Magnesium Salt 1989 04 24 NLM (1990) T442915 Magnesium Adenosine Triphosphate 2001 04 13 NLM (2002) T000791 MgATP 1989 04 24 NLM (1990) M0167313 Adenosine Triphosphate, Manganese Salt C0126945 56842-80-9 T114 Nucleic Acid, Nucleoside, or Nucleotide T123 Biologically Active Substance M0000395 M0167313 T197318 Adenosine Triphosphate, Manganese Salt NLM (2002) T197317 Manganese Adenosine Triphosphate NLM (2002) T197316 MnATP NLM (2002) M0372280 Atriphos C0701946 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance T123 Biologically Active Substance M0000395 M0372280 T000786 Atriphos 1989 06 07 NLM (1990) M0372281 Striadyne C0701945 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance T123 Biologically Active Substance M0000395 M0372281 T000787 Striadyne 1995 04 03 NLM (1996) D000256 Adenoviridae 1999 01 01 1993 06 04 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH a family of DNA viruses; adeno- refers to early isol from adenoids; infection = ADENOVIRIDAE INFECTIONS 81; was ADENOVIRUSES 1975-80, was ADENOVIRUS 1963-74 use ADENOVIRIDAE to search ADENOVIRUSES 1975-80 & ADENOVIRUS 1966-74 81; was ADENOVIRUSES 1975-80, was ADENOVIRUS 1963-74 B04.280.030 B04.909.204.097 NLM AGS PLS M0000403 Adenoviridae C0001483 A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. T005 Virus T000799 Adenoviridae 1999 01 01 NLM (1966) T000800 Adenoviruses 1980 05 14 UNK (19XX) T000800 Adenovirus D000257 Adenoviridae Infections 1999 01 01 1996 06 10 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI GEN or unspecified; prefer specifics; ADENOVIRUS INFECTIONS, HUMAN is available 94; was ADENOVIRUS INFECTIONS 1963-93 use ADENOVIRIDAE INFECTIONS to search ADENOVIRUS INFECTIONS 1966-93 94; was ADENOVIRUS INFECTIONS 1963-93 C02.256.076 NLM TGC PLS M0000404 Adenoviridae Infections C0001486 Virus diseases caused by the ADENOVIRIDAE. T047 Disease or Syndrome T000804 Adenoviridae Infections 1999 01 01 ADENOVIRIDAE INFECT NLM (1966) T000801 Infections, Adenovirus 1993 05 05 INFECT ADENOVIRUS NLM (1994) T000801 Adenovirus Infection T000801 Infection, Adenovirus T000802 Adenovirus Infections 1993 05 25 ADENOVIRUS INFECT NLM (1994) T000803 Infections, Adenoviridae 1993 05 05 INFECT ADENOVIRIDAE NLM (1994) T000803 Adenoviridae Infection T000803 Infection, Adenoviridae D000258 Adenovirus Infections, Human 1999 01 01 1990 05 01 1991 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI 91(77); was see under ADENOVIRUS INFECTIONS 1977-90; PHARYNGO-CONJUNCTIVAL FEVER was see under ADENOVIRUS INFECTIONS 1963-76 use ADENOVIRUS INFECTIONS, HUMAN to search PHARYNGO-CONJUNCTIVAL FEVER 1977-present; use ADENOVIRUS INFECTIONS 1966-76 91; was see under ADENOVIRUS INFECTIONS 1977-90; PHARYNGO-CONJUNCTIVAL FEVER was see under ADENOVIRUS INFECTIONS 1963-76 C02.256.076.045 NLM NLM PLS M0000405 Adenovirus Infections, Human C0001487 Respiratory and conjunctival infections caused by 33 identified serotypes of human adenoviruses. T047 Disease or Syndrome M0000405 M0000406 T000807 Adenovirus Infections, Human 1999 01 01 ADENOVIRUS INFECT HUMAN NLM (1975) T000805 Human Adenovirus Infections 1990 04 25 HUMAN ADENOVIRUS INFECT NLM (1991) T000805 Adenovirus Infection, Human T000805 Human Adenovirus Infection T000805 Infection, Human Adenovirus T000806 Infections, Human Adenovirus 1990 04 25 INFECT HUMAN ADENOVIRUS NLM (1991) M0000406 Pharyngo-Conjunctival Fever C0031351 T047 Disease or Syndrome M0000405 M0000406 T000808 Pharyngo-Conjunctival Fever 1976 05 17 UNK (19XX) T000808 Fever, Pharyngo-Conjunctival T000808 Pharyngo Conjunctival Fever D000259 Aviadenovirus 1976 04 16 2001 07 25 1991 01 01 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection: coord IM with ADENOVIRIDAE INFECTIONS (IM) 1994(1977) 1994; see ADENOVIRUSES, AVIAN 1990-93, see ADENOVIRIDAE 1981-1990, see ADENOVIRUSES 1977-1980 Adenoviruses (1966-1974) B04.280.030.100 B04.909.204.097.100 FPG ags sjn M0000407 Aviadenovirus C0001489 A genus of ADENOVIRIDAE that infects birds. The type species is FOWL ADENOVIRUS A. T005 Virus T000811 Aviadenovirus 1999 01 01 NLM (1977) T000811 Aviadenoviruses T000809 Adenoviruses, Avian 1992 11 05 NLM (1994) T000809 Adenovirus, Avian T000809 Avian Adenovirus T000810 Avian Adenoviruses 1992 11 06 NLM (1994) D000260 Adenoviruses, Human 1976 04 16 2003 07 09 1977 01 01 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection = ADENOVIRUS INFECTIONS, HUMAN 1977 1977; for APC VIRUS (Adenoidal-Pharyngeal-Conjunctival virus) see ADENOVIRUSES 1975-1976, see ADENOVIRUS 1963-1974 Adenoviridae (1966-1974) B04.280.030.500.350 B04.909.204.097.500.350 FPG ags sjn M0000409 Adenoviruses, Human C0001490 Species of the genus MASTADENOVIRUS, causing a wide range of diseases in humans. Infections are mostly asymptomatic, but can be associated with diseases of the respiratory, ocular, and gastrointestinal systems. Serotypes (named with arabic numbers) have been grouped into species designated Human adenovirus A-F. T005 Virus T000815 Adenoviruses, Human 1999 01 01 NLM (1977) T000815 Adenovirus, Human T000815 Human Adenovirus T000815 Human Adenoviruses T000816 APC Viruses 1976 04 16 UNK (19XX) T000816 APC Virus D000261 Adenoviruses, Simian 1974 12 12 1996 06 10 1991 01 01 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH species of the genus Mastadenovirus; infection: coord IM with ADENOVIRIDAE INFECTIONS (IM) 91(75); was see under ADENOVIRIDAE 1981-90; was see under ADENOVIRUSES 1975-80 91; was see under ADENOVIRIDAE 1981-90; was see under ADENOVIRUSES 1975-80 B04.280.030.500.700 B04.909.204.097.500.700 NLM AGS PLS M0000411 Adenoviruses, Simian C0001491 Species of the genus MASTADENOVIRUS associated with respiratory and enteric infections in primate hosts. T005 Virus T000819 Adenoviruses, Simian 1999 01 01 NLM (1975) T000818 Simian Adenoviruses 1974 12 05 UNK (19XX) T000818 Adenovirus, Simian T000818 Simian Adenovirus D000262 Adenylate Cyclase 1999 01 01 2003 07 09 1972 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 98(68) 98; see ADENYL CYCLASE 1972-97 Adenine Nucleotides (1966-1967) Enzymes (1966-1967) D08.811.520.650.200 NLM ssb sjn M0000412 Adenylate Cyclase C0001492 ATP pyrophosphate-lyase (cyclizing) EC 4.6.1.1 An enzyme of the lyase class that catalyzes the formation of CYCLIC AMP and pyrophosphate from ATP. EC 4.6.1.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme T000821 Adenylate Cyclase 1999 01 01 NLM (1968) T000821 Cyclase, Adenylate T000822 Adenylyl Cyclase 1981 01 08 UNK (19XX) T000822 Cyclase, Adenylyl T000820 Adenyl Cyclase 1996 11 15 NLM (1998) T000820 Cyclase, Adenyl D000263 Adenylate Kinase 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under PHOSPHOTRANSFERASES, ATP 1975-90 91; was see under PHOSPHOTRANSFERASES, ATP 1975-90 Adenosine Monophosphate (1974) Phosphotransferases, ATP (1974) D08.811.913.696.650.025 NLM ssb sjn M0000413 Adenylate Kinase C0001497 ATP:AMP phosphotransferase EC 2.7.4.3 An enzyme that catalyzes the phosphorylation of AMP to ADP in the presence of ATP or inorganic triphosphate. EC 2.7.4.3. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9013-02-9 (CAS RN) T000823 Adenylate Kinase 1999 01 01 NLM (1975) T000823 Kinase, Adenylate T000824 AMP Kinase 1980 08 18 UNK (19XX) T000824 Kinase, AMP T000825 ATP-AMP Phosphotransferase 1982 12 06 UNK (19XX) T000825 ATP AMP Phosphotransferase T000825 Phosphotransferase, ATP-AMP T000826 ATP-AMP Transphosphorylase 1983 03 30 UNK (19XX) T000826 ATP AMP Transphosphorylase T000826 Transphosphorylase, ATP-AMP T000827 Myokinase 1974 11 11 UNK (19XX) T000828 Adenylokinase 1991 01 14 NLM (1992) D000264 Adenylosuccinate Lyase 1978 05 16 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(79); was see under LYASES 1979-90 91; was see under LYASES 1979-90 Adenosine Monophosphate (1971-1978) Lyases (1966-1978) Succinates (1966-1978) D08.811.520.232.300.200 RLS ssb sjn M0000414 Adenylosuccinate Lyase C0001502 N(6)-(1,2-Dicarboxyethyl)AMP AMP-lyase EC 4.3.2.2 An enzyme that, in the course of purine ribonucleotide biosynthesis, catalyzes the conversion of 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole to 5'-phosphoribosyl-4-carboxamide-5-aminoimidazole and the conversion of adenylosuccinic acid to AMP. EC 4.3.2.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9027-81-0 (CAS RN) T000830 Adenylosuccinate Lyase 1999 01 01 NLM (1979) T000830 Lyase, Adenylosuccinate T000829 Adenylosuccinase 1978 05 16 UNK (19XX) D000265 Adenylosuccinate Synthase 1978 05 16 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 98(79) 98; see ADENYLOSUCCINATE SYNTHETASE 1991-97; see LIGASES 1979-90 Aspartic Acid (1966-1978) Inosine Monophosphate (1975-1978) Inosine Nucleotides (1971-1978) Ligases (1966-1978) D08.811.464.259.100 RLS ssb sjn M0000415 Adenylosuccinate Synthase C0001503 IMP:L-aspartate ligase (GDP-forming) EC 6.3.4.4 A carbon-nitrogen ligase. During purine ribonucleotide biosynthesis, this enzyme catalyzes the synthesis of adenylosuccinate from GTP; IMP; and aspartate with the formation of orthophosphate and GDP. EC 6.3.4.4. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9023-57-8 (CAS RN) T000833 Adenylosuccinate Synthase 1999 01 01 NLM (1979) T000833 Synthase, Adenylosuccinate T000831 Adenylosuccinate Synthetase 1996 11 05 NLM (1998) T000831 Synthetase, Adenylosuccinate T000832 Succino-AMP Synthetase 1984 09 18 UNK (19XX) T000832 Succino AMP Synthetase T000832 Synthetase, Succino-AMP D000266 Adenylyl Imidodiphosphate 1975 07 23 1990 05 30 1991 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted; DF: APPNHP 91(76); was see under ADENOSINE TRIPHOSPHATE 1976-90 91; was see under ADENOSINE TRIPHOSPHATE 1976-90 Adenosine Diphosphate (1973-1974) Adenosine Triphosphate/analogs & derivatives (1975) Imides (1973-1975) Phosphoric Acids (1973-1974) D13.695.667.138.236.050 D13.695.827.068.236.050 RLS PLS PLS M0000416 Adenylyl Imidodiphosphate C0001506 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid 25612-73-1 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000416 M0000417 T000835 Adenylyl Imidodiphosphate 1999 01 01 APPNHP NLM (1976) T000835 Imidodiphosphate, Adenylyl T000834 Adenosine 5'-(beta,gamma-Imino)triphosphate 1980 07 31 UNK (19XX) T000836 AMPPNP 1980 08 18 UNK (19XX) T000837 ATP(beta,gamma-NH) 1982 11 23 UNK (19XX) T000838 beta,gamma-imido-ATP 1982 11 23 UNK (19XX) T000838 beta,gamma imido ATP T000839 gamma-Imido-ATP 1980 08 21 UNK (19XX) T000839 gamma Imido ATP T000840 gamma-Imino-ATP 1975 06 30 UNK (19XX) T000840 gamma Imino ATP T000841 Adenyl Imidodiphosphate 1975 06 30 UNK (19XX) T000841 Imidodiphosphate, Adenyl T000842 Adenylimidodiphosphate 1980 08 18 UNK (19XX) T000843 Adenylylimidodiphosphate 1980 08 18 UNK (19XX) T000844 AMP-PNP 1980 08 01 UNK (19XX) M0000417 Mg-5'-Adenylylimidodiphosphate C0025895 0 T114 Nucleic Acid, Nucleoside, or Nucleotide T121 Pharmacologic Substance M0000416 M0000417 T000845 Mg-5'-Adenylylimidodiphosphate 1982 11 23 UNK (19XX) T000845 Mg 5' Adenylylimidodiphosphate T000846 Mg AMP-PNP 1986 12 03 UNK (19XX) T000846 AMP-PNP, Mg T000846 Mg AMP PNP D000267 Adhesions 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI IM GEN only; coord NIM with organ/dis precoord (IM) C23.550.051 NLM KEV sjn M0000418 Adhesions C0001511 Pathological processes consisting of the union of the opposing surfaces of a wound. T020 Acquired Abnormality T047 Disease or Syndrome T000847 Adhesions 1999 01 01 POPLINE (1978) T000847 Adhesion D000268 Adhesiveness 1999 01 01 1992 03 25 1974 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE almost never IM 74(69) 74 Surface Properties (1966-1968) D010973 Platelet Adhesiveness H01.181.529.875.139 NLM TAP PLS M0000419 Adhesiveness C0001515 T070 Natural Phenomenon or Process T000848 Adhesiveness 1999 01 01 NLM (1969) T000848 Adhesivenesses D000269 Adhesives 1977 04 22 2003 07 09 1978 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif; coord IM with DENTURE RETENTION (IM) for denture adhesives; spray adhesives: coord IM with AEROSOLS (NIM) if pertinent; available also are BONE CEMENTS & DENTAL CEMENTS 78 78 D014014 Tissue Adhesives D27.720.013 J01.637.016 SH ssb sjn M0000420 Adhesives C0001516 0 Substances that cause the adherence of two surfaces. They include glues (properly collagen-derived adhesives), mucilages, sticky pastes, gums, resins, or latex. T073 Manufactured Object T122 Biomedical or Dental Material M0000420 M0000421 M0000420 M0000422 T000849 Adhesives 1999 01 01 NLM (1978) T000849 Adhesive M0000421 Glues C0017780 0 T073 Manufactured Object M0000420 M0000421 T000850 Glues 1977 04 18 UNK (19XX) T000850 Glue M0000422 Mucilages C0026679 0 T073 Manufactured Object M0000420 M0000422 T000851 Mucilages 1982 11 23 UNK (19XX) T000851 Mucilage D000270 Adie Syndrome 1999 01 01 1999 11 23 2000 2000A 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 2000 (1963) 2000; see ADIE'S SYNDROME 1963-1999 C10.177.045 C10.292.600.200 C11.590.436.200 C11.710.800.180 NLM ags ags M0000423 Adie Syndrome C0001519 A syndrome characterized by a TONIC PUPIL that occurs in combination with decreased lower extremity reflexes. The affected pupil will respond more briskly to accommodation than to light (light-near dissociation) and is supersensitive to dilute pilocarpine eye drops, which induce pupillary constriction. Pathologic features include degeneration of the ciliary ganglion and postganglionic parasympathetic fibers that innervate the pupillary constrictor muscle. (From Adams et al., Principles of Neurology, 6th ed, p279) T047 Disease or Syndrome T365309 Adie Syndrome 1999 11 03 NLM (2000) T365309 Syndrome, Adie T000852 Adie's Syndrome 1999 01 01 NLM (1966) T000852 Syndrome, Adie's T000853 Holmes-Adie Syndrome 1989 03 22 NLM (1990) T000853 Holmes Adie Syndrome T000853 Syndrome, Holmes-Adie D000272 Adipic Acids 1999 01 01 1995 05 18 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 75; was ADIPIC ACID 1963-74 use ADIPIC ACIDS to search ADIPIC ACID 1966-74 75; was ADIPIC ACID 1963-74 D02.241.081.337.052 NLM KEV PLS M0000424 Adipic Acids C0001522 0 A group of dicarboxylic acids that are structurally related to hexanedioic acid (adipic acid). (From Stedman, 25th ed) T109 Organic Chemical T000854 Adipic Acids 1999 01 01 NLM (1966) T000854 Acids, Adipic D000273 Adipose Tissue 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI inflammation = PANNICULITIS; /surg: consider also LIPECTOMY D002001 Brown Fat D012885 Skinfold Thickness D015187 Lipectomy D017667 Adipocytes A10.165.114 NLM jls sjn M0000425 Adipose Tissue C0001527 Connective tissue composed of fat cells lodged in the meshes of areolar tissue. T024 Tissue T000855 Adipose Tissue 1999 01 01 NLM (1966) T000855 Adipose Tissues T000855 Tissue, Adipose T000855 Tissues, Adipose T000856 Fatty Tissue 1974 03 29 UNK (19XX) T000856 Fatty Tissues T000856 Tissue, Fatty T000856 Tissues, Fatty D000274 Adiposis Dolorosa 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C17.800.849.077 C18.452.872.077 NLM nns sjn M0000426 Adiposis Dolorosa C0001529 A rare disease, believed to be autosomal dominant, manifested by fatty deposits that press on nerves causing weakness and pain. T047 Disease or Syndrome T000857 Adiposis Dolorosa 1999 01 01 NLM (1966) T000858 Dercum Disease 1984 06 15 DERCUM DIS UNK (19XX) T000858 Disease, Dercum T000859 Dercum's Disease 1974 03 29 DERCUMS DIS UNK (19XX) T000859 Dercums Disease T000859 Disease, Dercum's D000275 Adjustment Disorders 1999 01 01 1997 06 20 1969 01 01 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI 81; was DEPRESSION, REACTIVE 1966-80 (Prov 1966-68) use ADJUSTMENT DISORDERS to search DEPRESSION, REACTIVE 1966-80 (as Prov 1966-68) 81; was DEPRESSION, REACTIVE 1969-80 F03.075 NLM JLS SJN M0000427 Adjustment Disorders C0001546 Maladaptive reactions to identifiable psychosocial stressors occurring within a short time after onset of the stressor. They are manifested by either impairment in social or occupational functioning or by symptoms (depression, anxiety, etc.) that are in excess of a normal and expected reaction to the stressor. T048 Mental or Behavioral Dysfunction M0000427 M0000428 M0000427 M0000429 M0000427 M0000430 T000861 Adjustment Disorders 1999 01 01 ADJUSTMENT DIS NLM (1966) T000860 Adjustment Disorder 1980 05 21 UNK (19XX) T000860 Disorder, Adjustment T000860 Disorders, Adjustment T000862 Reactive Disorders 1980 05 21 REACTIVE DIS UNK (19XX) T000862 Disorder, Reactive T000862 Disorders, Reactive T000862 Reactive Disorder M0000428 Anniversary Reaction C0003099 T048 Mental or Behavioral Dysfunction M0000427 M0000428 T000863 Anniversary Reaction 1986 03 25 UNK (19XX) T000863 Anniversary Reactions T000863 Reaction, Anniversary T000863 Reactions, Anniversary M0000429 Depression, Reactive C0011579 T048 Mental or Behavioral Dysfunction M0000427 M0000429 T000864 Depression, Reactive 1980 05 21 UNK (19XX) T000864 Depressions, Reactive T000864 Reactive Depression T000864 Reactive Depressions M0000430 Transient Situational Disturbance C0040701 T048 Mental or Behavioral Dysfunction M0000427 M0000430 T000865 Transient Situational Disturbance 1983 06 06 UNK (19XX) T000865 Disturbance, Transient Situational T000865 Disturbances, Transient Situational T000865 Situational Disturbance, Transient T000865 Situational Disturbances, Transient T000865 Transient Situational Disturbances D000276 Adjuvants, Immunologic 1999 01 01 2003 07 09 1965 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG DF: ADJUVANTS IMMUNOL 65 65 D24.611.062 D24.611.274.050 D27.505.696.444.611.062 D27.505.696.444.611.274.050 NLM ssb sjn M0000431 Adjuvants, Immunologic C0001551 0 Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. T121 Pharmacologic Substance T129 Immunologic Factor T000868 Adjuvants, Immunologic 1999 01 01 ADJUVANTS IMMUNOL NLM (1965) T000866 Adjuvant, Immunologic 1990 10 02 ADJUVANT IMMUNOL NLM (1992) T000866 Immunologic Adjuvant T000869 Immunoactivators 1978 12 15 UNK (19XX) T000871 Immunomodulators 1978 12 15 IMMUNOMOD UNK (19XX) T000873 Immunostimulants 1978 12 15 UNK (19XX) T000875 Immunological Adjuvant 1993 01 27 IMMUNOL ADJUVANT NLM (1994) T000875 Adjuvant, Immunological T000874 Adjuvants, Immunological 1978 06 26 UNK (19XX) T000874 Immunological Adjuvants T000872 Immunopotentiators 1978 12 15 UNK (19XX) T000870 Immunoadjuvants 1978 12 15 UNK (19XX) T000867 Immunologic Adjuvants 1988 07 29 IMMUNOL ADJUVANTS UNK (19XX) D000277 Adjuvants, Pharmaceutic 1999 01 01 2003 07 09 1975 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif; DF: ADJUVANTS PHARM 75; was see under PHARMACEUTIC AIDS 1969-74 search PHARMACEUTIC AIDS 1969-74 75; was see under PHARMACEUTIC AIDS 1969-74 Pharmaceutic Aids (1968-1974) D26.650.064 D27.720.744.064 NLM ssb sjn M0000432 Adjuvants, Pharmaceutic C0001552 0 Agents that aid or increase the action of the principle drug or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug in such a way as to enhance its effects. T120 Chemical Viewed Functionally T000879 Adjuvants, Pharmaceutic 1999 01 01 ADJUVANTS PHARM NLM (1975) T000876 Pharmaceutic Adjuvants 1993 01 11 PHARM ADJUVANTS NLM (1994) T000877 Adjuvant, Pharmaceutic 1993 01 22 ADJUVANT PHARM NLM (1994) T000881 Pharmaceutical Adjuvants 1993 01 22 NLM (1994) T000883 Pharmaceutical Adjuvant 1993 01 22 NLM (1994) T000882 Adjuvant, Pharmaceutical 1993 01 22 NLM (1994) T000880 Adjuvants, Pharmaceutical 1978 06 26 UNK (19XX) T000878 Pharmaceutic Adjuvant 1993 01 22 PHARM ADJUVANT NLM (1994) D000278 Administration, Buccal 1987 05 07 1991 05 12 1988 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every buccally administered drug; no qualif 88 88 Administration, Oral (1971-1987) Administration, Topical (1975-1987) Cheek (1966-1987) E05.300.100.028 E05.300.120.040 SCD TGC PLS M0000433 Administration, Buccal C0001557 Administration of a soluble dosage form between the cheek and gingiva. It may involve direct application of a drug onto the buccal mucosa, as by painting or spraying. T061 Therapeutic or Preventive Procedure T000885 Administration, Buccal 1999 01 01 ADMIN BUCCAL NLM (1988) T000884 Buccal Administration 1987 05 07 BUCCAL ADMIN UNK (19XX) T000884 Administrations, Buccal T000884 Buccal Administrations T000886 Buccal Drug Administration 1987 05 07 BUCCAL DRUG ADMIN UNK (19XX) T000886 Administration, Buccal Drug T000886 Administrations, Buccal Drug T000886 Buccal Drug Administrations T000886 Drug Administrations, Buccal T000887 Drug Administration, Buccal 1987 05 07 DRUG ADMIN BUCCAL UNK (19XX) D000279 Administration, Cutaneous 1986 06 25 1991 05 12 1987 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here rountinely for every cutaneously administered drug; no qualif 87 87 Administration, Topical (1966-1986) D012869 Skin Absorption E05.300.120.060 SH PLS PLS M0000434 Administration, Cutaneous C0001558 The application of suitable drug dosage forms to the skin for either local or systemic effects. T061 Therapeutic or Preventive Procedure M0000434 M0000435 M0000434 M0000436 T000889 Administration, Cutaneous 1999 01 01 ADMIN CUTANEOUS NLM (1987) T000888 Cutaneous Administration 1991 05 12 CUTANEOUS ADMIN NLM (1992) T000888 Administrations, Cutaneous T000888 Cutaneous Administrations T000890 Cutaneous Administration, Drug 1991 05 12 CUTANEOUS ADMIN DRUG NLM (1987) T000890 Cutaneous Administrations, Drug T000891 Drug Administration, Cutaneous 1991 05 12 DRUG ADMIN CUTANEOUS NLM (1992) T000891 Administration, Cutaneous Drug T000891 Administrations, Cutaneous Drug T000891 Cutaneous Drug Administrations T000891 Drug Administrations, Cutaneous T000892 Cutaneous Drug Administration 1986 06 25 CUTANEOUS DRUG ADMIN UNK (19XX) T000893 Dermal Drug Administration 1986 06 25 DERMAL DRUG ADMIN UNK (19XX) T000893 Administration, Dermal Drug T000893 Administrations, Dermal Drug T000893 Dermal Drug Administrations T000893 Drug Administrations, Dermal T000894 Drug Administration, Dermal 1986 06 25 DRUG ADMIN DERMAL UNK (19XX) T000895 Skin Administration, Drug 1991 05 12 SKIN ADMIN DRUG NLM (1987) T000895 Drug Skin Administrations T000895 Skin Administrations, Drug T000896 Skin Drug Administration 1986 06 25 SKIN DRUG ADMIN UNK (19XX) T000896 Skin Drug Administrations T000897 Administration, Dermal 1991 05 12 ADMIN DERMAL NLM (1992) T000897 Administrations, Dermal T000897 Dermal Administrations T000898 Dermal Administration 1991 05 12 DERMAL ADMIN NLM (1992) M0000435 Percutaneous Administration C0030988 T061 Therapeutic or Preventive Procedure M0000434 M0000435 T000899 Percutaneous Administration 1986 06 25 PERCUTANEOUS ADMIN UNK (19XX) T000899 Administration, Percutaneous T000899 Administrations, Percutaneous T000899 Percutaneous Administrations M0000436 Administration, Transcutaneous C0040652 T061 Therapeutic or Preventive Procedure M0000434 M0000436 T000900 Administration, Transcutaneous 1988 06 25 ADMIN TRANSCUTANEOUS UNK (19XX) T000900 Administrations, Transcutaneous T000900 Transcutaneous Administrations T000901 Transcutaneous Administration 1986 06 25 TRANSCUTANEOUS ADMIN UNK (19XX) T000902 Administration, Transdermal 1986 06 25 ADMIN TRANSDERMAL UNK (19XX) T000902 Administrations, Transdermal T000902 Transdermal Administrations T000903 Transdermal Administration 1986 06 25 TRANSDERMAL ADMIN UNK (19XX) D000280 Administration, Inhalation 1986 06 04 1999 11 03 1987 01 01 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every drug admin by inhalation; no qualif 87 87 Aerosols (1966-1986) Lung (1966-1986) Respiration (1966-1986) Respiratory Therapy (1978-1986) D000281 Administration, Intranasal D000336 Aerosols D000769 Anesthesia, Inhalation D009330 Nebulizers and Vaporizers D012138 Respiratory Therapy E05.300.050 SH adp sjn M0000437 Administration, Inhalation C0001559 The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. T061 Therapeutic or Preventive Procedure M0000437 M0000438 M0000437 M0000439 T000905 Administration, Inhalation 1999 01 01 ADMIN INHALATION NLM (1987) T000906 Drug Administration, Inhalation 1986 06 04 DRUG ADMIN INHALATION UNK (19XX) T000906 Administration, Inhalation Drug T000908 Drug Administration, Respiratory 1986 06 04 DRUG ADMIN RESPIRATORY UNK (19XX) T000908 Administration, Respiratory Drug T000904 Inhalation Administration 1986 06 04 INHALATION ADMIN UNK (19XX) T000907 Inhalation Drug Administration 1986 06 04 INHALATION DRUG ADMIN UNK (19XX) T000909 Respiratory Drug Administration 1986 06 04 RESPIRATORY DRUG ADMIN UNK (19XX) M0000438 Drug Aerosol Therapy C0013156 T061 Therapeutic or Preventive Procedure M0000437 M0000438 T000913 Drug Aerosol Therapy 1986 06 04 DRUG AEROSOL THER UNK (19XX) T000910 Aerosol Drug Therapy 1991 11 22 AEROSOL DRUG THER NLM (1992) T000910 Therapy, Aerosol Drug T000911 Aerosol Therapy, Drug 1986 06 04 AEROSOL THER DRUG UNK (19XX) T000911 Therapy, Drug Aerosol T000912 Drug Therapy, Aerosol 1991 11 22 DRUG THER AEROSOL NLM (1992) M0000439 Inhalation of Drugs C0086464 T061 Therapeutic or Preventive Procedure M0000437 M0000439 T000914 Inhalation of Drugs 1986 06 04 UNK (19XX) D000281 Administration, Intranasal 1999 01 01 1999 11 03 1973 01 01 2000 2001 2002 2003 2004 73 73 specific drug/administration & dosage (1966-1972) D000280 Administration, Inhalation D009330 Nebulizers and Vaporizers E05.300.080 E05.300.120.080 NLM adp sjn M0000440 Administration, Intranasal C0001560 The administration of drugs through the nasal passage. T061 Therapeutic or Preventive Procedure T000916 Administration, Intranasal 1999 01 01 ADMIN INTRANASAL NLM (1973) T000917 Administration, Intranasal Drug 1974 03 29 ADMIN INTRANASAL DRUG UNK (19XX) T000917 Administrations, Intranasal Drug T000917 Drug Administrations, Intranasal T000917 Intranasal Drug Administrations T000919 Drug Administration, Intranasal 1974 03 29 DRUG ADMIN INTRANASAL UNK (19XX) T000915 Intranasal Administration 1974 03 29 INTRANASAL ADMIN UNK (19XX) T000915 Administrations, Intranasal T000915 Intranasal Administrations T000918 Intranasal Drug Administration 1974 03 29 INTRANASAL DRUG ADMIN UNK (19XX) D000282 Administration, Intravaginal 1986 06 04 1991 11 02 1990 01 01 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every intravaginally administered drug; no qualif 90(87); was see under ADMINISTRATION, TOPICAL 1987-89 90; was see under ADMINISTRATION, TOPICAL 1987-89 Administration, Topical (1974-1986) Vagina (1966-1986) Vaginal Creams, Foams and Jellies (1975-1986) D014622 Vaginal Creams, Foams and Jellies E05.300.120.500 SH PLS PLS M0000441 Administration, Intravaginal C0001561 The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories. T061 Therapeutic or Preventive Procedure M0000441 M0000442 T000921 Administration, Intravaginal 1999 01 01 ADMIN INTRAVAGINAL NLM (1987) T000920 Intravaginal Administration 1986 06 04 INTRAVAGINAL ADMIN UNK (19XX) T000920 Administrations, Intravaginal T000920 Intravaginal Administrations T000922 Vaginal Administration 1986 06 04 VAGINAL ADMIN UNK (19XX) T000922 Administrations, Vaginal T000922 Vaginal Administrations T000923 Administration, Vaginal 1986 06 04 ADMIN VAGINAL UNK (19XX) M0000442 Instillation, Vaginal C0086184 T061 Therapeutic or Preventive Procedure M0000441 M0000442 T000924 Instillation, Vaginal 1986 06 04 UNK (19XX) T000924 Instillations, Vaginal T000924 Vaginal Instillation T000924 Vaginal Instillations T000925 Drug Administration, Vaginal 1986 06 04 DRUG ADMIN VAGINAL UNK (19XX) T000925 Administration, Vaginal Drug T000925 Administrations, Vaginal Drug T000925 Drug Administrations, Vaginal T000925 Vaginal Drug Administrations T000926 Vaginal Drug Administration 1986 06 04 VAGINAL DRUG ADMIN UNK (19XX) D000283 Administration, Intravesical 1986 06 04 1990 06 01 1987 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every intravesically administered drug; no qualif 87 87 Administration, Topical (1974-1986) Bladder (1966-1986) E05.300.120.505 SH TGC PLS M0000443 Administration, Intravesical C0001562 The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms. T061 Therapeutic or Preventive Procedure M0000443 M0000444 M0000443 M0000445 T000928 Administration, Intravesical 1999 01 01 ADMIN INTRAVESICAL NLM (1987) T000927 Intravesical Administration 1986 06 04 INTRAVESICAL ADMIN UNK (19XX) T000927 Administrations, Intravesical T000927 Intravesical Administrations T000929 Bladder Drug Administration 1989 02 15 BLADDER DRUG ADMIN NLM (1990) T000929 Administration, Bladder Drug T000929 Administrations, Bladder Drug T000929 Bladder Drug Administrations T000929 Drug Administrations, Bladder T000930 Drug Administration, Bladder 1986 06 04 DRUG ADMIN BLADDER UNK (19XX) T000931 Administration, Intravesical Drug 1986 06 04 ADMIN INTRAVESICAL DRUG UNK (19XX) T000931 Administrations, Intravesical Drug T000931 Drug Administration, Intravesical T000931 Drug Administrations, Intravesical T000931 Intravesical Drug Administrations T000932 Intravesical Drug Administration 1986 06 04 INTRAVESICAL DRUG ADMIN UNK (19XX) M0000444 Intravesical Injection C0021916 T061 Therapeutic or Preventive Procedure M0000443 M0000444 T000934 Intravesical Injection 1986 06 04 INTRAVESICAL INJECT UNK (19XX) T000933 Injections, Intravesical 1990 01 03 INJECT INTRAVESICAL NLM (1991) T000933 Injection, Intravesical T000933 Intravesical Injections M0000445 Instillation, Bladder C0021917 T061 Therapeutic or Preventive Procedure M0000443 M0000445 T000935 Instillation, Bladder 1986 06 04 UNK (19XX) T000935 Bladder Instillation T000935 Bladder Instillations T000935 Instillations, Bladder T000936 Intravesical Instillation 1986 06 04 UNK (19XX) T000936 Instillation, Intravesical T000936 Instillations, Intravesical T000936 Intravesical Instillations D000284 Administration, Oral 1999 01 01 1991 05 12 1973 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every orally administered drug; no qualif 73(70) 73 specific drug/administration & dosage (1966-1969) E05.300.100 NLM TGC PLS M0000446 Administration, Oral C0001563 The giving of drugs, chemicals, or other substances by mouth. T061 Therapeutic or Preventive Procedure T000938 Administration, Oral 1999 01 01 ADMIN ORAL NLM (1970) T000937 Oral Administration 1974 03 29 ORAL ADMIN UNK (19XX) T000937 Administrations, Oral T000937 Oral Administrations T000939 Administration, Oral Drug 1974 03 29 ADMIN ORAL DRUG UNK (19XX) T000939 Administrations, Oral Drug T000939 Drug Administrations, Oral T000939 Oral Drug Administrations T000940 Oral Drug Administration 1974 03 29 ORAL DRUG ADMIN UNK (19XX) T000941 Drug Administration, Oral 1974 03 29 DRUG ADMIN ORAL UNK (19XX) D000285 Administration, Rectal 1986 06 04 1989 07 13 1987 01 01 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every rectally administered drug; no qualif 87 87 Intestinal Absorption (1966-1986) Rectum (1966-1986) Suppositories (1966-1986) D000774 Anesthesia, Rectal D013488 Suppositories E05.300.110 E05.300.120.610 SH PLS PLS M0000447 Administration, Rectal C0001564 The insertion of drugs into the rectum, usually for confused or incompetent patients, like children, infants, and the very old or comatose. T061 Therapeutic or Preventive Procedure T000943 Administration, Rectal 1999 01 01 ADMIN RECTAL NLM (1987) T000942 Rectal Administration 1986 06 04 RECTAL ADMIN UNK (19XX) T000942 Administrations, Rectal T000942 Rectal Administrations T000944 Drug Administration, Anal 1986 06 04 DRUG ADMIN ANAL UNK (19XX) T000944 Administration, Anal Drug T000944 Administrations, Anal Drug T000944 Anal Drug Administrations T000944 Drug Administrations, Anal T000945 Anal Drug Administration 1986 06 04 ANAL DRUG ADMIN UNK (19XX) T000946 Instillation, Rectal 1986 06 04 UNK (19XX) T000946 Instillations, Rectal T000946 Rectal Instillation T000946 Rectal Instillations T000947 Drug Administration, Rectal 1986 06 04 DRUG ADMIN RECTAL UNK (19XX) T000947 Administration, Rectal Drug T000947 Administrations, Rectal Drug T000947 Drug Administrations, Rectal T000947 Rectal Drug Administrations T000948 Rectal Drug Administration 1986 06 04 RECTAL DRUG ADMIN UNK (19XX) D000286 Administration, Sublingual 1987 05 07 1991 05 12 1988 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 NIM but only if discussed: do not index here routinely for every sublingually administered drug; no qualif 88 88 Administration, Oral (1971-1987) E05.300.100.878 SCD TGC PLS M0000448 Administration, Sublingual C0001565 Administration of a soluble dosage form by placement under the tongue. T061 Therapeutic or Preventive Procedure T000950 Administration, Sublingual 1999 01 01 ADMIN SUBLINGUAL NLM (1988) T000949 Sublingual Administration 1987 05 07 SUBLINGUAL ADMIN UNK (19XX) T000949 Administrations, Sublingual T000949 Sublingual Administrations T000951 Drug Administration, Sublingual 1987 05 07 DRUG ADMIN SUBLINGUAL UNK (19XX) T000951 Administration, Sublingual Drug T000951 Administrations, Sublingual Drug T000951 Drug Administrations, Sublingual T000951 Sublingual Drug Administrations T000952 Sublingual Drug Administration 1987 05 07 SUBLINGUAL DRUG ADMIN UNK (19XX) D000287 Administration, Topical 1999 01 01 2001 07 25 1974 01 01 2002 2003 2004 NIM but only if discussed: do not index here routinely for every topically administered drug; no qualif; consider also OINTMENTS; LINIMENTS & POWDERS; ADMINISTRATION, CUTANEOUS is also available 74 74 E05.300.120 NLM mdb sjn M0000449 Administration, Topical C0001566 T061 Therapeutic or Preventive Procedure T000954 Administration, Topical 1999 01 01 ADMIN TOPICAL NLM (1974) T000955 Administration, Topical Drug 1974 03 29 ADMIN TOPICAL DRUG UNK (19XX) T000955 Administrations, Topical Drug T000955 Drug Administrations, Topical T000955 Topical Drug Administrations T000957 Drug Administration, Topical 1974 03 29 DRUG ADMIN TOPICAL UNK (19XX) T000953 Topical Administration 1974 03 29 TOPICAL ADMIN UNK (19XX) T000953 Administrations, Topical T000953 Topical Administrations T000956 Topical Drug Administration 1974 03 29 TOPICAL DRUG ADMIN UNK (19XX) D000288 Administrative Personnel 1999 01 01 1994 03 17 1968 01 01 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000193 education ED Q000523 psychology PX 68 68 Organization and Administration (1966-1967) M01.526.070 NLM PLS PLS M0000450 Administrative Personnel C0001568 Individuals responsible for the development of policy and supervision of the execution of plans and functional operations. T097 Professional or Occupational Group M0000450 M0000451 M0000450 M0000452 T000958 Administrative Personnel 1999 01 01 POPLINE (1978) T000958 Personnel, Administrative M0000451 Administrators C0085751 T097 Professional or Occupational Group M0000450 M0000451 T000959 Administrators 1978 12 04 BIOETHICS (1978) T000959 Administrator M0000452 Policy Makers C0242170 T097 Professional or Occupational Group M0000450 M0000452 T000960 Policy Makers 1994 03 15 POPLINE (1993) T000960 Policy Maker D000289 Admitting Department, Hospital 1977 05 19 1992 03 25 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES DF: ADMIT DEP 91(Aug 77); was see under HOSPITAL DEPARTMENTS 1977-90 91; was see under HOSPITAL DEPARTMENTS 1977-90 N02.278.354.422.040 N04.452.442.422.040 EC TGC PLS M0000454 Admitting Department, Hospital C0001573 Hospital department responsible for the flow of patients and the processing of admissions, discharges, transfers, and also most procedures to be carried out in the event of a patient's death. T093 Health Care Related Organization M0000454 M0000453 T000963 Admitting Department, Hospital 1999 01 01 ADMITTING DEP HOSP NLM (1977) T000962 Hospital Admitting Department 1977 05 19 HOSP ADMITTING DEP UNK (19XX) T000962 Admitting Departments, Hospital T000962 Department, Hospital Admitting T000962 Departments, Hospital Admitting T000962 Hospital Admitting Departments T000964 Hospital Admissions Office 1977 05 19 HOSP ADMISSIONS OFFICE UNK (19XX) T000964 Admissions Office, Hospital T000964 Admissions Offices, Hospital T000964 Hospital Admissions Offices T000964 Office, Hospital Admissions T000964 Offices, Hospital Admissions M0000453 Admitting Department C0001572 T093 Health Care Related Organization M0000454 M0000453 T000961 Admitting Department 1990 03 08 ADMIT DEP NLM (1991) T000961 Admitting Departments T000961 Department, Admitting T000961 Departments, Admitting D000290 Adnexa Uteri 1999 01 01 2002 07 02 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI seen in titles more frequently in adjective form "adnexal"; inflammation = ADNEXITIS D000291 Adnexal Diseases A05.360.319.114 NLM lkt sjn M0000455 Adnexa Uteri C0001575 Appendages of the UTERUS which include the FALLOPIAN TUBES, the OVARY, and the supporting ligaments of the uterus (BROAD LIGAMENT; ROUND LIGAMENT). T023 Body Part, Organ, or Organ Component T000965 Adnexa Uteri 1999 01 01 NLM (1966) T470418 Uterine Appendages 2001 11 19 NLM (2003) T470418 Appendage, Uterine T470418 Appendages, Uterine T470418 Uterine Appendage D000291 Adnexal Diseases 1999 01 01 2002 07 02 1966 01 01 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI inflamm dis = PELVIC INFLAMMATORY DISEASE 66 66 C13.371.056 NLM lkt sjn M0000457 Adnexal Diseases C0001576 Diseases of the uterine appendages (ADNEXA UTERI) including diseases involving the OVARY, the FALLOPIAN TUBES, and ligaments of the uterus (BROAD LIGAMENT; ROUND LIGAMENT). T047 Disease or Syndrome T000967 Adnexal Diseases 1999 01 01 ADNEXAL DIS NLM (1966) T000967 Adnexal Disease T000967 Disease, Adnexal T000967 Diseases, Adnexal D000292 Pelvic Inflammatory Disease 1999 01 01 2002 07 02 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI female only: note category; "male adnexitis": index under GENITAL DISEASES, MALE or PELVIC INFECTION 2003 (1963) 2003; see ADNEXITIS 1963-2002 C01.539.635.500 C13.371.056.750 NLM lkt sjn M0000460 Pelvic Inflammatory Disease C0242172 A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility. T047 Disease or Syndrome M0000460 M0000458 T000974 Pelvic Inflammatory Disease 1974 03 29 PELVIC INFLAMM DIS NLM (1966) T000974 Disease, Pelvic Inflammatory T000974 Diseases, Pelvic Inflammatory T000974 Inflammatory Diseases, Pelvic T000974 Pelvic Inflammatory Diseases T000971 Inflammatory Disease, Pelvic 1995 03 09 INFLAMM DIS PELVIC NLM (1996) T000972 Inflammatory Pelvic Disease 1995 03 09 INFLAMM PELVIC DIS NLM (1996) T000972 Disease, Inflammatory Pelvic T000972 Diseases, Inflammatory Pelvic T000972 Inflammatory Pelvic Diseases T000972 Pelvic Diseases, Inflammatory T000973 Pelvic Disease, Inflammatory 1995 03 09 PELVIC DIS INFLAMM NLM (1996) M0000458 Adnexitis C0001577 Inflammation of the uterine appendages (ADNEXA UTERI) including infection of the FALLOPIAN TUBES (SALPINGITIS), the ovaries (OOPHORITIS), or the supporting ligaments (PARAMETRITIS). T047 Disease or Syndrome M0000460 M0000458 T000968 Adnexitis 1999 01 01 NLM (1963) D000293 Adolescent 1999 01 01 2002 07 02 2003 2004 Q000331 legislation & jurisprudence LJ Q000502 physiology PH age 13-18 yr; IM as psychol & sociol entity; check tag ADOLESCENT for NIM; Manual 18.5.12, 34.9.5 D000293 Adolescent Q000523 psychology D000297 Adolescent Psychology D033242 Minors M01.060.057 NLM jrf sjn M0000462 Adolescent C0001587 A person 13 to 18 years of age. T100 Age Group M0000462 M0000461 M0000462 M0000463 M0000462 M0000464 M0000462 M0000467 M0000462 M0000466 T483695 Adolescent 2002 02 27 NLM (2003) T000976 Adolescents 1977 03 17 BIOETHICS (1974) NLM (1978) M0000461 Adolescence C0001578 The period of life beginning with the appearance of secondary sex characteristics and terminating with the cessation of somatic growth. The years usually referred to as adolescence lie between 13 and 18 years of age. T100 Age Group M0000462 M0000461 T000975 Adolescence 1999 01 01 NLM (1966) M0000463 Adolescents, Female C0001588 T100 Age Group M0000462 M0000463 T000977 Adolescents, Female 1978 12 18 NLM (1979) T000977 Adolescent, Female T000977 Female Adolescent T000977 Female Adolescents M0000464 Adolescents, Male C0001589 T100 Age Group M0000462 M0000464 T000978 Adolescents, Male 1978 12 18 NLM (1978) T000978 Adolescent, Male T000978 Male Adolescent T000978 Male Adolescents M0000467 Teens C0205653 T100 Age Group M0000462 M0000467 T000981 Teens 1993 02 01 NLM (1994) T000981 Teen T483696 Teenagers 2002 02 27 NLM (2003) T483696 Teenager M0000466 Youth C0087178 T100 Age Group M0000462 M0000466 T000980 Youth 1974 03 29 NLM (1987) T000980 Youths D000294 Adolescent Behavior 1980 05 07 2003 07 09 1981 01 01 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES Q000208 ethnology EH Q000523 psychology PX check also tag ADOLESCENCE 81 81 Adolescent Psychology (1967-1980) D041923 Adolescent Development F01.145.022 EC lkt sjn M0000468 Adolescent Behavior C0001580 Any observable response or action of an adolescent. T055 Individual Behavior T000983 Adolescent Behavior 1999 01 01 NLM (1981) T000982 Behavior, Adolescent 1980 05 07 UNK (19XX) T000982 Adolescent Behaviors T000982 Behaviors, Adolescent D000295 Adolescent Medicine 1979 05 29 2002 07 03 1980 01 01 2003 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES SPEC; SPEC qualif; when permitted for "adolescent dis": Manual 28.10.1; relation to ADOLESCENCE: Manual 28.10.1; DF: ADOLESCENT MED 80 80 Adolescence (1966-1979) G02.403.028 EC sjn sjn M0000469 Adolescent Medicine C0001581 A branch of medicine pertaining to the diagnosis and treatment of diseases occurring during the period beginning with puberty until the cessation of somatic growth. T091 Biomedical Occupation or Discipline T000985 Adolescent Medicine 1999 01 01 ADOLESCENT MED NLM (1980) T000984 Medicine, Adolescent 1989 11 29 MED ADOLESCENT NLM (1991) D000296 Adolescent Psychiatry 1999 01 01 2002 07 03 1967 01 01 2003 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES SPEC: SPEC qualif; not for mental disorders in adolescents ( = MENTAL DISORDERS (IM) + ADOLESCENT (NIM) ): Manual 27.9 67 67 Child Psychiatry (1966) Psychiatry (1966) Psychoanalysis (1966) F04.096.544.065 G02.403.642.080 NLM sjn sjn M0000470 Adolescent Psychiatry C0001583 The medical science that deals with the origin, diagnosis, prevention, and treatment of mental disorders in individuals 13-18 years. T091 Biomedical Occupation or Discipline T000986 Adolescent Psychiatry 1999 01 01 POPLINE (1994) T000986 Psychiatry, Adolescent D000297 Adolescent Psychology 1999 01 01 1996 06 10 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES SPEC but also the way a normal adolescent thinks & acts; when SPEC, SPEC qualif; Manual 27.11; DF: ADOLESCENT PSYCHOL 67 67 F04.096.628.065 NLM TAP PLS M0000471 Adolescent Psychology C0001584 Field of psychology concerned with the normal and abnormal behavior of adolescents. It includes mental processes as well as observable responses. T091 Biomedical Occupation or Discipline T000988 Adolescent Psychology 1999 01 01 ADOLESCENT PSYCHOL NLM (1966) T000987 Psychology, Adolescent 1986 01 01 PSYCHOL ADOLESCENT UNK (19XX) D000298 Adolescent, Hospitalized 1982 04 28 2002 07 02 1983 01 01 2003 2004 Q000193 education ED Q000523 psychology PX Q000706 statistics & numerical data SN not for dis in adolescent in hosp for diag or ther: use only for hospitalized adolescents as a psychol, sociol or social entity; check also tag ADOLESCENT 83 83 Adolescence (1966-1982) Hospitalization (1966-1982) D000299 Adolescent, Institutionalized M01.643.050 EC jls sjn M0000472 Adolescent, Hospitalized C0001585 Adolescent hospitalized for short term care. T101 Patient or Disabled Group T000989 Adolescent, Hospitalized 1999 01 01 NLM (1983) T000989 Adolescents, Hospitalized T000989 Hospitalized Adolescent T000989 Hospitalized Adolescents D000299 Adolescent, Institutionalized 1982 04 28 2002 07 02 1983 01 01 2003 2004 Q000193 education ED Q000523 psychology PX Q000706 statistics & numerical data SN check also tag ADOLESCENT 83 83 Adolescence (1966-1982) Institutionalization (1979-1982) Residential Facilities (1968-1982) M01.643.154 EC jls sjn M0000473 Adolescent, Institutionalized C0001586 An adolescent who is receiving long-term in-patient services or who resides in an institutional setting. T101 Patient or Disabled Group T000990 Adolescent, Institutionalized 1999 01 01 NLM (1983) T000990 Adolescents, Institutionalized T000990 Institutionalized Adolescents T363892 Institutionalized Adolescent 1999 11 04 NLM (2000) D000300 Adoption 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000331 legislation & jurisprudence LJ Q000523 psychology PX I01.880.225.140 NLM TPW SJN M0000474 Adoption C0001593 Voluntary acceptance of a child of other parents to be as one's own child, usually with legal confirmation. T054 Social Behavior T000991 Adoption 1999 01 01 BIOETHICS (1989) POPLINE (1981) T000991 Adoptions D000301 Adosterol 1978 05 16 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(79); was see under CHOLESTEROL 1989-90; was see under STEROLS 1979-88 91; was see under CHOLESTEROL 1989-90; was see under STEROLS 1979-88 Cholestenes (1973-1978) Iodine Radioisotopes (1966-1978) Sterols (1966-1978) D04.808.247.808.050 RLS TWD sjn M0000475 Adosterol C0001595 19-Norcholest-5(10)-en-3-ol, 6-(iodomethyl)-, (3beta,6beta)- 55623-03-5 A sterol usually substituted with radioactive iodine. It is an adrenal cortex scanning agent with demonstrated high adrenal concentration and superior adrenal imaging. T110 Steroid T130 Indicator, Reagent, or Diagnostic Aid M0000475 M0351200 M0000475 M0351201 T000993 Adosterol 1999 01 01 NLM (1979) T000992 6-Iodomethylnorcholesterol 1978 05 16 IODOMETHYLNORCHOLESTEROL 06 UNK (19XX) T000992 6 Iodomethylnorcholesterol M0351200 NCL-6 C0878400 0 T110 Steroid T130 Indicator, Reagent, or Diagnostic Aid M0000475 M0351200 T000994 NCL-6 1980 07 30 UNK (19XX) T000994 NCL 6 T000994 NCL6 M0351201 NP-59 C0878401 0 T110 Steroid T130 Indicator, Reagent, or Diagnostic Aid M0000475 M0351201 T000995 NP-59 1978 05 16 NP A 059 UNK (19XX) T000995 NP59 D000302 Adrenal Cortex 1999 01 01 1998 06 10 1978 01 01 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI PITUITARY-ADRENAL SYSTEM is available; also available are the 3 zonae of the cortex: ZONA GLOMERULOSA (outer), ZONA FASCICULATA (middle) & ZONA RETICULARIS (inner) 78(75)63-67; was see under ADRENAL GLANDS 1968-77 search ADRENAL GLANDS 1966-74 78,63-67; was see under ADRENAL GLANDS 1968-77 Adrenal Glands (1966-1974) A06.407.071.140 NLM MSR SJN M0000476 Adrenal Cortex C0001613 The outer layer of the adrenal gland. It secretes mineralocorticoids, androgens, and glucocorticoids. T023 Body Part, Organ, or Organ Component M0000476 M0000477 T000996 Adrenal Cortex 1999 01 01 NLM (1975) T000996 Cortex, Adrenal M0000477 Adrenal Cortex Effects C0001615 T038 Biologic Function M0000476 M0000477 T000997 Adrenal Cortex Effects 1978 12 18 ADRENAL CORTEX EFF POPLINE (1978) T000997 Adrenal Cortex Effect T000997 Cortex Effect, Adrenal T000997 Cortex Effects, Adrenal T000997 Effect, Adrenal Cortex T000997 Effects, Adrenal Cortex D000303 Adrenal Cortex Diseases 1999 01 01 1990 05 29 1979 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 79(75)63-67; was see under ADRENAL GLAND DISEASES 1975-78 search ADRENAL GLAND DISEASES 1966-74 79,63-67; was see under ADRENAL GLAND DISEASES 1975-78 Adrenal Gland Diseases (1966-1974) C19.053.098 NLM PLS NLM M0000478 Adrenal Cortex Diseases C0001614 T047 Disease or Syndrome T000998 Adrenal Cortex Diseases 1999 01 01 ADRENAL CORTEX DIS NLM (1975) T000998 Adrenal Cortex Disease T000998 Cortex Disease, Adrenal T000998 Cortex Diseases, Adrenal T000998 Disease, Adrenal Cortex T000998 Diseases, Adrenal Cortex D000304 Adrenal Cortex Function Tests 1999 01 01 1997 06 20 1991 01 01 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES 91(75)63-67; was see under PITUITARY-ADRENAL FUNCTION TESTS 1975-90; was heading 1963-67 search PITUITARY-ADRENAL FUNCTION TESTS 1966-74 91,63-67; was see under PITUITARY-ADRENAL FUNCTION TESTS 1975-90; was heading 1963-67 E01.370.374.050 NLM PXP SJN M0000479 Adrenal Cortex Function Tests C0001616 T060 Diagnostic Procedure T000999 Adrenal Cortex Function Tests 1999 01 01 NLM (1975) D000305 Adrenal Cortex Hormones 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN only; avoid: prefer specifics; /defic: consider also ADRENAL GLAND HYPOFUNCTION D000308 Adrenal Gland Hyperfunction D000309 Adrenal Gland Hypofunction D011965 Receptors, Glucocorticoid D06.472.040 NLM TAP PLS M0000480 Adrenal Cortex Hormones C0001617 0 T110 Steroid T125 Hormone T001000 Adrenal Cortex Hormones 1999 01 01 POPLINE (1978) T001000 Hormones, Adrenal Cortex T001001 Corticoids 1974 03 29 UNK (19XX) T001002 Corticosteroids 1975 01 01 UNK (19XX) D000306 Adrenal Cortex Neoplasms 1999 01 01 1999 11 03 1979 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI coord IM with histol type of neopl (IM) 79(75)63-67; was see under ADRENAL GLAND NEOPLASMS 1975-78 search ADRENAL GLAND NEOPLASMS 1966-74 79,63-67; was see under ADRENAL GLAND NEOPLASMS 1975-78 Adrenal Gland Neoplasms (1966-1974) C04.588.322.078.265 C19.053.098.265 C19.053.347.265 C19.344.078.265 NLM nns sjn M0000481 Adrenal Cortex Neoplasms C0001618 Tumors or cancers of the cortex of the adrenal gland. T191 Neoplastic Process M0000481 M0331834 T001004 Adrenal Cortex Neoplasms 1999 01 01 ADRENAL CORTEX NEOPL NLM (1975) T001003 Neoplasms, Adrenal Cortex 1993 09 01 NEOPL ADRENAL CORTEX NLM (1995) T001003 Adrenal Cortex Neoplasm T001003 Neoplasm, Adrenal Cortex M0331834 Adrenocortical Cancer C0346402 T191 Neoplastic Process M0000481 M0331834 T362376 Adrenocortical Cancer 1999 11 03 NLM (2000) T362376 Adrenocortical Cancers T362376 Cancer, Adrenocortical T362376 Cancers, Adrenocortical T362378 Adrenal Cortex Cancer 1999 11 03 NLM (2000) T362378 Cancer, Adrenal Cortex T362378 Cancers, Adrenal Cortex T362377 Cancer of Adrenal Cortex 1999 11 03 NLM (2000) T362377 Adrenal Cortex Cancers T362379 Cancer of the Adrenal Cortex 1999 11 03 NLM (2000) D000307 Adrenal Gland Diseases 1999 01 01 1998 06 10 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI coord IM with ADRENAL MEDULLA (IM) for dis of adrenal medulla; for adrenal hyperplasia see note at ADRENAL GLANDS C19.053 NLM MSR SJN M0000482 Adrenal Gland Diseases C0001621 T047 Disease or Syndrome T001005 Adrenal Gland Diseases 1999 01 01 ADRENAL GLAND DIS NLM (1966) T001005 Adrenal Gland Disease T001005 Disease, Adrenal Gland T001005 Diseases, Adrenal Gland T001005 Gland Disease, Adrenal T001005 Gland Diseases, Adrenal D000308 Adrenal Gland Hyperfunction 1999 01 01 1996 06 10 1968 01 01 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with ADRENAL GLAND HYPOFUNCTION; do not use /congen ( = ADRENAL HYPERPLASIA, CONGENITAL) & do not coord with INFANT, NEWBORN, DISEASES; non-congen adrenal hyperplasia: index under ADRENAL GLANDS /pathol (IM) + HYPERPLASIA (NIM) 68; ADRENAL CORTEX HYPERFUNCTION was heading 1963-67 use ADRENAL GLAND HYPERFUNCTION to search ADRENAL CORTEX HYPERFUNCTION 1966-67 68; ADRENAL CORTEX HYPERFUNCTION was heading 1963-67 D000308 Adrenal Gland Hyperfunction Q000151 congenital D000312 Adrenal Hyperplasia, Congenital D017588 Hyperandrogenism C19.053.181 NLM TGC PLS M0000483 Adrenal Gland Hyperfunction C0001622 T047 Disease or Syndrome T001006 Adrenal Gland Hyperfunction 1999 01 01 NLM (1968) T001006 Adrenal Gland Hyperfunctions T001006 Gland Hyperfunction, Adrenal T001006 Gland Hyperfunctions, Adrenal T001006 Hyperfunction, Adrenal Gland T001006 Hyperfunctions, Adrenal Gland T001007 Hypercorticism 1974 03 29 UNK (19XX) T001007 Hypercorticisms D000309 Adrenal Gland Hypofunction 1999 01 01 1995 05 18 1968 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with ADRENAL GLAND HYPERFUNCTION 68; ADRENAL CORTEX HYPOFUNCTION was heading 1963-67 use ADRENAL GLAND HYPOFUNCTION to search ADRENAL CORTEX HYPOFUNCTION 1966-67 68; ADRENAL CORTEX HYPOFUNCTION was heading 1963-67 C19.053.264 NLM KEV PLS M0000484 Adrenal Gland Hypofunction C0001623 Adrenocortical hypofunction includes all conditions in which adrenal steroid hormone secretion falls below the requirements of the body. Adrenal insufficiency may be divided into two general categories: (1) those associated with primary inability of the adrenal to elaborate sufficient quantities of hormone and (2) those associated with a secondary failure due to a primary failure in the elaboration of adrenocorticotropin. (Harrison's Principles of Internal Medicine, 13th ed, p1970) T047 Disease or Syndrome T001008 Adrenal Gland Hypofunction 1999 01 01 NLM (1968) T001008 Adrenal Gland Hypofunctions T001008 Gland Hypofunction, Adrenal T001008 Gland Hypofunctions, Adrenal T001008 Hypofunction, Adrenal Gland T001008 Hypofunctions, Adrenal Gland D000310 Adrenal Gland Neoplasms 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000556 secondary SC Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI coord IM with histol type of neopl (IM) C04.588.322.078 C19.053.347 C19.344.078 NLM KEV sjn M0000485 Adrenal Gland Neoplasms C0001624 Tumors or cancer of the adrenal gland. T191 Neoplastic Process M0000485 M0331848 T001009 Adrenal Gland Neoplasms 1999 01 01 ADRENAL GLAND NEOPL NLM (1966) T001009 Adrenal Gland Neoplasm T001009 Neoplasm, Adrenal Gland T362407 Neoplasms, Adrenal Gland 1999 11 08 NEOPL ADRENAL GLAND NLM (2000) M0331848 Adrenal Cancer C0750887 T191 Neoplastic Process M0000485 M0331848 T362408 Adrenal Cancer 1999 11 08 NLM (2000) T362408 Adrenal Cancers T362408 Cancer, Adrenal T362408 Cancers, Adrenal T362409 Adrenal Gland Cancer 1999 11 08 NLM (2000) T362409 Adrenal Gland Cancers T362409 Cancer, Adrenal Gland T362409 Cancers, Adrenal Gland T362410 Cancer of the Adrenal Gland 1999 11 08 NLM (2000) D000311 Adrenal Glands 1999 01 01 1991 06 20 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /surg = probably ADRENALECTOMY; hypothalamo-pituitary-adrenal axis: coord HYPOTHALAMO-HYPOPHYSEAL SYSTEM + PITUITARY-ADRENAL SYSTEM; hyperplasia = ADRENAL GLANDS /pathol (IM) + HYPERPLASIA (NIM); congenital adrenal hyperplasia (CAH) = ADRENAL HYPERPLASIA, CONGENITAL D000315 Adrenalectomy A06.407.071 NLM TGC PLS M0000486 Adrenal Glands C0001625 Paired glands situated in the retroperitoneal tissues at the superior pole of each kidney. T023 Body Part, Organ, or Organ Component T001010 Adrenal Glands 1999 01 01 NLM (1966) T001010 Adrenal Gland T001010 Gland, Adrenal T001010 Glands, Adrenal D000312 Adrenal Hyperplasia, Congenital 1999 01 01 2003 07 09 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 80; was ADRENOGENITAL SYNDROME 1963-79 use ADRENAL HYPERPLASIA, CONGENITAL to search ADRENOGENITAL SYNDROME 1966-79 80; was ADRENOGENITAL SYNDROME 1963-79 D011629 Puberty, Precocious D013252 Steroid 11-beta-Hydroxylase D013254 Steroid 17-alpha-Hydroxylase D013255 Steroid 21-Hydroxylase D014770 Virilism C16.320.033 C16.320.565.925.249 C18.452.648.925.249 C19.053.440 C19.391.090 NLM jmp sjn M0000487 Adrenal Hyperplasia, Congenital C0001627 A group of syndromes caused by inherited defects in cortisol (HYDROCORTISONE) and/or ALDOSTERONE biosynthesis. There are several types including simple virilizing forms (adrenogenital syndrome), salt-wasting forms, and virilizing hypertension forms depending on the enzyme of defects. Defects in STEROID 21-HYDROXYLASE are most common. Other defects occur in STEROID 11-BETA-HYDROXYLASE, STEROID 17-ALPHA-HYDROXYLASE, or 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES). T047 Disease or Syndrome M0000487 M0000488 T001013 Adrenal Hyperplasia, Congenital 1999 01 01 ADRENAL HYPERPLASIA CONGEN NLM (1966) T001011 Congenital Adrenal Hyperplasia 1979 06 13 CONGEN ADRENAL HYPERPLASIA UNK (19XX) T001011 Adrenal Hyperplasias, Congenital T001011 Congenital Adrenal Hyperplasias T001011 Hyperplasias, Congenital Adrenal T001012 Hyperplasia, Congenital Adrenal 1979 06 13 HYPERPLASIA CONGEN ADRENAL UNK (19XX) M0000488 Adrenogenital Syndrome C0376146 T047 Disease or Syndrome M0000487 M0000488 T001014 Adrenogenital Syndrome 1979 06 13 UNK (19XX) T001014 Adrenogenital Syndromes T001014 Syndrome, Adrenogenital T001014 Syndromes, Adrenogenital D000313 Adrenal Medulla 1999 01 01 1998 06 10 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI dis = ADRENAL MEDULLA (IM) + ADRENAL GLAND DISEASES (IM); medulla enucleation: for physiol studies, ADRENAL MEDULLA /physiol, for surg ther, ADRENAL MEDULLA /surg A06.407.071.265 NLM MSR SJN M0000489 Adrenal Medulla C0001629 The inner part of the adrenal gland; it synthesizes, stores and releases catecholamines. T023 Body Part, Organ, or Organ Component T001015 Adrenal Medulla 1999 01 01 NLM (1966) T001015 Adrenal Medullas T001015 Medulla, Adrenal T001015 Medullas, Adrenal D000314 Adrenal Rest Tumor 1999 01 01 1995 06 08 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000098 blood supply BS Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000557 secretion SE Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI /blood supply /chem /secret /ultrastruct permitted; coord IM with OVARIAN NEOPLASMS (IM) 82; was ADRENAL CORTICAL REST TUMOR 1963-81 use ADRENAL REST TUMOR to search ADRENAL CORTICAL REST TUMOR 1966-81 82; was ADRENAL CORTICAL REST TUMOR 1963-81 C04.557.475.040 NLM KEV PLS M0000490 Adrenal Rest Tumor C0001630 A rare, usually benign, ovarian tumor thought to be derived from embryonic rest cells of the adrenals. This tumor causes various degrees of masculinization. T191 Neoplastic Process T001017 Adrenal Rest Tumor 1999 01 01 NLM (1966) T001017 Adrenal Rest Tumors T001017 Rest Tumor, Adrenal T001017 Rest Tumors, Adrenal T001017 Tumor, Adrenal Rest T001017 Tumors, Adrenal Rest T001016 Adrenal Cortical Rest Tumor 1981 05 19 UNK (19XX) D000315 Adrenalectomy 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000534 rehabilitation RH Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES excision of entire adrenal; enucleation: see note under ADRENAL MEDULLA E04.270.115 NLM PXP SJN M0000491 Adrenalectomy C0001632 Excision of one or both adrenal glands. (From Dorland, 28th ed) T061 Therapeutic or Preventive Procedure T001018 Adrenalectomy 1999 01 01 NLM (1966) T001018 Adrenalectomies D000316 Adrenergic alpha-Agonists 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT GEN or unspecified; prefer specifics; do not confuse with ADRENERGIC ALPHA-ANTAGONISTS; DF: ADREN ALPHA AGON or ADREN ALPHA AG 95; was ADRENERGIC ALPHA RECEPTOR AGONISTS 1969-94 (Prov 1969-72) use ADRENERGIC ALPHA-AGONISTS to search ADRENERGIC ALPHA RECEPTOR AGONISTS 1969-94 (as Prov 1969-72) 95; was ADRENERGIC ALPHA RECEPTOR AGONISTS 1973-94 Sympathomimetics (1966-1968) D14.100.050.100.100 D27.505.519.625.050.100.100 D27.505.696.577.050.100.100 NLM ssb sjn M0000492 Adrenergic alpha-Agonists C0001640 0 Drugs that selectively bind to and activate alpha adrenergic receptors. T121 Pharmacologic Substance T001028 Adrenergic alpha-Agonists 1999 01 01 ADRENERGIC AGONISTS ALPHA ADREN ALPHA AG NLM (1969) T001028 Adrenergic alpha Agonists T001028 alpha-Agonists, Adrenergic T001025 Adrenergic alpha-Agonist 1994 04 19 ADREN ALPHA AGON NLM (1995) T001025 Adrenergic alpha Agonist T001025 alpha-Agonist, Adrenergic T001026 alpha-Adrenergic Agonist 1994 05 13 ALPHA ADREN AG NLM (1995) T001026 Agonist, alpha-Adrenergic T001026 alpha Adrenergic Agonist T001020 Receptor Agonists, Adrenergic alpha 1994 04 25 RECEPT AGON ADREN ALPHA NLM (1995) T001022 alpha-Adrenergic Receptor Agonist 1994 05 13 ALPHA ADREN RECEPT AG NLM (1995) T001022 Agonist, alpha-Adrenergic Receptor T001022 Receptor Agonist, alpha-Adrenergic T001022 alpha Adrenergic Receptor Agonist T001024 alpha-Adrenergic Receptor Agonists 1974 03 29 ALPHA ADREN RECEPT AGON UNK (19XX) T001024 alpha Adrenergic Receptor Agonists T001023 Adrenergic alpha-Receptor Agonists 1994 01 28 ADRENERGIC RECEPTOR AGONISTS ALPHA ADREN ALPHA RECEPT AGON NLM (1995) T001023 Adrenergic alpha Receptor Agonists T001023 Agonists, Adrenergic alpha-Receptor T001023 alpha-Receptor Agonists, Adrenergic T001021 Receptor Agonists, alpha-Adrenergic 1994 04 25 RECEPT AGON ALPHA ADREN NLM (1995) T001021 Agonists, alpha-Adrenergic Receptor T001021 Receptor Agonists, alpha Adrenergic T001019 Adrenergic alpha-Receptor Agonist 1994 05 26 ADREN ALPHA RECEPT AG NLM (1995) T001019 Adrenergic alpha Receptor Agonist T001019 Agonist, Adrenergic alpha-Receptor T001019 alpha-Receptor Agonist, Adrenergic T001027 alpha-Adrenergic Agonists 1994 01 28 ALPHA ADREN AGON NLM (1995) T001027 Agonists, alpha-Adrenergic T001027 alpha Adrenergic Agonists D000317 Adrenergic alpha-Antagonists 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT GEN or unspecified; prefer specifics; do not confuse with ADRENERGIC ALPHA-AGONISTS; DF: ADREN ALPHA ANTAG 95; was ADRENERGIC ALPHA RECEPTOR BLOCKADERS 1969-94 (Prov 1969-72) use ADRENERGIC ALPHA-ANTAGONISTS to search ADRENERGIC ALPHA RECEPTOR BLOCKADERS 1969-94 (as Prov 1969-72) 95; was ADRENERGIC ALPHA RECEPTOR BLOCKADERS 1973-94 Sympatholytics (1966-1968) D14.100.050.200.100 D27.505.519.625.050.200.100 D27.505.696.577.050.200.100 NLM ssb sjn M0000493 Adrenergic alpha-Antagonists C0001641 0 Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. T121 Pharmacologic Substance T001035 Adrenergic alpha-Antagonists 1999 01 01 ADRENERGIC ANTAGONISTS ALPHA ADREN ALPHA ANTAG NLM (1969) T001035 Adrenergic alpha Antagonists T001035 alpha-Antagonists, Adrenergic T001029 alpha-Adrenergic Receptor Blockaders 1974 03 29 ALPHA ADREN RECEPT BLOCK UNK (19XX) T001029 Blockaders, alpha-Adrenergic Receptor T001029 Receptor Blockaders, alpha-Adrenergic T001029 alpha Adrenergic Receptor Blockaders T001030 Adrenergic alpha-Receptor Blockaders 1994 02 02 ADRENERGIC RECEPTOR BLOCKADERS ALPHA ADREN ALPHA RECEPT BLOCK NLM (1995) T001030 Adrenergic alpha Receptor Blockaders T001030 Blockaders, Adrenergic alpha-Receptor T001030 alpha-Receptor Blockaders, Adrenergic T001031 alpha-Adrenergic Blocking Agents 1989 04 17 ALPHA ADREN BLOCK AGENTS IOM (1990) T001031 Agents, alpha-Adrenergic Blocking T001031 Blocking Agents, alpha-Adrenergic T001031 alpha Adrenergic Blocking Agents T001032 Adrenergic alpha-Blockers 1994 02 02 ADREN ALPHA BLOCKERS NLM (1995) T001032 Adrenergic alpha Blockers T001033 alpha-Adrenergic Blockers 1994 03 14 ALPHA ADREN BLOCK NLM (1995) T001033 Blockers, alpha-Adrenergic T001033 alpha Adrenergic Blockers T001034 alpha-Blockers, Adrenergic 1989 04 17 ALPHA BLOCK ADREN IOM (1990) T001034 alpha Blockers, Adrenergic D000318 Adrenergic beta-Agonists 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT GEN or unspecified; prefer specifics; do not confuse with ADRENERGIC BETA-ANTAGONISTS; DF: ADREN BETA AGON or ADREN BETA AG 95; was ADRENERGIC BETA RECEPTOR AGONISTS 1969-94 (Prov 1969-72) use ADRENERGIC BETA-AGONISTS to search ADRENERGIC BETA RECEPTOR AGONISTS 1969-94 (as Prov 1969-72) 95; was ADRENERGIC BETA RECEPTOR AGONISTS 1973-94 Sympathomimetics (1966-1968) D14.100.050.100.200 D27.505.519.625.050.100.200 D27.505.696.577.050.100.200 NLM ssb sjn M0000494 Adrenergic beta-Agonists C0001644 0 Drugs that selectively bind to and activate beta-adrenergic receptors. T121 Pharmacologic Substance T001045 Adrenergic beta-Agonists 1999 01 01 ADRENERGIC AGONISTS BETA ADREN BETA AG NLM (1969) T001045 Adrenergic beta Agonists T001045 beta-Agonists, Adrenergic T001036 Adrenergic beta-Receptor Agonist 1994 05 26 ADREN BETA RECEPT AG NLM (1995) T001036 Adrenergic beta Receptor Agonist T001036 Agonist, Adrenergic beta-Receptor T001036 beta-Receptor Agonist, Adrenergic T001037 Receptor Agonists, beta-Adrenergic 1994 04 25 RECEPT AGON BETA ADREN NLM (1995) T001037 Agonists, beta-Adrenergic Receptor T001037 Receptor Agonists, beta Adrenergic T001038 Receptors Agonists, Adrenergic beta 1994 04 25 RECEPT AGON ADREN BETA NLM (1995) T001039 beta-Adrenergic Receptor Agonist 1994 05 13 BETA ADREN RECEPT AG NLM (1995) T001039 Agonist, beta-Adrenergic Receptor T001039 Receptor Agonist, beta-Adrenergic T001039 beta Adrenergic Receptor Agonist T001040 Adrenergic beta-Receptor Agonists 1994 01 28 ADRENERGIC RECEPTOR AGONISTS BETA ADREN BETA RECEPT AGON NLM (1995) T001040 Adrenergic beta Receptor Agonists T001040 Agonists, Adrenergic beta-Receptor T001040 beta-Receptor Agonists, Adrenergic T001041 beta-Adrenergic Receptor Agonists 1974 03 29 BETA ADREN RECEPT AGON UNK (19XX) T001041 beta Adrenergic Receptor Agonists T001042 Adrenergic beta-Agonist 1994 04 19 ADREN BETA AGON NLM (1995) T001042 Adrenergic beta Agonist T001042 beta-Agonist, Adrenergic T001043 beta-Adrenergic Agonist 1994 05 13 BETA ADREN AG NLM (1995) T001043 Agonist, beta-Adrenergic T001043 beta Adrenergic Agonist T001044 beta-Adrenergic Agonists 1994 01 28 BETA ADREN AGON NLM (1995) T001044 Agonists, beta-Adrenergic T001044 beta Adrenergic Agonists D000319 Adrenergic beta-Antagonists 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT GEN or unspecified; prefer specifics; do not confuse with ADRENERGIC BETA-AGONISTS; DF: ADREN BETA ANTAG 95: was ADRENERGIC BETA RECEPTOR BLOCKADERS 1969-94 (Prov 1969-72) use ADRENERGIC BETA-ANTAGONISTS to search ADRENERGIC BETA RECEPTOR BLOCKADERS 1973-94 (as Prov 1969-72) 95: was ADRENERGIC BETA RECEPTOR BLOCKADERS 1973-94 Sympatholytics (1966-1968) D14.100.050.200.200 D27.505.519.625.050.200.200 D27.505.696.577.050.200.200 NLM ssb sjn M0000495 Adrenergic beta-Antagonists C0001645 0 Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. T121 Pharmacologic Substance T001051 Adrenergic beta-Antagonists 1999 01 01 ADRENERGIC ANTAGONISTS BETA ADREN BETA ANTAG NLM (1969) T001051 Adrenergic beta Antagonists T001051 beta-Antagonists, Adrenergic T001046 Adrenergic beta-Receptor Blockaders 1994 02 02 ADRENERGIC RECEPTOR BLOCKADERS BETA ADREN BETA RECEPT BLOCK NLM (1995) T001046 Adrenergic beta Receptor Blockaders T001046 Blockaders, Adrenergic beta-Receptor T001046 beta-Receptor Blockaders, Adrenergic T001047 beta-Adrenergic Receptor Blockaders 1974 03 29 BETA ADREN RECEPT BLOCK UNK (19XX) T001047 Blockaders, beta-Adrenergic Receptor T001047 Receptor Blockaders, beta-Adrenergic T001047 beta Adrenergic Receptor Blockaders T001048 beta-Adrenergic Blocking Agents 1989 04 17 BETA ADREN BLOCK AGENTS IOM (1990) T001048 Agents, beta-Adrenergic Blocking T001048 Blocking Agents, beta-Adrenergic T001048 beta Adrenergic Blocking Agents T001049 beta-Adrenergic Blockers 1994 03 14 BETA ADREN BLOCK NLM (1995) T001049 Blockers, beta-Adrenergic T001049 beta Adrenergic Blockers T001050 beta-Blockers, Adrenergic 1989 04 17 BETA BLOCKERS ADREN IOM (1990) T001050 Adrenergic beta-Blockers T001050 beta Blockers, Adrenergic D000320 Adrenergic Fibers 1976 04 27 1993 06 18 1977 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI 77 77 Sympathetic Nervous System (1966-1976) A08.663.542.075 MM RAZ PLS M0000496 Adrenergic Fibers C0001646 Nerve fibers liberating catecholamines at a synapse after an impulse. T024 Tissue T001052 Adrenergic Fibers 1999 01 01 NLM (1977) T001052 Adrenergic Fiber T001052 Fiber, Adrenergic T001052 Fibers, Adrenergic T001053 Sympathetic Fibers 1976 04 27 UNK (19XX) T001053 Fiber, Sympathetic T001053 Fibers, Sympathetic T001053 Sympathetic Fiber D000322 Adrenergic Agonists 1999 01 01 2003 07 09 1975 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT do not confuse with ADRENERGIC ANTAGONISTS; DF: ADREN AGON or ADREN AG 95; was ADRENERGIC RECEPTOR AGONISTS 1975-94 use ADRENERGIC AGONISTS to search ADRENERGIC RECEPTOR AGONISTS 1975-94 95; was ADRENERGIC RECEPTOR AGONISTS 1975-94 Sympathomimetics (1966-1974) D14.100.050.100 D27.505.519.625.050.100 D27.505.696.577.050.100 NLM ssb sjn M0000497 Adrenergic Agonists C0001648 0 Drugs that bind to and activate adrenergic receptors. T121 Pharmacologic Substance T001058 Adrenergic Agonists 1999 01 01 ADREN AG NLM (1975) T001058 Agonists, Adrenergic T001057 Adrenergic Agonist 1994 04 19 ADREN AGON NLM (1995) T001057 Agonist, Adrenergic T001056 Adrenergic Receptor Agonist 1994 05 13 ADREN RECEPT AG NLM (1995) T001056 Agonist, Adrenergic Receptor T001056 Receptor Agonist, Adrenergic T001054 Adrenergic Receptor Agonists 1994 01 27 ADREN RECEPT AGON NLM (1995) T001054 Agonists, Adrenergic Receptor T055558 Adrenomimetics 1994 04 06 NLM (1995) T001055 Receptor Agonists, Adrenergic 1993 02 12 RECEPT AGON ADREN NLM (1994) D000323 Adrenochrome 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /physiol permitted D03.438.473.025 D11.557.061 NLM TWD sjn M0000498 Adrenochrome C0001652 1H-Indole-5,6-dione, 2,3-dihydro-3-hydroxy-1-methyl- 54-06-8 Pigment obtained by the oxidation of epinephrine. T109 Organic Chemical T123 Biologically Active Substance T001059 Adrenochrome 1999 01 01 NLM (1966) D000324 Corticotropin 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG a neurotransmitter pituitary hormone; /biosyn /physiol permitted; DF: note short X ref 94,63-86; was ADRENOCORTICOTROPIC HORMONE 1987-93; /adv eff-pois-tox was CORTICOTROPIN TOXICOLOGY 1963-65; /ther use was CORTICOTROPIN, THERAPEUTIC 1965 use CORTICOTROPIN to search ADRENOCORTICOTROPIC HORMONE 1987-93 94,63-86; was ADRENOCORTICOTROPIC HORMONE 1987-93; /adverse effects /poisoning /toxicity were CORTICOTROPIN TOXICOLOGY 1963-65; /therapeutic use was CORTICOTROPIN, THERAPEUTIC 1965 D017591 Petrosal Sinus Sampling D018043 Receptors, Corticotropin D06.472.699.631.525.690.130 D06.472.734.525.690.130 D12.644.400.120 D12.644.548.691.525.690.130 D12.776.641.650.120 D14.600.600.192 NLM jmp sjn M0000499 Corticotropin C0001655 Corticotropin 9002-60-2 Pituitary hormone that stimulates the secretion of adrenal cortical steroids and induces growth of the adrenal cortex. It is also present in human female urine and in the serum of pregnant mares. The substance is a single-chain polypeptide containing 39 amino acids, the first 24 of which are identical in all species. This 24-amino acid segment is said to be responsible for the biological activity of the peptide while the remaining 15-amino acid segment is said to be necessary for any immunological specificity. (From Merck Index, 11th ed) T116 Amino Acid, Peptide, or Protein T124 Neuroreactive Substance or Biogenic Amine T125 Hormone T001065 Corticotropin 1999 01 01 NLM (1966) T001060 1-39 ACTH 1981 06 25 UNK (19XX) T001061 ACTH (1-39) 1983 09 09 UNK (19XX) T001062 ACTH 1974 03 29 UNK (19XX) T001067 Corticotrophin (1-39) 1990 03 19 NLM (1991) T001069 Corticotrophin 1990 03 19 NLM (1991) T001068 Adrenocorticotrophic Hormone 1990 03 19 NLM (1991) T001068 Hormone, Adrenocorticotrophic T001066 Corticotropin (1-39) 1981 04 27 UNK (19XX) T001063 Adrenocorticotropic Hormone 1993 04 19 NLM (1994) T001063 Hormone, Adrenocorticotropic T001064 Adrenocorticotropin 1987 05 04 UNK (19XX) D000325 Adrenodoxin 1974 11 19 2002 07 02 1975 09 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG an iron-sulfur protein 75 75 Carrier Proteins (1974) Ferredoxins (1966-1974) Metalloproteins (1974) D12.776.157.427.374.375.025 D12.776.556.579.374.375.025 NLM TPW sjn M0000500 Adrenodoxin C0001657 Adrenodoxins 12687-22-8 An iron-sulfur protein which serves as an electron carrier in enzymatic steroid hydroxylation reactions in adrenal cortex mitochondria. The electron transport system which catalyzes this reaction consists of adrenodoxin reductase, NADP, adrenodoxin, and cytochrome P-450. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance T001070 Adrenodoxin 1999 01 01 NLM (1975) D000326 Adrenoleukodystrophy 1982 04 27 2002 07 02 1991 01 01 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with ADRENOLEUKODYSTROPHY, NEONATAL see PEROXISOMAL DISORDERS 1991(1983) 1991; see CEREBRAL SCLEROSIS, DIFFUSE 1983-1990 Adrenal Gland Hypofunction (1968-1982) Cerebral Sclerosis, Diffuse (1966-1982) Demyelinating Diseases (1966-1982) C10.228.140.163.100.680.100 C10.314.400.250 C10.597.606.643.455.124 C16.320.322.500.124 C16.320.400.525.124 C16.320.565.150.680.100 C16.320.565.556.750.112 C18.452.100.100.680.100 C18.452.648.151.680.100 C18.452.648.556.750.112 C19.053.264.270 RC nns sjn M0000501 Adrenoleukodystrophy C0001661 An X-linked recessive leukodystrophy characterized by an abnormal accumulation of saturated very long chain fatty acids in LYSOSOMES. It primarily affects the white matter of the CENTRAL NERVOUS SYSTEM and the ADRENAL CORTEX. This disorder results from defective beta-oxidation and occurs almost exclusively in males and has multiple phenotypes. Relatively common clinical features include the childhood onset of ATAXIA; NEUROBEHAVIORAL MANIFESTATIONS; HYPERPIGMENTATION; adrenal insufficiency; SEIZURES; MUSCLE SPASTICITY; and DEMENTIA. A related condition, adrenomyeloneuropathy, usually has its onset in adult life and is characterized by spastic paraparesis, adrenal insufficiency, neuropathy, and HYPOGONADISM. (From Neuropediatrics 1998 Feb;29(1):3-13; Menkes, Textbook of Child Neurology, 5th ed, p188) The defective gene for this disorder has been localized to the long arm of the X chromosome (Xq28). T047 Disease or Syndrome M0000501 M0000502 T001071 Adrenoleukodystrophy 1999 01 01 NLM (1983) T001071 Adrenoleukodystrophies T366221 Schilder-Addison Complex 1999 11 03 NLM (2000) T366221 Schilder Addison Complex T366222 X-linked Adrenoleukodystrophy 1999 11 03 NLM (2000) T366222 Adrenoleukodystrophies, X-linked T366222 Adrenoleukodystrophy, X-linked T366222 X linked Adrenoleukodystrophy T366222 X-linked Adrenoleukodystrophies T366223 ALD (Adrenoleukodystrophy) 1999 11 03 NLM (2000) T366223 ALDs (Adrenoleukodystrophy) M0000502 Adrenomyeloneuropathy C0162309 T047 Disease or Syndrome M0000501 M0000502 T001072 Adrenomyeloneuropathy 1991 09 26 NLM (1993) T001072 Adrenomyeloneuropathies D000327 Adsorption 1999 01 01 1992 03 25 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE almost never IM; coord NIM with substance /pharmacokin (IM) H01.181.529.047 NLM TAP PLS M0000503 Adsorption C0001674 The condensation of gases, liquids, or dissolved substances on the surfaces of solids. It includes adsorptive phenomena of bacteria and viruses as well as of tissues treated with exogenous drugs and chemicals. T059 Laboratory Procedure T001073 Adsorption 1999 01 01 NLM (1966) T001073 Adsorptions D000328 Adult 1999 01 01 1997 06 20 1966 01 01 1998 1999 2000 2001 2002 2003 2004 Q000523 psychology PX age 19-44 yr; almost never IM; IM only as social, sociol, polit, etc. entity; NIM as check tag; no qualif when NIM, /psychol permitted when IM but ADULT as IM is unlikely; Manual 18.5+, 34.10 66 pre-explosion = ADULT (PX) 66 M01.060.116 NLM TGC SJN M0000504 Adult C0001675 A person having attained full growth or maturity. Adults are of 19 through 44 years of age. T100 Age Group T001075 Adult 1999 01 01 POPLINE (1978) T001074 Adults 1977 03 17 BIOETHICS (1989) D000329 Advertising 1999 01 01 2002 07 24 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000379 methods MT IM; med advert: do not coord with MEDICINE; coord with subject of advert & medium if relevant (IM); do not confuse with Publication Type ADVERTISEMENTS for newspaper, magazine, billboard, etc. advertising J01.219.687.274 L01.143.050 NLM sjn sjn M0000505 Advertising C0001690 The act or practice of calling public attention to a product, service, need, etc., especially by paid announcements in newspapers, magazines, on radio, or on television. (Random House Unabridged Dictionary, 2d ed) T057 Occupational Activity M0000505 M0000507 M0000505 M0000506 T001076 Advertising 1999 01 01 BIOETHICS (1989) M0000507 Advertisement C0949214 A public notice, usually a paid announcement and usually printed in newspapers and magazines, posted on billboards, or disseminated via motion pictures, television, or other broadcast media. T170 Intellectual Product M0000505 M0000507 T001078 Advertisement 1979 09 27 UNK (19XX) T001078 Advertisements M0000506 Promotion C0033414 T057 Occupational Activity M0000505 M0000506 T001077 Promotion 1978 12 18 POPLINE (1978) D000330 Aedes 1999 01 01 2003 07 09 2004 Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI mosquito; /microbiol /parasitol /virol permitted; do not use /drug eff for insecticides: TN 111 B01.500.131.617.289.275.100 NLM ags sjn M0000508 Aedes C0001692 A genus of mosquitoes (CULICIDAE) frequently found in tropical and subtropical regions. YELLOW FEVER and DENGUE are two of the diseases that can be transmitted by species of this genus. T009 Invertebrate T001079 Aedes 1999 01 01 NLM (1966) D000331 Aequorin 1974 11 19 1992 05 07 1991 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG a luminescent protein from jellyfish Aequorea 91(75); was see under LUMINESCENT PROTEINS 1979-90; was see under PROTEINS 1975-78 91; was see under LUMINESCENT PROTEINS 1979-90; was see under PROTEINS 1975-78 Coelenterata (1972-1974) Proteins (1972-1974) D12.776.532.020 NLM TAP PLS M0000509 Aequorin C0001694 Aequorins 50934-79-7 A photoprotein isolated from the bioluminescent jellyfish Aequorea. It emits visible light by an intramolecular reaction when a trace amount of calcium ion is added. The light-emitting moiety in the bioluminescence reaction is believed to be 2-amino-3-benzyl-5-(p-hydroxyphenyl)pyrazine (AF-350). T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance T001080 Aequorin 1999 01 01 NLM (1975) T001081 Aequorine 1984 10 02 UNK (19XX) D000332 Aerobiosis 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES almost never IM 91(71); was see under METABOLISM 1971-90 91; was see under METABOLISM 1971-90 G06.184.035 NLM adp sjn M0000510 Aerobiosis C0001702 Life or metabolic reactions occurring in an environment containing oxygen. T040 Organism Function T001082 Aerobiosis 1999 01 01 NLM (1971) T001082 Aerobioses D000333 Aeromonas 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI in fish; infection: coord IM with GRAM-NEGATIVE BACTERIAL INFECTIONS (IM) B03.440.450.019.025 B03.660.250.017.025 NLM ags sjn M0000511 Aeromonas C0001705 A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs singly, in pairs, or in short chains. Its organisms are found in fresh water and sewage and are pathogenic to humans, frogs, and fish. T007 Bacterium T001083 Aeromonas 1999 01 01 NLM (1966) D000334 Aerophagy 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C23.888.821.061 NLM KEV sjn M0000512 Aerophagy C0001707 Spasmodic swallowing of air. T046 Pathologic Function T184 Sign or Symptom T001084 Aerophagy 1999 01 01 NLM (1966) T001085 Air Swallowing 1980 05 07 UNK (19XX) T001085 Swallowing, Air D000335 Aerosol Propellants 1999 01 01 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT IM; coord with propellant if relevant (IM); D25-26 qualif with discretion 91(73); was see under AEROSOLS 1973-90; was in Cat D & J 1973-82 91; was see under AEROSOLS 1973-90; was in Cat D & J 1973-82 Aerosols (1966-1972) specific chemical (1966-1972) D26.255.165.055.055 D27.720.280.165.055.055 NLM ssb sjn M0000513 Aerosol Propellants C0001711 0 Compressed gases or vapors in a container which, upon release of pressure and expansion through a valve, carry another substance from the container. They are used for cosmetics, household cleaners, and so on. Examples are BUTANES; CARBON DIOXIDE; FLUOROCARBONS; NITROGEN; and PROPANE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) T120 Chemical Viewed Functionally T001086 Aerosol Propellants 1999 01 01 NLM (1973) T001086 Propellants, Aerosol D000336 Aerosols 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT IM for general only, qualif permitted; NIM (no qualif) with specific drug IM (with qualif); /adv eff permitted but be careful: it may be the adv eff of the drug in aerosol form, not the aerosol was in Cat D & J 1973-82, was in Cat D only 1963-72 D26.255.165.055 D27.720.280.165.055 NLM ssb sjn M0000514 Aerosols C0001712 0 Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellent agents. T104 Chemical Viewed Structurally T001087 Aerosols 1999 01 01 NLM (1966) D000337 Aerospace Medicine 1979 05 29 2003 07 09 1980 01 01 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES specialty; med, physiol or psychol aspects of AVIATION go here but med, physiol or psychol aspects of space flight go under SPACE FLIGHT or other space related terms: Manual 28.8; DF: AEROSPACE MED 80; was see SPACE FLIGHT 1975-79; AVIATION MEDICINE was heading 1963-79; AVIATION DENTISTRY was heading 1965-79 search SPACE FLIGHT 1975-79; use AEROSPACE MEDICINE to search AVIATION MEDICINE 1966-74; use AEROSPACE MEDICINE + DENTISTRY to search AVIATION DENTISTRY 1966-79 80; was see SPACE FLIGHT 1975-79; AVIATION MEDICINE was heading 1963-79; AVIATION DENTISTRY was heading 1965-79 Space Flight (1975-1979) D000060 Accidents, Aviation D000531 Altitude D003665 Decompression Sickness D013026 Space Flight G02.403.776.014 EC nns sjn M0000515 Aerospace Medicine C0001713 A specialty which is concerned with the health and medical problems of man in AVIATION (aviation medicine) and SPACE FLIGHT. T091 Biomedical Occupation or Discipline M0000515 M0000516 M0000515 M0000517 T001089 Aerospace Medicine 1999 01 01 AEROSPACE MED NLM (1980) T001088 Medicine, Aerospace 1989 11 28 MED AEROSPACE NLM (1991) M0000516 Aviation Medicine C0004431 T091 Biomedical Occupation or Discipline M0000515 M0000516 T001091 Aviation Medicine 1979 05 29 AVIATION MED UNK (19XX) T001090 Medicine, Aviation 1989 11 28 MED AVIATION NLM (1991) M0000517 Medicine, Space C0037743 T091 Biomedical Occupation or Discipline M0000515 M0000517 T001092 Medicine, Space 1989 11 28 MED SPACE NLM (1991) T001093 Space Medicine 1979 05 29 SPACE MED UNK (19XX) D000338 beta-Aminoethyl Isothiourea 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000031 analogs & derivatives AA 2001(1967); for S-(2-AMINOETHYL)ISOTHIOTHIOUREA use ISOTHIUREA, (BETA-AMINOETHYL) (NM) 1997-2000 2001; see AET 1967-2000; for S-(2-AMINOETHYL)ISOTHIOTHIOUREA see ISOTHIUREA, (BETA-AMINOETHYL) 1997-2000 D02.886.904.100 D02.948.898.100 NLM CCR sjn M0330729 beta-Aminoethyl Isothiourea C0541378 151-16-6 A radiation-protective agent that can inhibit DNA damage by binding to the DNA. It also increases the susceptibility of blood cells to complement-mediated lysis. T109 Organic Chemical T121 Pharmacologic Substance D011837 Radiation-Protective Agents 18144-22-4 2141-04-0 56-10-0 63680-10-4 63680-11-5 63680-12-6 63680-13-7 871-25-0 M0330729 M0330732 M0330729 M0000518 M0330729 M0330736 M0330729 M0330734 M0330729 M0330733 M0330729 M0330731 M0330729 M0330735 M0330729 M0330730 M0330729 M0352391 T413978 beta-Aminoethyl Isothiourea 2000 05 11 NLM (2001) T413978 Isothiourea, beta-Aminoethyl T413978 beta Aminoethyl Isothiourea T360923 Isothiourea, (2-Aminoethyl) 1999 09 13 NLM (1999) T308932 S-(2-Aminoethyl)isothiourea NLM (2001) M0330732 beta-Aminoethylisothiuronium Diacetate C0887534 63680-10-4 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330732 T413972 beta-Aminoethylisothiuronium Diacetate 2000 05 11 NLM (2001) T413972 Diacetate, beta-Aminoethylisothiuronium T413972 beta Aminoethylisothiuronium Diacetate T413980 2-Aminoethylisothiuronium Diacetate 2000 05 11 NLM (2001) T413980 2 Aminoethylisothiuronium Diacetate T413980 Diacetate, 2-Aminoethylisothiuronium M0000518 beta-Aminoethylisothiuronium Dihydrobromide C0001716 56-10-0 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0000518 T413979 beta-Aminoethylisothiuronium Dihydrobromide 2000 05 11 NLM (2001) T413979 Dihydrobromide, beta-Aminoethylisothiuronium T413979 beta Aminoethylisothiuronium Dihydrobromide T001096 2-Aminoethylisothiuronium Bromide 1992 02 13 AMINOETHYLISOTHIURONIUM BROMIDE 02 NLM (1993) T001096 2 Aminoethylisothiuronium Bromide T001096 Bromide, 2-Aminoethylisothiuronium T001094 AET 1999 01 01 NLM (1966) T001097 Aminoethylisothiuronium Bromide Hydrobromide 1992 01 16 NLM (1993) T001097 Hydrobromide, Aminoethylisothiuronium Bromide T413971 beta-Aminoethylisothiuronium Bromide 2000 05 11 NLM (2001) T413971 Bromide, beta-Aminoethylisothiuronium T413971 beta Aminoethylisothiuronium Bromide T413970 Carbamimidothioic acid, 2-aminoethyl ester, dihydrobromide 2000 05 11 NLM (2001) M0330736 beta-Aminoethylisothiuronium Dihydrochloride C0887538 871-25-0 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330736 T360930 beta-Aminoethylisothiuronium Dihydrochloride 1999 09 13 NLM (1999) T360930 Dihydrochloride, beta-Aminoethylisothiuronium T360930 beta Aminoethylisothiuronium Dihydrochloride T413981 2-Aminoethylisothiuronium Dihydrochloride 2000 05 11 NLM (2001) T413981 2 Aminoethylisothiuronium Dihydrochloride T413981 Dihydrochloride, 2-Aminoethylisothiuronium M0330734 beta-Aminoethylisothiuronium Dihydroiodide C0887536 63680-12-6 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330734 T360928 beta-Aminoethylisothiuronium Dihydroiodide 1999 09 13 NLM (1999) T360928 Dihydroiodide, beta-Aminoethylisothiuronium T360928 beta Aminoethylisothiuronium Dihydroiodide T413982 2-Aminoethylisothiuronium Dihydroiodide 2000 05 11 NLM (2001) T413982 2 Aminoethylisothiuronium Dihydroiodide T413982 Dihydroiodide, 2-Aminoethylisothiuronium M0330733 beta-Aminoethylisothiuronium Diperchlorate C0887535 63680-11-5 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330733 T360927 beta-Aminoethylisothiuronium Diperchlorate 1999 09 13 NLM (1999) T360927 Diperchlorate, beta-Aminoethylisothiuronium T360927 beta Aminoethylisothiuronium Diperchlorate T413983 2-Aminoethylisothiuronium Diperchlorate 2000 05 11 NLM (2001) T413983 2 Aminoethylisothiuronium Diperchlorate T413983 Diperchlorate, 2-Aminoethylisothiuronium M0330731 beta-Aminoethylisothiuronium Monohydrobromide C0887533 2141-04-0 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330731 T360925 beta-Aminoethylisothiuronium Monohydrobromide 1999 09 13 NLM (1999) T360925 Monohydrobromide, beta-Aminoethylisothiuronium T360925 beta Aminoethylisothiuronium Monohydrobromide T413984 2-Aminoethylisothiuronium Monohydrobromide 2000 05 11 NLM (2001) T413984 2 Aminoethylisothiuronium Monohydrobromide T413984 Monohydrobromide, 2-Aminoethylisothiuronium M0330735 beta-Aminoethylisothiuronium Phosphate (1:1) C0887537 63680-13-7 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330735 T360929 beta-Aminoethylisothiuronium Phosphate (1:1) 1999 09 13 NLM (1999) T413985 2-Aminoethylisothiuronium Phosphate (1:1) 2000 05 11 NLM (2001) M0330730 beta-Aminoethylisothiuronium Sulfate (1:1) C0887532 18144-22-4 T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0330730 T360924 beta-Aminoethylisothiuronium Sulfate (1:1) 1999 09 13 NLM (1999) T413986 2-Aminoethylisothiuronium Sulfate (1:1) 2000 05 11 NLM (2001) M0352391 Ixecur C0878234 0 Tradename for beta-Aminoethylisothiuronium Bromide T109 Organic Chemical T121 Pharmacologic Substance M0330729 M0352391 T001095 Ixecur 1981 12 18 UNK (19XX) D000339 Affect 1999 01 01 1992 03 25 1965 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 65(64); was see under EMOTIONS 1963-64 65; was see under EMOTIONS 1963-64 F01.470.047 NLM TAP PLS M0000520 Affect C0001721 The feeling-tone accompaniment of an idea or mental representation. It is the most direct psychic derivative of instinct and the psychic representative of the various bodily changes by means of which instincts manifest themselves. T041 Mental Process M0000520 M0000521 T001098 Affect 1999 01 01 NLM (1964) T001098 Affects M0000521 Mood C0026516 T041 Mental Process M0000520 M0000521 T001099 Mood 1987 04 30 UNK (19XX) T001099 Moods D000341 Affective Disorders, Psychotic 1980 05 21 1997 06 20 1981 01 01 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI 81; DEPRESSION, REACTIVE, PSYCHOTIC was see under PSYCHOSES 1977-80; AFFECTIVE DISTURBANCES was heading 1969-80 use AFFECTIVE DISORDERS, PSYCHOTIC to search DEPRESSION, REACTIVE, PSYCHOTIC 1977-80; search AFFECTIVE DISTURBANCES under AFFECTIVE SYMPTOMS 1969-80 81; DEPRESSION, REACTIVE, PSYCHOTIC was see under PSYCHOSES 1977-80; AFFECTIVE DISTURBANCES was heading 1969-80 F03.600.150 EC JLS SJN M0000522 Affective Disorders, Psychotic C0001723 Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc. T048 Mental or Behavioral Dysfunction M0000522 M0000523 M0000522 M0000524 T001101 Affective Disorders, Psychotic 1999 01 01 AFFECTIVE DIS PSYCHOTIC NLM (1981) T001100 Psychotic Affective Disorders 1991 06 11 PSYCHOTIC AFFECTIVE DIS NLM (1992) T001100 Affective Disorder, Psychotic T001100 Disorder, Psychotic Affective T001100 Disorders, Psychotic Affective T001100 Psychotic Affective Disorder T001102 Psychoses, Affective 1980 05 21 UNK (19XX) T001102 Affective Psychoses M0000523 Depression, Reactive, Psychotic C0011580 T048 Mental or Behavioral Dysfunction M0000522 M0000523 T001103 Depression, Reactive, Psychotic 1980 06 06 UNK (19XX) M0000524 Psychotic Mood Disorders C0086640 T048 Mental or Behavioral Dysfunction M0000522 M0000524 T001104 Psychotic Mood Disorders 1991 06 11 PSYCHOTIC MOOD DIS NLM (1992) T001104 Mood Disorder, Psychotic T001104 Psychotic Mood Disorder T001105 Mood Disorders, Psychotic 1984 05 29 MOOD DIS PSYCHOTIC UNK (19XX) D000342 Affective Symptoms 1999 01 01 2002 07 02 1969 01 01 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI human only; do not confuse with AFFECTIVE DISORDERS: read MeSH definitions & follow text 81; was AFFECTIVE DISTURBANCES 1969-80 use AFFECTIVE SYMPTOMS to search AFFECTIVE DISTURBANCES 1969-80 81; was AFFECTIVE DISTURBANCES 1969-80 Affect (1966-1968) Anxiety (1966-1968) Emotions (1966-1968) F01.145.126.100 NLM JLS sjn M0000525 Affective Symptoms C0001726 Mood or emotional responses dissonant with or inappropriate to the behavior and/or stimulus. T184 Sign or Symptom M0000525 M0000526 M0000525 M0000527 T001106 Affective Symptoms 1999 01 01 NLM (1969) T001106 Affective Symptom T001106 Symptom, Affective T001106 Symptoms, Affective M0000526 Alexithymia C0002020 T184 Sign or Symptom M0000525 M0000526 T001107 Alexithymia 1983 07 05 UNK (19XX) T001107 Alexithymias M0000527 Emotional Disturbances C0013985 T048 Mental or Behavioral Dysfunction T184 Sign or Symptom M0000525 M0000527 T001108 Emotional Disturbances 1974 03 29 UNK (19XX) T001108 Disturbance, Emotional T001108 Disturbances, Emotional T001108 Emotional Disturbance D000343 Afferent Loop Syndrome 1999 01 01 2003 07 09 1970 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 70(69); was see under DUMPING SYNDROME 1963-69 search DUMPING SYNDROME 1966-68 70; was see under DUMPING SYNDROME 1963-69 Dumping Syndrome (1966-1968) C06.405.469.531.099 C23.550.767.050 NLM lkt sjn M0000528 Afferent Loop Syndrome C0001727 A complication of gastrojejunostomy (BILLROTH II PROCEDURE), a reconstructive GASTROENTEROSTOMY. It is caused by acute (complete) or chronic (intermittent) obstruction of the afferent jejunal loop due to HERNIA, intussusception, kinking, VOLVULUS, etc. It is characterized by PAIN and VOMITING of BILE-stained fluid. T047 Disease or Syndrome T001109 Afferent Loop Syndrome 1999 01 01 NLM (1969) T001109 Afferent Loop Syndromes T001109 Loop Syndrome, Afferent T001109 Loop Syndromes, Afferent T001109 Syndrome, Afferent Loop T001109 Syndromes, Afferent Loop D000344 Afferent Pathways 1975 07 25 1992 03 25 1976 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI coord NIM with origin (IM) + termination (IM) 76; was NON MESH before 1976 76 Neural Transmission (1968-1975) Neurons, Afferent (1969-1975) Receptors, Sensory (1966-1975) specific central nervous system heading specific sensory receptor A08.612.220 SMH TAP PLS M0000529 Afferent Pathways C0001728 Nerve structures through which impulses are conducted from a peripheral part toward a nerve center. T023 Body Part, Organ, or Organ Component T001110 Afferent Pathways 1999 01 01 NLM (1976) T001110 Afferent Pathway T001110 Pathway, Afferent T001110 Pathways, Afferent D000345 Affinity Labels 1974 11 19 2003 07 09 1975 09 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif; use with caution: few apply 75 75 Binding Sites (1968-1974) Indicators and Reagents (1968-1974) D27.720.470.410.080 NLM ssb sjn M0000530 Affinity Labels C0001730 0 Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. T130 Indicator, Reagent, or Diagnostic Aid T001112 Affinity Labels 1999 01 01 NLM (1975) T001112 Labels, Affinity T001111 Affinity Labeling Reagents 1974 11 11 UNK (19XX) T001111 Labeling Reagents, Affinity T001111 Reagents, Affinity Labeling D000346 Afghanistan 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP Z01.252.245.500.125 Z01.586.500.125 NLM PLS PLS M0000531 Afghanistan C0001732 T083 Geographic Area T001113 Afghanistan 1999 01 01 POPLINE (1978) D000347 Afibrinogenemia 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI a blood coag disord C15.378.100.141.072 C15.378.100.425.056 C15.378.463.067 C16.320.099.056 NLM nns sjn M0000532 Afibrinogenemia C0001733 A deficiency or absence of fibrinogen (coagulation factor I) in the blood. (Dorland, 27th ed) T047 Disease or Syndrome T001114 Afibrinogenemia 1999 01 01 NLM (1966) T001114 Afibrinogenemias T001116 Fibrinogen Deficiency 1974 03 29 FIBRINOGEN DEFIC UNK (19XX) T001115 Deficiency, Fibrinogen 1974 03 29 DEFIC FIBRINOGEN UNK (19XX) T001115 Deficiencies, Fibrinogen T001115 Fibrinogen Deficiencies D000348 Aflatoxins 1999 01 01 2001 07 25 1967 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG mycotoxins; /antag permitted but consider also ANTITOXINS 75; was AFLATOXIN 1965-74 (Prov 1965-66) use AFLATOXINS to search AFLATOXIN 1966-74 75; was AFLATOXIN 1967-74 D24.185.926.587.142 NLM mdb sjn M0000533 Aflatoxins C0001734 0 A group of closely related toxic metabolites that are designated mycotoxins. They are produced by Aspergillus flavus and A. parasiticus. Members of the group include AFLATOXIN B1; aflatoxin B2, aflatoxin G1, aflatoxin G2; AFLATOXIN M1; and aflatoxin M2. T123 Biologically Active Substance T131 Hazardous or Poisonous Substance T001118 Aflatoxins 1999 01 01 NLM (1965) T001117 Aflatoxin 1976 09 05 UNK (19XX) D000349 Africa 1999 01 01 1993 05 24 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP for the continent or unspecified only: prefer smaller geog subdivisions, as AFRICA, NORTHERN; AFRICA, CENTRAL; etc. Z01.058 NLM TGC PLS M0000534 Africa C0001737 T083 Geographic Area T001119 Africa 1999 01 01 POPLINE (1978) D000350 Africa, Central 1999 01 01 2001 07 25 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a geog area; prefer specific countries Z01.058.290.100 NLM mdb sjn M0000535 Africa, Central C0001740 The geographical area of Africa comprising CAMEROON; CENTRAL AFRICAN REPUBLIC; CHAD; CONGO; EQUATORIAL GUINEA; GABON; and DEMOCRATIC REPUBLIC OF THE CONGO. T083 Geographic Area T001120 Africa, Central 1999 01 01 NLM (1966) D000351 Africa, Eastern 1999 01 01 2001 07 25 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a geog area; prefer specific countries Z01.058.290.120 NLM mdb sjn M0000536 Africa, Eastern C0001741 The geographical area of Africa comprising BURUNDI; DJIBOUTI; ETHIOPIA; KENYA; RWANDA; SOMALIA; SUDAN; TANZANIA; and UGANDA. T083 Geographic Area M0000536 M0000537 T001122 Africa, Eastern 1999 01 01 NLM (1966) T001121 Eastern Africa 1986 12 31 POPLINE (1983) M0000537 British Indian Ocean Territory C0006196 T083 Geographic Area M0000536 M0000537 T001123 British Indian Ocean Territory 1986 12 31 POPLINE (1983) D000352 Africa, Northern 1999 01 01 2001 07 25 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP = Algeria, Egypt, Libya, Morocco, Tunisia collectively: prefer specifics; titles often refer to the Maghreb or Maghrib, the Arabic name for Algeria, Morocco, Tunisia & sometimes Libya collectively: check text for possible specificity, otherwise index under AFRICA, NORTHERN Z01.058.266 NLM mdb sjn M0000538 Africa, Northern C0001745 The geographical area of Africa comprising ALGERIA; EGYPT; LIBYA; MOROCCO; and TUNISIA. It includes also the vast deserts and oases of the Sahara. It is often referred to as North Africa, French-speaking Africa, or the Magreb. (From Webster's New Geographical Dictionary, 1988, p856) T083 Geographic Area M0000538 M0000539 T001125 Africa, Northern 1999 01 01 NLM (1966) T001126 Africa, French-Speaking 1992 11 23 NLM (1994) T001127 French Speaking Africa 1994 03 11 POPLINE (1983) T001128 French-Speaking Africa 1992 11 23 NLM (1994) T001130 Maghreb 1995 02 17 NLM (1996) T001131 Maghrib 1995 02 17 NLM (1996) T001129 North Africa 1994 11 16 NLM (1996) T001124 Northern Africa 1986 12 31 POPLINE (1983) M0000539 Sahara C0205654 T083 Geographic Area M0000538 M0000539 T001132 Sahara 1993 01 19 NLM (1994) D000353 Africa, Southern 1999 01 01 2001 07 25 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a geog area: prefer specific countries; do not confuse with SOUTH AFRICA ( = Union of South Africa 1910-60) Z01.058.290.175 NLM mdb sjn M0000540 Africa, Southern C0001746 The geographical area of Africa comprising ANGOLA; BOTSWANA; LESOTHO; MALAWI; MOZAMBIQUE; NAMIBIA; SOUTH AFRICA; SWAZILAND; ZAMBIA; and ZIMBABWE. It includes what was formerly called South-West Africa or German Southwest Africa but it was terminated in 1966 by a United Nations resolution. (From Webster's New Geographical Dictionary, 1988, p1144) T083 Geographic Area T001134 Africa, Southern 1999 01 01 NLM (1966) T001133 Southern Africa 1986 12 31 POPLINE (1983) D000354 Africa, Western 1999 01 01 2001 07 25 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a geog area: prefer specific countries Z01.058.290.190 NLM mdb sjn M0000541 Africa, Western C0001747 The geographical area of Africa comprising BENIN; BURKINA FASO; COTE D'IVOIRE; GAMBIA; GHANA; GUINEA; GUINEA-BISSAU; LIBERIA; MALI; MAURITANIA; NIGER; NIGERIA; SENEGAL; SIERRA LEONE; and TOGO. T083 Geographic Area M0000541 M0000542 T001136 Africa, Western 1999 01 01 NLM (1966) T001135 Western Africa 1986 12 31 POPLINE (1983) M0000542 Cape Verde C0006893 T083 Geographic Area M0000541 M0000542 T001137 Cape Verde 1992 09 08 POPLINE (1983) D000355 African Horse Sickness 1999 01 01 2003 07 30 1970 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI caused by an Orbivirus; in horses, mules & donkeys; if in horses don't forget also HORSES (NIM) & check tag ANIMALS; if in mules or donkeys, coord IM with EQUIDAE (IM) & check tag ANIMALS 98 98; see AFRICAN HORSESICKNESS 1970-97 Horse Diseases (1966-1969) Reovirus Infections (1968-1979) C02.081.030 C02.782.791.142 C22.488.088 NLM ags sjn M0000543 African Horse Sickness C0001748 An insect-borne reovirus infection of horses, mules and donkeys in Africa and the Middle East; characterized by pulmonary edema, cardiac involvement, and edema of the head and neck. T047 Disease or Syndrome T001138 African Horse Sickness 1999 01 01 NLM (1970) T001138 African Horse Sicknesses T001138 Horse Sickness, African T001138 Horse Sicknesses, African T001138 Sickness, African Horse T001138 Sicknesses, African Horse T001140 African Horsesickness 1997 01 14 NLM (1998) T001140 African Horsesicknesses T001140 Horsesickness, African T001140 Horsesicknesses, African T001139 Equine Plague 1996 08 07 NLM (1998) T001139 Equine Plagues T001139 Plague, Equine T001139 Plagues, Equine D000356 African horse sickness virus 1974 11 19 2001 07 25 1991 01 01 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection = AFRICAN HORSE SICKNESS 98(75) 98; see AFRICAN HORSESICKNESS VIRUS 1991-97, see REOVIRIDAE 1981-90, see REOVIRUSES 1975-80 B04.820.630.550.050 B04.909.777.714.550.050 NLM ags sjn M0000544 African horse sickness virus C0001749 A species of ORBIVIRUS that causes disease in horses, mules, and donkeys.Via its principal vector CULICOIDES, it can also infect dogs, elephants, camels, cattle, sheep, goats, and, in special circumstances, humans. T005 Virus T001142 African horse sickness virus 1999 01 01 NLM (1975) T001141 African Horsesickness Virus 1997 01 14 NLM (1998) T001141 African Horsesickness Viruses T001141 Horsesickness Virus, African T001141 Horsesickness Viruses, African D000357 African Swine Fever 1999 01 01 2001 07 25 1970 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI do not confuse with SWINE FEVER see CLASSICAL SWINE FEVER 70 70 Swine Diseases (1966-1969) Virus Diseases (1966-1969) C02.081.885.125 C02.256.142 C22.905.072 NLM ags sjn M0000545 African Swine Fever C0001752 A sometimes fatal ASFIVIRUS infection of pigs, characterized by fever, cough, diarrhea, hemorrhagic lymph nodes, and edema of the gallbladder. It is transmitted between domestic swine by direct contact, ingestion of infected meat, or fomites, or mechanically by biting flies or soft ticks (genus Ornithodoros). T047 Disease or Syndrome T001143 African Swine Fever 1999 01 01 NLM (1970) T443758 Swine Fever, African 2001 04 20 NLM (2002) T001144 Wart-Hog Disease 1992 01 27 WART HOG DIS NLM (1993) T001144 Wart Hog Disease T001144 Wart-Hog Diseases D000358 African Swine Fever Virus 1974 12 12 2001 07 25 1991 01 01 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection = AFRICAN SWINE FEVER: see note there 91(75); was see under IRIDOVIRIDAE 1981-90; was see under IRIDOVIRUSES 1978-80; was see under DNA VIRUSES 1975-77 91; was see under IRIDOVIRIDAE 1981-90; was see under IRIDOVIRUSES 1978-80; was see under DNA VIRUSES 1975-77 DNA Viruses (1966-1974) B04.280.049.035 B04.909.204.102.035 NLM ags sjn M0000546 African Swine Fever Virus C0001753 The lone species of the genus Asfivirus. It infects domestic and wild pigs, warthogs, and bushpigs. Disease is endemic in domestic swine in many African countries and Sardinia. Soft ticks of the genus Ornithodoros are also infected and act as vectors. T005 Virus T001145 African Swine Fever Virus 1999 01 01 NLM (1975) T001146 Wart-Hog Disease Virus 1974 12 05 WART HOG DIS VIRUS UNK (19XX) T001146 Virus, Wart-Hog Disease T001146 Wart Hog Disease Virus D000359 Aftercare 1999 01 01 2002 07 02 1968 01 01 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000523 psychology PX med, nurs, psychiat care after discharge from a hosp or other health facil; differentiate from REHABILITATION which is for getting a person back to pre-illness work or other activity 94; was AFTER CARE 1968-93 use AFTERCARE to search AFTER CARE 1968-93 94; was AFTER CARE 1968-93 Progressive Patient Care (1966-1967) D006208 Halfway Houses E02.760.058 N02.421.585.058 NLM mdb sjn M0000547 Aftercare C0001758 The care and treatment of a convalescent patient, especially that of a patient after surgery. T058 Health Care Activity M0000547 M0000548 M0000547 M0000549 T001147 Aftercare 1999 01 01 NLM (1968) T001149 After Care 1992 07 23 NLM (1994) T001148 After-Treatment 1990 09 06 NLM (1992) T001148 After Treatment T001148 After-Treatments M0000548 Postabortal Programs C0032752 T058 Health Care Activity M0000547 M0000548 T001150 Postabortal Programs 1978 12 18 POPLINE (1978) T001150 Postabortal Program T001150 Program, Postabortal T001150 Programs, Postabortal M0000549 Postabortion C0032753 T058 Health Care Activity M0000547 M0000549 T001151 Postabortion 1978 12 18 POPLINE (1978) D000360 Afterimage 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES differentiate from FIGURAL AFTEREFFECT which is displacement of (usually) geometric pattern in shape & space; while both are in the field of perception, AFTERIMAGE is likely to be in ophthalmol jrnls, FIGURAL AFTEREFFECT, in psychol jrnls F02.463.593.932.073 G11.697.677.040 NLM nns sjn M0000550 Afterimage C0001762 Continuation of visual impression after cessation of stimuli causing the original image. T041 Mental Process T042 Organ or Tissue Function T001152 Afterimage 1999 01 01 NLM (1966) T001152 Afterimages D000361 Agammaglobulinemia 1999 01 01 2003 07 09 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI DYSGAMMAGLOBULINEMIA is also available D011504 Protein-Losing Enteropathies C15.378.147.142 C15.604.515.032 C20.673.088 NLM lkt sjn M0000551 Agammaglobulinemia C0001768 An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood. T047 Disease or Syndrome M0000551 M0000552 T001153 Agammaglobulinemia 1999 01 01 NLM (1966) T001153 Agammaglobulinemias M0000552 Hypogammaglobulinemia C0086438 T047 Disease or Syndrome M0000551 M0000552 T001154 Hypogammaglobulinemia 1977 06 16 UNK (19XX) T001154 Hypogammaglobulinemias D000362 Agar 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000648 ultrastructure UL D25-26 qualif D09.203.698.360.041 NLM CCR sjn M0000553 Agar C0001771 Agar 9002-18-0 A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis. T118 Carbohydrate T121 Pharmacologic Substance T130 Indicator, Reagent, or Diagnostic Aid D003470 Culture Media T001155 Agar 1999 01 01 NLM (1966) D000363 Agaricales 1974 11 19 2003 07 09 1975 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI note x ref MUSHROOMS; pois = MUSHROOM POISONING 86(75); for MUSHROOMS use BASIDIOMYCOTA 1963-98; for AGARICACEAE use BASIDIOMYCOTA 1966-74 86; for MUSHROOMS see BASIDOMYCETES 1986-98, see MUSHROOMS 1963-85; for CORTINARIUS see CORTINARIUS 1991-96, see AGARICALES 1986-90; for AGARICACEAE see AGARICACEAE 1975-85, see MUSHROOMS 1963-74 Basidiomycetes (1966-1974) B05.179.100 NLM ags sjn M0000555 Agaricales C0001774 An extensive order of basidiomycetous fungi whose fruiting bodies are commonly call mushrooms. T004 Fungus M0000555 M0000554 M0000555 M0000556 T001157 Agaricales 1999 01 01 NLM (1975) T001158 Mushrooms 1997 12 10 NLM (1999) M0000554 Agaricaceae C0001773 T004 Fungus M0000555 M0000554 T001156 Agaricaceae 1985 02 08 UNK (19XX) M0000556 Cortinarius C0010135 T004 Fungus M0000555 M0000556 T001159 Cortinarius 1996 04 12 NLM (1997) D000364 Agaricus 1985 02 08 2003 07 09 1991 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI a basidiomycete 91(86); was see under AGARICALES 1986-90 91; was see under AGARICALES 1986-90 Agaricales (1966-1985) Basidiomycetes (1966-1985) B05.179.100.105 RC ags sjn M0000557 Agaricus C0001775 A basidiomycetous fungal genus of the family Agaricaceae, order Agaricales, which includes the field mushroom (A. campestris) and the commercial mushroom (A. bisporus). T004 Fungus T001160 Agaricus 1999 01 01 NLM (1986) D000365 Age Determination by Skeleton 1999 01 01 1997 06 20 1967 01 01 1998 1999 2000 2001 2002 2003 2004 Q000379 methods MT Q000662 veterinary VE 67; was SKELETAL AGE MEASUREMENT 1965-66 use AGE DETERMINATION BY SKELETON to search SKELETAL AGE MEASUREMENT 1966 67; was SKELETAL AGE MEASUREMENT 1965-66 E01.370.350.700.050 NLM PXP SJN M0000558 Age Determination by Skeleton C0001780 T060 Diagnostic Procedure T001161 Age Determination by Skeleton 1999 01 01 NLM (1967) T001162 Bone Age Measurement 1974 03 29 UNK (19XX) T001162 Age Measurement, Bone T001162 Age Measurements, Bone T001162 Bone Age Measurements T001162 Measurement, Bone Age T001162 Measurements, Bone Age T001163 Skeletal Age Measurement 1974 03 29 UNK (19XX) T001163 Age Measurement, Skeletal T001163 Age Measurements, Skeletal T001163 Measurement, Skeletal Age T001163 Measurements, Skeletal Age T001163 Skeletal Age Measurements D000366 Age Determination by Teeth 1999 01 01 1997 06 20 1967 01 01 1998 1999 2000 2001 2002 2003 2004 Q000379 methods MT Q000662 veterinary VE 67(64) 67 E01.370.350.700.720.050 E06.342.764.142 NLM PXP SJN M0000559 Age Determination by Teeth C0001781 T060 Diagnostic Procedure T001164 Age Determination by Teeth 1999 01 01 NLM (1964) D000367 Age Factors 1999 01 01 2000 06 21 1968 01 01 2001 2002 2003 2004 NIM; no qualif; human & animal; related to cause & effect: do not confuse with AGE DISTRIBUTION which is largely statistical; differentiate from AGING, a physiol concept; policy: Manual 35.7 68; AGE-SEX DISTRIBUTION was see AGE FACTORS 1990-92 use AGE DISTRIBUTION and SEX DISTRIBUTION to search AGE-SEX DISTRIBUTION 1994 forward; use AGE FACTORS to search AGE-SEX DISTRIBUTION 1990-92 68; AGE-SEX DISTRIBUTION was see AGE FACTORS 1990-92 Aging (1966-1967) G03.850.490.250 N05.715.350.075 NLM jls sjn M0000561 Age Factors C0001783 Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. T079 Temporal Concept M0000561 M0000562 T001166 Age Factors 1999 01 01 BIOETHICS (1997) POPLINE (1978) T001166 Age Factor T001166 Factor, Age T001166 Factors, Age M0000562 Age Reporting C0001785 T079 Temporal Concept M0000561 M0000562 T001167 Age Reporting 1978 12 18 POPLINE (1978) D000368 Aged 1999 01 01 1999 11 03 1966 01 01 2000 2001 2002 2003 2004 Q000523 psychology PX Q000706 statistics & numerical data SN Q000502 physiology PH age 65-79 if IM, age 65 & over as check tag; AGED, 80 AND OVER is also available; IM as physiol, psychol or sociol entity; NIM as check tag; Manual 18.5+, 34.10.1; differentiate from AGING, a physiol process, & AGE FACTORS & AGE DISTRIBUTION, statist concepts 66; was see under GERIATRICS 1963-65 pre-explosion = AGED (PX) 66; was see under GERIATRICS 1963-65 D006299 Health Services for the Aged D006707 Homes for the Aged D010415 Pensions D012179 Retirement D016852 Housing for the Elderly M01.060.116.100 NLM kle sjn M0000563 Aged C0001792 A person 65 through 79 years of age. For a person older than 79 years, AGED, 80 AND OVER is available. T100 Age Group T001168 Aged 1999 01 01 BIOETHICS (1989) POPLINE (1978) T001169 Elderly 1990 04 05 NLM (1989) D000369 Aged, 80 and over 1986 03 25 1999 11 08 1987 01 01 2000 2001 2002 2003 2004 Q000502 physiology PH Q000523 psychology PX Q000706 statistics & numerical data SN age 80 yr & over; IM as psychol or sociol entity; NIM as for AGED check tag; whether IM or NIM check tag AGED; Manual 18.5+, 34.10.1; DF: AGED 80 87; CENTENERIANS, NONAGENARIANS, & OCTOGENARIANS were CENTENARIAN, NONAGENARIAN, & OCTOGENARIAN 1987-95 87; CENTENARIANS, NONAGENARIANS, & OCTOGENARIANS were CENTENARIAN, NONAGENARIAN, & OCTOGENARIAN 1987-95 Aged (1966-1986) M01.060.116.100.080 EC kle sjn M0000564 Aged, 80 and over C0001795 A person 80 years of age and older. T100 Age Group M0000564 M0000565 M0000564 M0000566 M0000564 M0000567 T001170 Aged, 80 and over 1999 01 01 AGED 80 POPLINE (1987) T001171 Oldest Old 1986 03 25 UNK (19XX) M0000565 Centenarians C0007667 T100 Age Group M0000564 M0000565 T001172 Centenarians 1986 03 25 UNK (19XX) T001172 Centenarian M0000566 Nonagenarians C0028296 T100 Age Group M0000564 M0000566 T001173 Nonagenarians 1986 03 25 UNK (19XX) T001173 Nonagenarian M0000567 Octogenarians C0028829 T100 Age Group M0000564 M0000567 T001174 Octogenarians 1986 03 25 UNK (19XX) T001174 Octogenarian D000370 Ageusia 1999 01 01 1999 11 04 1991 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI do not confuse with DYSGEUSIA, distortion of sense of taste 1991(1975) 1991; see TASTE DISORDERS 1975-1990 C10.597.751.861.184 C23.888.592.763.861.184 NLM KEV sjn M0000568 Ageusia C0001800 Complete or severe loss of the subjective sense of taste, frequently accompanied by OLFACTION DISORDERS. T184 Sign or Symptom M0000568 M0336546 M0000568 M0336545 M0000568 M0336547 T001175 Ageusia 1999 01 01 NLM (1975) M0336546 Hypogeusia C0151934 T184 Sign or Symptom M0000568 M0336546 T371278 Hypogeusia 1999 11 04 NLM (2000) T371278 Hypogeusias M0336545 Ageusia, Hysterical C0750888 T048 Mental or Behavioral Dysfunction T184 Sign or Symptom M0000568 M0336545 T371277 Ageusia, Hysterical 1999 11 04 NLM (2000) T371277 Ageusias, Hysterical T371277 Hysterical Ageusia T371277 Hysterical Ageusias M0336547 Taste-Blindness C0278155 T184 Sign or Symptom M0000568 M0336547 T371279 Taste-Blindness 1999 11 04 NLM (2000) T371279 Taste Blindness D000371 Agglutination 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES NIM, no qualif; when IM, qualif permitted G04.610.143.100 NLM ags sjn M0000569 Agglutination C0001801 T044 Molecular Function T001176 Agglutination 1999 01 01 NLM (1966) T001176 Agglutinations D000372 Agglutination Tests 1999 01 01 1997 06 20 1966 01 01 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000379 methods MT Q000401 mortality MO Q000451 nursing NU Q000523 psychology PX Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000662 veterinary VE Q000706 statistics & numerical data SN Q000744 contraindications CT Q000941 ethics ES NIM 66 66 E01.450.495.735.050 NLM PXP SJN M0000570 Agglutination Tests C0001802 Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed) T059 Laboratory Procedure T001177 Agglutination Tests 1999 01 01 NLM (1966) T001177 Agglutination Test T001177 Test, Agglutination T001177 Tests, Agglutination D000373 Agglutinins 1999 01 01 2002 07 02 1973 01 01 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT cold agglutinin disease = COLD AGGLUTININ DISEASE see ANEMIA, HEMOLYTIC, AUTOIMMUNE 73 73 Antibodies (1966-1972) D24.611.093 NLM TGC sjn M0000571 Agglutinins C0001804 0 Substances, usually of biological origin, that cause cells or other organic particles to aggregate and stick to each other. They also include those antibodies which cause aggregation or agglutination of a particulate or insoluble antigen. T129 Immunologic Factor T001178 Agglutinins 1999 01 01 NLM (1973) D000374 Aggression 1999 01 01 2002 07 02 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES Q000523 psychology PX human & animal; "agression" in French is translated "stress" & indexed under a STRESS heading; "agressologie" = STRESS F01.145.126.125 F01.145.813.045 NLM TPW sjn M0000572 Aggression C0001807 A form of behavior which leads to self-assertion; it may arise from innate drives and/or a response to frustration; may be manifested by destructive and attacking behavior, by covert attitudes of hostility and obstructionism, or by healthy self-expressive drive to mastery. (Dorland 27th ed) T048 Mental or Behavioral Dysfunction T054 Social Behavior T055 Individual Behavior T001179 Aggression 1999 01 01 BIOETHICS (1989) POPLINE (1986) T001179 Aggressions D000375 Aging 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000187 drug effects DE Q000208 ethnology EH Q000235 genetics GE Q000276 immunology IM Q000378 metabolism ME Q000502 physiology PH Q000523 psychology PX Q000528 radiation effects RE Q000652 urine UR Q000941 ethics ES Q000473 pathology PA human & animal; IM; aging process anywhere between birth & old age; differentiation from other age-related terms: Manual 28.16, 34.10; "aging" of lower organisms, cultures, drugs, etc. is probably TIME FACTORS; AGING, PREMATURE is also available D015595 Skin Aging D016922 Cell Aging G07.168 NLM adp sjn M0000573 Aging C0001811 The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. T040 Organism Function T079 Temporal Concept M0000573 M0000574 M0000573 M0000575 T001180 Aging 1999 01 01 NLM (1966) M0000574 Biological Aging C0085759 T040 Organism Function T079 Temporal Concept M0000573 M0000574 T001182 Biological Aging 1986 12 31 BIOL AGING POPLINE (1981) T001181 Aging, Biological 1989 08 31 AGING BIOL NLM (1990) M0000575 Senescence C0086970 T040 Organism Function T079 Temporal Concept M0000573 M0000575 T001183 Senescence 1974 03 29 UNK (19XX) D000376 Agmatine 1974 11 19 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under GUANIDINES 1975-90 91; was see under GUANIDINES 1975-90 Butylamines (1973-1974) Guanidines (1968-1974) D02.078.370.060 NLM CCR sjn M0000576 Agmatine C0001814 Guanidine, (4-aminobutyl)- 306-60-5 Decarboxylated arginine, isolated from several plant and animal sources, e.g., pollen, ergot, herring sperm, octopus muscle. T109 Organic Chemical T123 Biologically Active Substance T001185 Agmatine 1999 01 01 NLM (1975) T001184 1-Amino-4-guanidinobutane 1980 08 21 UNK (19XX) T001184 1 Amino 4 guanidinobutane T001186 4-(Aminobutyl)guanidine 1995 05 17 NLM (1996) D000377 Agnosia 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI coord IM with type of stimulus that is not recognized (IM) C10.597.606.762.100 C23.888.592.604.764.100 F01.700.750.100 NLM KEV sjn M0000577 Agnosia C0001816 Loss of the ability to comprehend the meaning or recognize the importance of various forms of stimulation that cannot be attributed to impairment of a primary sensory modality. Tactile agnosia is characterized by an inability to perceive the shape and nature of an object by touch alone, despite unimpaired sensation to light touch, position, and other primary sensory modalities. T048 Mental or Behavioral Dysfunction M0000577 M0337184 M0000577 M0337185 M0000577 M0337186 M0000577 M0337187 M0000577 M0337179 M0000577 M0337188 M0000577 M0337189 M0000577 M0337190 M0000577 M0337180 M0000577 M0337191 M0000577 M0337192 M0000577 M0337181 M0000577 M0337193 M0000577 M0337182 M0000577 M0337194 M0000577 M0337195 M0000577 M0337183 M0000577 M0337196 M0000577 M0337197 T001187 Agnosia 1999 01 01 NLM (1966) T001187 Agnosias M0337184 Agnosia for Pain C0563625 T048 Mental or Behavioral Dysfunction M0000577 M0337184 T372317 Agnosia for Pain 1999 11 08 NLM (2000) M0337185 Agnosia for Smell C0234503 T048 Mental or Behavioral Dysfunction M0000577 M0337185 T372318 Agnosia for Smell 1999 11 08 NLM (2000) T372320 Olfactory Agnosia 1999 11 08 NLM (2000) T372320 Agnosia, Olfactory T372320 Agnosias, Olfactory T372320 Olfactory Agnosias M0337186 Agnosia for Taste C0234504 T048 Mental or Behavioral Dysfunction M0000577 M0337186 T372319 Agnosia for Taste 1999 11 08 NLM (2000) T372319 Agnosia for Tastes M0337187 Agnosia for Temperature C0563626 T048 Mental or Behavioral Dysfunction M0000577 M0337187 T372321 Agnosia for Temperature 1999 11 08 NLM (2000) M0337179 Auditory Agnosia C0234501 T048 Mental or Behavioral Dysfunction M0000577 M0337179 T372312 Auditory Agnosia 1999 11 08 NLM (2000) T372312 Agnosia, Auditory T372312 Agnosias, Auditory T372312 Auditory Agnosias M0337188 Auditory Agnosia, Congenital C0454653 T048 Mental or Behavioral Dysfunction M0000577 M0337188 T372322 Auditory Agnosia, Congenital 1999 11 08 AUDITORY AGNOSIA CONGEN NLM (2000) T372322 Agnosia, Congenital Auditory T372322 Agnosias, Congenital Auditory T372322 Auditory Agnosias, Congenital T372322 Congenital Auditory Agnosias T372323 Congenital Auditory Agnosia 1999 11 08 CONGEN AUDITORY AGNOSIA NLM (2000) M0337189 Body-Image Agnosia C0234511 T048 Mental or Behavioral Dysfunction M0000577 M0337189 T372324 Body-Image Agnosia 1999 11 08 NLM (2000) T372324 Agnosia, Body-Image T372324 Agnosias, Body-Image T372324 Body Image Agnosia T372324 Body-Image Agnosias M0337190 Developmental Agnosia C0395013 T048 Mental or Behavioral Dysfunction M0000577 M0337190 T372325 Developmental Agnosia 1999 11 08 NLM (2000) T372325 Agnosia, Developmental T372325 Agnosias, Developmental T372325 Developmental Agnosias M0337180 Finger Agnosia C0234509 T048 Mental or Behavioral Dysfunction M0000577 M0337180 T372313 Finger Agnosia 1999 11 08 NLM (2000) T372313 Agnosia, Finger T372313 Agnosias, Finger T372313 Finger Agnosias M0337191 Ideational Agnosia C0234510 T048 Mental or Behavioral Dysfunction M0000577 M0337191 T372326 Ideational Agnosia 1999 11 08 NLM (2000) T372326 Agnosia, Ideational T372326 Agnosias, Ideational T372326 Ideational Agnosias M0337192 Position Agnosia C0563624 T048 Mental or Behavioral Dysfunction M0000577 M0337192 T372327 Position Agnosia 1999 11 08 NLM (2000) T372327 Agnosia, Position T372327 Agnosias, Position T372327 Position Agnosias M0337181 Sensory Agnosia C0422891 T048 Mental or Behavioral Dysfunction M0000577 M0337181 T372314 Sensory Agnosia 1999 11 08 NLM (2000) T372314 Agnosia, Sensory T372314 Agnosias, Sensory T372314 Sensory Agnosias M0337193 Somatosensory Agnosia C0459888 T048 Mental or Behavioral Dysfunction M0000577 M0337193 T372328 Somatosensory Agnosia 1999 11 08 NLM (2000) T372328 Agnosia, Somatosensory T372328 Agnosias, Somatosensory T372328 Somatosensory Agnosias M0337182 Tactile Agnosia C0234505 T048 Mental or Behavioral Dysfunction M0000577 M0337182 T372315 Tactile Agnosia 1999 11 08 NLM (2000) T372315 Agnosia, Tactile T372315 Agnosias, Tactile T372315 Tactile Agnosias M0337194 Time Agnosia C0234506 T048 Mental or Behavioral Dysfunction M0000577 M0337194 T372329 Time Agnosia 1999 11 08 NLM (2000) T372329 Agnosia, Time T372329 Agnosias, Time T372329 Time Agnosias M0337195 Topographical Agnosia C0271189 T048 Mental or Behavioral Dysfunction M0000577 M0337195 T372330 Topographical Agnosia 1999 11 08 NLM (2000) T372330 Agnosia, Topographical T372330 Agnosias, Topographical T372330 Topographical Agnosias T372331 Visual Disorientation Syndrome 1999 11 08 NLM (2000) T372331 Syndrome, Visual Disorientation T372331 Syndromes, Visual Disorientation T372331 Visual Disorientation Syndromes M0337183 Visual Agnosia C0234502 T048 Mental or Behavioral Dysfunction M0000577 M0337183 T372316 Visual Agnosia 1999 11 08 NLM (2000) T372316 Agnosia, Visual T372316 Agnosias, Visual T372316 Visual Agnosias M0337196 Visual Agnosia for Objects C0563621 T048 Mental or Behavioral Dysfunction M0000577 M0337196 T372332 Visual Agnosia for Objects 1999 11 08 NLM (2000) M0337197 Visuospatial Agnosia C0563622 T048 Mental or Behavioral Dysfunction M0000577 M0337197 T372333 Visuospatial Agnosia 1999 11 08 NLM (2000) T372333 Agnosia, Visuospatial T372333 Agnosias, Visuospatial T372333 Visuospatial Agnosias D000378 Agonistic Behavior 1999 01 01 2002 07 02 1991 01 01 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 91(75); was see under AGGRESSION 1975-90 search AGGRESSION 1968-74 91; was see under AGGRESSION 1975-90 F01.145.126.125.100 NLM JLS sjn M0000578 Agonistic Behavior C0001817 Any behavior associated with conflict between two individuals. T054 Social Behavior T001188 Agonistic Behavior 1999 01 01 NLM (1975) T001188 Agonistic Behaviors T001188 Behavior, Agonistic T001188 Behaviors, Agonistic D000379 Agoraphobia 1999 01 01 1997 06 20 1990 01 01 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI 90(75); was see under PHOBIC DISORDERS 1981-89; was see under PHOBIAS 1968-80 90; was see under PHOBIC DISORDERS 1981-89; was see under PHOBIAS 1968-80 F03.080.100 NLM JLS SJN M0000579 Agoraphobia C0001818 Obsessive, persistent, intense fear of open places. T048 Mental or Behavioral Dysfunction T001189 Agoraphobia 1999 01 01 NLM (1975) T001189 Agoraphobias D000380 Agranulocytosis 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C15.378.553.546.184 NLM KEV sjn M0000580 Agranulocytosis C0001824 A decrease in the number of GRANULOCYTES (BASOPHILS, EOSINOPHILS, and NEUTROPHILS). T033 Finding T047 Disease or Syndrome T001190 Agranulocytosis 1999 01 01 NLM (1966) T001190 Agranulocytoses T001191 Granulocytopenia 1974 03 29 UNK (19XX) T001191 Granulocytopenias D000381 Agraphia 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI C10.597.606.150.500.050 C23.888.592.604.150.500.050 NLM ags sjn M0000581 Agraphia C0001825 Loss or impairment of the ability to write (letters, syllables, words, or phrases) due to an injury to a specific cerebral area or occasionally due to emotional factors. This condition rarely occurs in isolation, and often accompanies APHASIA. (From Adams et al., Principles of Neurology, 6th ed, p485; APA, Thesaurus of Psychological Index Terms, 1994) T048 Mental or Behavioral Dysfunction M0000581 M0336945 M0000581 M0336949 M0000581 M0336946 M0000581 M0355784 M0000581 M0336944 T001192 Agraphia 1999 01 01 NLM (1966) T001192 Agraphias M0336945 Acquired Agraphia C0750890 T048 Mental or Behavioral Dysfunction M0000581 M0336945 T371914 Acquired Agraphia 1999 11 04 NLM (2000) T371914 Acquired Agraphias T371914 Agraphia, Acquired T371914 Agraphias, Acquired T371915 Acquired Dysgraphia 1999 11 04 NLM (2000) T371915 Acquired Dysgraphias T371915 Dysgraphia, Acquired T371915 Dysgraphias, Acquired M0336949 Constructional Agraphia C0750893 T048 Mental or Behavioral Dysfunction M0000581 M0336949 T371920 Constructional Agraphia 1999 11 04 NLM (2000) T371920 Agraphia, Constructional T371920 Agraphias, Constructional T371920 Constructional Agraphias M0336946 Developmental Agraphia C0750895 T048 Mental or Behavioral Dysfunction M0000581 M0336946 T371916 Developmental Agraphia 1999 11 04 NLM (2000) T371916 Agraphia, Developmental T371916 Agraphias, Developmental T371916 Developmental Agraphias T371917 Developmental Dysgraphia 1999 11 04 NLM (2000) T371917 Developmental Dysgraphias T371917 Dysgraphia, Developmental T371917 Dysgraphias, Developmental M0355784 Dysgraphia C0234144 Some authorities use this term interchangeably with Agraphia and some do not. T048 Mental or Behavioral Dysfunction M0000581 M0355784 T371912 Dysgraphia 1999 11 04 NLM (2000) T371912 Dysgraphias M0336944 Pure Agraphia C0750896 T048 Mental or Behavioral Dysfunction M0000581 M0336944 T371913 Pure Agraphia 1999 11 04 NLM (2000) T371913 Agraphia, Pure T371913 Agraphias, Pure T371913 Pure Agraphias D000382 Agricultural Workers' Diseases 1999 01 01 1993 02 16 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI coord IM with specific dis (IM); specify geog if pertinent C21.447.080 NLM TGC PLS M0000582 Agricultural Workers' Diseases C0001828 Diseases in persons engaged in cultivating and tilling soil, growing plants, harvesting crops, raising livestock, or otherwise engaged in husbandry and farming. The diseases are not restricted to farmers in the sense of those who perform conventional farm chores: the heading applies also to those engaged in the individual activities named above, as in those only gathering harvest or in those only dusting crops. T047 Disease or Syndrome T001195 Agricultural Workers' Diseases 1999 01 01 AGRICULTURAL WORKERS DIS NLM (1966) T001195 Agricultural Workers Diseases T001195 Agricultural Workers' Disease T001195 Disease, Agricultural Workers' T001195 Diseases, Agricultural Workers' T001195 Workers' Disease, Agricultural T001195 Workers' Diseases, Agricultural T001193 Agricultural Worker Disease 1981 03 16 AGRICULTURAL WORKER DIS UNK (19XX) T001193 Agricultural Worker Diseases T001193 Disease, Agricultural Worker T001193 Diseases, Agricultural Worker T001193 Worker Disease, Agricultural T001193 Worker Diseases, Agricultural T001194 Agricultural Worker's Disease 1981 03 16 UNK (19XX) T001194 Agricultural Worker's Diseases T001194 Agricultural Workers Disease T001194 Disease, Agricultural Worker's T001194 Diseases, Agricultural Worker's T001194 Worker's Disease, Agricultural T001194 Worker's Diseases, Agricultural D000383 Agriculture 1999 01 01 1993 11 29 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000379 methods MT Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES SPEC: SPEC qualif J01.040 NLM PLS PLS M0000584 Agriculture C0001829 The science of soil cultivation, crop production, and livestock raising. T090 Occupation or Discipline M0000584 M0000583 M0000584 M0000585 M0000584 M0000586 T001197 Agriculture 1999 01 01 POPLINE (1978) M0000583 Agricultural Development C0001827 T090 Occupation or Discipline M0000584 M0000583 T001196 Agricultural Development 1986 12 31 POPLINE (1981) T001196 Development, Agricultural M0000585 Land Supply C0022996 T081 Quantitative Concept M0000584 M0000585 T001198 Land Supply 1986 12 31 POPLINE (1982) T001198 Land Supplies T001198 Supplies, Land T001198 Supply, Land M0000586 Agricultural Workers C0242176 T097 Professional or Occupational Group M0000584 M0000586 T001199 Agricultural Workers 1993 11 29 POPLINE (1981) T001199 Agricultural Worker T001199 Worker, Agricultural T001199 Workers, Agricultural D000385 Aid to Families with Dependent Children 1999 01 01 1999 11 03 1978 01 01 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES treed under SOCIAL SECURITY; specify geog; DF: AFDC 78(75); was see under PUBLIC ASSISTANCE 1968-77 search PUBLIC ASSISTANCE 1968-74 78; was see under PUBLIC ASSISTANCE 1968-77 N03.219.521.346.506.849.095 NLM kle sjn M0000588 Aid to Families with Dependent Children C0001843 Financial assistance provided by the government to indigent families with dependent children who meet certain requirements as defined by the Social Security Act, Title IV, in the U.S. T064 Governmental or Regulatory Activity M0000588 M0000589 T001201 Aid to Families with Dependent Children 1999 01 01 AFDC NLM (1975) M0000589 Family Allowances C0015577 T064 Governmental or Regulatory Activity M0000588 M0000589 T001202 Family Allowances 1978 12 18 POPLINE (1978) T001202 Allowance, Family T001202 Allowances, Family T001202 Family Allowance D000386 AIDS-Related Complex 1986 06 18 1996 02 12 1987 01 01 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI coord IM with HIV-1 or HIV-2 (IM) if pertinent; DF: note short X ref 87 87 Acquired Immunodeficiency Syndrome (1983-1986) C02.782.815.616.400.080 C02.800.801.400.080 C02.839.080 C20.673.480.080 SCD AGS PLS M0000590 AIDS-Related Complex C0001857 A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS. T047 Disease or Syndrome T001203 AIDS-Related Complex 1999 01 01 AIDS RELAT COMPLEX POPLINE (1988) T001203 AIDS Related Complex T001203 Complex, AIDS-Related T001204 ARC 1993 05 24 NLM (1994) T001205 Lymphadenopathy Syndrome 1986 06 18 UNK (19XX) T001205 Lymphadenopathy Syndromes T001205 Syndrome, Lymphadenopathy T001205 Syndromes, Lymphadenopathy D000387 Ainhum 1999 01 01 1999 11 23 2000 2000A 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C05.116.264.143 NLM ags ags M0000591 Ainhum C0001860 Spontaneous autoamputation of the fourth or fifth toe. T047 Disease or Syndrome T001206 Ainhum 1999 01 01 NLM (1966) T001207 Dactylolysis Spontanea 1974 03 29 UNK (19XX) D000388 Air 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000032 analysis AN Q000331 legislation & jurisprudence LJ Q000469 parasitology PS Q000592 standards ST do not confuse with ATMOSPHERE or OXYGEN D000388 Air Q000382 microbiology D000391 Air Microbiology D000388 Air Q000821 virology D000391 Air Microbiology G03.230.300.100.150 NLM adp sjn M0000592 Air C0001861 The mixture of gases present in the earth's atmosphere consisting of oxygen, nitrogen, carbon dioxide, and small amounts of other gases. T167 Substance T001208 Air 1999 01 01 NLM (1966) D000389 Air Conditioning 1999 01 01 1994 05 24 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000379 methods MT Q000592 standards ST Q000706 statistics & numerical data SN Q000941 ethics ES Q000295 instrumentation IS Q000639 trends TD G03.230.150.050 NLM JLS PLS M0000593 Air Conditioning C0001864 The maintenance of certain aspects of the environment within a defined space to facilitate the function of that space; aspects controlled include air temperature and motion, radiant heat level, moisture, and concentration of pollutants such as dust, microorganisms, and gases. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) T068 Human-caused Phenomenon or Process M0000593 M0000594 M0000593 M0000595 T001209 Air Conditioning 1999 01 01 NLM (1966) T001209 Air Conditionings T001209 Conditioning, Air T001209 Conditionings, Air M0000594 Air Revitalization C0242177 T068 Human-caused Phenomenon or Process M0000593 M0000594 T001210 Air Revitalization 1993 11 26 NLM (1995) T001210 Air Revitalizations T001210 Revitalization, Air T001210 Revitalizations, Air M0000595 Climate Control C0242178 T068 Human-caused Phenomenon or Process M0000593 M0000595 T001211 Climate Control 1993 11 26 NLM (1995) T001211 Climate Controls T001211 Control, Climate T001211 Controls, Climate D000390 Air Ionization 1999 01 01 1992 03 25 1970 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE 70(65) 70 G03.230.300.100.150.100 H01.181.529.065 NLM TAP PLS M0000596 Air Ionization C0001866 T070 Natural Phenomenon or Process T001212 Air Ionization 1999 01 01 NLM (1965) T001212 Air Ionizations T001212 Ionization, Air T001212 Ionizations, Air D000391 Air Microbiology 1999 01 01 2001 07 25 2002 2003 2004 Q000592 standards ST IM; coord IM with specific bact, virus or fungus (IM); DF: AIR MICROBIOL G01.273.540.274.110 G03.850.425.110 H01.158.273.540.274.110 NLM jls sjn M0000597 Air Microbiology C0001867 The presence of bacteria, viruses, and fungi in the air. This term is not restricted to pathogenic organisms. T067 Phenomenon or Process T001214 Air Microbiology 1999 01 01 AIR MICROBIOL NLM (1966) T001213 Microbiology, Air 1986 01 01 MICROBIOL AIR UNK (19XX) D000392 Air Movements 1999 01 01 1991 06 13 1974 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif; WIND is also available but see note there 74(72) 74 Air (1966-1971) Weather (1966-1971) G03.230.300.100.150.185 NLM TGC PLS M0000598 Air Movements C0001868 T070 Natural Phenomenon or Process T001215 Air Movements 1999 01 01 NLM (1972) T001215 Air Movement T001215 Movement, Air T001215 Movements, Air D000393 Air Pollutants 1999 01 01 2003 07 09 1975 09 01 2004 Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000819 agonists AG specify pollutant if pertinent (IM or NIM) 75 75 Air Pollution (1966-1974) D27.888.284.101 NLM ssb sjn M0000599 Air Pollutants C0001869 0 Substances which pollute the air. T131 Hazardous or Poisonous Substance T001216 Air Pollutants 1999 01 01 NLM (1975) T001216 Pollutants, Air D000394 Air Pollutants, Environmental 1999 01 01 2003 07 09 1984 01 01 2004 Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000819 agonists AG specify pollutant if pertinent (IM or NIM); DF: AIR POLLUTANTS ENVIR 84(75); was see under AIR POLLUTANTS 1975-83 84; was see under AIR POLLUTANTS 1975-83 D27.888.284.101.143 NLM ssb sjn M0000600 Air Pollutants, Environmental C0001870 0 Air pollutants which affect environmental conditions. T131 Hazardous or Poisonous Substance T001219 Air Pollutants, Environmental 1999 01 01 AIR POLLUTANTS ENVIR NLM (1975) T001217 Environmental Pollutants, Air 1995 03 08 ENVIR POLLUTANTS AIR NLM (1996) T001217 Air Environmental Pollutants T001217 Pollutants, Air Environmental T001218 Environmental Air Pollutants 1977 04 25 ENVIR AIR POLLUTANTS UNK (19XX) T001218 Pollutants, Environmental Air D000395 Air Pollutants, Occupational 1999 01 01 2003 07 09 1984 01 01 2004 Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000819 agonists AG specify pollutant or occup if pertinent (IM or NIM); DF: AIR POLLUTANTS OCCUP 84(75); was see under AIR POLLUTANTS 1975-83 84; was see under AIR POLLUTANTS 1975-83 D015920 Gas Scavengers D020378 Confined Spaces D27.888.284.101.268 NLM ssb sjn M0000601 Air Pollutants, Occupational C0001871 0 Air pollutants found in the work area. They are usually produced by the specific nature of the occupation. T131 Hazardous or Poisonous Substance T001221 Air Pollutants, Occupational 1999 01 01 AIR POLLUTANTS OCCUP NLM (1975) T001220 Occupational Air Pollutants 1977 04 25 OCCUP AIR POLLUTANTS UNK (19XX) T001220 Pollutants, Occupational Air D000396 Air Pollutants, Radioactive 1999 01 01 2003 07 09 1991 01 01 2004 Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000819 agonists AG specify radiopollutant if pertinent (IM or NIM) 91(75); was see under AIR POLLUTANTS 1975-90 91; was see under AIR POLLUTANTS 1975-90 D20.693.101 D27.888.284.101.393 NLM ssb sjn M0000602 Air Pollutants, Radioactive C0001872 0 Pollutants, present in air, which exhibit radioactivity. T131 Hazardous or Poisonous Substance T001223 Air Pollutants, Radioactive 1999 01 01 NLM (1975) T001222 Radioactive Air Pollutants 1977 04 25 UNK (19XX) T001222 Pollutants, Radioactive Air D000397 Air Pollution 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000032 analysis AN Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000517 prevention & control PC Q000706 statistics & numerical data SN Q000941 ethics ES includes pollen in the air (coord with POLLEN) G03.850.460.100 NLM kle sjn M0000603 Air Pollution C0001873 T069 Environmental Effect of Humans T001224 Air Pollution 1999 01 01 NLM (1966) T001224 Air Pollutions T001224 Pollution, Air T001224 Pollutions, Air D000398 Air Pollution, Radioactive 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000032 analysis AN Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000517 prevention & control PC Q000706 statistics & numerical data SN Q000941 ethics ES IM; coord with specific source of radiation (IM); specify geog if pertinent G03.850.460.100.110 G03.850.810.080 NLM kle sjn M0000604 Air Pollution, Radioactive C0001874 T069 Environmental Effect of Humans T001225 Air Pollution, Radioactive 1999 01 01 NLM (1966) T001225 Air Pollutions, Radioactive T001225 Pollution, Radioactive Air T001225 Pollutions, Radioactive Air T001225 Radioactive Air Pollution T001225 Radioactive Air Pollutions D000399 Air Pressure 1999 01 01 1990 04 13 1991 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif 91(75); was see under ATMOSPHERIC PRESSURE 1975-90 search ATMOSPHERIC PRESSURE 1966-74 91; was see under ATMOSPHERIC PRESSURE 1975-90 G03.230.300.100.185.100 NLM NLM PLS M0000605 Air Pressure C0001876 The force per unit area that the air exerts on any surface in contact with it. Primarily used for articles pertaining to air pressure within a closed environment. T070 Natural Phenomenon or Process T001226 Air Pressure 1999 01 01 NLM (1975) T001226 Air Pressures T001226 Pressure, Air T001226 Pressures, Air D000400 Air Sacs 1999 01 01 1998 06 10 1968 01 01 1999 2000 2001 2002 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI in birds, fish, insects & mammals; sacculitis in veterinary animals: coord IM with RESPIRATORY TRACT DISEASES/vet (IM) or RESPIRATORY TRACT INFECTIONS/vet (IM) 68; AIR BLADDER was heading 1968-80 use AIR SACS to search AIR BLADDER 1968-80 68; AIR BLADDER was heading 1968-80 Birds (1966-1967) Bronchi (1966-1967) A13.048 NLM MSR SJN M0000606 Air Sacs C0001878 Thin-walled sacs or spaces which function as a part of the respiratory system in birds, fishes, insects, and mammals. T023 Body Part, Organ, or Organ Component T001228 Air Sacs 1999 01 01 NLM (1968) T001228 Air Sac T001228 Sac, Air T001228 Sacs, Air T001227 Air Bladder 1980 05 22 UNK (19XX) T001227 Air Bladders T001227 Bladder, Air T001227 Bladders, Air T001229 Swimbladder 1980 05 12 UNK (19XX) T001229 Swimbladders D000401 Aircraft 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000592 standards ST Q000706 statistics & numerical data SN Q000941 ethics ES EJECTION SEATS was heading 1963-82 use AIRCRAFT to search EJECTION SEATS 1966-82 EJECTION SEATS was heading 1963-82 J01.937.285.100 NLM JLS SJN M0000607 Aircraft C0001881 A weight-carrying structure for navigation of the air that is supported either by its own buoyancy or by the dynamic action of the air against its surfaces. (Webster, 1973) T073 Manufactured Object M0000607 M0000608 M0000607 M0000609 T001230 Aircraft 1999 01 01 NLM (1966) T001230 Aircrafts M0000608 Ejection Seats C0013748 T073 Manufactured Object M0000607 M0000608 T001231 Ejection Seats 1982 06 10 UNK (19XX) T001231 Ejection Seat T001231 Seat, Ejection T001231 Seats, Ejection M0000609 Helicopters C0018875 T073 Manufactured Object M0000607 M0000609 T001232 Helicopters 1986 03 25 UNK (19XX) T001232 Helicopter D000402 Airway Obstruction 1999 01 01 1991 06 13 1972 01 01 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI acute: chronic airway obstruct, chronic airflow obstruct & COAD (chronic obstruct airway dis) go under LUNG DISEASES, OBSTRUCTIVE (see note there); NASAL OBSTRUCTION is also available 72(71) 72 Respiratory Tract Diseases (1966-1970) C08.618.846.185 NLM TGC PLS M0000610 Airway Obstruction C0001883 Any hindrance to the passage of air into and out of the lungs. T047 Disease or Syndrome M0000610 M0000611 T001233 Airway Obstruction 1999 01 01 NLM (1971) T001233 Airway Obstructions T001233 Obstruction, Airway T001233 Obstructions, Airway M0000611 Choking C0008301 T046 Pathologic Function T184 Sign or Symptom M0000610 M0000611 T001234 Choking 1981 05 19 UNK (19XX) D000403 Airway Resistance 1999 01 01 2003 07 09 1970 01 01 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 70 70 Respiration (1966-1970) Respiratory System/physiology (1966-1970) D015656 Respiratory Mechanics E01.370.386.700.050 G09.772.765.060 NLM nns sjn M0000612 Airway Resistance C0001884 Physiologically, the opposition to flow of air caused by the forces of friction. As a part of pulmonary function testing, it is the ratio of driving pressure to the rate of air flow. T034 Laboratory or Test Result T042 Organ or Tissue Function T001235 Airway Resistance 1999 01 01 NLM (1970) T001235 Airway Resistances T001235 Resistance, Airway T001235 Resistances, Airway D000404 Ajmaline 1999 01 01 2000 06 21 1973 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 73(71) 73 Rauwolfia (1966-1970) D03.132.973.641.119 D03.549.937.641.144 NLM TWD sjn M0000613 Ajmaline C0001888 Ajmalan-17,21-diol, (17R,21alpha)- 4360-12-7 An alkaloid found in the root of Rauwolfia serpentina, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials. T109 Organic Chemical T121 Pharmacologic Substance D000889 Anti-Arrhythmia Agents M0000613 M0354272 M0000613 M0000614 M0000613 M0354273 T001236 Ajmaline 1999 01 01 NLM (1971) M0354272 Gilurtymal C0878046 0 T109 Organic Chemical T121 Pharmacologic Substance M0000613 M0354272 T001237 Gilurtymal 1980 07 31 UNK (19XX) M0000614 Lorajmine C0024001 0 T109 Organic Chemical T121 Pharmacologic Substance M0000613 M0000614 T001239 Lorajmine 1980 05 21 UNK (19XX) M0354273 Tachmalin C0878045 0 T109 Organic Chemical T121 Pharmacologic Substance M0000613 M0354273 T001238 Tachmalin 1984 10 10 UNK (19XX) D000405 Akinetic Mutism 1999 01 01 1999 11 03 1971 01 01 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI 1971 1971 Mutism (1966-1970) D018458 Persistent Vegetative State C10.228.140.042 NLM KEV sjn M0000615 Akinetic Mutism C0001889 A syndrome characterized by a silent and inert state without voluntary motor activity despite preserved sensorimotor pathways and vigilance. Bilateral FRONTAL LOBE dysfunction involving the anterior cingulate gyrus and related brain injuries are associated with this condition. This may result in impaired abilities to communicate and initiate motor activities. (From Adams et al., Principles of Neurology, 6th ed, p348; Fortschr Neurol Psychiatr 1995 Feb;63(2):59-67) T048 Mental or Behavioral Dysfunction T001241 Akinetic Mutism 1999 01 01 NLM (1971) T363913 Akinetic Autism 1999 11 03 NLM (2000) T363913 Autism, Akinetic T363914 Coma Vigil 1999 11 03 NLM (2000) T363914 Vigil, Coma T363914 Vigils, Coma T363915 Coma Vigilans 1999 11 03 NLM (2000) T001240 Mutism, Akinetic 1974 03 29 UNK (19XX) T001240 Akinetic Mutisms D000406 AKR murine leukemia virus 1974 12 12 2002 07 02 1991 01 01 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH infection: coord IM with RETROVIRIDAE INFECTIONS (IM) + TUMOR VIRUS INFECTIONS (IM) + LEUKEMIA, EXPERIMENTAL (IM) or LEUKEMIA (IM) (for spontaneous leukemia) 2002 (1975) 2002; see AKR VIRUS 1991-2001, see MOUSE LEUKEMIA VIRUSES 1975-1990 B04.820.650.375.525.050 B04.909.574.807.375.525.050 B04.909.777.731.375.525.050 NLM ags sjn M0000616 AKR murine leukemia virus C0001892 A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice. T005 Virus T445673 AKR murine leukemia virus 2001 05 04 NLM (2002) T001242 AKR Virus 1999 01 01 NLM (1975) T001242 AKR Viruses T001242 Virus, AKR T001242 Viruses, AKR D000407 Alabama 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP Z01.107.567.875.075.100 Z01.107.567.875.750.100 NLM PXP SJN M0000617 Alabama C0001895 T083 Geographic Area T001243 Alabama 1999 01 01 POPLINE (1978) D000408 Alamethicin 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under ANTIBIOTICS 1975-90 91; was see under ANTIBIOTICS 1975-90 Antibiotics (1971-1975) Peptides, Cyclic (1973-1974) D12.644.641.040 NLM ssb sjn M0000618 Alamethicin C0001897 Alamethicin 27061-78-5 A cyclic nonadecapeptide antibiotic that can act as an ionophore and is produced by strains of Trichoderma viride. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) T116 Amino Acid, Peptide, or Protein T195 Antibiotic D000900 Anti-Bacterial Agents D007476 Ionophores D014475 Uncoupling Agents T001244 Alamethicin 1999 01 01 NLM (1975) D000409 Alanine 1999 01 01 2001 07 25 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG BETA-ALANINE is also available D12.125.042 NLM jmp sjn M0000619 Alanine C0001898 (L)-Alanine 56-41-7 A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance 6898-94-8 T001245 Alanine 1999 01 01 NLM (1966) T358925 L-Alanine 1999 11 09 NLM (2000) T361543 Alanine, L-Isomer 1999 09 13 NLM (1999) T361543 Alanine, L Isomer T361543 L-Isomer Alanine D000410 Alanine Transaminase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT /blood = SGPT /blood (not just SGPT) 98(66) 98; see ALANINE AMINOTRANSFERASE 1966-97; for GLUTAMIC-PYRUVIC TRANSMINASE see ALANINE 1963 D08.811.913.477.700.100 NLM ssb sjn M0000620 Alanine Transaminase C0001899 L-Alanine:2-oxoglutarate aminotransferase EC 2.6.1.2 An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000620 M0000621 T001250 Alanine Transaminase 1999 01 01 NLM (1966) T001250 Transaminase, Alanine T001246 Alanine Aminotransferase 1996 09 06 NLM (1998) T001246 Aminotransferase, Alanine T001247 Glutamic-Alanine Transaminase 1987 12 08 UNK (19XX) T001247 Glutamic Alanine Transaminase T001247 Transaminase, Glutamic-Alanine T001248 Glutamic-Pyruvic Transaminase 1974 03 29 UNK (19XX) T001248 Glutamic Pyruvic Transaminase T001248 Transaminase, Glutamic-Pyruvic T001249 Alanine-2-Oxoglutarate Aminotransferase 1990 01 12 NLM (1991) T001249 Alanine 2 Oxoglutarate Aminotransferase T001249 Aminotransferase, Alanine-2-Oxoglutarate M0000621 SGPT C0376147 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000620 M0000621 T001251 SGPT 1974 03 29 UNK (19XX) D000411 Alanine Racemase 1975 07 18 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(76); was see under AMINO ACID ISOMERASES 1976-90 91; was see under AMINO ACID ISOMERASES 1976-90 Alanine (1974-1975) Amino Acid Isomerases (1970-1975) D08.811.399.894.200.200 RLS ssb sjn M0000622 Alanine Racemase C0001900 Alanine racemase EC 5.1.1.1 A pyridoxal-phosphate protein that reversibly catalyzes the conversion of L-alanine to D-alanine. EC 5.1.1.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9024-06-0 (CAS RN) T001252 Alanine Racemase 1999 01 01 NLM (1976) T001252 Racemase, Alanine D000412 Alanine-tRNA Ligase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 98(75) 98; see ALANYL T RNA SYNTHETASE 1991-97; see AMINOACYL T RNA SYNTHETASES 1975-90 Alanine (1973-1974) Amino Acyl T RNA Synthetases (1973-1974) D08.811.464.263.200.050 NLM ssb sjn M0000623 Alanine-tRNA Ligase C0001904 L-Alanine:tRNA(Ala) ligase (AMP-forming) EC 6.1.1.7 An enzyme that activates alanine with its specific transfer RNA. EC 6.1.1.7. T116 Amino Acid, Peptide, or Protein T126 Enzyme T001254 Alanine-tRNA Ligase 1999 01 01 NLM (1975) T001254 Alanine tRNA Ligase T001254 Ligase, Alanine-tRNA T001253 Alanyl T RNA Synthetase 1996 11 05 NLM (1998) T409451 Alanyl-tRNA Synthetase 2000 03 16 NLM (2001) T409451 Alanyl tRNA Synthetase T409451 Synthetase, Alanyl-tRNA T409452 Ala-tRNA Ligase 2000 03 16 NLM (2001) T409452 Ala tRNA Ligase T409452 Ligase, Ala-tRNA D000413 Alaska 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP Z01.107.567.875.580.100 NLM PXP SJN M0000624 Alaska C0001905 T083 Geographic Area M0000624 M0000625 T001255 Alaska 1999 01 01 POPLINE (1978) M0000625 Aleutian Islands C0205655 T083 Geographic Area M0000624 M0000625 T001256 Aleutian Islands 1992 08 20 NLM (1994) D000415 Albania 1999 01 01 2001 12 03 2002 2002A 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP in translations of historical articles use spelling People's Republic, not Peoples' nor Peoples Z01.542.248.020 NLM sjn sjn M0000626 Albania C0001909 T083 Geographic Area T001257 Albania 1999 01 01 POPLINE (1978) D000416 Alberta 1999 01 01 1995 02 17 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a province of Canada Z01.107.567.176.064 NLM TGC PLS M0000627 Alberta C0001914 A province of western Canada, lying between the provinces of British Columbia and Saskatchewan. Its capital is Edmonton. It was named in honor of Princess Louise Caroline Alberta, the fourth daughter of Queen Victoria. (From Webster's New Geographical Dictionary, 1988, p26 & Room, Brewer's Dictionary of Names, 1992, p12) T083 Geographic Area T001258 Alberta 1999 01 01 NLM (1966) D000417 Albinism 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000648 ultrastructure UL Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI hypopigmentation of skin, hair, eye; GEN or unspecified; prefer specifics; do not use /congen & do not coord with INFANT, NEWBORN, DISEASES D002609 Chediak-Higashi Syndrome C11.270.040 C16.320.290.040 C16.320.565.066.102 C16.320.850.080 C17.800.621.440.102 C17.800.827.080 C18.452.648.066.102 NLM nns sjn M0000628 Albinism C0001916 General term for a number of inherited defects of amino acid metabolism in which there is a deficiency or absence of pigment in the eyes, skin, or hair. T019 Congenital Abnormality T001259 Albinism 1999 01 01 NLM (1966) D000418 Albumins 1999 01 01 1992 05 26 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D000418 Albumins Q000097 blood D012709 Serum Albumin D000418 Albumins Q000652 urine D000419 Albuminuria D011228 Prealbumin D017457 Receptors, Albumin D12.776.034 NLM PXP PLS M0000629 Albumins C0001924 0 Water-soluble proteins found in egg whites, blood, lymph, and other tissues and fluids. They coagulate upon heating. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance T001260 Albumins 1999 01 01 NLM (1966) D000419 Albuminuria 1999 01 01 2002 07 02 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C12.777.584.269 NLM lkt sjn M0000630 Albuminuria C0001925 The presence of albumin in the urine, an indicator of KIDNEY DISEASES. T034 Laboratory or Test Result T047 Disease or Syndrome T001261 Albuminuria 1999 01 01 NLM (1966) T001261 Albuminurias D000420 Albuterol 1999 01 01 2001 07 25 1974 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 74 74 D02.033.100.291.057 D02.092.063.291.057 D02.092.471.683.061 NLM ssb sjn M0000631 Albuterol C0001927 1,3-Benzenedimethanol, alpha1-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy- 18559-94-9 A racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol. It is a short-acting beta2-adrenergic agonist with its main clinical use in ASTHMA. T109 Organic Chemical T121 Pharmacologic Substance D000318 Adrenergic beta-Agonists D001993 Bronchodilator Agents D015149 Tocolytic Agents 51022-70-9 M0000631 M0000633 M0000631 M0359590 M0000631 M0359592 M0000631 M0000636 M0000631 M0362430 M0000631 M0000635 M0000631 M0000632 M0000631 M0359591 T001263 Albuterol 1999 01 01 USAN (1971) USP (19XX) T001262 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol 1980 08 25 UNK (19XX) M0000633 Albuterol Sulfate C0543495 51022-70-9 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0000633 T001265 Albuterol Sulfate 1994 08 08 NLM (1996) USAN (1974) USP (19XX) M0359590 Levalbuterol C0772501 0 The R-isomer of albuterol. T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0359590 T410487 Levalbuterol 2000 03 28 NLM (2001) M0359592 Levalbuterol Hydrochloride C0772502 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0359592 T410489 Levalbuterol Hydrochloride 2000 03 28 NLM (2001) T410489 Hydrochloride, Levalbuterol M0000636 Proventil C0699770 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0000636 T001268 Proventil 1986 11 19 UNK (19XX) M0362430 Salbutamol C0917913 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0362430 T001266 Salbutamol 1974 03 29 BAN (19XX) INN (19XX) UNK (19XX) M0000635 Sultanol C0699769 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0000635 T001267 Sultanol 1996 11 14 NLM (1998) M0000632 Ventolin C0033744 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0000632 T001264 Ventolin 1982 05 19 UNK (19XX) M0359591 Xopenex C0876218 0 T109 Organic Chemical T121 Pharmacologic Substance M0000631 M0359591 T410488 Xopenex 2000 03 28 NLM (2001) D000421 Alcaligenes 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI ALCALIGENES EUTROPHA see RALSTONIA EUTROPHA is available; infection: coord IM with GRAM-NEGATIVE BACTERIAL INFECTIONS (IM) 1976 (1963) 1976; see ACHROMOBACTER 1963-1975 B03.440.400.425.117.050 B03.660.075.027.050 NLM ags sjn M0000638 Alcaligenes C0001930 A genus of gram-negative, aerobic, motile bacteria that occur in water and soil. Some are common inhabitants of the intestinal tract of vertebrates. These bacteria occasionally cause opportunistic infections in humans. T007 Bacterium T001270 Alcaligenes 1999 01 01 NLM (1966) D000422 Alchemy 1999 01 01 1989 06 13 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 no qualif K01.419.075 NLM TGC PLS M0000639 Alchemy C0001932 T090 Occupation or Discipline T001271 Alchemy 1999 01 01 NLM (1966) T001271 Alchemies D000423 Alcian Blue 1974 11 19 1995 06 08 1991 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000031 analogs & derivatives AA D25-26 qualif 91(75); was see under INDOLES 1975-90 91; was see under INDOLES 1975-90 Indoles (1973-1974) Onium Compounds (1974) D03.438.473.050 NLM JRT PLS M0000640 Alcian Blue C0001933 Alcian Blue 12040-44-7 A copper-containing dye used as a gelling agent for lubricants, for staining of bacteria and for the dyeing of histiocytes and fibroblasts in vivo. T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid D004396 Dyes T001272 Alcian Blue 1999 01 01 NLM (1975) T001272 Blue, Alcian T001273 Alcian Blue 8GS 1986 09 29 UNK (19XX) T001273 8GS, Alcian Blue T001273 Blue 8GS, Alcian T001274 Alcian Blue 8GX 1980 08 25 UNK (19XX) T001274 8GX, Alcian Blue T001274 Blue 8GX, Alcian D000425 Alcohol Amnestic Disorder 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI 81; was KORSAKOFF'S SYNDROME 1963-80 use ALCOHOL AMNESTIC DISORDER to search KORSAKOFF'S SYNDROME 1966-80 81; was KORSAKOFF'S SYNDROME 1963-80 C10.720.112.100 C21.613.705.150.100 C21.739.100.087.193.100 F03.087.200.125 F03.900.100.050 NLM KEV sjn M0000641 Alcohol Amnestic Disorder C0001940 A mental disorder associated with chronic ethanol abuse (ALCOHOLISM) and nutritional deficiencies characterized by short term memory loss, confabulations, and disturbances of attention. (Adams et al., Principles of Neurology, 6th ed, p1139) T048 Mental or Behavioral Dysfunction T001275 Alcohol Amnestic Disorder 1999 01 01 ALCOHOL AMNESTIC DIS NLM (1966) T001275 Alcohol Amnestic Disorders T001275 Amnestic Disorder, Alcohol T001275 Amnestic Disorders, Alcohol T369099 Amnestic Psychosis, Alcohol-Induced 1999 11 03 AMNESTIC PSYCHOSIS ALCOHOL IND NLM (2000) T369099 Alcohol-Induced Amnestic Psychoses T369099 Amnestic Psychoses, Alcohol-Induced T369099 Amnestic Psychosis, Alcohol Induced T369099 Psychoses, Alcohol-Induced Amnestic T369099 Psychosis, Alcohol-Induced Amnestic T369100 Alcohol Amnestic Syndrome 1999 11 03 NLM (2000) T369100 Alcohol Amnestic Syndromes T369100 Amnestic Syndrome, Alcohol T369100 Amnestic Syndromes, Alcohol T369100 Syndrome, Alcohol Amnestic T369100 Syndromes, Alcohol Amnestic T369101 Alcohol-Induced Amnestic Psychosis 1999 11 03 ALCOHOL IND AMNESTIC PSYCHOSIS NLM (2000) T369101 Alcohol Induced Amnestic Psychosis T369097 Alcohol-Induced Amnestic Syndrome 1999 11 03 ALCOHOL IND AMNESTIC SYNDROME NLM (2000) T369097 Alcohol Induced Amnestic Syndrome T369097 Alcohol-Induced Amnestic Syndromes T369097 Amnestic Syndrome, Alcohol-Induced T369097 Amnestic Syndromes, Alcohol-Induced T369097 Syndrome, Alcohol-Induced Amnestic T369097 Syndromes, Alcohol-Induced Amnestic T369102 Alcohol-Induced Dysmnesic Psychosis 1999 11 03 ALCOHOL IND DYSMNESIC PSYCHOSIS NLM (2000) T369102 Alcohol Induced Dysmnesic Psychosis T369102 Alcohol-Induced Dysmnesic Psychoses T369102 Dysmnesic Psychoses, Alcohol-Induced T369102 Dysmnesic Psychosis, Alcohol-Induced T369102 Psychoses, Alcohol-Induced Dysmnesic T369102 Psychosis, Alcohol-Induced Dysmnesic T369103 Alcohol-Induced Dysmnesic Syndrome 1999 11 03 ALCOHOL IND DYSMNESIC SYNDROME NLM (2000) T369103 Alcohol Induced Dysmnesic Syndrome T369103 Alcohol-Induced Dysmnesic Syndromes T369103 Dysmnesic Syndrome, Alcohol-Induced T369103 Dysmnesic Syndromes, Alcohol-Induced T369103 Syndrome, Alcohol-Induced Dysmnesic T369103 Syndromes, Alcohol-Induced Dysmnesic T369104 Alcohol-Induced Korsakoff Syndrome 1999 11 03 ALCOHOL IND KORSAKOFF SYNDROME NLM (2000) T369104 Alcohol Induced Korsakoff Syndrome T369104 Alcohol-Induced Korsakoff Syndromes T369104 Korsakoff Syndrome, Alcohol-Induced T369104 Korsakoff Syndromes, Alcohol-Induced T369104 Syndrome, Alcohol-Induced Korsakoff T369104 Syndromes, Alcohol-Induced Korsakoff T369105 Alcohol-Induced Persisting Amnestic Disorder 1999 11 03 ALCOHOL IND PERSISTING AMNESTIC DIS NLM (2000) T369105 Alcohol Induced Persisting Amnestic Disorder T369098 Alcoholic Korsakoff Syndrome 1999 11 03 NLM (2000) T369098 Alcoholic Korsakoff Syndromes T369098 Korsakoff Syndrome, Alcoholic T369098 Korsakoff Syndromes, Alcoholic T369098 Syndrome, Alcoholic Korsakoff T369098 Syndromes, Alcoholic Korsakoff D000426 Alcohol Dehydrogenase 1986 04 09 2003 07 09 1987 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT a specific enzyme; do not confuse with ALCOHOL OXIDORECUCTASES 87 87 Alcohol Oxidoreductases (1966-1986) D08.811.682.047.070 RLS ssb sjn M0000643 Alcohol Dehydrogenase C0001942 Alcohol:NAD+ oxidoreductase EC 1.1.1.1 A zinc-containing enzyme which oxidizes primary and secondary alcohols or hemiacetals in the presence of NAD. In alcoholic fermentation, it catalyzes the final step of reducing an aldehyde to an alcohol in the presence of NADH and hydrogen. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000643 M0000645 M0000643 M0000644 M0000643 M0000646 T001278 Alcohol Dehydrogenase 1999 01 01 NLM (1987) T001278 Dehydrogenase, Alcohol T001282 Alcohol Dehydrogenase (NAD+) 1986 04 09 UNK (19XX) T001283 Alcohol-NAD+ Oxidoreductase 1986 04 09 UNK (19XX) T001283 Alcohol NAD+ Oxidoreductase T001283 Oxidoreductase, Alcohol-NAD+ M0000645 Alcohol Dehydrogenase II C0001945 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000643 M0000645 T001280 Alcohol Dehydrogenase II 1986 04 09 UNK (19XX) M0000644 Alcohol Dehydrogenase I C0001944 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000643 M0000644 T001279 Alcohol Dehydrogenase I 1986 04 09 UNK (19XX) M0000646 Yeast Alcohol Dehydrogenase C0043391 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000643 M0000646 T001281 Yeast Alcohol Dehydrogenase 1986 04 09 UNK (19XX) T001281 Alcohol Dehydrogenase, Yeast T001281 Dehydrogenase, Yeast Alcohol D000427 Alcohol Deterrents 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG consider also ALCOHOLISM /drug ther D15.020 D27.505.954.427.020 NLM ssb sjn M0000649 Alcohol Deterrents C0001947 0 Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism. T121 Pharmacologic Substance T001284 Alcohol Deterrents 1999 01 01 NLM (1966) T001284 Deterrents, Alcohol D000428 Alcohol Drinking 1999 01 01 2002 07 02 1969 01 01 2003 2004 Q000009 adverse effects AE Q000097 blood BL Q000134 cerebrospinal fluid CF Q000188 drug therapy DT Q000191 economics EC Q000453 epidemiology EP Q000208 ethnology EH Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000331 legislation & jurisprudence LJ Q000378 metabolism ME Q000401 mortality MO Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000628 therapy TH Q000639 trends TD Q000652 urine UR drunkenness = ALCOHOLIC INTOXICATION but binge drinking & acute alcohol intox = ETHANOL /pois; chronic alcohol consumption = ALCOHOLISM; TEMPERANCE is available for "abstinence from alcohol" but do not confuse with alcohol withdrawal (see note under ALCOHOL WITHDRAWAL DELIRIUM & SUBSTANCE WITHDRAWAL SYNDROME) 69 69 Alcoholic Beverages (1966-1968) D000437 Alcoholism D013695 Temperance F01.145.317.269 NLM PXP sjn M0000650 Alcohol Drinking C0001948 Behaviors associated with the ingesting of alcoholic beverages, including social drinking. T055 Individual Behavior T001287 Alcohol Drinking 1999 01 01 POPLINE (1981) T001285 Alcohol Consumption 1990 10 02 NLM (1992) T001285 Consumption, Alcohol T001286 Drinking, Alcohol 1974 03 29 UNK (19XX) D000429 Alcohol Oxidoreductases 1999 01 01 2003 07 09 1964 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 64 64 D08.811.682.047 NLM ssb sjn M0000651 Alcohol Oxidoreductases C0001954 EC 1.1 A subclass of enzymes which includes all dehydrogenases acting on primary and secondary alcohols as well as hemiacetals. They are further classified according to the acceptor which can be NAD+ or NADP+ (subclass 1.1.1), cytochrome (1.1.2), oxygen (1.1.3), quinone (1.1.5), or another acceptor (1.1.99). T116 Amino Acid, Peptide, or Protein T126 Enzyme T001288 Alcohol Oxidoreductases 1999 01 01 NLM (1964) T001288 Oxidoreductases, Alcohol T001290 Ketone Reductases 1981 01 30 UNK (19XX) T001290 Reductases, Ketone T001289 Carbonyl Reductases 1981 01 30 UNK (19XX) T001289 Reductases, Carbonyl D000430 Alcohol Withdrawal Delirium 1999 01 01 2003 07 09 1991 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI note X ref; do not confuse with "alcohol withdrawal syndrome" ( = SUBSTANCE WITHDRAWAL SYNDROME (IM) + ETHANOL /adv eff (IM)); ALCOHOL WITHDRAWAL SEIZURES is available 91(81); was see under PSYCHOSES, ALCOHOLIC 1981-90; was DELIRIUM TREMENS see under PSYCHOSES, ALCOHOLIC 1963-80 use ALCOHOL WITHDRAWAL DELIRIUM to search DELIRIUM TREMENS 1975-80 & use PSYCHOSES, ALCOHOLIC 1966-74 91; was see under PSYCHOSES, ALCOHOLIC 1981-90; was DELIRIUM TREMENS see under PSYCHOSES, ALCOHOLIC 1963-80 C10.720.112.200 C21.613.705.150.200 C21.739.100.087.193.200 C21.739.835.250 F03.900.100.100 F03.900.825.500 NLM lkt sjn M0000652 Alcohol Withdrawal Delirium C0001957 An acute organic mental disorder induced by cessation or reduction in chronic alcohol consumption. Clinical characteristics include CONFUSION; DELUSIONS; vivid HALLUCINATIONS; TREMOR; agitation; insomnia; and signs of autonomic hyperactivity (e.g., elevated blood pressure and heart rate, dilated pupils, and diaphoresis). This condition may occasionally be fatal. It was formerly called delirium tremens. (From Adams et al., Principles of Neurology, 6th ed, p1175) T047 Disease or Syndrome M0000652 M0335565 M0000652 M0335566 T001291 Alcohol Withdrawal Delirium 1999 01 01 NLM (1975) T001291 Delirium, Alcohol Withdrawal T369114 Alcohol Withdrawal-Induced Delirium Tremens 1999 11 03 ALCOHOL WITHDRAWAL IND DELIRIUM TREMENS NLM (2000) T369114 Alcohol Withdrawal Induced Delirium Tremens T001292 Delirium Tremens 1980 05 21 UNK (19XX) T369115 Delirium Tremens, Alcohol Withdrawal Induced 1999 11 03 DELIRIUM TREMENS ALCOHOL WITHDRAWAL IND NLM (2000) M0335565 Alcohol Withdrawal Hallucinosis C0302369 T047 Disease or Syndrome M0000652 M0335565 T369116 Alcohol Withdrawal Hallucinosis 1999 11 03 NLM (2000) T369116 Hallucinosis, Alcohol Withdrawal M0335566 Autonomic Hyperactivity, Alcohol Withdrawal Associated C0750897 T047 Disease or Syndrome M0000652 M0335566 T369117 Autonomic Hyperactivity, Alcohol Withdrawal Associated 1999 11 03 AUTONOMIC HYPERACTIVITY ALCOHOL WITHDRAWAL ASSOC NLM (2000) T369118 Alcohol Withdrawal Associated Autonomic Hyperactivity 1999 11 03 ALCOHOL WITHDRAWAL ASSOC AUTONOMIC HYPERACTIVITY NLM (2000) D000431 Ethanol 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG for "alcohol" unspecified; /antag: consider also ALCOHOL DETERRENTS; ethanol production by organisms = /metab; /pois: for acute alcohol pois, acute alcoholic intox, binge drinking, but ALCOHOLIC INTOXICATION is available for drunkenness & ALCOHOLISM for chronic alcohol intox; consider also ALCOHOLIC BEVERAGES; hypophysectomy by alcohol injection = HYPOPHYSECTOMY, CHEMICAL & do not index under ETHANOL unless particularly discussed; "abstinence from alcohol" = TEMPERANCE 98(63) 98; see ALCOHOL, ETHYL 1963-97 D000434 Alcoholic Beverages D02.033.375 NLM ADP SJN M0000653 Ethanol C0001962 Ethanol 64-17-5 A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. T109 Organic Chemical T121 Pharmacologic Substance D000891 Anti-Infective Agents, Local D002492 Central Nervous System Depressants D012997 Solvents M0000653 M0000654 T001294 Ethanol 1999 01 01 NLM (1966) T001293 Alcohol, Ethyl 1997 01 15 NLM (1998) T001293 Ethyl Alcohol T001295 Grain Alcohol 1997 01 15 NLM (1998) T001295 Alcohol, Grain M0000654 Absolute Alcohol C0085733 0 T109 Organic Chemical M0000653 M0000654 T001296 Absolute Alcohol 1984 09 20 UNK (19XX) T001296 Alcohol, Absolute D000432 Methanol 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG for wood alcohol 98; 98; see ALCOHOL, METHYL 1966-97 D02.033.623 NLM ADP SJN M0000655 Methanol C0001963 Methanol 67-56-1 A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness. T109 Organic Chemical T131 Hazardous or Poisonous Substance D012997 Solvents M0000655 M0000656 T001299 Methanol 1999 01 01 NLM (1966) T001297 Alcohol, Methyl 1997 01 15 NLM (1998) T001297 Methyl Alcohol T001300 Wood Alcohol 1997 01 15 NLM (1998) T001300 Alcohol, Wood T001298 Carbinol 1983 10 20 UNK (19XX) M0000656 Sodium Methoxide C0524477 0 T109 Organic Chemical T130 Indicator, Reagent, or Diagnostic Aid M0000655 M0000656 T001301 Sodium Methoxide 1997 01 15 NLM (1998) T001301 Methoxide, Sodium D000433 1-Propanol 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 98(63) 98; see ALCOHOL, PROPYL 1963-97 D000433 1-Propanol Q000031 analogs & derivatives D020005 Propanols D02.033.755.600 NLM ADP SJN M0000657 1-Propanol C0001964 1-Propanol 71-23-8 A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate. T109 Organic Chemical T001302 1-Propanol 1999 01 01 PROPANOL 01 NLM (1966) T001302 1 Propanol T001303 Alcohol, Propyl 1997 02 21 NLM (1998) T001303 Propyl Alcohol T001304 n-Propanol 1997 04 29 PROPANOL N NLM (1998) T001304 n Propanol T001305 Propanol 1997 04 29 NLM (1998) D000434 Alcoholic Beverages 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000009 adverse effects AE Q000032 analysis AN Q000145 classification CL Q000191 economics EC Q000266 history HI Q000382 microbiology MI Q000469 parasitology PS Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000633 toxicity TO Q000656 utilization UT Q000706 statistics & numerical data SN Q000821 virology VI GEN; BEER & WINE are available; chronic consumption of alcoholic bev = ALCOHOLISM J02.200.100 NLM adp sjn M0000658 Alcoholic Beverages C0001967 Drinkable liquids containing ETHANOL. T168 Food T001306 Alcoholic Beverages 1999 01 01 NLM (1966) T001306 Alcoholic Beverage T001306 Beverage, Alcoholic T001306 Beverages, Alcoholic D000435 Alcoholic Intoxication 1999 01 01 1999 11 08 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI human & animal C21.739.100.175 F03.900.100.300 NLM adp sjn M0000659 Alcoholic Intoxication C0001969 An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES. T037 Injury or Poisoning T048 Mental or Behavioral Dysfunction T001308 Alcoholic Intoxication 1999 01 01 ALCOHOLIC INTOX NLM (1966) T358964 Drunkenness 1999 11 08 NLM (2000) T358964 Drunkennesses T001307 Intoxication, Alcoholic 1981 05 14 INTOX ALCOHOLIC UNK (19XX) D000436 Alcoholics Anonymous 1999 01 01 1992 03 25 1974 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000191 economics EC Q000266 history HI Q000458 organization & administration OG IM CATALOG: use NAF Entry 74 74 N03.540.782.270 NLM TAP PLS M0000660 Alcoholics Anonymous C0001972 An organization of self-proclaimed alcoholics who meet frequently to reinforce their practice of abstinence. T095 Self-help or Relief Organization T001309 Alcoholics Anonymous 1999 01 01 NLM (1974) T001309 Anonymous, Alcoholics D000437 Alcoholism 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI human & animal; do not coord with CHRONIC DISEASE: alcoholism is presumed to be chronic; differentiate from ALCOHOLIC INTOXICATION, being drunk, not chronic; acute alcoholic intox & binge drinking is ETHANOL /pois; /drug ther: consider also ALCOHOL DETERRENTS; consider also LIVER DISEASES, ALCOHOLIC & its specifics FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC & LIVER CIRRHOSIS, ALCOHOLIC; also PANCREATITIS, ALCOHOLIC; also CARDIOMYOPATHY, ALCOHOLIC; PSYCHOSES, ALCOHOLIC & FETAL ALCOHOL SYNDROME; index other compl of alcoholism under ALCOHOLISM /compl (IM) + disease /etiol not /chem ind (IM); abstinence from alcohol in alcoholism: coord with TEMPERANCE (NIM); available is SKID ROW ALCOHOLICS see HOMELESS PERSONS but see note there D000437 Alcoholism Q000151 congenital D005310 Fetal Alcohol Syndrome D000427 Alcohol Deterrents D000436 Alcoholics Anonymous D005310 Fetal Alcohol Syndrome D011604 Psychoses, Alcoholic D013695 Temperance C21.739.100.250 F03.900.100.350 NLM mdb sjn M0000661 Alcoholism C0001973 A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) T048 Mental or Behavioral Dysfunction M0000661 M0000662 T001310 Alcoholism 1999 01 01 NLM (1966) T001311 Alcoholic Intoxication, Chronic 1996 07 10 ALCOHOLIC INTOX CHRONIC NLM (1998) T001311 Chronic Alcoholic Intoxication T001311 Intoxication, Chronic Alcoholic M0000662 Alcohol Abuse C0085762 T048 Mental or Behavioral Dysfunction M0000661 M0000662 T001312 Alcohol Abuse 1977 03 17 BIOETHICS (1976) T001312 Abuse, Alcohol D000438 Alcohols 1999 01 01 1997 06 20 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG do not use for "alcohol" ( = ETHANOL); diols = GLYCOLS; hypophysectomy by alcohol (ethanol) injection = HYPOPHYSECTOMY, CHEMICAL & do not index under ETHANOL unless particularly discussed D02.033 NLM ADP SJN M0000663 Alcohols C0001975 0 Alkyl compounds containing a hydroxyl group. They are classified according to relation of the carbon atom: primary alcohols, R-CH2OH; secondary alcohols, R2-CHOH; tertiary alcohols, R3-COH. (From Grant & Hackh's Chemical Dictionary, 5th ed) T109 Organic Chemical T001313 Alcohols 1999 01 01 POPLINE (1984) D000439 Pentanols 1999 01 01 2003 07 09 1974 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 98(72) 98; see ALCOHOLS, AMYL 1974-97 Alcohols (1966-1971) D02.033.415.640 D10.289.640 NLM ssb sjn M0000664 Pentanols C0001976 0 Isomeric forms and derivatives of pentanol (C5H11OH). T119 Lipid T001317 Pentanols 1999 01 01 NLM (1972) T001314 Alcohols, Amyl 1997 04 28 NLM (1998) T001314 Amyl Alcohols T001315 Hydroxypentanes 1980 08 21 UNK (19XX) T001318 Pentyl Alcohols 1997 04 28 NLM (1998) T001318 Alcohols, Pentyl T001316 Methylbutanols 1980 08 21 UNK (19XX) D000440 Butanols 1999 01 01 2003 07 09 1974 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 1-BUTANOL and TERT-BUTYL ALCOHOL also available 98(72) 98; see ALCOHOLS, BUTYL 1972-97 Alcohols (1966-1971) D02.033.415.110 D10.289.110 NLM ssb sjn M0000665 Butanols C0001977 0 Isomeric forms and derivatives of butanol (C4H9OH). T119 Lipid T001322 Butanols 1999 01 01 NLM (1972) T001319 Alcohols, Butyl 1997 04 24 NLM (1998) T001319 Butyl Alcohols T001320 Butylhydroxides 1980 08 21 UNK (19XX) T001321 Hydroxybutanes 1980 08 21 UNK (19XX) D000441 Hexanols 1999 01 01 2003 07 09 1974 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 98(72) 98; see ALCOHOLS, HEXYL 1974-97 D02.033.415.510 D02.033.480 D10.289.510 NLM ssb sjn M0000666 Hexanols C0001978 0 Isomeric forms and derivatives of hexanol (C6H11OH). T119 Lipid M0000666 M0000667 T001324 Hexanols 1999 01 01 NLM (1972) T001323 Alcohols, Hexyl 1997 04 25 NLM (1998) T001323 Hexyl Alcohols T001325 Hydroxyhexanes 1980 08 21 UNK (19XX) M0000667 Amylcarbinols C0002713 0 T119 Lipid M0000666 M0000667 T001326 Amylcarbinols 1980 08 21 UNK (19XX) D000442 Octanols 1999 01 01 2003 07 09 1974 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 1-OCTANOL is also available 98(72) 98; see ALCOHOLS, OCTYL 1974-97 D02.033.415.600 D10.289.600 NLM ssb sjn M0000668 Octanols C0001979 0 Isomeric forms and derivatives of octanol (C8H17OH). T119 Lipid T001330 Octanols 1999 01 01 NLM (1972) T001327 Alcohols, Octyl 1997 06 10 NLM (1998) T001327 Octyl Alcohols T001328 Heptylcarbinols 1980 08 21 UNK (19XX) T001331 Octylic Alcohols 1980 08 21 UNK (19XX) T001331 Alcohols, Octylic T001329 Hydroxyoctanes 1980 08 21 UNK (19XX) D000443 Alcuronium 1974 11 19 2001 07 25 1991 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under TOXIFERINE 1975-90; ALLOFERIN was see ALCURONIUM 1978-93 use ALCURONIUM to search ALLOFERIN 1978-93 91; was see under TOXIFERINE 1975-90; ALLOFERIN was see ALCURONIUM 1978-93 Allyl Compounds (1972-1974) Toxiferine (1972-1974) D02.092.102.844.050 D02.675.276.844.050 D03.132.436.500.712.050 D03.438.473.402.500.712.050 NLM ssb sjn M0000669 Alcuronium C0001981 Toxiferine I, 4,4'-didemethyl-4,4'-di-2-propenyl- 23214-96-2 A non-depolarizing skeletal muscle relaxant similar to TUBOCURARINE. It is used as an anesthesia adjuvant. T109 Organic Chemical T121 Pharmacologic Substance D000759 Adjuvants, Anesthesia D003473 Neuromuscular Nondepolarizing Agents D018733 Nicotinic Antagonists 15180-03-7 (dichloride) M0000669 M0330741 M0000669 M0351185 M0000669 M0000670 T001332 Alcuronium 1999 01 01 NLM (1975) T001333 Allnortoxiferine 1974 11 11 UNK (19XX) T001335 Diallylnortoxiferine 1974 11 11 UNK (19XX) M0330741 Alcuronium Chloride C0205658 15180-03-7 T109 Organic Chemical T121 Pharmacologic Substance M0000669 M0330741 T001338 Alcuronium Chloride 1993 03 01 BAN (19XX) INN (19XX) USAN (1967) T001337 N,N'-Diallylnortoxiferinium Dichloride 1980 09 17 UNK (19XX) T001337 Dichloride, N,N'-Diallylnortoxiferinium T360935 Alcuronium Dichloride 1999 09 13 NLM (1999) T360935 Dichloride, Alcuronium M0351185 Alloferin C0877917 0 T109 Organic Chemical T121 Pharmacologic Substance M0000669 M0351185 T001334 Alloferin 1993 03 01 NLM (1994) M0000670 Dialferine C0205656 0 T109 Organic Chemical T121 Pharmacologic Substance M0000669 M0000670 T001336 Dialferine 1980 09 17 UNK (19XX) D000444 Aldehyde Dehydrogenase 1984 04 11 2003 07 09 1985 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 85 85 Alcohol Oxidoreductases (1974-1979) Aldehyde Oxidoreductases (1980-1984) D08.811.682.075.100 RLS ssb sjn M0000673 Aldehyde Dehydrogenase C0001985 Aldehyde:NAD+ oxidoreductase EC 1.2.1.3 An enzyme that oxidizes an aldehyde in the presence of NAD+ and water to an acid and NADH. EC 1.2.1.3. Before 1978, it was classified as EC 1.1.1.70. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000673 M0000674 M0000673 M0000675 M0000673 M0000676 T001339 Aldehyde Dehydrogenase 1999 01 01 NLM (1985) T001339 Dehydrogenase, Aldehyde T001340 Aldehyde-NAD Oxidoreductase 1984 04 11 UNK (19XX) T001340 Aldehyde NAD Oxidoreductase T001340 Oxidoreductase, Aldehyde-NAD M0000674 Aldehyde Dehydrogenase E1 C0001986 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000673 M0000674 T001341 Aldehyde Dehydrogenase E1 1984 04 11 UNK (19XX) T001341 Dehydrogenase E1, Aldehyde T001341 E1, Aldehyde Dehydrogenase M0000675 Aldehyde Dehydrogenase E2 C0001987 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000673 M0000675 T001342 Aldehyde Dehydrogenase E2 1984 04 11 UNK (19XX) T001342 Dehydrogenase E2, Aldehyde T001342 E2, Aldehyde Dehydrogenase M0000676 D-Glucuronolactone Dehydrogenase C0010905 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000673 M0000676 T001343 D-Glucuronolactone Dehydrogenase 1984 04 11 GLUCURONOLACTONE DEHYDROGENASE D UNK (19XX) T001343 D Glucuronolactone Dehydrogenase T001343 Dehydrogenase, D-Glucuronolactone D000445 Aldehyde Oxidoreductases 1999 01 01 2003 07 09 1973 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 73 73 Oxidoreductases (1966-1972) D08.811.682.075 NLM ssb sjn M0000677 Aldehyde Oxidoreductases C0001988 EC 1.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme T001344 Aldehyde Oxidoreductases 1999 01 01 NLM (1973) T001344 Oxidoreductases, Aldehyde D000446 Aldehyde-Lyases 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT D08.811.520.224.062 NLM ssb sjn M0000678 Aldehyde-Lyases C0001990 EC 4.1.2. Enzymes that catalyze a reverse aldol condensation. A molecule containing a hydroxyl group and a carbonyl group is cleaved at a C-C bond to produce two smaller molecules (ALDEHYDES or KETONES). EC 4.1.2. T116 Amino Acid, Peptide, or Protein T126 Enzyme T001345 Aldehyde-Lyases 1999 01 01 NLM (1966) T001345 Aldehyde Lyases T414387 Aldolases 2000 05 16 NLM (2001) D000447 Aldehydes 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG D02.047 NLM adp sjn M0000679 Aldehydes C0001992 0 Organic compounds containing a carbonyl group in the form -CHO. T109 Organic Chemical T001346 Aldehydes 1999 01 01 NLM (1966) D000448 Aldicarb 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG TN 111 for eff on insects 91(72); was see under INSECTICIDES, CARBAMATE 1972-90 91; was see under INSECTICIDES, CARBAMATE 1972-90 Carbamates (1966-1971) Insecticides (1966-1971) D02.241.081.251.046 NLM CCR sjn M0000680 Aldicarb C0001994 Propanal, 2-methyl-2-(methylthio)-, O-((methylamino)carbonyl)oxime 116-06-3 Carbamate derivative used as an insecticide, acaricide, and nematocide. T109 Organic Chemical T131 Hazardous or Poisonous Substance D007308 Insecticides, Carbamate M0000680 M0351473 M0000680 M0351472 M0000680 M0351471 T001347 Aldicarb 1999 01 01 NLM (1972) M0351473 ENT-27,093 C0878237 0 T109 Organic Chemical T131 Hazardous or Poisonous Substance M0000680 M0351473 T001348 ENT-27,093 1980 07 30 UNK (19XX) T001348 ENT 27,093 T001348 ENT27,093 M0351472 Temik C0878236 0 T109 Organic Chemical T131 Hazardous or Poisonous Substance M0000680 M0351472 T001349 Temik 1980 07 30 UNK (19XX) M0351471 UC-21,149 C0878235 0 T109 Organic Chemical T131 Hazardous or Poisonous Substance M0000680 M0351471 T001351 UC-21,149 1980 07 30 UNK (19XX) T001351 UC 21,149 T001351 UC21,149 T001350 UC-21149 1990 03 19 NLM (1991) T001350 UC 21149 T001350 UC21149 D000449 Aldehyde Reductase 1975 07 23 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 92; was ALDOSE REDUCTASE 1976-91 (see under SUGAR ALCOHOL DEHYDROGENASES 1978-90, see under ALCOHOL OXIDOREDUCTASES 1976-77) use ALDEHYDE REDUCTASE to search ALDOSE REDUCTASE 1976-91 92; was ALDOSE REDUCTASE 1976-91 (see under SUGAR ALCOHOL DEHYDROGENASES 1978-90, see under ALCOHOL OXIDOREDUCTASES 1976-77) Alcohol Oxidoreductases (1972-1975) Sugar Alcohols (1972-1975) D08.811.682.047.150.700.075 RLS ssb sjn M0000681 Aldehyde Reductase C0002003 Alditol:NAD(P)+ 1-oxidoreductase EC 1.1.1.21 An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000681 M0000682 M0000681 M0000683 M0000681 M0000684 M0000681 M0000685 T001352 Aldehyde Reductase 1999 01 01 NLM (1976) T001352 Reductase, Aldehyde T001353 Aldose Reductase 1991 01 14 NLM (1992) T001353 Reductase, Aldose M0000682 Aldose Reductase Ia C0002004 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000681 M0000682 T001354 Aldose Reductase Ia 1985 01 03 UNK (19XX) T001354 Reductase Ia, Aldose M0000683 Aldose Reductase Ib C0002005 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000681 M0000683 T001355 Aldose Reductase Ib 1985 01 03 UNK (19XX) T001355 Reductase Ib, Aldose M0000684 Erythrose Reductase C0086253 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000681 M0000684 T001356 Erythrose Reductase 1990 09 28 NLM (1992) T001356 Reductase, Erythrose M0000685 Xylose Reductase C0087175 0 T116 Amino Acid, Peptide, or Protein T126 Enzyme M0000681 M0000685 T001357 Xylose Reductase 1991 01 14 NLM (1992) T001357 Reductase, Xylose D000450 Aldosterone 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted; /defic: consider also HYPOALDOSTERONISM; PSEUDOHYPOALDOSTERONISM is also available; consider also RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM see RENIN-ANGIOTENSIN SYSTEM & do not index under ALDOSTERONE unless particularly discussed D000450 Aldosterone Q000037 antagonists & inhibitors D000451 Aldosterone Antagonists D006929 Hyperaldosteronism D006994 Hypoaldosteronism D011546 Pseudohypoaldosteronism D012084 Renin-Angiotensin System D017458 Receptors, Aldosterone D04.808.745.745.654.062 D06.472.040.585.353.118 NLM ssb sjn M0000686 Aldosterone C0002006 Pregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11beta)- 52-39-1 A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium. T110 Steroid T121 Pharmacologic Substance T125 Hormone 125-77-9 ((+-)-isomer) 13479-36-2 ((11 beta,17 alpha)-isomer) M0000686 M0330742 M0000686 M0330743 T001358 Aldosterone 1999 01 01 NLM (1966) M0330742 Aldosterone, (+-)-Isomer C0887541 125-77-9 T110 Steroid T121 Pharmacologic Substance T125 Hormone M0000686 M0330742 T360936 Aldosterone, (+-)-Isomer 1999 09 13 NLM (1999) M0330743 Aldosterone, (11 beta,17 alpha)-Isomer C0887542 13479-36-2 T110 Steroid T121 Pharmacologic Substance T125 Hormone M0000686 M0330743 T360937 Aldosterone, (11 beta,17 alpha)-Isomer 1999 09 13 NLM (1999) D000451 Aldosterone Antagonists 1977 05 17 2003 07 09 1978 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG DF: ALDOSTERONE ANTAG 78,63-67 search ALDOSTERONE /AI 1968-77 & ALDOSTERONE 1966-67 78,63-67 Aldosterone (1966-1977) D06.347.050 D27.505.696.399.450.050 RLS ssb sjn M0000687 Aldosterone Antagonists C0002007 0 Compounds which inhibit or antagonize the biosynthesis or actions of aldosterone. T121 Pharmacologic Substance T001359 Aldosterone Antagonists 1999 01 01 ALDOSTERONE ANTAG NLM (1978) T001359 Antagonists, Aldosterone D000452 Aldrin 1999 01 01 1995 06 08 1973 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG TN 111 for eff on insects 73(71) 73 Hydrocarbons, Halogenated (1966-1970) Insecticides (1966-1970) D02.455.526.439.042 NLM JRT PLS M0000688 Aldrin C0002011 1,4:5,8-Dimethanonaphthalene, 1,2,3,4,10,10-hexachloro-1,4,4a,5,8,8a-hexahydro-, (1alpha,4alpha,4abeta,5alpha,8alpha,8abeta)- 309-00-2 A highly poisonous substance that was formerly used as an insecticide. The manufacture and use has been discontinued in the U.S. (From Merck Index, 11th ed) T109 Organic Chemical T131 Hazardous or Poisonous Substance D007309 Insecticides, Organochlorine M0000688 M0000689 T001360 Aldrin 1999 01 01 NLM (1971) M0000689 Isodrin C0022168 0 T109 Organic Chemical T131 Hazardous or Poisonous Substance M0000688 M0000689 T001361 Isodrin 1984 10 02 UNK (19XX) D000453 Aleutian Mink Disease 1999 01 01 2003 07 30 1971 01 01 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000601 surgery SU Q000628 therapy TH Q000635 transmission TM Q000652 urine UR Q000736 ultrasonography US Q000821 virology VI caused by a parvovirus; don't forget also MINK (NIM) & check tag ANIMALS 71 71 Carnivora (1966-1967) Mink (1968-1970) Virus Diseases (1966-1970) D002609 Chediak-Higashi Syndrome C02.256.700.091 C02.839.091 C20.673.774.257.270 C22.062 NLM ags sjn M0000690 Aleutian Mink Disease C0002016 A slow progressive disease of mink caused by the ALEUTIAN MINK DISEASE VIRUS. It is characterized by poor reproduction, weight loss, autoimmunity, hypergammaglobulinemia, increased susceptibility to bacterial infections, and death from renal failure. The disease occurs in all color types, but mink which are homozygous recessive for the Aleutian gene for light coat color are particularly susceptible. T047 Disease or Syndrome T001363 Aleutian Mink Disease 1999 01 01 ALEUTIAN MINK DIS NLM (1971) T001363 Disease, Aleutian Mink T001363 Mink Disease, Aleutian T001362 Aleutian Disease of Mink 1990 04 13 ALEUTIAN DIS MINK NLM (1991) D000454 Aleutian Mink Disease Virus 1974 11 19 1996 06 10 1991 01 01 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH a species of Parvovirus; infection = ALEUTIAN MINK DISEASE: see note there; DF: ALEUTIAN MINK DIS PARVOVIRUS 97,75-93; was ALEUTIAN MINK DISEASE PARVOVIRUS 1994-96; was see under PARVOVIRIDAE 1986-90, see under VERTEBRATE VIRUSES, UNCLASSIFIED 1975-85 97,75-93; was ALEUTIAN MINK DISEASE PARVOVIRUS 1994-96; was see under PARVOVIRIDAE 1986-90, see under VERTEBRATE VIRUSES, UNCLASSIFIED 1975-85 B04.280.580.650.600.100 B04.909.204.671.650.600.100 NLM AGS PLS M0000691 Aleutian Mink Disease Virus C0002017 A species of PARVOVIRUS that causes a disease in mink, mainly those homozygous for the recessive Aleutian gene which determines a desirable coat color. T005 Virus T001365 Aleutian Mink Disease Virus 1999 01 01 ALEUTIAN MINK DIS VIRUS NLM (1975) T001364 Aleutian Disease Virus 1990 04 13 ALEUTIAN DIS VIRUS NLM (1991) T001366 Aleutian Mink Disease Parvovirus 1995 09 27 NLM (1997) D000455 Medicago sativa 1999 01 01 2002 07 31 2003 2004 Q000009 adverse effects AE Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000633 toxicity TO Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000191 economics EC Q000266 history HI Q000592 standards ST Q000600 supply & distribution SD coord with specific PLANT COMPONENTS term if pertinent; for use in therapy coord IM with PHYTOTHERAPY (IM) + disease/drug ther (IM) + PLANT PREPARATIONS or its indentations/ther use (IM or NIM) + specific plant chemical /ther use (IM) if pertinent; Manual 26.29 2002(1963) 2002; see ALFALFA 1963-2001 Alfalfa (1963-2001) B06.388.100.401.590.500 J02.500.300.100.555 NLM ssb sjn M0000693 Medicago sativa C0002022 A plant species of the family FABACEAE widely cultivated for animal feed. T002 Plant T444630 Medicago sativa 2001 04 26 NLM (2002) T001367 Alfalfa 1999 01 01 NLM (1966) T001368 Lucerne 1974 03 29 UNK (19XX) D000456 Algae 1999 01 01 2003 07 09 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000382 microbiology MI Q000469 parasitology PS GEN or unspecified; prefer specifics B2 - ORGANISMS-ALGAE B02 NLM ags sjn M0000694 Algae C0002028 A major group of polyphyletic organisms of extremely varied morphology and physiology, mostly photosynthetic, but distinguished from plants by their complex form of sexual reproduction. They are freshwater and marine, terrestrial and subterranean; some are neustonic (living at the interface of water and the atmosphere). They live in various protozoa and within other plants. They live also in soil and on soil surfaces, on long-persistent snows, and in Antarctic rocks. Thermophilic algae inhabit hot springs. (From Webster, 3d ed; from Bold & Wynne, Introduction to the Algae, 2d ed, pp1-6) T003 Alga T001370 Algae 1999 01 01 NLM (1966) T535512 Alga 2003 03 13 NLM (2004) D000458 Cyanobacteria 1999 01 01 2003 07 09 1970 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI from Greek cyano-, blue; common genera: ANABAENA, Tolypothrix, Plectonema; do not confuse X ref CYANOPHYCEAE with CYANOPHORA see ALGAE 92; was ALGAE, BLUE-GREEN 1970-91; CYANOBACTERIA was see ALGAE, BLUE-GREEN 1978-91; CYANOPHYTA was see ALGAE, BLUE-GREEN 1970-91 use CYANOBACTERIA to search ALGAE, BLUE-GREEN & CYANOPHYTA 1970-91 92; was ALGAE, BLUE-GREEN 1970-91; CYANOBACTERIA was see ALGAE, BLUE-GREEN 1978-91; CYANOPHYTA was see ALGAE, BLUE-GREEN 1970-91 Algae (1966-1969) D010839 Phytoplankton B03.280 B03.440.475.100 NLM ags sjn M0000697 Cyanobacteria C0002030 A subgroup of the oxygenic photosynthetic bacteria comprised of unicellular to multicellular photosynthetic bacteria possessing CHLOROPHYLL a and carrying out oxygenic PHOTOSYNTHESIS. Cyanobacteria are the only known organisms capable of fixing both CARBON DIOXIDE (in the presence of light) and NITROGEN. Formerly called blue-green algae, cyanobacteria were traditionally treated as ALGAE. By the late 20th century, however, it was realized that the blue-green algae were unique and lacked the traditional NUCLEUS and CHLOROPLASTS of the green and other algae. The comparison of nucleotide base sequence data from 16S and 5S rRNA indicates that cyanobacteria represent a moderately deep phylogenetic unit within the GRAM-NEGATIVE BACTERIA. T007 Bacterium T001377 Cyanobacteria 1999 01 01 CYANOBACT NLM (1970) T001373 Algae, Blue Green 1991 04 15 NLM (1992) T001374 Blue Green Algae 1991 04 15 NLM (1992) T001378 Cyanophyceae 1974 03 29 UNK (19XX) T001380 Bacteria, Blue-Green 1991 04 10 BACT BLUE GREEN NLM (1992) T001382 Blue-Green Bacteria 1991 04 04 BLUE GREEN BACT NLM (1992) T001381 Blue Green Bacteria 1991 04 15 NLM (1992) T001379 Bacteria, Blue Green 1991 04 15 NLM (1992) T001375 Blue-Green Algae 1988 07 08 UNK (19XX) T001376 Algae, Blue-Green 1991 04 04 NLM (1992) D000459 Algae, Brown 1999 01 01 2003 07 09 1991 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000382 microbiology MI Q000469 parasitology PS GEN or unspecified; prefer specifics 91(71); was see under ALGAE 1971-90 91; was see under ALGAE 1971-90 Algae (1966-1970) B02.050 NLM ags sjn M0000698 Algae, Brown C0002031 Predominantly marine algae of the division Phaeophyta, having CHROMATOPHORES containing carotenoid pigments. ALGINATES and phlorotannins occur widely in all major orders. They are considered the most highly evolved algae because of their well-developed multicelluar organization and structural complexity. T003 Alga T001383 Algae, Brown 1999 01 01 NLM (1971) T534076 Brown Algae 2003 02 28 NLM (2004) T542320 Phaeophyceae 2003 06 03 NLM (2004) T531151 Phaeophyta 2003 01 28 NLM (2004) D000460 Algae, Green 1999 01 01 2003 07 09 1970 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000382 microbiology MI Q000469 parasitology PS GEN or unspecified; prefer specifics 70 70 Algae (1966-1969) D010839 Phytoplankton B02.080 NLM ags sjn M0000699 Algae, Green C0002032 Algae of the division Chlorophyta, in which the green pigment of CHLOROPHYLL is not masked by other pigments. Green algae have over 7000 species and live in a variety of primarily aquatic habitats. Only about ten percent are marine species, most live in freshwater. They are more closely related to the green vascular land PLANTS than any other group of algae. T003 Alga M0000699 M0000702 T001385 Algae, Green 1999 01 01 NLM (1970) T001386 Chlorophyta 1974 03 29 UNK (19XX) T001384 Green Algae 1990 09 11 NLM (1992) M0000702 Spirogyra C0524481 T003 Alga M0000699 M0000702 T001389 Spirogyra 1996 10 29 NLM (1998) D000461 Algae, Red 1999 01 01 2003 07 09 1974 01 01 2004 Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000472 pathogenicity PY Q000502 physiology PH Q000528 radiation effects RE Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI Q000382 microbiology MI Q000469 parasitology PS GEN or unspecified; prefer specifics 74(71) 74 Algae (1966-1970) B02.100 NLM ags sjn M0000704 Algae, Red C0002033 Algae of the division Rhodophyta, in which the red pigment (PHYCOERYTHRIN) predominates. However if this pigment is destroyed, the algae can appear purple, brown, green, or yellow. Two important substances found in the cell walls of red algae are AGAR and CARRAGEENAN. Red algae are thought to be closely related to the prokaryotic CYANOBACTERIA. T003 Alga T001391 Algae, Red 1999 01 01 NLM (1971) T001391 Red Algae T531244 Rhodophyta 2003 01 28 NLM (2004) D000462 Algeria 1999 01 01 1995 05 23 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000208 ethnology EH Q000453 epidemiology EP a country in northern Africa Z01.058.266.104 NLM KEV PLS M0000705 Algeria C0002037 A country in northern Africa between MOROCCO and LIBYA. Its capital is Algiers. It was known to the Romans as Numidia. From 430 A.D. until 1942 it was successively in the hands of the Vandals, the Eastern Roman Empire, the Arabs, the Ottoman Empire, and the French, and gained independence in 1962. The country took its name from its capital, from the Arabic al (the) + jaza'ir (islands), with reference to four islands lying off the coast at Algiers but joined to the mainland by 1525. (From Webster's New Geographical Dictionary, 1988, p31 & Room, Brewer's Dictionary of Names, 1992, p14) T083 Geographic Area T001392 Algeria 1999 01 01 POPLINE (1978) D000463 Algestone Acetophenide 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 74 74 D04.808.745.745.654.829.025.025 NLM lkt sjn M0000706 Algestone Acetophenide C0002039 Pregn-4-ene-3,20-dione, 16,17-((1-phenylethylidene)bis(oxy))-, (16alpha(R))- 24356-94-3 A progesterone that has been used in ESTRUS SYNCHRONIZATION and has been evaluated as an injectable contraceptive in combination with estradiol enanthate. It is also used therapeutically as a topical anti-inflammatory and is applied topically in the treatment of ACNE. T110 Steroid T121 Pharmacologic Substance D000893 Anti-Inflammatory Agents D003280 Contraceptives, Oral, Synthetic T001393 Algestone Acetophenide 1999 01 01 POPLINE (1984) USAN (1969) T001393 Acetophenide, Algestone T001394 Alphasone Acetophenide 1976 03 24 UNK (19XX) T001394 Acetophenide, Alphasone T001395 Dihydroxyprogesterone Acetophenide 1976 03 24 UNK (19XX) T001395 Acetophenide, Dihydroxyprogesterone D000464 Alginates 1999 01 01 2000 06 21 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT Q000648 ultrastructure UL D25-26 qualif D003760 Dental Impression Materials D09.203.698.068 NLM CCR sjn M0000707 Alginates C0002040 0 Salts of alginic acid that are extracted from marine kelp and used to make dental impressions and as absorbent material for surgical dressings. T118 Carbohydrate T121 Pharmacologic Substance T122 Biomedical or Dental Material T001396 Alginates 1999 01 01 NLM (1966) D000465 Algorithms 1986 06 18 2001 07 25 1987 01 01 2002 2003 2004 87 87 H01.548.035 H01.770.035 L01.700.568.110.050 EC nns sjn M0000708 Algorithms C0002045 A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. T170 Intellectual Product T001397 Algorithms 1999 01 01 NLM (1987) T001397 Algorithm D000466 Alkadienes 1999 01 01 1997 06 20 1974 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 74 74 D02.455.326.271.665.146 NLM TGC SJN M0000709 Alkadienes C0002053 0 Acyclic branched or unbranched hydrocarbons having two carbon-carbon double bonds. T109 Organic Chemical M0000709 M0000710 T001398 Alkadienes 1999 01 01 NLM (1974) T001399 Diolefins 1974 03 29 UNK (19XX) M0000710 Pentadienes C0524483 0 T109 Organic Chemical M0000709 M0000710 T001400 Pentadienes 1996 12 19 NLM (1998) D000468 Alkalies 1999 01 01 1993 06 04 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG singular form is "alkali"; /adv eff: consider also MILK-ALKALI SYNDROME see HYPERCALCEMIA D006934 Hypercalcemia D01.045 NLM TPW PLS M0000711 Alkalies C0002055 0 Usually a hydroxide of lithium, sodium, potassium, rubidium or cesium, but also the carbonates of these metals, ammonia, and the amines. (Grant & Hackh's Chemical Dictionary, 5th ed) T197 Inorganic Chemical T001403 Alkalies 1999 01 01 NLM (1966) T001401 Alkalis 1992 07 30 NLM (1994) T001402 Alkali 1992 07 30 NLM (1994) D000469 Alkaline Phosphatase 1999 01 01 2003 07 09 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT /defic: consider also HYPOPHOSPHATASIA /blood was BLOOD ALKALINE PHOSPHATASE 1963-67 use ALKALINE PHOSPHATASE to search BLOOD ALKALINE PHOSPHATASE 1966-67 /blood was BLOOD ALKALINE PHOSPHATASE 1963-67 D007014 Hypophosphatasia D08.811.277.352.650.035 NLM ssb sjn M0000712 Alkaline Phosphatase C0002059 Orthophosphoric-monoester phosphohydrolase (alkaline optimum) EC 3.1.3.1 An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1. T116 Amino Acid, Peptide, or Protein T126 Enzyme 9001-78-9 (CAS RN) T001404 Alkaline Phosphatase 1999 01 01 NLM (1966) D000470 Alkaloids 1999 01 01 1995 03 16 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN or unspecified; prefer specific groups or specific alkaloid; alkaloids from specific plants go here (IM) + name of plant or PLANTS, MEDICINAL, etc. D03.132 NLM PLS PLS M0000713 Alkaloids C0002062 0 Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed) T109 Organic Chemical T001405 Alkaloids 1999 01 01 POPLINE (1984) D000471 Alkalosis 1999 01 01 1999 11 03 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C18.452.076.354 NLM KEV sjn M0000714 Alkalosis C0002063 A pathological condition that removes acid or adds base to the body fluids. T047 Disease or Syndrome T001406 Alkalosis 1999 01 01 NLM (1966) T001406 Alkaloses D000472 Alkalosis, Respiratory 1999 01 01 1998 06 10 1974 01 01 1999 2000 2001 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI excess loss of CO2 from body 74(71) 74 Alkalosis (1966-1970) Hyperventilation (1966-1970) C08.618.501.271 C18.452.076.354.271 NLM SJN SJN M0000715 Alkalosis, Respiratory C0002064 A state due to excess loss of carbon dioxide from the body. (Dorland, 27th ed) T046 Pathologic Function T001408 Alkalosis, Respiratory 1999 01 01 NLM (1971) T001407 Respiratory Alkalosis 1974 03 29 UNK (19XX) T001407 Alkaloses, Respiratory T001407 Respiratory Alkaloses D000473 Alkanes 1999 01 01 1995 03 16 1966 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG cycloalkanes = CYCLOPARAFFINS 66 66 D02.455.326.146 NLM TGC PLS M0000716 Alkanes C0002065 0 The generic name for the group of aliphatic hydrocarbons Cn-H2n+2. They are denoted by the suffix -ane. (Grant & Hackh's Chemical Dictionary, 5th ed) T109 Organic Chemical T001409 Alkanes 1999 01 01 NLM (1966) D000474 Alkaptonuria 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI an inborn error of amino acid metab; do not use /congen & do not coord with INFANT, NEWBORN, DISEASES C16.320.565.066.187 C18.452.648.066.187 NLM nns sjn M0000717 Alkaptonuria C0002066 An inborn error of amino acid metabolism resulting from a defect in the enzyme homogentisate 1,2-dioxygenase and causing an accumulation of homogentisic acid in the urine. The condition is characterized by ochronosis in various tissues and arthritis. T047 Disease or Syndrome T001410 Alkaptonuria 1999 01 01 NLM (1966) D000475 Alkenes 1999 01 01 1997 06 20 1966 01 01 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66 66 D02.455.326.271 NLM TGC SJN M0000718 Alkenes C0002068 0 Unsaturated hydrocarbons of the type Cn-H2n, indicated by the suffix -ene. (Grant & Hackh's Chemical Dictionary, 5th ed, p408) T109 Organic Chemical M0000718 M0000719 T001411 Alkenes 1999 01 01 NLM (1966) T001412 Olefins 1974 03 29 UNK (19XX) M0000719 Pentenes C0524484 0 T109 Organic Chemical M0000718 M0000719 T001413 Pentenes 1996 12 19 NLM (1998) D000476 Alkanesulfonates 1999 01 01 1993 06 04 1973 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 94; was ALKYL SULFONATES 1973-93 use ALKANESULFONATES to search ALKYL SULFONATES 1973-93 94; was ALKYL SULFONATES 1973-93 Alkylating Agents (1966-1972) Sulfonic Acids (1966-1972) D02.455.326.146.100.050 D02.886.645.600.055.050 NLM TPW PLS M0000720 Alkanesulfonates C0002072 0 Organic esters or salts of sulfonic acid derivatives containing an aliphatic hydrocarbon radical. T109 Organic Chemical T001415 Alkanesulfonates 1999 01 01 NLM (1973) T001414 Alkyl Sulfonates 1993 05 10 NLM (1994) T001414 Sulfonates, Alkyl D000477 Alkylating Agents 1999 01 01 2003 07 09 1966 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66(64) 66 D27.505.519.124 D27.888.569.035 NLM ssb sjn M0000721 Alkylating Agents C0002073 0 Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. T121 Pharmacologic Substance T130 Indicator, Reagent, or Diagnostic Aid T131 Hazardous or Poisonous Substance T001416 Alkylating Agents 1999 01 01 NLM (1964) T001416 Agents, Alkylating T001417 Alkylators 1994 10 20 NLM (1996) D000478 Alkylation 1999 01 01 2000 06 21 1966 01 01 2001 2002 2003 2004 Q000187 drug effects DE Q000528 radiation effects RE almost never IM; enzymatic alkylation: coord NIM with TRANSFERASES (IM) + substrate (NIM); METHYLATION & METHYLTRANSFERASES are also available 66 66 G06.535.130 H01.181.404.146 NLM adp sjn M0000722 Alkylation C0002074 The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group. T070 Natural Phenomenon or Process T001418 Alkylation 1999 01 01 NLM (1966) T001418 Alkylations D000479 Alkylmercury Compounds 1976 04 16 1995 06 08 1977 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG DF: ALKYLMERCURY CPDS 80; was ALKYL MERCURY COMPOUNDS 1977-79 use ALKYLMERCURY COMPOUNDS to search ALKYL MERCURY COMPOUNDS 1977-79 80; was ALKYL MERCURY COMPOUNDS 1977-79 Mercury (1966-1976) Organometallic Compounds (1968-1976) D02.691.750.100 RLS JRT PLS M0000723 Alkylmercury Compounds C0002077 0 Organic mercury compounds in which the mercury is attached to an alkyl group. T109 Organic Chemical T131 Hazardous or Poisonous Substance T001420 Alkylmercury Compounds 1999 01 01 ALKYLMERCURY CPDS NLM (1977) T001420 Compounds, Alkylmercury T001419 Alkylmercurials 1976 04 14 UNK (19XX) T001421 Alkyl Mercury Compounds 1979 05 23 ALKYL MERCURY CPDS UNK (19XX) T001421 Compounds, Alkyl Mercury T001421 Mercury Compounds, Alkyl D000480 Alkynes 1999 01 01 1995 03 16 1966 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 66 66 D02.455.326.397 NLM TGC PLS M0000724 Alkynes C0002078 0 Acyclic hydrocarbons with one triple bond of the general formula Cn-H2n-2. (Grant & Hackh's Chemical Dictionary, 5th ed) T109 Organic Chemical T001422 Alkynes 1999 01 01 NLM (1966) D000481 Allantoin 1999 01 01 1990 05 30 1972 01 01 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /defic /physiol permitted 72(64) 72 D03.383.374.411.105 NLM PLS NLM M0000725 Allantoin C0002083 Urea, (2,5-dioxo-4-imidazolidinyl)- 97-59-6 T109 Organic Chemical T121 Pharmacologic Substance T123 Biologically Active Substance T001423 Allantoin 1999 01 01 NLM (1964) D000482 Allantois 1999 01 01 2002 07 02 1991 01 01 2003 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000098 blood supply BS Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000294 innervation IR Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000473 pathology PA Q000502 physiology PH Q000503 physiopathology PP Q000528 radiation effects RE Q000530 radiography RA Q000531 radionuclide imaging RI Q000557 secretion SE Q000601 surgery SU Q000637 transplantation TR Q000648 ultrastructure UL Q000736 ultrasonography US Q000737 chemistry CH Q000821 virology VI mammalian, avian or reptilian 91(75); was see under FETAL MEMBRANES 1975-90 search FETAL MEMBRANES 1966-74 91; was see under FETAL MEMBRANES 1975-90 A16.254.403.147 NLM mdb sjn M0000726 Allantois C0002084 An embryonic diverticulum of the hindgut of reptiles, birds, and mammals; in man its blood vessels give rise to those of the umbilical cord. T018 Embryonic Structure T001424 Allantois 1999 01 01 NLM (1975) D000483 Alleles 1999 01 01 2002 07 02 1968 01 01 2003 2004 no qualif; = allelomorphs 68 68 Genes (1966-1967) G14.330.077 G14.345.320.077 NLM TGC sjn M0000727 Alleles C0002085 Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental process. T028 Gene or Genome T001425 Alleles 1999 01 01 NLM (1968) T001425 Allele T001426 Allelomorphs 1996 07 25 NLM (1998) T001426 Allelomorph D000485 Allergens 1999 01 01 2000 06 21 1965 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT coord IM with specific allergen (IM), e.g., pollen as an allergen = ALLERGENS + POLLEN 65 65 D001733 Bites and Stings D004391 Dust D005241 Feathers D005658 Fungi D24.611.216.063 NLM adp sjn M0000728 Allergens C0002092 0 Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). T129 Immunologic Factor T001427 Allergens 1999 01 01 NLM (1965) D000486 Allergy and Immunology 1999 01 01 1996 06 10 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000193 education ED Q000266 history HI Q000295 instrumentation IS Q000331 legislation & jurisprudence LJ Q000364 manpower MA Q000458 organization & administration OG Q000592 standards ST Q000639 trends TD Q000706 statistics & numerical data SN Q000941 ethics ES SPEC: SPEC qualif; do not confuse with ALLERGY see HYPERSENSITIVITY (Cat C); consider also /immunol: Manual 19.7+, 19.8.37; immunohematology is indexed under BLOOD GROUPS; immunologic processes = IMMUNITY or specific; DF: ALLERGY IMMUNOL 80; IMMUNOLOGY was heading 1963-79; RADIATION IMMUNOLOGY was heading 1964-66 use ALLERGY AND IMMUNOLOGY to search IMMUNOLOGY 1966-79; search RADIATION IMMUNOLOGY under RADIATION EFFECTS 1966 80; IMMUNOLOGY was heading 1963-79; RADIATION IMMUNOLOGY was heading 1964-66 D000486 Allergy and Immunology Q000379 methods D007158 Immunologic Techniques G02.403.776.030 NLM TGC PLS M0000730 Allergy and Immunology C0002112 A medical specialty concerned with the hypersensitivity of the individual to foreign substances and protection from the resultant infection or disorder. T091 Biomedical Occupation or Discipline M0000730 M0000729 M0000730 M0000731 T001432 Allergy and Immunology 1999 01 01 ALLERGY IMMUNOLOGY NLM (1966) T001429 Allergy, Immunology 1979 05 29 ALLERGY IMMUNOL UNK (19XX) T001430 Immunology and Allergy 1979 05 29 IMMUNOLOGY ALLERGY UNK (19XX) T001431 Immunology, Allergy 1979 05 29 IMMUNOL ALLERGY UNK (19XX) M0000729 Allergy (Specialty) C0002111 T091 Biomedical Occupation or Discipline M0000730 M0000729 T001428 Allergy (Specialty) 1979 05 29 ALLERGY A UNK (19XX) T001428 Allergies (Specialty) M0000731 Immunology C0152036 T091 Biomedical Occupation or Discipline M0000730 M0000731 T001433 Immunology 1979 05 29 IMMUNOL UNK (19XX) D000487 Allethrin 1999 01 01 2003 07 09 1974 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG TN 111 for eff on insects 74(72) 74 Cycloparaffins (1966-1971) Pyrethrum (1966-1971) D02.455.849.575.812.272 NLM ssb sjn M0000732 Allethrin C0002119 Cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-, 2-methyl-4-oxo-3-(2-propenyl)-2-cyclopenten-1-yl ester 584-79-2 Synthetic analogs of the naturally occuring insecticides cinerin, jasmolin, and pyrethrin. (From Merck Index, 11th ed) T109 Organic Chemical T131 Hazardous or Poisonous Substance D007306 Insecticides T001435 Allethrin 1999 01 01 NLM (1972) T001434 Allethrins 1995 01 18 NLM (1996) D000488 Allied Health Personnel 1999 01 01 1994 10 19 1971 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000145 classification CL Q000191 economics EC Q000266 history HI Q000331 legislation & jurisprudence LJ Q000458 organization & administration OG Q000592 standards ST Q000600 supply & distribution SD Q000639 trends TD Q000656 utilization UT Q000706 statistics & numerical data SN Q000941 ethics ES Q000193 education ED Q000523 psychology PX 71 71 Health Manpower (1968-1970) Health Occupations (1966-1970) M01.526.485.067 N02.360.067 NLM PLS PLS M0000733 Allied Health Personnel C0002122 Health care workers specially trained and licensed to assist and support the work of health professionals. Often used synonymously with paramedical personnel, the term generally refers to all health care workers who perform tasks which must otherwise be performed by a physician or other health professional. T097 Professional or Occupational Group M0000733 M0000734 M0000733 M0000735 T001436 Allied Health Personnel 1999 01 01 BIOETHICS (1995) T001436 Health Personnel, Allied T001436 Personnel, Allied Health M0000734 Paramedics C0030450 T097 Professional or Occupational Group M0000733 M0000734 T001438 Paramedics 1983 06 22 UNK (19XX) T001438 Paramedic T001437 Paramedical Personnel 1978 05 03 PARAMED PERSONNEL POPLINE (1978) T001437 Personnel, Paramedical M0000735 Population Program Specialists C0032677 T097 Professional or Occupational Group M0000733 M0000735 T001439 Population Program Specialists 1978 12 18 POPLINE (1978) T001439 Population Program Specialist T001439 Program Specialist, Population T001439 Program Specialists, Population T001439 Specialist, Population Program T001439 Specialists, Population Program D000489 Alligators and Crocodiles 1974 12 12 2003 07 09 1991 01 01 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000601 surgery SU Q000652 urine UR Q000821 virology VI IM; qualif permitted; DF: ALLIGATORS 91(75); was see under REPTILES 1975-90 91; was see under REPTILES 1975-90 B01.150.900.833.100 NLM ags sjn M0000737 Alligators and Crocodiles C0002124 Large, long-tailed reptiles, including caimans, of the order Loricata. T014 Reptile M0000737 M0000736 M0000737 M0000738 M0000737 M0000739 T001441 Alligators and Crocodiles 1999 01 01 ALLIGATORS CROCODILES NLM (1975) T001441 Crocodiles and Alligators M0000736 Alligators C0002123 T014 Reptile M0000737 M0000736 T001440 Alligators 1979 03 29 UNK (19XX) T001440 Alligator M0000738 Crocodiles C0010345 T014 Reptile M0000737 M0000738 T001442 Crocodiles 1974 12 11 UNK (19XX) T001442 Crocodile M0000739 Caimans C0079078 T014 Reptile M0000737 M0000739 T001443 Caimans 1990 03 19 NLM (1991) T001443 Caiman T001444 Caymans 1990 03 19 NLM (1991) T001444 Cayman D000490 Allium 1985 05 03 2001 07 25 1986 01 01 2002 2003 2004 Q000009 adverse effects AE Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000633 toxicity TO Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI prefer specific plant; coord with specific PLANT COMPONENTS term if pertinent; for use in therapy coord IM with PHYTOTHERAPY (IM) + disease/drug ther (IM) + PLANT PREPARATION or its indentations/ther use (IM or NIM) + specific plant chemical /ther use (IM) if pertinent; Manual 26.29 86 86 Garlic (1966-1985) Plants (1966-1985) Vegetables (1966-1985) B06.388.100.610.100 J02.500.850.100 SH ssb sjn M0000740 Allium C0002125 A genus of the plant family Liliaceae (sometimes classified as Alliaceae) in the order Liliales. Many produce pungent, often bacteriostatic and physiologically active compounds and are used as food, condiment, and medicament, the latter in traditional medicine. T002 Plant T168 Food M0000740 M0000742 T001445 Allium 1999 01 01 NLM (1986) M0000742 Alliaceae C0524485 T002 Plant M0000740 M0000742 T001447 Alliaceae 1996 10 21 NLM (1998) D000492 Allophanate Hydrolase 1974 11 19 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT 91(75); was see under AMIDOHYDROLASES 1975-90 91; was see under AMIDOHYDROLASES 1975-90 Amidohydrolases (1974) Carboxylic Acids (1974) Urea (1974) D08.811.277.087.060 NLM ssb sjn M0000744 Allophanate Hydrolase C0002142 Urea-1-carboxylate amidohydrolase EC 3.5.1.54 An enzyme that catalyzes the hydrolysis of allophanic acid to two molecules of ammonia plus two molecules of "active carbon dioxide". EC 3.5.1.54. T116 Amino Acid, Peptide, or Protein T126 Enzyme T001450 Allophanate Hydrolase 1999 01 01 NLM (1975) T001450 Hydrolase, Allophanate D000493 Allopurinol 1999 01 01 2001 07 25 1968 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 68(67) 68 Enzymes (1966) Xanthine Oxidase (1966) D03.438.759.160 NLM ssb sjn M0000745 Allopurinol C0002144 4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro- 315-30-0 A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. T109 Organic Chemical T121 Pharmacologic Substance D000963 Antimetabolites D004791 Enzyme Inhibitors D006074 Gout Suppressants D016166 Free Radical Scavengers M0000745 M0353789 M0000745 M0353788 M0000745 M0353787 M0000745 M0353793 M0000745 M0353792 T001451 Allopurinol 1999 01 01 BAN (19XX) INN (19XX) JAN (19XX) USAN (1964) USP (19XX) M0353789 Cellidrin C0701100 0 T109 Organic Chemical T121 Pharmacologic Substance M0000745 M0353789 T001452 Cellidrin 1981 01 08 UNK (19XX) M0353788 Lopurin C0701099 0 T109 Organic Chemical T121 Pharmacologic Substance M0000745 M0353788 T001453 Lopurin 1986 11 19 UNK (19XX) M0353787 Milurit 0 T109 Organic Chemical T121 Pharmacologic Substance M0000745 M0353787 T001456 Milurit 1983 12 09 UNK (19XX) M0353793 Milurite 0 T109 Organic Chemical T121 Pharmacologic Substance M0000745 M0353793 T001454 Milurite 1981 01 08 UNK (19XX) M0353792 Zyloprim C0701096 0 T109 Organic Chemical T121 Pharmacologic Substance M0000745 M0353792 T001455 Zyloprim 1986 11 21 UNK (19XX) D000494 Allosteric Regulation 1999 01 01 1992 03 25 1978 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES almost never IM; DF: ALLOSTERIC REG 78(71); was see under BIOCHEMISTRY 1975-77 78; was see under BIOCHEMISTRY 1975-77 Binding Sites (1968-1970) Chemistry (1966-1970) Enzyme Activation (1969-1970) Enzyme Induction (1966-1970) Kinetics (1966-1970) G06.184.060 NLM TAP PLS M0000746 Allosteric Regulation C0002145 T044 Molecular Function T001458 Allosteric Regulation 1999 01 01 ALLOSTERIC REG NLM (1971) T001457 Regulation, Allosteric 1990 10 15 REG ALLOSTERIC NLM (1992) T001457 Allosteric Regulations T001457 Regulations, Allosteric D000495 Allosteric Site 1999 01 01 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000187 drug effects DE Q000235 genetics GE Q000276 immunology IM Q000502 physiology PH Q000528 radiation effects RE Q000941 ethics ES 91(75); was see under BINDING SITES 1975-90 search BINDING SITES 1968-74 91; was see under BINDING SITES 1975-90 G06.184.154.147 NLM adp sjn M0000747 Allosteric Site C0002146 A site on an enzyme which upon binding of a modulator, causes the protein to undergo a conformational change that may alter the catalytic or binding properties of the enzyme. T082 Spatial Concept T169 Functional Concept T001459 Allosteric Site 1999 01 01 NLM (1975) T001459 Allosteric Sites T001459 Site, Allosteric T001459 Sites, Allosteric D000496 Alloxan 1999 01 01 1992 05 07 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG ALLOXAN DIABETES indexed as DIABETES MELLITUS, EXPERIMENTAL (IM) + ALLOXAN (NIM) only if chem is particularly discussed D03.383.742.698.122 NLM TAP PLS M0000748 Alloxan C0002151 2,4,5,6(1H,3H)-Pyrimidinetetrone 50-71-5 T123 Biologically Active Substance T195 Antibiotic T001460 Alloxan 1999 01 01 NLM (1966) D000497 Alloys 1999 01 01 1993 06 04 1965 01 01 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000737 chemistry CH Q000744 contraindications CT D25-26 qualif 65 65 D01.552.033 D25.058 NLM TPW PLS M0000749 Alloys C0002154 0 A mixture of metallic elements or compounds with other metallic or metalloid elements in varying proportions. T122 Biomedical or Dental Material T197 Inorganic Chemical T001461 Alloys 1999 01 01 NLM (1965) D000498 Allyl Compounds 1999 01 01 1992 05 07 1973 01 01 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG DF: ALLYL CPDS 73(71) 73 Alkenes (1966-1970) D02.455.326.271.122 NLM TGC PLS M0000750 Allyl Compounds C0002156 0 T109 Organic Chemical T001462 Allyl Compounds 1999 01 01 ALLYL CPDS NLM (1971) T001462 Compounds, Allyl D000499 Allylamine 1975 07 23 2000 06 21 1991 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(76); was see under AMINES 1976-90 91; was see under AMINES 1976-90 Allyl Compounds (1974-1975) Amines (1974-1975) D02.092.050 D02.455.326.271.122.100 RLS CCR sjn M0000751 Allylamine C0002157 2-Propen-1-amine 107-11-9 Possesses an unusual and selective cytotoxicity for vascular smooth muscle cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial fibrosis or cardiac decompensation. T109 Organic Chemical T121 Pharmacologic Substance T131 Hazardous or Poisonous Substance T001464 Allylamine 1999 01 01 NLM (1976) T001463 3-Aminopropylene 1975 07 01 AMINOPROPYLENE 03 UNK (19XX) T001463 3 Aminopropylene D000500 Allylestrenol 1974 11 11 2003 07 09 1991 01 01 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(75); was see under ESTRENES 1975-90 91; was see under ESTRENES 1975-90 Allyl Compounds (1973-1974) Estranes (1970-1974) Hydroxysteroids (1973-1974) D04.808.365.415.050 NLM lkt sjn M0000752 Allylestrenol C0002158 Estr-4-en-17-ol, 17-(2-propenyl)-, (17beta)- 432-60-0 A synthetic steroid with progestational activity. T110 Steroid T121 Pharmacologic Substance D011372 Progestins M0000752 M0351225 M0000752 M0351232 T001465 Allylestrenol 1999 01 01 INN (19XX) T001466 Allyloestrenol 1989 02 08 BAN (1989) M0351225 Gestanon C0878079 0 T110 Steroid T121 Pharmacologic Substance M0000752 M0351225 T001467 Gestanon 1981 11 02 ES T505643 Gestanin 2002 07 23 UK T505644 Organon Brand of Allylestrenol 2002 07 23 NLM (2003) T505644 Allylestrenol Organon Brand M0351232 Turinal C0878078 0 T110 Steroid T121 Pharmacologic Substance M0000752 M0351232 T001468 Turinal 1981 12 09 UNK (19XX) D000501 Allylglycine 1979 05 23 2001 08 03 1991 01 01 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(80); was see under GLYCINE 1980-90 91; was see under GLYCINE 1980-90 Allyl Compounds (1971-1975) Analeptics (1966-1974) Convulsants (1974-1979) Glycine (1966-1974) /antagonists & inhibitors (1975-1979) D02.455.326.271.122.260 D12.125.481.100 RLS sjn sjn M0000753 Allylglycine C0002159 4-Pentenoic acid, 2-amino- 1069-48-3 An inhibitor of glutamate decarboxylase and an antagonist of GAMMA-AMINOBUTYRIC ACID. It is used to induce convulsions in experimental animals. T116 Amino Acid, Peptide, or Protein T121 Pharmacologic Substance D003292 Convulsants D018756 GABA Antagonists T001470 Allylglycine 1999 01 01 NLM (1980) T001469 2-Amino-4-Pentenoic Acid 1980 09 17 UNK (19XX) D000502 Allylisopropylacetamide 1999 01 01 1998 06 10 1991 01 01 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000031 analogs & derivatives AA Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000097 blood BL Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000176 diagnostic use DU Q000191 economics EC Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000506 poisoning PO Q000528 radiation effects RE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG 91(73); was see under ACETAMIDES 1973-90 91; was see under ACETAMIDES 1973-90 D02.065.064.189 D02.241.081.038.108.189 D02.455.326.271.122.272 NLM ADP SJN M0000754 Allylisopropylacetamide C0002160 4-Pentenamide, 2-(1-methylethyl)- 299-78-5 An allylic compound that acts as a suicide inactivator of CYTOCHROME P450 by covalently binding to its heme moiety or surrounding protein. T109 Organic Chemical T001472 Allylisopropylacetamide 1999 01 01 NLM (1973) T001471 2-Isopropyl-4-Pentenamide 1980 09 17 UNK (19XX) T001471 2 Isopropyl 4 Pentenamide D000503 Almanacs 1999 01 01 1996 06 10 1997 1998 1999 2000 2001 2002 2003 2004 Q000266 history HI for med almanacs, do not coord with MEDICINE; do not confuse with Publication Type ALMANACS L01.178.682.192.836.072 NLM TGC PLS M0000755 Almanacs C0376648 Publications, usually annual, containing a calendar for the coming year, the times of such events and phenomena as anniversaries, sunrises, sunsets, phases of the moon, tides, meteorological, and other statistical information and related topics. Almanacs are also annual reference books of useful and interesting facts relating to countries of the world, sports, entertainment, population groups, etc. (Random House Unabridged Dictionary, 2d ed) T170 Intellectual Product T001473 Almanacs 1999 01 01 NLM (1966) T001473 Almanac D000504 Aloe 1999 01 01 2002 07 02 1964 01 01 2003 2004 Q000009 adverse effects AE Q000033 anatomy & histology AH Q000145 classification CL Q000166 cytology CY Q000187 drug effects DE Q000196 embryology EM Q000201 enzymology EN Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000633 toxicity TO Q000648 ultrastructure UL Q000737 chemistry CH Q000821 virology VI for HESPERALOE see AGAVACEAE is also available; coord with specific PLANT COMPONENTS term if pertinent; for use in therapy coord IM with PHYTOTHERAPY (IM) + disease/drug ther (IM) + PLANT PREPARATION or its indentations/ther use (IM or NIM) + specific plant chemical /ther use (IM) if pertinent; Manual 26.29 91(78)63; was see under PLANTS, MEDICINAL 1978-90; was heading 1963-77; was in Cat B & D 1963-77 91,63-77; was see under PLANTS, MEDICINAL 1978-90; was heading 1963-77 B06.388.100.027 NLM ssb sjn M0000756 Aloe C0002168 A plant genus of the family Aloeaceae, order Liliales (or Asphodelaceae, Asparagales in APG system) which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN). T002 Plant M0000756 M0332424 T001474 Aloe 1999 01 01 NLM (1964) M0332424 Aloe vera C0718405 Aloe vera (L.) Burm. f. and other species are used medicinally. T002 Plant M0000756 M0332424 T363544 Aloe vera 1999 11 03 NLM (2000) D000505 Alopecia 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI C17.800.329.937.122 C23.300.035 NLM lkt sjn M0000757 Alopecia C0002170 Absence of hair from areas where it is normally present. T047 Disease or Syndrome T184 Sign or Symptom M0000757 M0000759 M0000757 M0000758 T001475 Alopecia 1999 01 01 POPLINE (1978) T001476 Baldness 1974 03 29 UNK (19XX) M0000759 Androgenetic Alopecia C0162311 T047 Disease or Syndrome M0000757 M0000759 T001478 Androgenetic Alopecia 1992 05 04 ANDROGENET ALOPECIA NLM (1993) T001479 Alopecia, Androgenetic 1992 05 04 ALOPECIA ANDROGENET NLM (1993) T001480 Alopecia, Male Pattern 1992 05 04 NLM (1993) T001480 Male Pattern Alopecia T001481 Male Pattern Baldness 1992 05 04 NLM (1993) T001481 Baldness, Male Pattern M0000758 Pseudopelade C0086873 T047 Disease or Syndrome M0000757 M0000758 T001477 Pseudopelade 1990 09 05 NLM (1992) D000506 Alopecia Areata 1999 01 01 2001 07 25 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI baldness in defined areas C17.800.329.937.122.147 NLM lkt sjn M0000760 Alopecia Areata C0002171 A microscopically inflammatory, usually reversible, patchy hair loss occurring in sharply defined areas and usually involving the beard or scalp. (Dorland, 27th ed) T047 Disease or Syndrome T001482 Alopecia Areata 1999 01 01 NLM (1966) D000507 Mucinosis, Follicular 1999 01 01 2001 07 25 1991 01 01 2002 2003 2004 Q000097 blood BL Q000134 cerebrospinal fluid CF Q000139 chemically induced CI Q000145 classification CL Q000150 complications CO Q000151 congenital CN Q000175 diagnosis DI Q000178 diet therapy DH Q000188 drug therapy DT Q000191 economics EC Q000196 embryology EM Q000201 enzymology EN Q000208 ethnology EH Q000209 etiology ET Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000378 metabolism ME Q000382 microbiology MI Q000401 mortality MO Q000451 nursing NU Q000453 epidemiology EP Q000469 parasitology PS Q000473 pathology PA Q000503 physiopathology PP Q000517 prevention & control PC Q000523 psychology PX Q000530 radiography RA Q000531 radionuclide imaging RI Q000532 radiotherapy RT Q000534 rehabilitation RH Q000601 surgery SU Q000628 therapy TH Q000652 urine UR Q000662 veterinary VE Q000736 ultrasonography US Q000821 virology VI a sebaceous gland dis 93; was ALOPECIA MUCINOSA 1965-92 (see under ALOPECIA 1965-90) use MUCINOSIS, FOLLICULAR to search ALOPECIA MUCINOSA 1966-92 93; was ALOPECIA MUCINOSA 1965-92 (see under ALOPECIA 1965-90) C17.300.550.550 C17.800.329.937.122.550 C17.800.794.550 NLM lkt sjn M0000761 Mucinosis, Follicular C0002173 A disease of the pilosebaceous unit, presenting clinically as grouped follicular papules or plaques with associated hair loss. It is caused by mucinous infiltration of tissues, and usually involving the scalp, face, and neck. It may be primary (idiopathic) or secondary to mycosis fungoides or reticulosis. T047 Disease or Syndrome T001484 Mucinosis, Follicular 1999 01 01 NLM (1965) T001484 Follicular Mucinoses T001484 Follicular Mucinosis T001484 Mucinoses, Follicular T001483 Alopecia Mucinosa 1992 04 06 NLM (1993) D000508 Alouatta 1974 11 11 2003 07 09 1991 01 01 2004 Q000002 abnormalities AB Q000033 anatomy & histology AH Q000097 blood BL Q000134 cerebrospinal fluid CF Q000145 classification CL Q000196 embryology EM Q000235 genetics GE Q000254 growth & development GD Q000276 immunology IM Q000293 injuries IN Q000378 metabolism ME Q000382 microbiology MI Q000469 parasitology PS Q000502 physiology PH Q000523 psychology PX Q000601 surgery SU Q000652 urine UR Q000821 virology VI New World monkey; NIM when exper animal: no qualif; when IM, qualif permitted; diseases: coord IM with MONKEY DISEASES (IM) 91(81); was see under CEBIDAE 1981-90; was HOWLER MONKEYS see under MONKEYS 1975-80 use ALOUATTA to search HOWLER MONKEYS 1975-80 91; was see under CEBIDAE 1981-90; was HOWLER MONKEYS see under MONKEYS 1975-80 B01.150.900.649.801.400.120.075.075 NLM ags sjn M0000762 Alouatta C0002184 A genus of the subfamily ALOUATTINAE, family CEBIDAE, composed of six species. They are A. belzebul (black and red howler), A. caraya (black howler), A. fusca (brown howler), A. palliata (mantled howler), A. seniculus (red howler), and A. villosa (also known as A. pigra; Guatemalan howler). They inhabit the forests of Central and South America. Howlers travel in groups and define their territories by howling accompanied by vigorously shaking and breaking branches. T015 Mammal T001485 Alouatta 1999 01 01 NLM (1975) T001485 Alouattas T001486 Howler Monkeys 1980 05 12 UNK (19XX) T001486 Howler Monkey T001486 Monkeys, Howler T001487 Monkey, Howler 1980 05 12 UNK (19XX) D000509 alpha-Fetoproteins 1974 11 11 1999 11 03 1977 01 01 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG /biosyn /physiol permitted 96; was ALPHA FETOPROTEINS 1975-95 (see under FETAL GLOBULINS 1975-76) use ALPHA-FETOPROTEINS to search ALPHA FETOPROTEINS 1975-95 96; was ALPHA FETOPROTEINS 1975-95 (see under FETAL GLOBULINS 1975-76) Fetal Proteins (1970-1974) D000757 Anencephaly D12.776.320.050 D24.185.101.840.050 NLM KEV sjn M0000763 alpha-Fetoproteins C0002210 0 The first alpha-globulins to appear in mammalian sera during development of the embryo and the dominant serum proteins in early embryonic life. They reappear in the adult serum during certain pathologic states, primarily hepatocellular carcinoma. They may also be elevated in the amniotic fluid and maternal serum during pregnancy in ANENCEPHALY. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000763 M0000764 T001490 alpha-Fetoproteins 1999 01 01 POPLINE (1979) T001490 alpha Fetoproteins T001488 AFP 1974 11 11 UNK (19XX) T001489 alpha-Fetoprotein 1987 05 11 UNK (19XX) T001489 alpha Fetoprotein T001491 Fetuin 1979 02 21 UNK (19XX) T001492 Fetuins 1974 11 11 UNK (19XX) M0000764 Fetoprotein C0015961 0 T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance M0000763 M0000764 T001493 Fetoprotein 1987 05 13 UNK (19XX) D000510 Alpha-Globulins 1999 01 01 2000 06 21 1965 01 01 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI Q000096 biosynthesis BI Q000134 cerebrospinal fluid CF Q000138 chemical synthesis CS Q000145 classification CL Q000172 deficiency DF Q000176 diagnostic use DU Q000187 drug effects DE Q000191 economics EC Q000235 genetics GE Q000266 history HI Q000276 immunology IM Q000302 isolation & purification IP Q000378 metabolism ME Q000493 pharmacokinetics PK Q000494 pharmacology PD Q000502 physiology PH Q000506 poisoning PO Q000528 radiation effects RE Q000557 secretion SE Q000592 standards ST Q000600 supply & distribution SD Q000627 therapeutic use TU Q000633 toxicity TO Q000648 ultrastructure UL Q000652 urine UR Q000737 chemistry CH Q000744 contraindications CT Q000819 agonists AG GEN or unspecified; prefer specifics 75; was ALPHA GLOBULIN 1964-74 (Prov 1964) use ALPHA-GLOBULINS to search ALPHA GLOBULIN 1966-74 75; was ALPHA GLOBULIN 1965-74 D12.776.124.790.106 D12.776.377.715.085 NLM adp sjn M0000765 Alpha-Globulins C0002211 0 Serum proteins that have the most rapid migration during ELECTROPHORESIS. This subgroup of globulins is divided into faster and slower alpha(1)- and alpha(2)-globulins. T116 Amino Acid, Peptide, or Protein T123 Biologically Active Substance T001495 Alpha-Globulins 1999 01 01 NLM (1964) T001495 Alpha Globulins T001494 Alpha-Globulin 1976 09 05 UNK (19XX) T001494 Alpha Globulin D000511 alpha-Macroglobulins 1975 07 18 1995 03 16 1976 01 01 1996 1997 1998 1999 2000 2001 2002 2003 2004 Q000008 administration & dosage AD Q000009 adverse effects AE Q000032 analysis AN Q000037 antagonists & inhibitors AI